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Abstract 
 
G protein-coupled receptors (GPCRs) elicit an ability to activate multiple 
downstream signalling pathways. It is becoming evident that for many 
GPCRs, agonists are able to activate several of these pathways, each to 
differing extents; a phenomenon termed pathway bias, or biased 
agonism.  
 
Here, work is presented quantifying biased agonism for the: adenosine A1 
and A2A receptors, as well as the calcitonin-like receptor (CLR). For the 
adenosine receptors, novel selective, and non-selective, agonists are 
identified and characterised. Further, the extent of biased agonism is 
determined for A1R agonists with respect to their abilities to positively and 
negatively regulate cAMP production, mobilise intracellular Ca2+ and 
activate ERK1/2. The activity of triazoloquinazoline compounds against 
the A2AR is validated, identifying 3 to be selective. Further investigations 
into the ability of triazoloquinazolines to mediate cAMP production and 
ERK1/2 activation uncovers each tested agonist to be biased towards 
activating ERK1/2, at the A2AR. A characterisation of the effects of 
receptor activity modifying proteins (RAMPs) upon signalling from the 
CLR is presented: quantifying the extent of biased agonism, with respect 
to the ability of RAMP-CLR heterodimers to: mediate cAMP production 
and inhibition, as well as mobilise intracellular Ca2+, uncovering this to be 
a Gαq/11-mediated process. Further, through applying a saturation 
mutagenesis approach to the CLR, a potential interaction is identified 
between intracellular loop 1 (ICL1) and helix 8, which is broken upon 
receptor activation, further identifying ICL1 to be a region of the CLR 
responsible for influencing G protein specificity.  
 
Ultimately, these findings relating to both adenosine and CLR-based 
receptors uncovers further evidence of biased agonism at GPCRs, which 
may have potential implications upon improving the efficacy and safety 
profiles of novel pharmaceutics targeting these clinically relevant GPCRs. 
1 
Chapter 1 
Introduction 
 
1.1 Cellular signalling 
 
In multicellular organisms, cells need to able to communicate to one 
another, resulting in complex modifications in either cellular behaviour, or 
gene expression. These can be brought about due to changes in the 
organism’s external environment, or in its own internal biochemistry. Such 
responses are governed by many differing types of stimuli, including, but 
not limited to: physical, such as touch, heat, light and pressure; or 
chemical, such as: neurotransmitters, lipids, nucleotides or peptides. For 
lipophilic signalling molecules, or ligands, these are able to directly cross 
the plasma membrane and affect their changes. Examples of such 
molecules include retinoids (derivatives of vitamin A), thyroid hormones, 
and sex hormones, such as testosterone and oestrogen. Each of these 
different ligand types will result in differing effects upon the target cell. 
These are brought about through binding to, what, in 1905, James 
Langley called the “receptive substance” (Langley, 1905), now more 
commonly termed ‘receptors’. However, many ligands are lipophobic, and 
thus are unable to directly cross the plasma membrane. Therefore, they 
are unable to interact with receptors located within the cell, unlike 
lipophilic molecules. Thus, to respond to these ligands, cells developed 
transmembrane (TM) receptors, residing within the plasma membrane, 
providing a conduit through which extracellular stimuli can transduce their 
signal, bringing about intracellular effects. 
 
Many different subtypes of TM-receptors exist, but the largest by far 
consist of G protein-coupled receptors (GPCRs). The human genome 
project identified 23,000 distinct genes (Venter et al, 2001), of which over 
800 were identified as potentially coding for GPCRs (Fredriksson et al, 
2003). Thus, >0.03% of our DNA encodes for this group of receptors. As 
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large a family as they are, they also bind, and respond to, an equally 
diverse array of ligands. Examples of these include photons, ions, 
proteins, lipids, nucleotides and sugars (Fredriksson et al, 2003). Each of 
these differing ligand types, bind distinct receptor subgroups, all of which 
are able to result in a wide range of intracellular effects, ranging from: 
gene expression changes and the regulation of enzymes, to the secretion 
of further signalling molecules. It is GPCRs that will form the focus of the 
research presented within this thesis. 
 
1.2 G protein-coupled receptors 
 
The large diversity in GPCR subtypes, ligands, and elicited responses 
underlies how important they are in regulating correct cellular function. 
Thus, perturbation, or malfunction, of these signalling pathways can have 
dire consequences. This is indicated by the fact that GPCRs are 
implicated in a wide array of pathological states including, but not limited 
to: cardiovascular disease, cancer, diabetes mellitus, migraine, 
hypertension, addiction and various neurological diseases such as 
Huntington’s, schizophrenia, Alzheimer’s and Parkinson’s (Bristow, 2000, 
Hack and Christie, 2003, Sloop et al, 2005, Hill, 2006, Ohta et al, 2006, 
Mehta and Griendling, 2007, Morelli et al, 2007, Branca et al, 2014, Lee 
and Chern, 2014, Villar-Menéndez et al, 2014, Walker et al, 2015). Due to 
their implications in such a wide array of diseases, GPCRs are currently 
the target of an estimated 30% of prescription drugs (Correll and 
McKittrick, 2014). Thus, a greater understanding of the function of this 
family of receptors will allow us to gain a more in-depth knowledge of 
their roles played in various pathologies, and have implications upon 
therapeutic intervention strategies.  
 
1.2.1 GPCR families 
 
Despite the wide diversity of receptor subtypes, all are grouped into one 
of six families, A-F, based upon similarities in: structure, function and 
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ligand binding (Krishnan et al, 2012) (Table 1.1). Of these, family A is the 
largest group, consisting of 719 distinct GPCRs, of which 87 currently 
have no known ligand, referred to as ‘orphan’ receptors (Davenport et al, 
2013). They are commonly called the ‘rhodopsin-like’ receptors, due to 
similarity to the prototypical GPCR, rhodopsin (Palczewski et al, 2000). 
They are so diverse that they have been further split into 19 subgroups 
(A1-19), based upon phylogenetic analysis (Joost and Methner, 2002).  
Examples of family A GPCRs include the: opioid, vasopressin, purinergic, 
cannabinoid, dopamine, adenosine and adrenergic receptors. The family 
as a whole, binds, and responds, to a diverse array of ligand types, such 
as purines, neurotransmitters, odorants and photons. Due to their 
diversity, members of this family of receptors have been implicated in 
many human pathological states such as: cancer, various 
neurodegenerative diseases, addiction and cardiovascular disease 
(Bristow, 2000, Hack and Christie, 2003, Morelli et al, 2007, Allard et al, 
2016). Thus, family A GPCRs have been of great interest to the 
pharmaceutical industry, in the treatment of human diseases. 
 
The second group of GPCRs, the secretin-like, or family B, GPCRs are a 
much smaller group than family A, consisting of 15 distinct receptors, only 
found to be expressed in animals. They are also a much less understood 
group than their family A counterparts. This is surprising, given they are 
implicated in many human disease states, including: diabetes, bone 
disorders, cardiovascular disease, migraine and various inflammatory 
diseases. They respond to a series of peptide hormones, ranging in size 
from 20-50 amino acids, via an extra large, extracellular N-terminus 
(Fredriksson et al, 2003). Such peptides include: glucagon, glucagon-like 
peptide-1 (GLP-1), corticotrophin-releasing factor (CRF), calcitonin (CT), 
calcitonin gene-related peptide (CGRP), amylin (AMY), adrenomedullin 
(AM) and adrenomedullin 2 (AM2), all of which play important metabolic 
and physiological roles within man.  
 
Family C GPCRs, the ‘metabotropic glutamate receptors’, bind ligands 
such as Ca2+ ions and glutamate. Members of this group include the 
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calcium-sensing receptor, GABAB and taste receptors. It is these first 
three families that are found in mammals, with families D and E being 
absent. Family D receptors are the fungal mating-pheromone receptors, 
whilst those in family E represent various cyclic adenosine 
monophosphate (cAMP) receptors. The final group, family F, is present in 
mammals and includes the frizzled/smoothened receptors. These play 
key roles in influencing cell proliferation and differentiation in response to 
binding secreted glycoproteins, Wnts. 
 
Table 1.1: G protein-coupled receptor families. 
 
 
 
 
 
 
 
 
 
1.2.2 GPCR structure 
 
GPCRs are expressed in every known eukaryotic organism (Krishnan et 
al, 2012), and regardless of the families to which they belong, they all 
share the same gross macro-structure. This consists of an extracellular 
N-terminus, 7 TM α-helical domains: each joined by a series of intra- and 
extracellular loops (ICL/ECL), ending in an intracellular C-terminus 
(Figure 1.1). 
 
The N-terminus, along with the ECLs, play roles in ligand recognition and 
binding (Olah et al, 1994, Avlani et al, 2007), whilst ICLs have roles in 
mediating downstream signalling, through interaction with other proteins 
(Bockaert and Pin, 1999, Ballesteros et al, 2001). The C-terminal domain 
of a GPCR commonly forms an 8th helix, which aligns with the plasma 
Family Type 
A Rhodopsin-like receptors 
B Secretin-like receptors 
C Metabotropic glutamate receptors 
D Fungal mating-pheromone receptors 
E Cyclic AMP receptors 
F Frizzled/Smoothened receptors 
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membrane (Wess et al, 2008, Conner et al, 2008), and is a region that 
has been shown to be bound by proteins responsible for desensitisation 
and further signalling (Lohse et al, 1990, Gurevich et al, 1995). 
 
The seven TM domains are the most highly conserved domains of all 
GPCRs (also known as 7-TM receptors). Upon ligand binding, and 
activation, a series of structural rearrangements occur within the TM 
bundle. This results in a conformational change from the ‘inactive’ to 
‘active’ state. The ‘inactive’ state is maintained, in many GPCRs, by an 
ionic lock, a D/ERY motif, in TM3. This motif interacts with a glutamic acid 
residue, located in TM6, and serves to ‘lock’ the receptor in its ‘inactive’ 
state. Upon transition to the active state, this ‘lock’ is ‘broken’, resulting in 
a twisting of TM3, away from TM6, by ~30°. As a consequence, the ICLs 
further move, allowing interaction with signalling machinery (Bockaert and 
Pin, 1999, Ballesteros et al, 2001), such as heterotrimeric guanine 
nucleotide-binding proteins (G proteins). 
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1.3 GPCR signal transduction 
 
1.3.1 G protein activation 
 
The main mechanisms through which GPCRs transduce signals are via 
heterotrimeric G proteins. These belong to a large superfamily, which 
also include monomeric G proteins. They all function as ‘binary switches’: 
whilst in an ‘inactive’ state, they are bound to guanosine diphosphate 
(GDP), becoming ‘active’ upon binding guanosine triphosphate (GTP) 
(Figure 1.2). This GDP/GTP binding is conferred by a conserved G 
domain of ~20 kDa (Lambright et al, 1994). The switch from a GDP to 
GTP-bound state can occur spontaneously, due to higher cellular 
concentrations of GTP. However, it can also be accelerated by guanine 
nucleotide exchange factors (GEFs) (Figure 1.2). This is achieved by the 
Figure 1.1: G protein-coupled receptor basic structure. 
  
A GPCR consists of 7 transmembrane (TM) domains (Blue), joined together by 
3 extracellular loops (ECLs) (Red), and 3 intracellular loops (ICLs) (Green), with 
an extracellular N-terminus, and intracellular C-terminus. 
COOH 
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6
5
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GEF inducing changes within the G protein: reducing its affinity for GDP, 
leading to its exchange for GTP. Once active, a G protein can also 
transition back to an ‘inactive’, GDP-bound state. This is facilitated either 
by: the G protein’s own intrinsic GTPase activity, or the action of GTPase 
activating proteins (GAPs) (Randazzo and Kahn, 1994, Bos et al, 2007) 
(Figure 1.2). 
 
 
1.3.2 Heterotrimeric G proteins 
 
Heterotrimeric G proteins consist of a Gα subunit associated with a dimer 
of Gβ and Gγ subunits (Hepler and Gilman, 1992), which couple to 
GPCRs. The Gα subunit consists of two domains, a nucleotide-binding 
domain and helical domain, whilst the Gβ subunit consists of seven 
repeated WD motifs, which arrange to form a propeller-like structure 
Figure 1.2: Activation cycle of G proteins. 
 
In a GDP-bound state, a G protein is inactive; however, through the 
action of guanine exchange factors (GEFs), their conversion to an 
active, GTP-bound state, is catalysed. Reversion to an inactive state 
occurs through a G protein’s own intrinsic GTPase activity, which can 
be accelerated by the action of GTPase-activating proteins (GAPs). 
 
  
!
Pi 
GEF 
GAP 
G protein G protein 
GDP GTP 
GDP GTP 
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(Sondek et al, 1996). The Gγ subunit is smaller than Gβ and is unstable 
in the absence of an associated Gβ subunit, hence these are found 
associated as a Gβγ dimer. 
 
Upon ligand-induced transition from ‘inactive’ to the ‘active’ state, a 
GPCR is able to promote the release of GDP from Gα, allowing exchange 
for GTP. In this manner, a GPCR serves to function as a GEF for Gα 
proteins. Upon activation, Gα dissociates from the Gβγ dimer due to loss 
of a hydrophobic binding pocket required for their association (Lambright 
et al, 1994). Transduction of the ligand-associated signal is therefore 
passed through a GPCR into a cell, and its intracellular effects mediated 
by either the active Gα or Gβγ dimer. 
 
1.3.2.1 Gα-dependent signalling 
 
The Gα subunit typically defines the heterotrimeric G protein, and often 
governs the response mediated by a given GPCR (Wettschureck and 
Offermanns, 2005). There are 17 differing Gα proteins, grouped into four 
families: Gαs, Gαi, Gαq and Gα12, based upon their intracellular targets 
and effects (Table 1.2).  
 
Table 1.2: Gα families. 
Gα family Members Effects 
Gαs Gαs and Gαolf 
Stimulates adenylate 
cyclase 
Gαi Gαi1, Gαi2, Gαi3, Gαoa, Gαob, Gαz, Gαt, Gαgust 
Inhibits adenylate 
cyclase 
Gαq Gαq, Gα11, Gα14, Gα15, Gα16 
Stimulates activity of 
phospholipase C-β 
 
Gα12 Gα12 and Gα13 
Modulates Rho 
family G proteins 
 
 
Where GPCR activation leads to signalling mediated via the Gαs family of 
G proteins, activation of adenylate cyclase (AC) occurs (Figure 1.3). AC 
serves to catalyse the conversion of adenosine triphosphate (ATP) to 
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cAMP. This in turn activates protein kinase A (PKA), through the binding 
of four cAMP molecules to its regulatory subunit, allowing dissociation 
from the, now active, catalytic subunit (Huang and Taylor, 1998). PKA 
then mediates further transduction of the ligand-induced signal, via the 
phosphorylation of further target proteins (Iwami et al, 1995). This can 
result in effects such as promoting glycolysis in the liver and skeletal 
muscle (Rui, 2014), regulating the cystic fibrosis transmembrane 
conductance regulator (CFTR) (Chappe et al, 2005), vasodilation through 
action in smooth muscle cells (Yang et al, 2008), and enhancing lipolysis 
in adipocytes (Tansey et al, 2003).  
 
Activation of Gαi/o directly opposes the action of Gαs: serving to inhibit the 
action of AC (Figure 1.3), thereby reducing cellular concentrations of 
cAMP. Further to this, Gαi/o proteins have also been shown to be able to 
activate phospholipase C (PLC), and G protein-coupled inwardly-
rectifying K+ channels (GIRKs) (Peleg et al, 2002, Lei et al, 2003, Lüscher 
and Slesinger, 2010). The Gαi1/2/3 and Gαoa/b members of this family are 
sensitive to pertussis toxin (PTX) from Bordetella pertussis. PTX serves 
to ADP-ribosylate the C-terminus of these G proteins, preventing their 
interaction with a GPCR (West et al, 1985). 
 
The Gαq family of G proteins all serve to stimulate the activity of PLC 
isoforms (Birnbaumer et al, 1990) (Figure 1.3). Once activated, PLC is 
able to cleave phosphatidylinositol 4,5-bisphopshate (PIP2), to inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 is then able to bind 
directly to IP3 receptors, located on both the endoplasmic and 
sarcoplasmic reticulums (ER and SR, respectively) (Shah et al, 2015). 
Activation of these receptors results in the release of free Ca2+ ions into 
the cell (Figure 1.3), having effects upon: muscle contraction and 
vasoconstriction, secretion of neurotransmitters and other signalling 
peptides, such as insulin (Seino and Shibasaki 2005). The final group of 
Gα proteins, Gα12, serve to regulate the activity of Rho family GTPases 
(Figure 1.3), which serve to modulate the cell’s actin cytoskeleton (Perez 
and Rinćon, 2010). 
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1.3.2.2 Gβγ-dependent signalling 
 
Each of the Gα proteins interacts with an associated Gβγ dimer. There 
are 5 Gβ proteins, and a further 12 Gγ subunits, in mammals (Gautam et 
al, 1998, McCudden et al, 2005). These dimers, which are released upon 
Gα activation, are also able to propagate signals in their own right. Such 
signal propagation includes: opening GIRK channels (Logothetis et al, 
1987, Huang et al, 1995, He et al, 2002) and Ca2+ channels (Herlitze et 
al, 1996), regulation of various kinases, such as: extracellular signal-
regulated kinases (ERK), and janus kinases (JNK) (McCudden et al, 
2005), as well as regulating monomeric G proteins (Clapham and Neer, 
1997) (Figure 1.3). 
 
 
 
Figure 1.3: GPCR-mediated G protein-dependent signalling pathways.  
  
GPCRs can activate several G protein-dependent pathways: activation of Gαs (Green) 
results in adenylate cyclase  (AC – Dark blue) activation and cAMP production, whilst Gαi 
activation (Brown) inhibits AC activity. Activation of: Gαq (Purple) results in PLC-dependent 
release of Ca2+ from ER stores, Gα12 (Orange) leads to actin cytoskeleton regulation via the 
action of RHO GTPases. Gβγ can also signal, leading to a multitude of downstream 
signalling events (Yellow/Red). 
RHO GTPase PLC 
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1.3.3 G protein-independent signalling  
 
As well as utilising G proteins as a conduit to transduce extracellular 
signals, GPCRs are also able to signal in manners independent of G 
proteins. The most common, and well-known, method is via β-arrestin 
recruitment. This group of proteins was initially thought to ‘arrest’ GPCR 
signalling, but have subsequently been implicated in acting as scaffolds 
for the recruitment, and activation, of other signalling proteins. The most 
characterised of these are the mitogen activated protein kinases 
(MAPKs), particularly ERK1/2 (Shenoy and Lefkowitz, 2005 and 2011). In 
this instance, the activated GPCR is phosphorylated, at its C-terminus, by 
G protein-coupled receptor kinases (GRKs). This allows recruitment of β-
arrestins, to the C-terminus (Lefkowitz, 2005), in turn, facilitating 
recruitment of the MAPK kinase kinase (MAPKKK), Raf-1. This serves to 
phosphorylate the MAPK kinase (MAPKK), MEK-1, which subsequently 
phosphorylates the MAPKs, ERK1/2 (Pierce et al, 2001). Activation of the 
MAPK pathway can have effects upon cells, such as: cell cycle arrest, 
cytokine secretion, promoting proliferation and inducing apoptosis 
(Kranenburg and Moolenaar, 2001, Pierce et al, 2001). As well as 
coupling MAPK activation to GPCRs, β-arrestins have also been 
observed to regulate phosphodiesterases (PDEs), thereby influencing G 
protein-dependent signalling pathways (DeFea, 2011). 
 
1.4 Regulation of GPCR signal transduction 
 
As cells have developed methods to detect signals from their external 
environment, they are also in need of a way to ‘turn off’ these signals. 
Upon ligand activation of a given GPCR, a number of signalling cascades 
will be initiated, to effect the desired changes required by a cell. Without a 
method to halt these signals, they will continue to function indefinitely, 
perhaps with detrimental effects upon the cell or organism. Thus, cells 
have evolved mechanisms to return the levels of secondary messengers 
or phosphorylated proteins, to resting, basal, levels.  
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1.4.1 Regulating GPCR signalling via ligand depletion 
 
One method, by which cells can prevent their continual response to a 
stimulus, is to remove it. This is elegantly illustrated by two family B 
receptors, the: GLP-1, and gastric inhibitory peptide (GIP) receptors. 
These respond to 2 peptide hormones, secreted by pancreatic β-cells, in 
response to the ingestion of food (Baggio and Drucker, 2007). Activation 
by these hormones, of their associated receptor, results in the secretion 
of insulin. In order to prevent prolonged stimulation and over production 
of insulin, cells express an enzyme, dipeptidyl peptidase–IV (DPP-IV), 
upon their surface (Mentlein et al, 1993), which rapidly cleaves both GLP-
1 and GIP to inactive metabolites (Kieffer et al, 1995). Through 
degradation of these hormones, the cells prevent overexpression of 
insulin (Yabe and Seino, 2011), and serve to help maintain blood glucose 
homeostasis. 
 
1.4.2 Receptor internalisation 
 
Another method of regulating signalling, and returning a cell to its basal 
state, prior to receptor activation, is via internalisation of the GPCR. 
Ligand-bound, active receptors become the target for GRKs, which 
phosphorylate serine and threonine residues located with ICL3 and the C-
terminus (Figure 1.4). The phosphorylated C-terminus facilitates 
interaction with β-arrestins (Lefkowitz, 2005) (Figure 1.4). There are four 
arrestins: 1-4, with 2 and 3 also referred to as β-arrestins 1 and 2, 
respectively (Shenoy and Lefkowitz, 2011). Each of these 4 proteins 
share a similar structure, consisting of 12 polar residues flanked by an N- 
and C-terminus (Hirsch et al. 1999). Upon binding a GPCR’s 
phosphorylated C-terminus, the β-arrestin’s own C-terminus becomes 
exposed. This serves to inhibit further G protein-mediated signalling, and 
serves to facilitate internalisation of the receptor, via clathrin-mediated 
endocytosis (Figure 1.4). This is brought about by direct interaction of the 
arrestin with clathrin (Krupnick et al, 1997, Kang et al, 2009), or the 
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clathrin adaptor protein, AP-2 (Figure 1.4) (Laporte et al, 1999, 2000, Kim 
and Benovic, 2002, Schmid et al, 2006, Burtey et al, 2007). The 
internalised receptor can then either be: recycled back to the cell surface, 
or targeted for degradation (Figure 1.4) (Marchese et al, 2008, Correll 
and McKittrick, 2014). Indeed, it has been observed that some GPCRs, 
notably the β2-adrenergic receptor, can continue to signal whilst located 
within the endosome (Vilardaga et al, 2014).  
 
 
Some GPCRs can also be internalised in a β-arrestin-independent 
manner. For example: the PAR-2 receptor can itself, directly interact with 
AP-2, and thus clathrin, resulting in internalisation (Paing et al, 2004). 
Other GPCRs, such as the M3 muscarinic receptor, are also able to be 
Figure 1.4: β-arrestins can mediate internalisation of active GPCRs.  
  
Once activated by a ligand, the C-terminus of a GPCR can be phosphorylated 
by GRKs. This results in recruitment of β-arrestin to the C-terminus. β-arrestin 
then facilitates the further recruitment of the clathrin adapter protein, AP-2, 
resulting in clathrin-mediated endocytosis of the GPCR. Once internalised, the 
receptor can either be targeted for degradation, or recycled back to the plasma 
membrane. 
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internalised using clathrin-independent mechanisms (Scarselli and 
Donaldson, 2009). 
 
1.4.3 Receptor phosphorylation 
 
As well as being phosphorylated by GRKs, numerous other enzymes are 
also able to phosphorylate GPCRs, in a regulatory manner. This can 
occur via the action of downstream enzymes, activated through the 
receptor, in a negative feedback manner. One such example is that of 
PKA, which is able to phosphorylate ICL3 and the C-terminus of the β2-
adrenergic receptor (Benovic et al, 1985), preventing signalling by 
sterically inhibiting its interaction with a G protein (Benovic et al, 1985, 
Lefkowitz et al, 1990). Similarly, the angiotensin II type 1 receptor (AT1), 
which couples to Gαq, activates protein kinase C (PKC), resulting in the 
subsequent phosphorylation of AT1’s C-terminus. The β2-adrenergic 
receptor has also been observed to be phosphorylated by receptor 
tyrosine kinases (RTKs) (Karoor and Malbon, 1996, Karoor et al, 1998), 
and Akt/protein kinase B (PKB) (Doronin et al, 2002).  
 
1.4.4 Regulation of G protein-dependent signalling 
 
Whilst a GPCR functions as a GEF, to facilitate the activation of various 
G proteins, a cell requires a method to terminate this signalling. This is 
able to occur due to the intrinsic GTPase activity of the G protein, 
converting the bound GTP, back to GDP, thereby inactivating Gα. GDP-
bound Gα is then able to re-associate with its Gβγ, reforming the 
heterotrimer, also serving to halt, Gβγ-mediated signalling. This process 
can be catalysed by regulator of G protein signalling (RGS) proteins 
(Dohlman et al, 1995). These serve to increase the rate of GTP 
hydrolysis, thereby speeding G protein inactivation. 
 
Where cAMP production has been facilitated via the action of Gαs, simply 
inhibiting the G protein will not ‘turn off’ signalling. Reverting Gαs to a 
Introduction   !
! 15 
GDP-bound state will prevent further activation of AC, but cAMP levels 
will remain elevated. To deal with this, cells express PDEs. These 
catalyse the degradation of phosphodiester bonds in cyclic secondary 
messengers, such as cAMP and cyclic guanine monophosphate (cGMP). 
They are therefore able to regulate both the amplitude and duration of a 
response, as well as spatial regulation, through containment of signalling 
to specified ‘microdomains’, particularly for cAMP-mediated signalling 
(Rich et al, 2001, 2007, Zaccolo and Pozzan, 2002, Terrin et al, 2006, 
Oliveira et al, 2010, Mika et al, 2012). 
 
1.5 GPCR pharmacology 
 
1.5.1 Classification of agonists and their action 
 
Many differing ligands bind GPCRs, inducing conformational changes, 
resulting in the activation of downstream signalling pathways. When a 
ligand brings about this response, it is termed an agonist (Table 1.3). 
Each differing GPCR will only respond to a specific set of agonists, 
serving to give the global GPCR system specificity, thereby preventing 
aberrant signalling. Some receptors will only be activated by a single, 
endogenous, agonist, such as the: adenosine, β2-adrenergic, dopamine, 
glucagon and muscarinic receptors (Table 1.3), whilst others, such as the 
calcitonin-like and opioid receptors can be activated by multiple agonists 
(Table 1.3). To date there are around 150 orphan GPCRs (Davenport et 
al, 2013). Of the GPCRs with known ligands, only ~10% are targeted by 
existing therapeutic drugs (Garland, 2013). 
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Table 1.3: Endogenous GPCR ligands. 
GPCR Endogenous ligand 
Adenosine receptors Adenosine 
β2-adrenergic receptor Adrenaline 
Calcitonin-like receptor CGRP, Adrenomedullin, Adrenomedullin 2 
Dopamine receptors Dopamine 
Glucagon receptor Glucagon 
Muscarinic receptors Acetylcholine 
Opioid receptors Opioids (dynorphins, endorphins, nociceptin) 
 
Regardless of which ligand acts as an agonist at a given GPCR, they will 
fall into one of three classes, based upon their action. Agonists can be 
classified as either: full, partial, or inverse. Both full and partial agonists 
will increase the level of a measured response as the concentration of 
stimulating agonist is increased (dose-dependency) (Figure 1.5). Full 
agonists, will generate the maximal response (Emax), for a given pathway, 
at a given receptor (Figure 1.5). A single GPCR may have multiple full 
agonists. On the other hand, partial agonists will bring about a response, 
but with a lower Emax than that observed for a full agonist (Figure 1.5). In 
contrast, an inverse agonist is one that binds a receptor, resulting in a 
decrease in activity, in a dose-dependent manner (Figure 1.5). 
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Figure 1.5: The different effects of 
ligands acting as agonists. 
  
Agonists can exert differing effects upon 
a GPCR. Activation brought about by a 
full agonist will generate the maximal, 
largest, response observed for that 
receptor (Emax). Partial agonists will still 
result in receptor activation, but the 
maximal response will be lower than that 
observed for a full agonist. Inverse 
agonists, on the other hand, cause a 
receptor with constitutive activity, to 
transit to an inactive state, thereby 
reducing activity at higher agonist 
concentrations. 
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Another measure of how an agonist activates a GPCR is its potency 
(EC50). This essentially displays how ‘well’ an agonist activates a GPCR. 
It is defined as the concentration of drug required to affect half maximal 
response (Figure 1.6). Thus, where a drug induces 100% response, the 
EC50 would be the concentration required to affect a 50% response. Thus, 
agonists may be defined as being more, or less, potent compared to 
others. This is particularly important clinically, where a higher potency 
requires a lower dose of drug to be administered.  
 
 
 
1.5.2 Two-state receptor model 
 
The phenomena whereby agonists can have differing effects, with respect 
to both Emax and EC50, can be explained by the two-state receptor model 
(Kenakin, 2004) (Figure 1.7). This predicts that receptors exist in two 
distinct states: the inactive (R), and the agonist-bound active (R*) states. 
Agonists thus serve to move the equilibrium of the receptor system 
towards the active R* state, whilst inverse agonists reverse this, shifting 
equilibrium towards the R state (Kenakin, 2004), (Figure 1.7). Thereby, it 
can be envisaged that full agonists (Figure 1.5) shift the extent of 
equilibrium further towards a system with full R*, whilst partial agonists 
(Figure 1.5) result in a lesser shift. Potency can also be envisaged as 
how ‘effective’ an agonist is at mediating this transition: those more 
effective being the more potent agonists. 
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Figure 1.6: The concentration at 50% 
of maximal response defines potency. 
  
The potency (EC50) of an agonist is 
defined as the concentration of agonist, 
that affects a response equal to 50% of 
the maximal response observed. 
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1.5.3 Constitutively active receptors 
 
Some receptors spontaneously exist in an R* state, in the absence of a 
stimulating agonist, thus exhibiting constitutive activity. Such receptors 
are inherently able to activate downstream signalling pathways, as was 
first observed for the β2-adrenergic receptor in 1984 (Cerione et al, 1984). 
However, upon agonist binding, their equilibrium is further shifted towards 
the R* state, resulting in an amplification of their signalling output. Such 
receptors exist naturally, but can also arise due to mutation, causing 
constitutively active mutants (CAMs). Naturally occurring CAMs have 
been implicated in pathological states such as hyperthyroidism and 
retinitis pigmentosa (Hwa et al, 1997). Indeed, loss of constitutive activity 
can also lead to a pathological state (Srinivasan et al, 2004). CAM 
GPCRs can also be artificially generated; mimicking the active receptor 
(Ladds et al, 2005a), providing a system whereby the structure of the 
active state can be investigated (Kobilka and Deupi, 2007). 
 
1.5.4 GPCR dimerisation 
 
GPCRs are predominantly considered to exist as distinct monomeric 
units, however some have been show to form higher order oligomers. 
These may be homodimers, such as for the β2-adrenergic receptor 
R" R*"Inverse"agonist"Agonist"
Figure 1.7: Two-state model of receptor activation. 
  
The two-state model of receptor activation predicts that 
receptors exist in one of two states: the inactive (R), and 
the ligand-bound, active (R*) state. Inverse agonists thus 
push the equilibrium towards a predominantly R state, 
whilst agonists shift equilibrium to the R* state. (Adapted 
from Kenakin, 2004) 
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(Lohse, 2010), or heterodimers between two different GPCRs, this being 
observed for both adenosine and dopamine receptors (Franco et al, 
2000). Such dimers have been seen to form due to interactions between 
the TM domains of the different receptors involved (Milligan et al, 2007, 
Rivero-Müller et al, 2013). Dimerisation, or indeed oligomerisation, can 
have various implications for the GPCRs involved. Indeed, it can impact 
upon receptor trafficking from the ER to the cell surface (Reviewed by 
Milligan, 2009), as well as ligand binding and activation, whereby one 
protomer allosterically influences the other (Rozenfeld and Devi, 2010, 
Hill et al, 2014). This can potentially pose challenges for the development 
of novel pharmaceuticals targeting GPCRs that undergo dimerisation. 
 
1.6 Biased agonism of GPCRs 
 
GPCRs regulate, and govern, a complex system of signalling pathways, 
in response to agonist-induced activation. The ultimate outcomes from a 
single GPCR are both varied and diverse. We have seen how agonists 
can have differing effects upon a single signalling pathway. This can 
manifest as full or partial responses (Figure 1.5), and differing potencies 
of the stimulating agonist. Thus, for two agonists of the same receptor, 
activating the same single pathway, two differing magnitudes of response 
can be observed. This is complex enough for some receptors, such as 
the neurotensin receptor, which can only bind and activate a single 
pathway (Gαi in this instance) (Mustain et al, 2011). However, many 
GPCRs express an ability to activate a network of multiple, yet distinct, 
signalling pathways, both G protein-dependent (Figure 1.3) and 
independent (Koole et al, 2010, Weston et al, 2014, 2016, Knight et al, 
2016). It is therefore clear that multiple, diverse responses can occur 
through the activation of a single GPCR. This is further complicated by 
the fact that some receptors bind, and are activated by, multiple 
endogenous ligands (Table 1.3). Thus, a single GPCR can be activated 
by different ligands, which activate multiple signalling pathways to 
differing extents. The difference between these ligands’ ability to activate 
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different pathways is a phenomenon termed: biased agonism, functional 
selectivity, pathway or signalling bias (Figure 1.8). 
 
 
Despite much research into quantifying the extent of pathway bias at 
GPCRs, little is understood about how this phenomenon occurs, at both a 
structural and functional level. Multiple structures have been observed for 
each of the receptors, for which crystal structures have been resolved 
(Wacker et al, 2013, Fenalti et al, 2014). Indeed, differing structures have 
been found for the β2-adrenergic receptor, dependent upon the bound 
ligand (Swaminath et al, 2004, 2005). These different structures, and the 
fact that GPCRs exhibit pathway bias, has lead to the postulation that 
ligands stabilise different receptor conformations, allowing activation of 
specific pathways (Violin et al, 2014), something not accounted for by the 
two state model of receptor activation (Figure 1.7) (Kenakin, 2004). 
GPCR%
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Figure 1.8: Biased agonism results in agonist-induced activation of specific 
pathways. 
  
Activation of a GPCR by a given agonist will, potentially, result in activation of multiple 
downstream signalling pathways. These may also be activated to differing extents. Here, 
the agonist results in receptor-mediated activation of three G protein-dependent 
pathways: Gαs, Gαi, and Gαq. A large response is mediated via Gαs (indicated by a thick, 
bold arrow), resulting in downstream cAMP production. An intermediate Ca2+ response is 
mediated by Gαq activation, whilst a weak Gαi response is also activated (indicated by a 
dotted line). In terms of biased agonism, this agonist would therefore be biased towards 
cAMP production, over all pathways, and biased towards Ca2+ mobilisation over cAMP 
inhibition. 
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A classical example of pathway bias is that of the µ-opioid receptor. This 
receptor plays key roles in our feeling of pain. As such, it is the target of 
many analgesics, perhaps the most well known of which being morphine. 
This brings about its analgesic effects through the activation of Gα12-
mediated signalling (Pradhan et al, 2010, 2012). Chronic dosing of 
morphine however, results in increased tolerance, reducing morphine’s 
efficacy as an analgesic (Dumas and Pollack, 2008). Complications 
further associated with this include: respiratory suppression, constipation 
and addiction (Rawal and Wattwil, 1984, Ammon-Treiber and Höllt, 2005 
Huang et al, 2017). This was shown, by Raehal and colleagues, to be 
due to morphine-induced, µ-opioid receptor-dependent activation of β-
arrestin 2 signalling (Raehal et al, 2005). Thus, pathway bias can have 
direct implications upon drug efficacy and safety. Indeed, drugs have 
subsequently been developed that preferentially activate Gα12-mediated 
signalling, over β-arrestin 2 signalling, at the µ-opioid receptor (Chen et 
al, 2013, DeWire et al, 2013). 
 
1.6.1 Quantifying biased agonism 
 
Qualitative analysis of bias for a ligand between two activating pathways 
can be determined through the comparison of dose-response curves for 
measured responses at each pathway. However, this does not provide a 
quantitative measure of the extent of bias towards one pathway, over the 
other. In order to achieve this, several methods have been developed 
which utilise data obtained via secondary messenger assays (Reviewed 
by Rajagopal et al, 2011).  
 
The most commonly used methods of quantifying biased agonism rely on 
fitting data with the operational model of pharmacological agonism (Black 
and Leff, 1983). This model revolutionised the field of receptor 
pharmacology and hence, signalling bias. The model allows the 
calculation of two parameters that perfectly describe an agonist’s ability to 
activate a receptor, and transduce a signal. These are: Ka, the ligand’s 
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intrinsic affinity for its receptor, and log τ, its intrinsic efficacy. The model 
states that a ligand binds a receptor, with an affinity, Ka, forming a ligand-
receptor (LR) complex (Figure 1.9). This is then able to transduce the 
ligand’s signal with a transduction coefficient, KE (Figure 1.9). The 
efficiency of this signal is thus a function of the number of LR complexes 
formed, and therefore dependent upon the number of free receptors, R, 
available to bind ligand. Hence, the efficacy of a ligand, log τ, is a function 
of the number of LR complexes and KE. Alternatively, log τ is given by [!"]!! . Evaluation of this at steady-state yields:  
 !"#$%&#" = !"#"$ + ! !!"#!!"#"$!∙!!∙[!"#$%&']!!∙! !"#!"#$ !( !"#$%&' !! ")!   Equation 1.1 
 
whereby ‘Response’ is the level of response generated for a given 
concentration of stimulating agonist, ‘Emax’ is the maximal response 
observed upon activation, whilst ‘Basal’ is the level of response observed 
in the absence of an agonist.  
 
 
 
 
Response'
L'
LR'
R'
Ka'
KE'
Figure 1.9: Summary of the operational model of pharmacological 
agonism. 
 
A ligand (L), binds a receptor (R), with an affinity (Ka), forming an active ligand-
receptor (LR) complex. This is then able to transduce a response with a signal 
transduction coefficient (KE).   
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In this model (Equation 1.1), efficacy, τ, and intrinsic affinity, Ka, are 
related to the potency of an agonist (EC50) by the following equation:  
 !"!" = ! !"!!!!   Equation 1.2 
 
Having calculated log τ and Ka, a transduction coefficient can then be 
calculated as the ratio between these two parameters (τ/Ka). Through 
calculating the degree of change in the transduction coefficient (Δ τ/Ka) 
for a given ligand between different signalling pathways, biased agonism 
can be quantified (Figure 1.10) (Baltos et al, 2016, Qin et al, 2017). This 
thesis will specifically investigate, and quantify, the extent of biased 
agonism at 2 family A GPCRs, the adenosine A1 and A2A receptors, as 
well as a family B GPCR, the calcitonin-like receptor (CLR). 
 
 
 
1.7 Adenosine receptors 
 
The adenosine receptors (AR) are a small sub-group of family A GPCRs, 
consisting of four members: The A1R, A2AR, A2BR and the A3R (Fredholm 
et al, 2011). All four of these receptors bind to, and are activated by, the 
purinergic nucleoside, adenosine. They are widely expressed within the 
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Figure 1.10: Quantification of bias for an example agonist activating three signalling pathways. 
 
Representative data obtained from fitting the operational model of pharmacological agonism (Black and Leff, 
1983) to an agonist activating three signalling pathways: A, B and C (A), can be utilised to create a web of bias 
(B) that displays the extent of the agonist’s bias (Δ τ/Ka) to activating each pathway. Here we observe the 
agonist to be heavily biased towards activating pathway B over A and C, whilst being least biased towards 
activating pathway A. 
Δ τ/Ka 
A. B. 
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human body, residing in such tissues as the: lung, colon, brain, liver, 
cardiac tissue, and both the central and peripheral nervous systems 
(Jacobson and Gao, 2006, Cheong et al, 2013). Due to this wide ranging 
pattern of expression, they have been implicated in many human 
diseases including, but not limited to: Alzheimer’s, Parkinson’s, 
Huntington’s, cardiovascular disease, cancer, sleep disorders and 
inflammation (Chen et al, 2007, Fredholm et al, 2005, Dale and Frenguelli 
2009, Sharma et al, 2010, Sachdeva and Gupta, 2013, Allard et al, 
2016). 
 
1.7.1 The adenosine A1 receptor 
 
The adenosine A1 receptor (A1R) is a predominantly Gαi/o-coupled 
receptor, activation of which serves to inhibit the activity of adenylate 
cyclase, thereby lowering cellular cAMP levels. In contrast to this, it has 
also been observed to couple to Gαs, resulting in the production of cAMP 
(Cordeaux et al, 2000 and 2004). Thus, the A1R displays an ability to 
activate two, diametrically opposing, signalling pathways. Indeed, Stewart 
et al managed to show that the A1R mediates cAMP inhibition, via 
specific coupling to Gαi1, Gαi3, Gαo (Stewart et al, 2009). It has further 
been shown to couple to GPA1/Gαz in yeast (Knight et al, 2016). Aside 
from its ability to modulate cAMP levels within a cell, the A1R is also able 
to mediate the mobilisation of intracellular Ca2+ (Dickenson and Hill, 
1993), in a PTX-sensitive manner (Gao and Jacobson, 2016). Thus 
suggesting that A1R-mediated Ca2+ release occurs in a Gαi/o-dependent 
manner. PTX-treatment has also been observed to be efficient in ablating 
A1R-mediated ERK1/2 activation (Gao and Jacobson, 2016, Hussain et 
al, 2007), suggesting that, unlike the β2-adrenergic receptor (Shenoy et 
al, 2006), this occurs in a β-arrestin-independent manner. Interestingly, 
activation of ERK1/2 signalling by the A1R has been seen to be 
cytoprotective in CHO-K1 cells (Baltos et al, 2016). Further, the A1R has 
an ability to modulate the activity of K+ channels, particularly in the 
cardiovascular system (Belardinelli et al, 1995). Due to these signalling 
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properties, activation of the A1R has been found to be, primarily, cardio-
protective. This is particularly true in ischemia-reperfusion, where pre-
treatment with an A1R agonist, prior to reperfusion, has beneficial effects 
(Zhao et al, 1994, Hochhauser et al, 2007). 
 
Due to its effects upon the cardiovascular system, many drugs target the 
A1R. However, with such a diversity of activated pathways, in response to 
a single endogenous ligand (that activates all four ARs), it is unsurprising 
that many pharmaceuticals targeting the A1R fail in clinical trials (Massie 
et al, 2010). In an attempt to address this, several groups have attempted 
to develop agonists that are selective for the A1R, over other ARs 
(Hutchinson et al, 1999, Ashton et al, 2007, Franchetti et al, 2009, Nell 
and Albrecht-Küpper, 2009, Petrelli et al, 2015). Many of the compounds 
developed, that target the A1R, actually fail due to poor patient 
compliance, due to the consumption of caffeine (Robeiro and Sebastiao, 
2010). A large proportion of people drink tea or coffee on a regular basis, 
both of which contain caffeine, an antagonist of the A1R. This binds to 
ARs, as would adenosine, but does not result in activation. Thus, caffeine 
serves to reduce the response observed for a given dose of drug 
targeting ARs. However, there is still a demand for the discovery of 
selective A1R compounds. Indeed, the crystal structure of the A1R has 
identified structural, and conformational, differences between ECL2 of the 
A1R, compared to the A2AR, as well as a wider extracellular cavity and the 
existence of a second ligand-binding pocket (Glukhova et al, 2017). It is 
believed that these differences may govern ligand selectivity for the A1R, 
over the A2AR. 
 
1.7.2 The adenosine A2A receptor 
 
The structure of the adenosine A2A receptor  (A2AR) was the first of the 
ARs to be solved, with structures for both unbound, and ligand-bound 
forms (Lebon et al, 2011, Xu et al, 2011). It is a Gαs-coupled receptor, 
serving to activate adenylate cyclase, thereby elevating cellular levels of 
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cAMP. Unlike the other ARs, the A2AR is well known for having high 
levels of constitutive activity (Ibrisimovic et al, 2012, Bertheleme et al, 
2013). Additionally, in the striatum, A2AR-mediated activation of adenylate 
cyclase has been observed via Gαolf (Kull et al, 2000). However, it has 
also been shown to be able to dimerise with the A1R (Ciruela et al, 2006. 
Ferré et al, 2008), allowing A2AR activation to result in the subsequent 
activation of Gαi/o (Casadó et al, 2010). In addition, the A2AR is also able 
to form heterodimers with: dopamine D2 (Kamiya et al, 2003, Fuxe et al, 
2005) and D3 receptors (Torvinen et al, 2005), cannabinoid CB1 receptor 
(Ferré et al, 2009) and glutamate mGluR5 (Zezula and Freissmuth, 2008), 
as well as forming a CB1R-A2AR-D2R heterotrimer (Marcellino et al, 
2008).  
 
As with other ARs, the A2AR is widely expressed within the human body, 
but is particularly abundant within the striatum and olfactory bulb of the 
CNS (Lynge and Hellsten, 2000), as well as platelets (Dionisotti et al, 
1996), heart, lungs and kidney (Peterfreund et al, 1996). In addition to its 
diverse expression, the A2AR has been implicated in many pathological 
states, and physiological processes including: hypotension, tachycardia, 
inflammation, angiogenesis, immunosuppression and cancer, as well as 
many neurological diseases such as: drug addiction, Huntington’s, 
Parkinson’s and schizophrenia (Shin et al, 2000, Hack and Christie, 2003, 
Sullivan, 2003, Dhalla et al, 2006, Ohta et al, 2006, Morelli et al, 2007, 
Ahmad et al, 2009, Lee and Chern, 2014, Villar-Menéndez et al, 2014, 
Allard et al, 2016). Indeed, due to its importance in human physiology and 
pathology, there have been many ligands developed that show selectivity 
for the A2AR, over other ARs (Ongini et al, 2001, Baraldi et al, 2002, 
2003, Christalli et al, 2003, Weiss et al, 2003). 
 
1.7.3 The adenosine A2B receptor 
 
Of the ARs, the adenosine A2B receptor (A2BR) is, perhaps, the least 
studied and understood (Jacobson, 2009). It couples to Gαs elevating 
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cAMP levels, via adenylate cyclase activation. Coupling to Gαq has also 
been reported (Linden et al, 1999), as has activation of ERK1/2 (Hasakó 
et al, 2009). Unlike the other ARs, the A2BR only appears to be activated 
under high levels of adenosine, available in times of physiological stress 
and pathology (Hasakó et al, 2009). This being particularly true within 
tumours, where A2BR activation has been shown to promote metastasis 
(Desmet et al, 2013, Ntantie et al, 2013, Mittal et al, 2016). A2BR 
activation has also been found to have immunosuppressive effects 
(Hasakó et al, 2009, Morello and Miele, 2014), as well as promoting 
angiogenesis (Sorrentino et al, 2015). Due to these effects, targeting the 
A2BR has so far proved beneficial in mouse models of cancer (Cekic et al, 
2012, Iannone et al, 2013, Wei et al, 2013, Mittal et al, 2016). 
 
1.7.4 The adenosine A3 receptor 
 
The adenosine A3 receptor (A3R) is a Gαi/o-coupled GPCR, activation of 
which results in a lowering of cellular cAMP levels. The A3R has also 
been observed to mediate Ca2+ release (Fossetta et al, 2003) in a PTX-
sensitive, G protein-dependent manner (Shneyvays et al, 2004). In 
addition, ERK1/2 activation can arise from A3R-mediated signalling, also 
in a PTX-sensitive manner (Schulte and Fredholm, 2000, Hammarberg et 
al, 2003). To date there is no known crystal structure of the A3R, 
however, several homology models have been generated (Cheong et al, 
2013). 
 
The A3R has been found to be specifically expressed within the CNS, in 
cell types such as: glial cells (Ochaion et al, 2009), peripheral (Ru et al, 
2011) and central neurons (Zhang et al, 2010), in addition to both the 
brain and spinal cord (Borea et al, 2015, Haeusler et al, 2015). As such it 
has become a target in the treatment of pain. Indeed, agonists targeting 
the A3R have been shown to have analgesic actions (Janes et al, 2016), 
and may provide one method of treating pain without targeting the µ-
opioid receptors. 
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1.8 The calcitonin receptor family 
 
The CLR is a family B GPCR, which, as its name suggests, is closely 
related to the calcitonin receptor (CTR). They both respond to a series of 
peptide hormones, namely: calcitonin (CT, 32 amino acids), amylin (AMY, 
37 amino acids), α and β calcitonin gene-related peptide (CGRP, 37 
amino acids), adrenomedullin (AM, 52 amino acids) and adrenomedullin 
2/Intermedin (AM2/IM, 53 amino acids). All of these ligands share a 
similar secondary structure, consisting of: an amidated C-termius, an α-
helical region, and a N-terminus consisting of a six amino-acid ring 
structure (seven for CT) (Poyner et al, 2002). This homology at the 
secondary structure level is surprising considering that they display low 
homology at the amino acid level (Poyner et al, 2002). Of these agonists, 
all five have been identified as being able to activate the CTR, whilst only 
CGRP, AM and AM2 are able to activate the CLR (Albrandt et al, 1995, 
Armour et al, 1999, Leuthauser et al, 2000, Poyner et al, 2002, Kuwasako 
et al, 2003, 2004, Chang et al, 2004, Roh et al, 2004, Takei et al, 2004, 
Hay et al, 2005, Wunder et al, 2008, Qi et al, 2011, Bailey et al, 2012, 
Gingell et al, 2014). Of those agonists activating the CLR, CGRP and AM 
have been identified as being potent vasodilators, as well as being 
implicated in cardiovascular disease (Woolley and Conner, 2013). CGRP 
has also been observed to play key roles within migraine (Russo, 2015). 
However, to date little is known about the role of AM2 within the body. In 
order for these agonists to exert their effects they need to bind, and 
activate, the CLR, however, unlike all other GPCRs, the CLR is unable to 
traffic to the cell surface on its own. In order for surface expression to be 
achieved the CLR requires association of one of three molecular 
chaperone proteins called receptor activity-modifying proteins (RAMPs) 
(McLatchie et al, 1998). Formation of a RAMP-CLR heterodimer results in 
trafficking to the cell surface and also has implications upon downstream 
signalling observed from the CLR in response to CGRP, AM and AM2. 
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1.9 Receptor activity-modifying proteins 
 
Receptor activity-modifying proteins (RAMPs) were initially identified, by 
Foord and colleagues, in attempts to clone the calcitonin-like receptor 
(CLR) (McLatchie et al, 1998). RAMPs are type 1 single span membrane 
proteins, that exist in three distinct isoforms in humans (although 5 exist 
in Takifugu obscurus (Nag et al, 2006)): RAMP1 (148 amino acids), 
RAMP2 (174 amino acids) and RAMP3 (148 amino acids). All three 
human RAMPs display similar α-helical structures, despite only sharing 
~30% amino acid homology (Udawela et al, 2004).  
 
To date, RAMP expression has been found in nearly all tissues that have 
been studied (McLatchie et al, 1998, Husmann et al, 2000, Sexton et al, 
2001). Particularly high expression has been observed in: the 
cardiovascular system and skeletal muscle, RAMP1 in the pancreas, and 
RAMPs 2 and 3 in the lungs (McLatchie et al, 1998). They have also 
been shown to be expressed in tissues where no known RAMP 
interacting partner has been found, suggesting that they play a crucial 
role in the modulation of GPCR-mediated signalling, and may have, as 
yet, unknown functions. Whilst little is currently known about how RAMP 
levels are regulated, several studies have shown changes in RAMP 
expression within the cardiovascular system in various pathological states 
(Totsune et al, 2000, Cueille et al, 2002, Qi et al, 2003), indicating that 
RAMPs potentially provide one mechanism by which cells are able to 
respond to physiological stress. 
 
1.9.1 RAMP-GPCR interactions 
 
RAMPs were initially identified as interacting with the CLR (McLatchie et 
al, 1998). Since then, much research has been carried out into identifying 
new RAMP-GPCR interactions. Such receptors are predominantly found 
within family B, but interacting receptors have also been identified in 
families A and C. These interactions are summarised in Table 1.4. 
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Table 1.4: Known RAMP interacting GPCRs. 
GPCR Family Interacting RAMP Refs 
GPR30 
 
A 
 
RAMP 3 
 
 
Lenhart et al, 2013, 
Broselid et al, 2014 
 
CLR 
 
B 
 
RAMPs 1, 2 and 3 
 
McLatchie et al, 1998, 
Weston et al, 2016 
 
CTR 
 
B 
 
RAMPs 1, 2 and 3 
 
Poyner et al, 2002, 
Morfis et al, 2008 
 
CRF1R 
 
B 
 
RAMP 2 
 
Wootten et al, 2013 
 
Glucagon 
 
B 
 
RAMP 2 
 
Weston et al, 2014, 
2015 
 
PTH1 
 
B 
 
RAMP 2 
 
Christopoulos et al, 
2003 
 
PTH2 
 
B 
 
RAMP 3 
 
Christopoulos et al, 
2003 
 
Secretin 
 
B 
 
RAMP 3 
 
Harikumar et al, 2009 
 
VPAC1 
 
B 
 
RAMPs 1, 2 and 3 
 
Christopoulos et al, 
2003 
 
VPAC2 
 
B 
 
RAMPs 1, 2 and 3 
 
Wootten et al, 2013 
 
CaSR 
 
C 
 
RAMPs 1 and 3 
 
Huang and Miller, 2007, 
Desi et al, 2014. 
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1.9.2 The role of RAMPs in receptor trafficking and 
internalisation 
 
It was initially identified that RAMPs play roles in receptor glycosylation, 
as well as regulating trafficking to the plasma membrane; indeed, CLR 
can only reach the cell surface in conjunction with RAMPs (McLatchie et 
al, 1998). However, more recently, it has been found that receptors, 
which can be functionally expressed without an associating RAMP, can 
also interact (Poyner et al, 2002, Christopoulos et al, 2003, Morfis et al, 
2008, Harikumar et al, 2009, Wootten et al, 2013, Weston et al, 2014, 
2015). Thus, RAMPs are not absolutely required to allow their GPCR 
partner to be trafficked to the cell surface. However, RAMPs require 
interaction with an associating GPCR for their own expression at the cell 
surface (Sexton et al, 2009). Once a RAMP-GPCR oligomer has formed, 
in the ER/Golgi apparatus, it is thought that they stay associated for the 
life of the receptor (Kuwasako et al, 2000, Hilairet et al, 2001a, 2001b). 
As this is a non-dynamic process, it further shows that RAMPs do not 
exist purely for receptor trafficking or localisation. In addition to roles in 
trafficking, it has also been identified that they may play roles in 
influencing receptor internalisation; however, little is know about this 
process (Kuwasako et al, 2006). 
 
1.9.3 The effects of RAMPs upon receptor pharmacology 
 
One of the most interesting aspects of RAMP-GPCR interactions is that 
they have an ability to modulate the pharmacology of their associated 
GPCR. Indeed, these interactions can have such dramatic effects that 
they form distinct receptor phenotypes, dependent upon the interacting 
RAMP. In some instances, RAMP association can lead to the loss of 
ligand-receptor interaction, for example RAMP2 abolishes GLP-1 
interaction with the GCGR (Weston et al, 2015). RAMPs can also induce 
changes in both: ligand affinity and potency (Reviewed by Hong et al, 
2012), as well as modulating G protein coupling (Udawela et al, 2006a). 
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These effects have been mapped to the individual domains of the 
RAMPs; whereby the N-terminus has implications for ligand binding, with 
the C-terminal domain influencing receptor ‘output’ (Udawela et al, 
2006a). Further, the transmembrane domain has been implicated in 
forming interactions with the GPCR (Udawela et al, 2006b). 
 
All these effects exerted by RAMPs upon GPCRs provide cells with a 
mechanism whereby they can modulate the pharmacology of the 
receptors they express, allowing differing effects to be exerted by one 
receptor subtype. Thus, there is growing interest in the possibility that 
many family B GPCRs may be modulated by RAMPs, and that these 
interactions may alter signalling induced by various ligands, thereby 
further contributing to pathway bias at these receptors. 
 
1.9.4 The effects of RAMP-CLR interactions 
 
The CLR on its own is unable to traffic to the cell surface, and cannot 
bind any known ligand. However, upon association with any of the three 
RAMPs, a functional receptor is formed (McLatchie et al, 1998). This 
association results in the formation of three distinct receptor phenotypes, 
each of which can be activated by CGRP, AM and AM2. Dimerisation 
between RAMP1 and the CLR forms the CGRP receptor (CGRPR); 
RAMP2-CLR, the adrenomedullin (AM1) receptor; and RAMP3-CLR, the 
adrenomedullin 2 (AM2) receptor (Figure 1.11) (McLatchie et al, 1998, 
Poyner et al, 2002). To date, it is not know if these RAMP-CLR 
heterodimers can bind the other calcitonin family peptides, namely CT or 
amylin. 
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All RAMP-CLR dimers display an ability to couple to Gαs, resulting in the 
downstream production of cAMP, in response to either CGRP, AM or 
AM2 (Poyner et al, 2002, Hay et al, 2003, Hong et al, 2012, Weston et al, 
2016). In addition, some evidence exists for a Gαi/o component for the 
CLR-based receptors, when stimulated with CGRP, as indicated by PTX-
sensitivity in several investigations (Kim, 1991, Wiley et al, 1992, Main et 
al, 1998, Disa et al, 2000). This has also been observed for AM 
stimulation (Kuwasako et al, 2010). Despite this evidence, little follow up 
work has been undertaken to confirm signalling via Gαi/o. There is also 
evidence to suggest that RAMP-CLR heteromers can signal via Gαq/11 
(Hay et al, 2003, Dickerson, 2010), as well as activating ERK1/2 (Yu et al, 
2009, Wang et al, 2009), although this has not been fully described.  
 
Study of CLR, and CTR, pharmacology has predominantly utilised a 
subset of the aforementioned ligands against each receptor. However, 
considering the similarity between each of the six ligands, and the 
promiscuity of the ligands at each receptor subset (CTR or CLR-based), it 
would not be surprising if those ligands traditionally associated with CLR-
based receptors would activate the CT receptors, and vice-versa. To 
date, only one study has looked at these ligands upon all receptors; 
however, this only focused upon CT, CGRP, AM and AM2. This identified 
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Figure 1.11: RAMP-CLR heterodimers form distinct receptor 
phenotypes. 
 
The CLR is able to interact with all three RAMPs. RAMP1-CLR forms the 
CGRP receptor, with CGRP being the cognate ligand. RAMP2-CLR 
forms the AM1 receptor, with AM being the cognate ligand. RAMP3-CLR 
forms the AM2 receptor, with AM also being the cognate ligand. 
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that all four ligands were able to bind to, and activate, the CT receptors 
with varying potencies (Hay et al, 2005). 
 
Differing RAMP associations have effects upon CLR pharmacology. The 
predominant effect observed in published literature is that the differing 
RAMPs modulate the potency of CGRP, AM and AM2 upon the CLR, in 
terms of Gαs-mediated signalling (Table 1.5). In the case of the RAMP1-
CLR, CGRP is seen to be the most potent ligand, with AM and AM2 being 
approximately equipotent, thus CGRP is termed the cognate ligand for 
this receptor. Whilst for RAMP2-CLR heteromers, a general rank order of 
potency of AM > AM2 > CGRP, is observed, which is similar to that seen 
with RAMP3. Thus, for RAMP2/3-CLR complexes, AM is the cognate 
ligand. 
 
As can be seen, the RAMPs greatly modulate CLR-mediated signalling. 
However, the above data is all obtained from experiments measuring 
cAMP production. To date, little focus has been paid to other pathways. 
Thus, there is the potential for unexplored bias at these receptors to be 
uncovered: something that this thesis aims to address. An in-depth 
investigation of this nature will allow us to quantify bias, which may 
ultimately aid in the design of drugs targeting specific CLR-activated 
pathways. 
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Table 1.5: pEC50a of the calcitonin peptide family of ligands upon RAMP-
CLR heteromers. 
Ligand 
CLR-based receptor 
RAMP1-CLR1,2-7 RAMP2-CLR1,4,7 RAMP3-CLR1, 2-6 
CT ND ND ND 
Amylin ND ND ND 
αCGRP 9.5-10.1 6.4-7.7 6.8-8.0 
AM 8.0-9.8 8.8-9.9 8.0-9.9 
AM2 8.0-9.1 7.5-8.3 8.7-10.1 
 
a Negative logarithm of agonist concentration producing half-maximal response 
ND – Not determined 
References; 1Hay et al, 2005, 2Qi et al, 2011, 3Roh et al, 2004, 4Takei et al, 2004, 
5Chang et al, 2004, 6Wunder et al, 2008, 7Poyner et al, 2002. 
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1.10 Aims 
 
This work aims to investigate and quantify biased agonism for both 
adenosine receptors, and the calcitonin-like receptor. In terms of 
adenosine receptors, this will focus upon the A1R and A2AR, whilst work 
upon the CLR will focus upon all three RAMP-CLR heteromers. 
 
Work focusing on the adenosine receptors relates directly to projects 
involved in developing novel, selective agonists, to each receptor. With 
this I aim to: 
 
! Quantify the extent of biased agonism for A1R-selective agonists 
! Identify A2AR-selective agonists  
! Quantify biased agonism of A2AR-selective agonists 
 
Work relating to the CLR will aim to investigate the effects of RAMPs 
upon: 
 
! CLR-mediated cAMP production 
! CLR-mediated Gαi/o activation 
! CLR-mediated mobilisation of intracellular Ca2+ and determine its 
underlying mechanism 
! Biased agonism 
 
Investigative work will als be performed to attempt to uncover the role of 
ICL1 in RAMP1-CLR-mediated signalling and activation.  
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Chapter 2 
Materials and Methods 
 
2.1 Materials 
 
2.1.1 General laboratory reagents 
 
All general laboratory reagents were supplied by Sigma-Aldrich (Poole, 
Dorset, UK) and of analytical grade, unless specifically stated. YM-
254890 was supplied by Alpha Laboratories (Hampshire, UK). Ionomycin 
and Rolipram were purchased from Cayman chemicals (Michigan, USA). 
 
2.1.2 Ligands 
 
Human (h) α-CGRP, hAM, hAM2 (1-47) were purchased from Bachem 
(Bubendorf, Switzerland) and dissolved in dH2O to 1 mM, containing 
0.1% bovine serum albumin (BSA). Ionomycin was dissolved in ethanol to 
produce 10 mM stocks. Phorbol 12-myristate 13-acetate and forskolin 
were prepared in dimethyl sulphoxide (DMSO), to 10 mM. 5’-N-
Ethylcarboxamidoadenosine (NECA), adenosine, 2-Chloro-N6-
cyclopentyladenosine (CCPA), and CGS21680 were purchased from 
Tocris Bioscience (Wiltshire, UK) and made to 10 mM in DMSO or dH2O 
(for adenosine). All compounds tested against the A1R (Cmpd prefix) 
were synthesised by Dr. J. Hemmings (University Bern, Switzerland), 
whilst those with a TZQ prefix were purchased from Ambinter (Orleans, 
France), and made to 10 mM stocks in DMSO.  
 
2.1.3 Bacterial strains 
 
Plasmid amplification was performed using DH5α Escherichia coli (E. 
coli) from Stratagene (Cambridge, UK). DH5α genotype: supE44 hsdR17 
endA96 thi-1 relA1 recA1 gyrA96.  
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2.1.4 Growth media 
 
S. cerevisiae strains were routinely grown in either yeast extract (YE) 
media (Table 2.1), or synthetic dropout media lacking uracil (SD-URA) 
(Table 2.2). Plates were prepared as per liquid media with the addition of 
15 g/l select agar. All media were made through dissolving the required 
reagents in reverse osmotically (RO) filtered water, and autoclaved prior 
to first use. 
 
Dulbecco’s modified Eagle’s medium/F-12 (DMEM/F-12) and HAM’s F-12 
were supplied by Life Technologies (Paisely, UK) and supplemented with 
10% heat inactivated fetal bovine serum (FBS), purchased from Sigma-
Aldrich (Poole, Dorset, UK).  
 
 
Table 2.1: Yeast extract media (YE) (per litre). 
Yeast extract 5 g 
Glucose 30 g 
 
 
Table 2.2: Synthetic dropout media (SD) (per litre). 
Yeast nitrogen base (without amino acids) 6.7 g 
Glucose 20 g 
Amino acid mix (Table 2.3) 1.5 g 
Selection amino acid mix (Table 2.4) 0.5 g 
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Table 2.3: Amino acid mix. 
L-alanine 2 g 
L-arginine 2 g 
L-asparagine 2 g 
L-cysteine 2 g 
L-glutamine 2 g 
L-glutamate 2 g 
L-glycine 2 g 
L-isoleucine 2 g 
L-lysine 2 g 
L-phenylalanine 2 g 
L-proline 2 g 
L-serine 2 g 
L-threonine 2 g 
L-tryptophan 2 g 
L-tyrosine 2 g 
L-valine 2 g 
Myo-inositol 2 g 
Para-amino benzoic acid 0.4g 
 
 
 
Table 2.4: Select amino acid mix. 
Adenine 2 g 
L-histidine 2 g 
L-leucine 4 g 
L-methionine 2 g 
 
 
 
 
 
 
Materials and Methods   !
! 40 
 
2.1.5 Saccharomyces cerevisiae strains 
 
Standard nomenclature has been used throughout this thesis to describe 
the genotypes of S. cerevisiae strains used (Table 2.5). Gene deletions 
are denoted gpa1Δ, in the case of deletion of the gpa1 locus. Gene 
replacement is shown as gpa1Δ::ADE2, indicating that gpa1 has been 
deleted and replaced with ADE2. Whilst replacement using G418 
resistance is indicated: ste2::G418R. 
 
In order to utilise S. cerevisiae for the study of GPCR signalling, their 
endogenous GPCR, STE2, is deleted. The gpa1 locus is also deleted, 
preventing expression of GPA1 (the yeast Gα protein). This is then 
replaced with genes encoding yeast-human chimeric G proteins that have 
the final 5 C-terminal amino acids of human Gα proteins transplanted 
onto GPA1 (Brown et al, 2000). To allow measurement of receptor 
activation, the pheromone response gene, fus1, promoter has been 
linked to his3 and lacZ. Thus, receptor activation leads to increased 
expression of his3 (encoding imidazoleglycerol-phosphate dehydratase, 
required for histidine biosynthesis), as well as lacZ, resulting in increased 
expression of β-galactosidase (Brown et al, 2000). Output from this 
system can therefore be measured as growth in media lacking histidine, 
or via a β-galactosidase assay. 
 
To increase output in β-galactosidase assays, cell-cycle arrest in 
response to pheromone has been inhibited via the deletion of far1. far1 
encodes FAR1, a cyclin-dependent kinase interacting protein, which 
leads to cell-cycle arrest (Tyers and Futcher, 1993). In order to further 
increase sensitivity, the gene encoding endogenous RGS proteins 
(SST2) has also been deleted (Brown et al. 2000). 
 
S.cerevisiae are able to undergo mating type switching (between MATa 
and MATα). In order to prevent cells switching to MATα (which express 
another GPCR, STE3), all cells are MATaΔ. To allow selection for cells 
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expressing both the required GPCR, and chimeric G protein, all strains 
have his3, trp1 and ura3 deleted, as well as the gene encoding arginine 
permease (can1), thereby preventing amino acid uptake (Brown et al, 
2000). This allows amino acids to be used as nutritional selectors.  
 
To enable expression of the adenosine A1, A2A or A2B receptors, 
ADORA1, ADORA2A, or ADORA2B, respectively, have been integrated 
at the ura3 loci, utilising p426-GPD (Knight et al, 2016, Appendix 1).  
 
Table 2.5: Saccharomyces cerevisiae strains. 
Strain Genotype Source 
SC13 
MATa his3 leu2 trp1 ura3 can1 gpa1Δ::ADE2 
fus1::FUS1-HIS3 LEU2::FUS1-lacZ far1Δ::ura3Δ 
sst2Δ::ura3Δ ste2Δ::G418R TRP::GPA1/Gαi1/2(5) 
URA3::ADORA1 
Knight et 
al, 2016 
SC217 
MATa his3 leu2 trp1 ura3 can1 gpa1Δ::ADE2 
fus1::FUS1-HIS3 LEU2::FUS1-lacZ far1Δ::ura3Δ 
sst2Δ::ura3Δ ste2Δ::G418R TRP::GPA1/Gαs(5) 
URA3::ADORA2A 
Knight et 
al, 2016 
SC224 
MATa his3 leu2 trp1 ura3 can1 gpa1Δ::ADE2 
fus1::FUS1-HIS3 LEU2::FUS1-lacZ far1Δ::ura3Δ 
sst2Δ::ura3Δ ste2Δ::G418R TRP::GPA1/Gαs(5) 
URA3::ADORA2B 
Knight et 
al, 2016 
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2.1.6 Plasmids and expression vectors  
 
Plasmids and expression vectors used within this thesis are displayed in 
Table 2.6. Whilst CLR ICL1 mutants, pIRES-RAMP1-SNAP-CLR (X), are 
displayed in Table 2.7, where X represents each substitution within the 
table. 
 
Table 2.6: Plasmids used within this thesis. 
Plasmid Source 
pcDNA3.1-GFP S. Allen 
pcDNA3.1-cMyc-CLR-GFP M. Bouvier 
pcDNA3.1-HA-CLR H. Watkins 
pcDNA3.1-A1R cDNA resource centre 
pcDNA3.1-A2AR cDNA resource centre 
pcDNA3.1-FLAG-RAMP1 Wootten et al, 2013 
pcDNA3.1-FLAG-RAMP2 Wootten et al, 2013 
pcDNA3.1-FLAG-RAMP3 Wootten et al, 2013 
pIRES-RAMP1-SNAP-CLR(WT) Heptares therapeutics 
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2.2 Methods 
 
2.2.1 E. coli transformation 
 
Competent DH5α E. coli were transformed by addition of 100-1000 ng 
DNA to 100 µl of cells, kept on ice for 5 minutes, followed by heat shock 
for 2 minutes at 37°C, and then placed on ice for a further 5 minutes. 100 
µl Luria broth (LB) was then added and cells allowed to recover for 30-60 
minutes at 37°C with constant agitation, before growth in liquid LB or on 
LB-agar plates containing either ampicillin (100 mg/ml) or kanamycin (50 
mg/ml), as appropriate. 
 
2.2.2 Plasmid amplification and purification 
 
All plasmids used in this study were prepared through transformation of 
E. coli, followed by growth in 5-100 ml liquid LB cultures containing 
antibiotics, as required, overnight at 37°C with constant agitation. DNA 
was then purified using either a QIAprep maxiprep or miniprep kit 
(Qiagen, Manchester, UK), as per manufacturers protocols, with DNA 
eluted and resuspended in dH2O.  
 
2.2.3 Double stranded DNA sequencing 
 
Prior to first use in experiments, all DNA was sequenced with 
oligonucleotides binding specific regions of the vector to confirm that the 
plasmid contained the correct insert, and that no mutations had been 
introduced. This was performed using Sanger sequencing outsourced to 
either GATC biotech (Constance, Germany) or the Department of 
Biochemistry (University of Cambridge, UK). 
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2.2.4 Saccharomyces cerevisiae culture 
 
All S. cerevisiae stocks were stored at -80°C. Upon first use, an aliquot 
was plated onto the required media, and incubated at 30°C for 16-24 
hours. Cells were then re-streaked onto fresh plates and grown as 
previously. These were then stored at 4°C for up to one week. Prior to 
assay, 10 ml cultures were inoculated in SD-URA media, and grown for 
16 hours, at 30°C with constant agitation. 
 
2.2.5 β-galactosidase assays 
 
S. cerevisiae cells strain expressing adenosine receptors were grown as 
described and β-galactosidase activity determined in a similar manner to 
Hoffman et al (Hoffman et al, 2002). On the day of assay, cultures were 
diluted 1:10 in SD-URA media, and grown for 8 hours. These cultures 
were then further diluted 1:100 and seeded onto 96 wells plates, and 
stimulated with a range of ligand concentrations (100 µM – 10 pM) for 16 
hours, at 30°C. 20 µl of cells were then added to 250 µl Z buffer (Table 
2.8), and incubated at 30°C for 90 minutes. The reaction was then 
terminated by addition of 50 µl 2M Na2CO3. β-galactosidase activity was 
determined using a mithras LB940 plate reader, reading OD430. 
 
Table 2.8: Z-buffer 
Na2HPO4 60 mM 
NaH2PO4 42 mM 
KCl 10 mM 
MgSO4 1 mM 
β-mercaptoethanol 50 mM 
Chloroform 0.5% (v/v) 
SDS 
o-nitophenyl-D-galactopyranoside 
0.005% (w/v) 
0.067% (w/v) 
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In order to account for variable cell number, measurements were also 
taken to determine cell density at OD620. β-galactosidase activity was thus 
calculated as:  !"#$%$#& = !!"!"# − !"!"#!"!"#  
 
2.2.6 Mammalian cell culture and transfection 
 
HEK 293 cells, gifted by Prof. C. Taylor (University of Cambridge, UK), 
were grown in DMEM/F-12 supplemented with 10% FBS, at 37°C in a 
humidified atmosphere containing 5% CO2. CHO-K1 cells, gifted by Dr E. 
St. John Smith (University of Cambridge, UK), were cultured in Ham’s F-
12 nutrient mix, supplemented with 10% FBS, in the same conditions as 
HEK 293 cells. CHO-K1 cells stably expressing the A3R (CHO-A3R) were 
kindly donated by Dr. K-N. Klotz (University of Wuerzburg, Germany), 
and grown as per CHO-K1 cells. 
 
24 hours prior to transfection, cells were seeded onto 24 well plates. All 
cells were transfected with 250 ng total DNA, utilising either Fugene6 
(Roche), or polyethylenimine (PEI), at a 1:3 (w/v) DNA:Fugene/PEI ratio. 
Where required, a 1:1 pcDNA3.1-FLAG-RAMP:pcDNA3.1-cMyc-CLR-
GFP, or pcDNA3.1-HA-CLR, ratio was utilised. Cells were then grown for 
24-48 hours prior to assay and, where appropriate, treated with 200 ng/ml 
pertussis toxin (PTX) 16 hours before assaying, in order to uncouple Gαi/o 
subunits from the GPCRs, through ADP-ribosylation of the C-terminus of 
the G proteins (West et al, 1985). 
 
2.2.7 Generating a CHO-K1 cell line stably expressing the 
A1R 
 
CHO-K1 cells, transfected with pcDNA3.1-A1R, were cultured in 24 well 
plates in Ham’s F-12 nutrient mix, supplemented with 10% FBS, and 800 
µg/ml G418 (Sigma-Aldrich, Dorset, UK), in order to select for transfected 
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cells. G418-containing media was replaced every 48 hours. Wells that 
attained 100% confluency were sub-cultured into 24 well plates, at a ratio 
of 1:4 (Cell suspension: Ham’s F-12 media). Cells were then grown to 
80% confluency and tested for their ability to inhibit forskolin-mediated 
cAMP production, in response to NECA stimulation. Responding cells 
were further cultured in the presence of 800 µg/ml G418, and frozen 
stocks made by gradually freezing to -80°C in FBS + 10% DMSO, before 
being stored in the vapour phase of liquid nitrogen. 
 
2.2.8 cAMP accumulation assays 
 
Transfected cells were brought to single cell suspension using a solution 
of trypsin containing 0.05% EDTA. Cells were then washed with 
phosphate-buffered saline (PBS), followed by resuspension in stimulation 
buffer (PBS containing 0.1% BSA, and either 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX) or 25 µM rolipram). Assays were then performed 
using a LANCE® cAMP detection kit (PerkinElmer, Boston, MA), as per 
manufacturer’s protocol, with 2000 cells per well of a 384-well white 
optiplate (PerkinElmer, Boston, MA), stimulated with a range of ligand 
concentrations (1 pM – 1 mM) for 8 minutes, and cAMP levels measured 
using a Mithras LB 940 multimode microplate reader (Berthold 
technologies, Germany) (excitation: 340 nm, emission: 665 nm). Where 
receptors that couple to Gαi/o (A1R and A3R) were assayed, cells were co-
stimulated with ligand and 10 µM forskolin (to stimulate cAMP 
production), for 30 minutes. All assays were run in conjunction with a 
standard curve and a dose-response curve for forskolin. Where 
appropriate, cells were treated overnight with 200 ng/ml PTX to inhibit 
Gαi/o-mediated signalling. 
 
The LANCE® kit is a time-resolved fluorescence energy transfer (TR-
FRET) immunoassay, that utilises Alexa Fluro® 647-labelled cAMP 
specific antibodies. A complex of biotin-cAMP and europium-labelled 
streptavidin compete with cAMP produced by cells, for binding to this 
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antibody (Figure 2.1). In the absence of free cAMP, excitation at 340 nm 
causes an energy transfer from the biotin-europium complex to the Alexa 
dye, resulting in an emission at 665 nm (Figure 2.1). Thus, in the 
presence of cAMP produced by cells, a reduction in signal intensity at 
665 nm is observed (Figure 2.1). The use of PDE inhibitors in assays 
serves to prevent the breakdown of cAMP, thereby increasing the range 
of signal observed. For assays involving adenosine receptors, rolipram, a 
selective PDE 4 inhibitor, was used, whilst all other assays utilised IBMX, 
a pan-PDE inhibitor.  
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Figure 2.1: LANCE® cAMP accumulation assay. 
  
Alexa Fluro® 647-labelled cAMP specific antibodies compete for binding 
to free cAMP, or a complex of europium (Eu)-labelled streptavadin (SA) 
and biotin-cAMP. Upon excitation at 340 nm, the Eu-SA fluoresces at 615 
nm. In the presence of low intracellular cAMP levels, there is an energy 
transfer from this complex to the Alexa Fluro® 647 antibody, exciting it, 
resulting in a TR-FRET emission at 665 nM. In the presence of high 
intracellular cAMP levels, the Alexa Fluro® 647 binds free cAMP, 
preventing TR-FRET occurring, resulting in a decreased emission at 665 
nm. 
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2.2.9 Intracellular calcium mobilisation assays 
 
Transfected cells were seeded onto a black, clear bottomed, 96 well 
plates and grown for 24 hours, until confluent. The media was then 
removed and cells washed with Hank’s balanced salt solution (HBSS), 
followed by addition of 50 µl of 10 µM Fluo-4/AM (Invitrogen, Paisely, UK) 
containing 2.5 mM probenecid, in order to prevent dye leakage. These 
were then incubated at room temperature for 1 hour, and washed a 
further 3 times in HBSS. Prior to assaying, HBSS was replaced with 100 
µl Ca2+-free HBSS, and the plate transferred to a Mithras LB 940 
multimode microplate reader. Agonist injection occurred robotically and 
fluorescence reading occurred immediately (excitation: 485 nm, emission: 
535 nm) at intervals of 0.5 s for 120 s. Where appropriate, cells were 
either pre-treated with 200 ng/ml PTX for 16-18 hours, or 100 nM YM-
254890 for 30 min, to inhibit either Gαi/o- or Gαq/11-mediated signalling, 
respectively. All assays contained at least a single well that was 
stimulated with 100 µM ionomycin, to account for day-to-day cell 
variability, and differential dye loading between experiments. 
 
2.2.10 ERK1/2 assays 
 
ERK1/2 phosphorylation was measured using a Phospho-ERK1/2 
(Thr202/Tyr 204) kit (Cisbio, Codolet, France). Transfected cells were 
serum starved overnight prior to assaying for ERK1/2 activation, in an 
attempt to lower basal pERK1/2 levels, and gain a larger signalling 
window. These cells were then harvested using trypsin as described, 
followed by the addition of an equal volume of serum-free media. Cells 
were then washed in HBSS, followed by seeding 35,000 cells per well, of 
a white 384-well optiplate (PerkinElmer, Boston, MA). These were then 
stimulated for 5 minutes, with ligands ranging from 1 µM – 1 pM. Cells 
were then lysed using lysis buffer containing Triton™ X-100 (0.25% w/w) 
and sodium orthovanadate (0.25% w/w), for 30 min. Finally, a mixture of 
pERK1/2 d2 and pERK1/2 cryptate antibodies (vol/vol) were added and 
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incubated in the dark for 2 hours, at room temperature. Plates were then 
read using a Mithras LB 940 multimode microplate reader (excitation: 340 
nm, emission: 665 nm and 620 nm). ERK1/2 phosphorylation is then 
expressed as a ratio between the signals observed at 665 nm and 620 
nm. On all assays, a phorbol 12-myristate 13-acetate (PMA) dose-
response curve (100 µM – 100 pM) is also generated to allow for day-to-
day variability of cells. 
 
2.2.11 Molecular and structural analysis of GPCRs 
 
Structures of the GCGR (PDB – 5XEZ (Zhang et al, 2017)) and the GLP-
1R (PDB – 5VEX (Song et al, 2017), 5VAI (Zhang et al, 2017)) were 
analysed using the PyMOL molecular graphics system v1.7.4.5 
(Schrödinger, LLC), whilst structural alignments of ICL1 and helix 8 were 
performed using gpcrdb.org. 
 
2.2.12 Data analysis 
 
Data obtained from all experiments was analysed using GraphPad Prism 
6.0e (San Diego, CA). For cAMP assays, values were converted to cAMP 
concentrations, through interpolation to a standard curve run in parallel to 
the assay. For intracellular calcium mobilisation assays, maximum 
fluorescence intensity was calculated using 5 point smoothing and 
corrected for background fluorescence. Whilst for ERK1/2 assays, 
fluorescence ratios were calculated as described. These values were 
then utilised for construction of concentration-response curves. To allow 
for the stochastic nature of biological systems, all concentration-response 
curves were normalised to either: 100 µM forskolin (cAMP assays), 10 
µM ionomycin (calcium mobilisation assays) or 100 µM PMA (pERK1/2 
assays). All data were fitted using a three-parameter logistic equation 
(Equation 2.1) to obtain pEC50, and Emax values.  
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Equation 2.1: Three-parameter logistic equation ! = !"#"$ + ! (!!"#!!"#"$)!!!!"(!"#!"!"!!)    
 
Equation 2.2: Operational model of pharmacological agonism (Black and 
Leff, 1983) !"#$%&#" = !"#"$ + ! !!"#!!"#"$!∙!!∙[!"#$%&']!!∙! !"#$%&' !( !"#$%&' !! ")!!  
 
Where necessary, the operational model of pharmacological agonism 
(Equation 2.2) (Black and Leff, 1983) was implemented to calculate Log τ 
(efficacy) and the equilibrium dissociation constant (pKa). These were 
then utilised to quantify signalling bias through calculating the 
transduction ratio (τ/Ka). To determine signalling bias, relative to a given 
pathway, the change in transduction ratios for a given pathway was 
calculated relative to a reference pathway (Baltos et al, 2016) (Equation 
2.3). 
 
 Equation 2.3: Relative bias ∆!"# !!" = !"# !!" !"#!!"# − !!"# !!" !"#.!"#!!"#! 
 
To allow for system-dependent effects upon the responses observed, 
values were calculated relative to the cognate ligand (Figueroa et al, 
2009) in each instance (Equation 2.4): CGRP for RAMP1-CLR, AM for 
RAMP2/3-CLR, and NECA for the A1R, or CGS21680 for the A2AR. 
 
 
Equation 2.4: Transduction ratio ∆∆!"# !!! = ∆!"# !!! !"#$%& − !∆!"# !!! !"#$%&'!!"#$%& ! 
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This can then be expressed as a bias factor (Baltos et al, 2016) (Equation 
2.5). 
 
Equation 2.5: Bias factor !"#$!!"#$%& = !10∆∆!"# !!"  
 
Statistical significance was calculated using a: one-way ANOVA with 
either a Bonferroni’s correction, or Dunnet’s post-test; or a Student’s t-
test, as appropriate, p < 0.05 was considered significant.  
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Chapter 3 
Characterising adenosine receptor 
pharmacology 
 
3.1 Introduction  
 
The adenosine receptor (AR) family consists of four distinct receptor 
subtypes, the: A1R, A2AR, A2BR and A3R (Fredholm et al, 2011), all 
belonging to the rhodopsin-like family: family A. Each of the different 
subtypes bind, and respond to, the purinergic nucleoside, adenosine, 
resulting in differing effects upon a cell. The A1R and A3R are both 
predominantly coupled to inhibitory Gαi/o proteins, serving to inhibit the 
activity of adenylate cyclase and subsequently lower intracellular levels of 
cAMP. Opposing the action of these receptors are the A2AR and A2BR, 
which both predominantly couple to Gαs, resulting in increased adenylate 
cyclase activity upon receptor activation. The ARs have been observed to 
be expressed in a wide variety of tissue types including, but not limited to, 
the central and peripheral nervous system, the colon, liver and lungs, as 
well as cardiac tissue (Jacobson and Gao, 2006, Cheong et al, 2013). 
The roles played by all four AR subtypes are as equally diverse as their 
expression patterns, with AR activity being implicated in pathological 
states such as Alzheimer’s, Parkinson’s, Huntington’s and various 
cardiovascular diseases, as well as cancer, sleep disorders and 
inflammation (Fredholm et al, 2005, Chen et al, 2007, Dale and 
Frenguelli, 2009, Sharma et al, 2010, Sachdeva and Gupta, 2013, Allard 
et al, 2016). With the ARs having such a diverse range of expression, and 
playing roles in so many disease states, there is a need to develop 
pharmaceuticals that will allow intervention and potential treatment. In 
order to do this it is necessary to develop compounds that are selective 
for a single AR subtype, and to quantify the extent of pathway bias 
observed by these compounds, in order to be able to produce drugs with 
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reduced side-effects and improved safety profiles. Therefore, the work 
presented in this chapter pertains to the development and 
characterisation of agonists for the A1R and the A2AR. 
 
3.2 Identifying a suitable cell line for investigating 
adenosine receptors 
 
It is essential to perform investigations into AR pharmacology in a system 
that has a null background, with regards to endogenous AR expression. It 
was initially proposed to utilise HEK 293 cells: thus, to test for 
endogenous responses to AR agonists, HEK 293 cells, transfected with 
pcDNA3.1-GFP, were stimulated with NECA (concentrations ranging 100 
µM – 100 pM) and cAMP accumulation measured (Figure 3.1A). This 
indicated that HEK 293 cells endogenously express a receptor(s) that 
leads to the activation of adenylate cyclase, in response to NECA 
stimulation. As a consequence, it was not possible to utilise HEK 293 
cells in experiments pertaining to AR pharmacology. Thus, CHO-K1 cells 
were analysed to determine if they would provide an appropriate, AR-null, 
background. As with HEK 293 cells, pcDNA3.1-GFP-transfected CHO-K1 
cells were stimulated with NECA and cAMP accumulation measured. No 
increase in cAMP, above basal levels, was observed (Figure 3.1B), and 
as such there could be confidence that these cells do not endogenously 
express a functional Gαs-coupled receptor that responds to NECA. It was 
further sought to determine if CHO-K1 cells expressed any functional 
Gαi/o-coupled receptors that may respond to NECA. To achieve this cells 
were co-stimulated with both NECA and 1 µM forskolin. The forskolin 
served to promote cAMP production, via activation of adenylate cyclase, 
which would then be inhibited by NECA, if any Gαi/o-coupled adenosine 
receptors were being expressed. Upon NECA stimulation no reduction in 
intracellular cAMP levels was observed (Figure 3.1B), thus there was 
confidence that there would be no observable endogenous responses in 
assays when stimulating with AR agonists. Hence, all experiments 
pertaining to AR pharmacology were performed using CHO-K1 cells. 
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3.3 Adenosine A1 receptor 
 
The work pertaining to characterising A1R agonists in this chapter initially 
arose due to a collaborative project between Professor M. Lochner 
(University of Bern, Switzerland) and ourselves. The focus of this project 
was to develop novel AR agonists, with an aim to produce agonists 
displaying selectivity for the A1R. This was achieved by utilising the 
structures of NECA and adenosine upon which to design new 
compounds. Novel compounds were then synthesised by creating a 
series of N6-bicyclic and N6-(2-hydroxy)-cyclopentyl derivatives of 
adenosine and NECA (Figure 3.2). A previous PhD student in our 
laboratory screened these compounds in yeast expressing either the A1R 
(SC13, Table 2.5), A2AR (SC217, Table 2.5), or the A2BR (SC224, Table 
2.5). This identified compounds (Cmpds) 20 and 21, to be non-selective, 
acting as agonists against all three ARs tested, whilst Cmpds 5, 6, 16 and 
18 displayed selectivity for the A1R over the other AR subtypes 
investigated (Knight et al, 2016). This work, however, lacked any 
investigation into the action of these compounds upon the A3R as, to 
date, there are no published accounts of the A3R being functionally 
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Figure 3.1: HEK 293 cells endogenously express adenosine receptors, which are absent in 
CHO-K1 cells.  
 
Treatment of HEK 293 cells  with NECA results in elevation of intracellular cAMP (A). CHO-K1 cells 
treated with NECA, or co-stimulated with NECA and 1 µM forskolin, failed to generate a response. 
Data represented as a percentage of the cAMP produced upon treatment with 100 µM forskolin, ± 
SEM, of 3 replicates. 
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expressed in yeast. Thus, in order to characterise the compounds action 
upon this receptor CHO-K1 cells were utilised, that stably express the 
A3R, and cAMP inhibition measured in response to stimulation with 
compounds. Further, it was also sought to investigate the action of 
agonists upon the A1R in mammalian cells; thus, CHO-K1 cells stably 
expressing the A1R were also utilised, again measuring cAMP inhibition. 
This served to give a comparator to which A3R results could be 
compared. These findings were subsequently published in the Journal of 
Medicinal Chemistry (Knight et al, 2016, Appendix 1). Within this chapter, 
data pertaining to the action of these compounds upon the A1R and A3R 
is presented, with respect to their ability to mediate cAMP inhibition. 
Further, a more in-depth, pharmacological characterisation of the action 
of these agonists at the A1R, is provided. 
 
 
 
 
 
 
 
NECA Adenosine CCPA 
Compound 5 Compound 6 Compound 16 
Compound 18 Compound 20 Compound 21 
Figure 3.2: Structures of known adenosine A1R agonists. 
 
Structures for prototypical agonists: NECA, adenosine and CCPA are shown, as well as atypical 
agonists: Compounds 5, 6, 16, 18, 20, 21. Compounds 5, 6, 16 and 18 having formerly displayed 
A1R selectivity at < 1 µM (Knight et al, 2016, Appendix 1). 
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3.3.1 Identifying A1R selectivity, over the A3R 
 
Having previously established the selectivity profiles of the compounds 
between the A1R, A2AR and A2BR in yeast (Knight et al, 2016, Appendix 
1), their efficacy against the A3R was also tested. In order to achieve this, 
CHO-K1 cells stably expressing the A3R, were utilised. In order to 
measure a Gαi/o-mediated response, whereby the activity of adenylate 
cyclase is inhibited, cells first need to be stimulated to produce cAMP. To 
achieve this, cells were stimulated with 1 µM forskolin, in order to activate 
adenylate cyclase, and co-stimulated with each agonist (Figure 3.2) in 
order to identify if it was possible to observe agonist-induced inhibition of 
the forskolin-mediated cAMP production. This identified that all three 
prototypical agonists, NECA, adenosine and CCPA, are agonists of the 
A3R (Figure 3.3, Table 3.1). Of these, NECA and adenosine appeared the 
most potent agonists (pEC50: 9.31±0.2, 8.94±0.2, respectively), with 
CCPA being less potent (pEC50: 7.95±0.1); however, all were full agonists 
(Figure 3.3, Table 3.1). Stimulation with atypical agonists failed to 
generate any response for Cmpds 5, 6, 16 or 18 (Figure 3.3, Table 3.1). 
In contrast, Cmpds 20 and 21 displayed an ability to inhibit forskolin-
stimulated cAMP production, in an A3R-dependent manner, with Cmpd 21 
being equipotent to NECA (pEC50: 8.64±0.1), and Cmpd 20 displaying a 
greatly reduced potency (pEC50: 6.57±0.2) (Figure 3.3, Table 3.1). 
Therefore, this identified that Cmpds 20 and 21 are agonists of the A3R; 
taken in conjunction with our data previously obtained from yeast (Knight 
et al, 2016, Appendix 1), thus 2 non-selective AR agonists (Cmpds 20 
and 21), and 4 A1R-selective agonists (Cmpds 5, 6, 16 and 18) have 
been developed (Knight et al, 2016, Appendix 1). 
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Figure 3.3: Prototypical agonists, Compounds 20 and 21, mediate A3R-dependent 
cAMP inhibition. 
 
CHO-K1, stably expressing the A3R, stimulated with NECA-based compounds (A) and 
adenosine-based compounds (B), display an ability to inhibit cAMP production stimulated 
with 1 µM forskolin, only in response to NECA, adenosine, CCPA, Cmpd 20 and 21. Data 
represented as the percentage cAMP response relative to that observed upon stimulation 
with 1 µM forskolin,  ± SEM, of 5-8 replicates. 
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Table 3.1: Potency (pEC50) and range of response for cAMP inhibition in 
CHO-K1 cells stably expressing the A3R, upon stimulation with 
prototypical and atypical adenosine receptor agonists. 
 
 
 
 
 
 
 
 
 
 
 
 Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Range of response measured as a percentage reduction in response 
obtained for stimulation with 10 µM forskolin. 
NR – No response. 
Statistical difference between each agonist and NECA was calculated 
using a one-way ANOVA with Dunnet’s post-test (**, p < 0.01, ***, p < 
0.001). 
 
In order to investigate the agonistic action of the compounds upon the 
A1R in a mammalian system, the CHO-K1 cells previously identified as 
lacking expression of any functional AR subtypes (Figure 3.1B) were 
utilised. From these a CHO-K1 cell line stably expressing the A1R (CHO-
K1-A1R) was generated, in which cAMP inhibition was subsequently 
measured, using the same method as with CHO-K1-A3R cells. Upon 
stimulation with the prototypical adenosine agonists (NECA, adenosine 
and CCPA), it was possible to observe robust inhibition of forskolin-
mediated cAMP production (Figure 3.4, Table 3.2), with all three agonists 
displaying similar potencies to NECA (pEC50: 9.65 ± 0.2), and all being 
full agonists. In comparison, of the NECA-based compounds (Cmpds 16, 
18, 20 and 21), all were observed to be full agonists, with responses 
ranging from -51.22%±3.8 to -63.75%±3.5 inhibition of 10 µM forskolin-
 pIC50a Rangeb n 
NECA 9.31±0.2*** 44.09±3.0 8 
Adenosine 8.94±0.2*** 38.67±2.5 5 
CCPA 7.95±0.1*** 36.74±2.3 8 
Cmpd 5 NR NR 8 
Cmpd 6 NR NR 6 
Cmpd 16 NR NR 6 
Cmpd 18 NR NR 6 
Cmpd 20 6.57±0.2*** 37.65±4.0 5 
Cmpd 21 8.64±0.1*** 37.87±1.2 5 
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stimulated cAMP production (Figure 3.4A, Table 3.2). However, whilst 
Cmpds 16, 18 and 21 display a reduced potency relative to NECA, Cmpd 
20 is equipotent to NECA (Figure 3.4A, Table 3.2). Fitting the operational 
model of pharmacological agonism (Black and Leff, 1983) to this data 
allows calculation of the intrinsic affinity (pKa) and efficacy (Log τ) for the 
agonists. Analysis of these pKa values identified a similar pattern to the 
observed response range, whereby Cmpd 20 has an equal pKa to NECA, 
in comparison to Cmpds 16, 18 and 21 which all have greatly reduced 
pKa values (Table 3.2). Of the adenosine-based compounds (Cmpds 5 
and 6), it was observed that both are full agonists with a response range 
of -56.03%±6.3 and -68.16%±2.8, respectively (Figure 3.4B, Table 3.2). 
However, Cmpd 5 displays a ~3600 fold reduction in potency relative to 
adenosine, whilst Cmpd 6 displays a ~20 fold reduction, relative to 
adenosine (Figure 3.4B, Table 3.2). This order of potencies again 
matches that observed for pKa values, whereby Cmpd 5 displays a 
greatly reduced pKa, compared to a slight reduction for Cmpd 6 (Table 
3.2). There is also an apparent correlation between Emax (response range 
in this instance) and each agonist’s efficacy (Log τ). This was observed 
for both prototypical and atypical agonists, none of which display any 
statistical difference to NECA, with regards to either response range or 
efficacy (Log τ) (Table 3.2). 
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Figure 3.4: Prototypical and atypical agonists mediate a reduction in intracellular 
cAMP in an A1R-dependent manner. 
 
CHO-K1 cells stably expressing the A1R, stimulated with NECA-based compounds (A) and 
adenosine-based compounds (B), display an ability to inhibit cAMP production stimulated 
with 1 µM forskolin. Data represented as the percentage cAMP response relative to that 
observed upon stimulation with 1 µM forskolin,  ± SEM, of 4 replicates. 
A B 
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3.3.2 A1R agonists promote Gαs-mediated cAMP 
production 
 
Having identified that the A1R agonists are able to activate the canonical 
Gαi/o pathway, and elicit responses whereby the A1R serves to reduce 
intracellular cAMP levels, it was decided to attempt to identify through 
which specific Gαi/o these agonists mediated their responses. In order to 
do this it was planned to transfect CHO-K1-A1R cells with plasmids 
containing PTX insensitive Gαi/o proteins. These cells would then be 
treated with 200 ng/ml PTX, for 16-18 hours, to ADP-ribosylate the C-
termini of Gαi, in order to uncouple them from GPCRs (West et al, 1985). 
This would ablate activity from the endogenous inhibitory pathway, which 
the compounds activate (Figure 3.4, Table 3.2). Following this, cells 
would be stimulated with each prototypical or atypical agonist, and 
inhibition of cAMP accumulation measured, in order to identify specific 
Gαi/o couplings. However, upon performing control experiments with cells 
which had not been transfected with vectors containing the PTX 
insensitive G proteins, it was identified that all agonists were able to 
induce elevations in cAMP above basal levels. From this it was observed 
that none of the compounds displayed any statistical difference to NECA, 
in terms of potency (Figure 3.5, Table 3.3). The same trend was also 
observed for the pKa values obtained for each agonist (Table 3.3). In 
terms of maximal signalling, Cmpds 5 and 18 appear as partial agonists 
(Emax: 36.10%±5.4 and 34.82%±2.4), relative to NECA, with Cmpd 18 
also displaying a reduced efficacy (Figure 3.5, Table 3.3). What was thus 
observed is that the A1R displays an ability to mediate the production of 
cAMP, presumably in a Gαs-dependent manner. This opposing action to 
its canonical Gαi/o pathway is, however, only observed at higher agonist 
concentrations. Indeed, the agonist concentrations required to activate 
this pathway are near identical to those whereby a reduction in inhibition 
of forskolin-mediated cAMP production is observed (Figure 3.5C-D). This 
is particularly apparent for Cmpd 20, when fitted with a biphasic dose-
response curve (Figure 3.5C), where an upward inflection occurs at 
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agonist concentrations >100 nM. This curve has a higher ‘goodness of fit’ 
value, R2, compared to when fitted with the standard 3-parameter logistic 
equation (0.810 vs 0.783, p < 0.001), implying that Cmpd 20, at least, 
does indeed display a biphasic response. For all the other compounds, 
the 3-parameter logistic equation gave a better fit, suggesting that over 
the concentration range which the cAMP inhibition assays were 
performed, the compounds do not show a high enough level of cAMP 
production to show true biphasic responses. At this point it still remains 
unclear whether the production of cAMP occurs at these higher 
concentrations; due to the level of receptor or G protein expression, it is 
indeed possible that at a higher receptor number, other A1Rs, not coupled 
to Gαi/o, are then able to couple to Gαs. It is also feasible that the 
receptors sit in ‘pools’ or micro-domains, whereby individual groups of 
A1R are differentially coupled to differing G proteins, and that the Gαi/o 
‘pool’ is the larger, more dominant, thereby overcoming any response 
mediated via a smaller Gαs-coupled ‘pool’. 
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Figure 3.5: A1R agonists display an ability to elevate intracellular cAMP levels in PTX-
treated cells. 
 
CHO-K1 cells stably expressing the A1R, treated with 200 ng/ml PTX, for 16-18 hours, display 
an ability to produce cAMP when stimulated with NECA-based (A) and adenosine-based 
compounds (B). Data represented relative to cAMP levels observed with 100 µM forskolin, ± 
SEM, of 2-4 replicates. To allow comparison between A1R-mediated cAMP production and Gαi/o 
activation, cAMP inhibition data, fitted with biphasic dose-response curves, is presented for 
NECA-based (C) and adenosine-based compounds (D); this indicates that only Cmpd 20 
displays a truly biphasic response. Data represented as the percentage cAMP response relative 
to that observed upon stimulation with 1 µM forskolin,  ± SEM, of 4 replicates.   
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3.3.3 Intracellular calcium mobilisation at the A1R 
 
In order to investigate the ability of both prototypical and atypical agonists 
to mediate the mobilisation of intracellular Ca2+ (iCa2+), CHO-K1-A1R 
cells, which had been loaded with FLUO-4/AM, were utilised. If agonist 
stimulation results in mobilisation of iCa2+, an increase in fluorescence, at 
506 nm, would be observed, upon Ca2+ binding FLUO-4, when excited at 
494 nm (Gee et al, 2000). In each experiment, stimulation with 100 µM 
ATP was used as a control to confirm both: sufficient loading of the dye, 
and the ability of the cells to mobilise iCa2+. All assays were run in Ca2+-
free HBSS, in order to prevent Ca2+ influx via the opening of cell surface 
calcium channels. 
 
Initially, the prototypical adenosine receptor agonists NECA, adenosine 
and CCPA were tested, with all three displaying an ability to mediate the 
mobilisation of iCa2+, in a dose-dependent manner (Figures 3.6A-C). 
Immediately post-injection, a rapid increase in iCa2+ mobilisation was 
observed (as an increase in fluorescence), for both NECA and 
adenosine, at agonist concentrations ranging 10 nM to 1 µM (Figures 
3.6A-B). For adenosine, no response was observed when cells were 
stimulated with less than 10 nM. However, with NECA, small responses 
were recorded at concentrations as low as 10 pM, but responses were 
seen to be slower than those at higher agonist concentrations (Figure 
3.6A). With CCPA stimulation, rapid iCa2+ mobilisation was observed for 1 
µM, whilst 100 nM and 10 nM generated smaller responses that were 
slower than those observed at 1 µM (Figure 3.6C). 
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Having confirmed the ability of the cells to mobilise iCa2+, in an A1R-
dependent manner, in response to prototypical agonists, the effects of the 
atypical agonists were further investigated. Utilising the same approach 
as with the prototypical agonists, it was observed that all 6 compounds 
being tested were able to elevate iCa2+ (Figure 3.6D-I). For all 
compounds, a rapid increase in fluorescence upon agonist stimulation 
was evident, except for Cmpd 20, which generated a slower increase 
compared to the others (Figure 3.6D-I). Stimulation with 100 nM also 
resulted in rapid increases in iCa2+ mobilisation for all compounds, with 
the exception of Cmpd 20 (Figure 3.6D-I), whilst 10 nM generated a 
slower response, except for Cmpd 18, which elicited a response as rapid 
as those seen at 1 µM and 100 nM (Figure 3.6D-I). At concentrations 
below 10 nM, only Cmpds 18 and 21 were able to generate a response, 
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Figure 3.6: A1R agonists display an ability to mobilise iCa2+ in CHO-K1 cells. 
 
CHO-K1 cells stably expressing the A1R, loaded with FLUO-4/AM in Ca2+-free HBSS, were stimulated with 
both NECA-based (A) and adenosine-based (B) compounds, identifying that all agonists are able to lead to 
mobilisation of iCa2+. Data shown as the fluorescence relative to that prior to agonist injection, with the dotted 
line indicated point of agonist injection. Traces representative of the average response obtained from 3-5 
replicates. 
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which occurs at 1 nM, with no compound displaying agonistic activity at 
<10 pM (Figure 3.6D-I). 
 
It is clear that each of the compounds tested display an ability to mobilise 
iCa2+. However, to characterise this pharmacologically, the calcium traces 
obtained (Figure 3.6) were converted to dose-response curves in order to 
allow calculation of pEC50 and Emax. In order to account for the variability 
of cells on differing days, and subsequently differing passage numbers, 
as well as differential dye loading between experiments, this data is 
required to be presented relative to a control agonist. Thus, 100 µM ATP 
was utilised as a control, to which all data was normalised. The response 
of each different agonist concentration, at the time point when 1 µM 
generated the maximal response, was then plotted as a dose-response 
curve (Figure 3.7). This identified that, of the prototypical agonists, NECA 
and adenosine are the most potent mediators of iCa2+ mobilisation 
(pEC50: 8.20±0.1 and 8.08±0.1, respectively) with both being full agonists 
(Emax: 102.6%±3.0 and 99.38%±3.5, respectively) (Figure 3.7, Table 3.4). 
These observations regarding NECA’s ability to mediate mobilisation of 
iCa2+ closely match previously reported data, obtained from CHO cells 
(Gao and Jacobson, 2016). Interestingly, in comparison to cAMP data 
(Figures 3.4 and 3.5, Tables 3.2 and 3.3), CCPA is greatly reduced in 
potency, relative to both NECA and adenosine (pEC50: 6.94±0.1), and is 
also observed to be a partial agonist (Emax: 79.02%±6.4) (Figure 3.7, 
Table 3.4). Indeed, CCPA is one of the least potent mediators of iCa2+ 
mobilisation, as is Cmpd 20 (pEC50: 6.65±0.2), which is also a partial 
agonist (Emax: 68.84%±9.0) (Figure 3.7, Table 3.4). 
 
Of the atypical agonists, only Cmpds 18 and 21 are as equally potent as 
NECA (pEC50: 8.03±0.1 and 7.92±0.1, respectively); however, Cmpd 18 is 
a partial agonist (Emax: 67.02%±2.4), whilst Cmpd 21 is a full agonist 
(Emax: 96.13%±5.7) (Figure 3.7A, Table 3.4). Cmpd 16 is also observed to 
be a full agonist (Emax: 99.61%±6.1), but displays a ~15 fold reduction in 
potency, compared to NECA (pEC50: 7.02±0.1) (Figure 3.7A, Table 3.4). 
Of the adenosine-based compounds (Cmpds 5 and 6), both are full 
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agonists (Emax: 88.79%±4.8 and 97.95%±2.9, respectively) with reduced 
potencies relative to NECA (pEC50: 7.60±0.1 and 7.36±0.1, respectively) 
(Figure 3.7B, Table 3.4). It is interesting to note, that in contrast to data 
pertaining to the effects of the agonists upon cAMP production, there is 
no correlation between pKa and Log τ, to potency and Emax (Table 3.4). In 
terms of pKa, none of the agonists display any statistical difference to 
NECA, whilst for Log τ, only Cmpd 18 displays any reduction (Table 3.4).  
 
It has thus been observed that the A1R is able to mediate mobilisation of 
iCa2+ in response to the cognate agonist, adenosine, as well as NECA 
and the synthetic A1R selective agonist, CCPA. It has also been identified 
that by utilising NECA and adenosine as scaffolds, upon which to design 
new A1R agonists, each agonist still displays an ability to bring about the 
mobilisation of iCa2+. Some of the developed compounds displayed 
responses similar to NECA, such as Cmpd 21, whereas others were less 
potent than NECA, but still full agonists, in the case of Cmpds 5, 6, and 
16. Some compounds have also been produced that are equipotent to 
NECA but are partial agonists, such as Cmpd 18.  
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Figure 3.7: A1R agonists display differential efficacies when mobilising iCa2+. 
 
Calcium trace data (Figure 3.5) was converted to dose-response curves by plotting the value of 
each concentration, at the time point that gives the maximal response at 1 µM of agonist. Data 
represented as the percentage of the maximal response observed with 100 µM ATP, ± SEM, of 
3-5 replicates. 
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3.3.4 ERK1/2 activation by the A1R 
 
In order to measure the ability of both the prototypical and atypical 
agonists to mediate the activation of ERK1/2, CHO-K1-A1R cells were 
serum-starved overnight in an attempt to reduce basal levels of ERK 
phosphorylation, potentially brought about by the action of growth factors 
within the growth media which these cells were cultured in. Through 
measuring the total amount of phospho-ERK generated in response to 
agonist stimulation, it was observed that of the prototypical agonists 
(NECA, adenosine and CCPA), all are full, potent agonists with a pEC50 
of ~8.6 (Figure 3.8, Table 3.5). In comparison, of the atypical agonists, 
only Cmpds 6 and 21 display equipotency to NECA (pEC50: 8.70±0.3 and 
8.27±0.2, respectively), however both are partial agonists (Emax: 
23.05%±1.5 and 21.02%±1.5, respectively) (Figure 3.8, Table 3.5). In 
contrast, one agonist, Cmpd 20, displays a ~6.5 fold increase in potency, 
relative to NECA, but is also a partial agonist (Emax: 17.32%±1.3) (Figure 
3.8A, Table 3.5). Of the remaining atypical agonists, all display a reduced 
potency, relative to NECA, and all are partials, except Cmpd 16, which is 
a full agonist (Emax: 52.99%±4.1) (Figure 3.8, Table 3.5). Thus, a rank 
order of potency for all agonists of Cmpd 20 > CCPA = Adenosine = 
NECA > Cmpd 6 > Cmpd 21 > Cmpd 18 = Cmpd 16 > Cmpd 5 was 
observed (Figure 3.8, Table 3.5). As with other assay data in this thesis, 
there was a strong correlation between Emax and the efficacy (Log τ) for 
each agonist; however, only Cmpd 5 displays a reduced pKa, whilst 
Cmpd 20 displays an increased pKa, relative to NECA (Table 3.5). 
Therefore, by changing the various functional groups of NECA and 
adenosine on the atypical agonist, it has been possible to produce a 
series of compounds that are partial agonists, in terms of ERK1/2 
activation, and one, Cmpd 16, which is a full agonist (Figure 3.8, Table 
3.5). 
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Figure 3.8: A1R agonists display an ability to activate ERK1/2 in CHO-K1 cells. 
 
Serum-starved CHO-K1 cells, stably expressing the A1R, were stimulated with both NECA-
based (A) and adenosine-based (B) compounds, identifying that all agonists are able to 
result in phosphorylation of ERK1/2. Data represented as the percentage of the maximal 
response observed with 100 µM PMA stimulation, ± SEM, of 3-5 replicates. 
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3.3.5 Quantifying biased agonism at the A1R 
 
This work has identified that the A1R is able to activate its canonical 
signalling pathway: activation of Gαi/o, bringing about an inhibition of the 
activity of adenylate cyclase, serving to lower intracellular cAMP levels 
(Figure 3.4, Table 3.2). Further, the A1R has been observed to mediate: 
the activation of a pathway leading to stimulation of adenylate cyclase, 
thereby elevating intracellular cAMP, presumably in a Gαs–dependent 
manner (Figure 3.5, Table 3.3), as well as the ability to mobilise iCa2+ 
(Figures 3.6 and 3.7, Table 3.4) and activate ERK1/2 (Figure 3.8, Table 
3.5). All of the agonists tested in this chapter, both prototypical and 
atypical, were able to activate these pathways to differing extents. There 
is, therefore, a degree of inherent biased agonism at the A1R. In order to 
quantify this, all data was fitted with the operational model of 
pharmacological agonism (Black and Leff, 1983), and transduction 
coefficients (Log τ/Ka) calculated. These were then analysed for the 
degree of change between each differing pathway (Δ τ/Ka), for each 
agonist studied (Figure 3.9). This identified that all agonists are more 
biased towards the inhibition of cAMP production, than its stimulation, 
with Cmpd 18 exhibiting only a slight bias towards inhibition. Of all 
agonists, it is the natural cognate agonist, adenosine, which displays the 
greatest extent of bias towards the canonical, inhibitory pathway (Figure 
3.9). Cmpd 21 displays the greatest extent of bias towards the 
mobilisation of iCa2+ (Figure 3.9). In terms of ERK1/2 activation bias, 
CCPA is most heavily biased agonist towards this pathway, being as 
equally biased towards the inhibition of cAMP production (Figure 3.9). It is 
interesting to observe that the pathway opposing the canonical Gαi/o 
pathway, cAMP production, is the one to which all agonists display the 
lowest level of bias towards (Figure 3.9).  
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It is also possible to quantitate bias relative to a reference ligand (ΔΔ 
τ/Ka), NECA in this instance. This serves to present the quantification of 
bias in a system-independent manner, which should be translatable to 
other systems (Kenakin et al, 2012). Through calculating relative bias, 
NECA is perceived to display no bias towards any of the four pathways 
studied (Figure 3.10), thus the extent of bias for other agonists is now 
apparent, relative to NECA. This indicates that adenosine is more biased 
towards the: inhibition of cAMP, mobilisation of iCa2+, and ERK1/2 
activation than NECA. CCPA is more biased towards ERK1/2 activation 
than NECA, more so than any of the other agonists studied (Figure 3.10). 
However, CCPA is also less biased towards the mobilisation of iCa2+, but 
is equally biased towards both cAMP production and inhibition (Figure 
0.1!1!
10!100!
1000!10000!
NECA 
Adenosine 
CCPA 
Cmpd 5 
Cmpd 6 Cmpd 16 
Cmpd 18 
Cmpd 20 
Cmpd 21 
cAMP inhibition cAMP production Calcium mobilisation pERK 1/2 
Δ τ/Ka 
Figure 3.9: Pathway bias plot (Δ τ/Ka) for prototypical and atypical A1R 
agonists. 
 
Quantification of pathway bias (Δ τ/Ka) between: cAMP inhibition, cAMP 
production, iCa2+ mobilisation and ERK1/2 activation, for both prototypical and 
atypical A1R agonists. Bias is shown relative to the ability of each agonist to 
stimulate cAMP production. 
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3.10). Cmpd 5 displays a greater relative bias towards iCa2+ mobilisation, 
but also displays a greatly reduced bias towards the inhibition of cAMP 
production, relative to NECA (Figure 3.10). Indeed, all of the atypical 
agonists are least biased towards signalling via Gαi/o, over any other 
pathway, relative to NECA, except for Cmpd 20 (Figure 3.10). Cmpd 6 is 
as equally biased as NECA towards the activation of ERK1/2 and the 
production of cAMP, whilst being slightly less biased towards iCa2+ 
mobilisation and cAMP inhibition, with Cmpd 16 displaying a similar 
pattern of bias (Figure 3.10). Cmpd 18 is the only agonist that displays 
relative bias toward the production of cAMP over all other pathways, it 
being equivalent to NECA, whilst being less biased towards ERK1/2 
activation and cAMP inhibition than NECA (Figure 3.10). Cmpd 20 
appears equally biased as NECA towards both the inhibition and 
production of cAMP production, whilst also displaying a slightly greater 
level of bias towards ERK1/2 activation, and also displaying a much lower 
level of bias towards iCa2+ mobilisation (Figure 3.10). Cmpd 21 is more 
biased toward iCa2+ signalling and ERK1/2 activation than NECA, as well 
as being less biased than NECA towards the inhibition of cAMP 
production, as with all atypical agonists (barring Cmpd 20) (Figure 3.10). 
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Figure 3.10: Relative bias plot (ΔΔ τ/Ka) for both prototypical and atypical 
A1R agonists. 
 
Quantification of relative pathway bias (ΔΔ τ/Ka) between: cAMP inhibition, 
cAMP production, iCa2+ mobilisation and ERK1/2 activation, for both prototypical 
and atypical A1R agonists. Bias is shown relative to a reference pathway (cAMP 
production) and the reference agonist (NECA). 
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3.4 Adenosine A2A receptor 
 
The work in the following sections of this chapter pertains to a 
collaborative project between Leen Kalash, a member of Dr. A. Bender’s 
research group (University of Cambridge, UK), and ourselves. In this 
project, Dr. Bender’s group were searching for multi-target, dual A2AR 
agonists and phosphodiesterase (PDE) 10A inhibitors. The rationale for 
this is that agonism of the A2AR will promote cAMP production, in a Gαs-
dependent manner, whilst inhibition of PDE10A will prevent the 
subsequent breakdown of cAMP by the cell. They utilised an in silico 
approach to identify compounds that fit these criteria. This identified a 
series of known PDE10A inhibitors, triazoloquinazolines (Kehler et al, 
2011), which displayed suitable docking scores to the A2AR. We then 
sought to pharmacologically validate these results, and characterise the 
identified compounds in vitro. In order to maintain integrity of this 
validation of the in silico findings all work was performed while blinded as 
to the structures of the compounds.  
 
3.4.1 Identifying novel A2AR selective agonists 
 
In order to confirm the in silico results obtained by our collaborators, it 
was required to confirm two points: 1) the compounds are agonists of the 
A2AR, and 2) the compounds are selective for the A2AR over other ARs. In 
order to achieve this, the GlaxoSmithKline yeast-screening platform 
(Brown et al, 2000) was initially utilised. The advantage of this model over 
immortalised mammalian cells is that yeast provides a cheap and fast 
growing organism to culture. They can be readily grown in cheap media, 
and are easy to genetically manipulate. A major advantage for the study 
of GPCRs is that they provide a ‘clean’ background upon which to study a 
GPCR of interest, with limited ‘cross talk’ between signalling pathways 
(Ladds et al, 2005b). The main advantage of this limited interplay is that 
one pathway can be manipulated, to study a drug of interest, without the 
other modulating the observed response. In contrast, mammalian cells 
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display a complex network of interconnected signalling pathways, 
providing great difficulty in elucidating the effect of an agonist upon a 
specific pathway. They also provide a system whereby agonist selectivity 
can rapidly be assessed, as each constructed strain will only express a 
single GPCR subtype. 
 
Human GPCRs can be transformed into yeast cells, expressing chimeric 
yeast-human G proteins. These chimeras consist of the yeast homologue 
of Gα, GPA1, with the final 5 C-terminal amino acids being replaced with 
those of each individual human Gα subunit (GPA1/Gα) (Brown et al, 
2000). This is sufficient to allow the chimeric G protein to interact with the 
GPCR. Upon receptor activation, GPA1/Gα is able to mediate the 
activation of the yeast mating response gene, FUS1 (Brown et al, 2000). 
The promoter of FUS1 is linked to LacZ (Brown et al, 2000), allowing 
GPCR activation to be measured via conventional β-galactosidase 
assays. This system was previously utilised to investigate the A1R, A2AR 
and A2BR (Knight et al, 2016, Appendix 1). Here, this system is again 
utilised for the screening of test triazoloquinazoline compounds, identified 
from our collaborators’ in silico screen. 
 
NECA and test triazoloquinazoline compounds 1-5 (TZQ 1-5) were 
applied to yeast cells expressing the: A1R and GPA1/Gαi1/2 (SC13, Table 
2.5), A2AR and GPA1/Gαs (SC13, Table 2.5), or the A2BR and GPA1/Gαs 
(SC224, Table 2.5). β-galactosidase activity was measured to determine 
agonistic activity, as well as selectivity for the A2AR (Figure 3.11). Initially, 
the ability of NECA to activate each AR in the yeast strains was tested. 
NECA stimulation of yeast expressing the A1R resulted in a potent 
response (pEC50 5.87±0.1), as did stimulation of the A2AR (pEC50: 
5.50±0.2) (Figure 3.11A, Table 3.6). In contrast, NECA-mediated 
activation of the A2BR generated a weak response (pEC50: 4.14±0.1) 
(Figure 3.11A, Table 3.6), which is consistent with previous studies using 
this strain (Knight et al, 2016, Appendix 1).  
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Upon stimulating the yeast strains expressing the three ARs with TZQ 1, 
it was only possible to observe a response at the A2AR. This identified 
TZQ 1 to be slightly less potent than NECA (pEC50: 5.4±0.3), as well as 
being a partial agonist (Emax: 63.68%±6.5) (Figure 3.11B, Table 3.6). 
Testing the actions of TZQs 2 and 3 also identified that these compounds 
only acted as agonists upon the A2AR, with TZQ 2 displaying an 
increased potency (pEC50: 5.98±0.4) relative to NECA, and TZQ 3 being 
equipotent to NECA (Figure 3.11C-D, Table 3.6). As with TZQ 1, TZQs 2 
and 3 were observed to be partial agonists, with TZQ 3 generating the 
smallest response (Emax: 45.90%±8.3) (Figure 3.11C-D, Table 3.6) 
 
Contrasting with TZQ 1-3, TZQ 4 displayed an ability to act as an agonist 
of all three ARs under investigation, being most potent upon the A2AR 
(pEC50: 6.14±0.5) (Figure 3.11E, Table 3.6). A rank order of potency, 
between the three receptors, of A2AR > A1R > A2BR was observed; 
however, like TZQ 1-3, TZQ 4 was also a partial agonist of all three 
receptors (Figure 3.11E, Table 3.6). Upon testing TZQ 5 against each 
AR, only limited activity was observed, with the largest response being 
observed through activation of the A1R (Emax: 12.94%±3.9); however, 
TZQ 5 was identified as being more potent than NECA at both the A1R 
and A2AR (pEC50: 7.39±1.2 and 8.20±0.8, respectively) (Figure 3.11F, 
Table 3.6). This data thus confirms that TZQ 1-5 are agonists of the A2AR, 
whilst TZQ 1-3 display no efficacy at the A1R or A2BR. TZQ 1-3 are, 
therefore, selective agonists for the A2AR over the A1R and A2BR.  
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Figure 3.11: Triazoloquinazolines display agonistic activity against adenosine receptors in 
yeast. 
 
Dose-response curves for NECA and TZQ 1-5 were constructed in yeast strains expressing either 
the: A1R and GPA1/Gαi1/2, A2AR and GPA1/Gαs, or A2BR with GPA1/Gαs. Reporter gene activity was 
determined using β-galactosidase assays, following 16 hour stimulation with either: NECA (A), TZQ 
1 (B), TZQ 2 (C), TZQ 3 (D), TZQ 4 (E) or TZQ 5 (F). All data represented as the percentage 
response relative to NECA stimulation for each given receptor, ± SEM, of 5 replicates. 
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In order to determine if TZQ 1-3 are wholly selective for the A2AR over all 
AR subtypes, it was required to test for activity against the A3R. However, 
to date, no reports of successful expression of functional A3R in yeast 
have been published. Thus, in order to test the A3R, CHO-K1 cells stably 
expressing the human A3R were utilised, and each compound tested for 
its ability to inhibit 1 µM forskolin-mediated cAMP production. Upon 
stimulation with NECA, it was possible to observe a reduction in forskolin-
mediated cAMP production of 34.35%±2.2, with a pEC50 of 9.75±0.1 
(Figure 3.12, Table 3.7). When stimulated with the triazoloquinazoline 
compounds, no inhibition was observed for TZQs 1, 2, 3 or 5; however, 
TZQ 4 displayed agonistic activity, with a pEC50 of 9.45±0.2 and a 
16.59%±1.1 inhibition of forskolin-mediated cAMP production (Figure 
3.12, Table 3.7). 
 
From the experiments performed in yeast upon the A1R, A2AR and A2BR, 
and in CHO-K1 cells upon the A3R, it is possible to confirm that all five 
triazoloquinazolines are A2AR agonists; TZQ 4 and 5 are also A1R and 
A2BR agonists, with TZQ 4 also being an agonist of the A3R. Thus, this 
work identified one non-selective AR agonist (TZQ 4), one that is 
selective for the A1, A2A and A2B receptors over the A3R (TZQ 5), and 
three (TZQ 1-3) that are selective for the A2AR over all other AR 
subtypes. 
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Figure 3.12: Triazoloquinazolines display 
limited agonistic activity at the A3R. 
 
CHO-K1 cells stably expressing the A3R were 
co-stimulated with 1 µM forskolin, to promote 
cAMP production, as well as either NECA or 
TZQ 1-5. Data represented as the percentage 
response relative to 100 µM forskolin, ± SEM, 
of 5 replicates. 
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Table 3.7: Potency (pEC50) and range of response for cAMP inhibition in 
CHO-K1 cells stably expressing the A3R, upon stimulation with NECA 
and TZQ 1-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Range of response measured as a percentage reduction in response 
obtained for stimulation with 10 µM forskolin. 
NR – No response. 
Statistical difference between each agonist and NECA was calculated 
using a one-way ANOVA with Dunnet’s post-test (**, p < 0.01). 
 
3.4.2 Triazoloquinazolines as A2AR agonists in mammalian 
cells 
 
Having confirmed the activity of the triazoloquinazolines upon the A2AR in 
yeast, these findings were further validated in mammalian cells. In order 
to do this, CHO-K1 cells were utilised, due to their lack of an endogenous 
response to the non-selective adenosine agonist, NECA (Figure 3.1). In 
order to achieve this, cells were transfected with pcDNA3.1-A2AR and 
stimulated with a selective A2AR agonist, CGS21680, as a reference 
ligand, as well as with each triazoloquinazoline. The data obtained for 
CGS21680 however, resulted in a more linear relationship than the fitting 
of a dose-response curve suggests (Figure 3.1.3); this is potentially a 
result of averaging each data point before fitting a dose-response curve, 
rather than creating an average of each curve for each individual 
replicate. Upon stimulation with each TZQ compound it was apparent that 
each are indeed A2AR agonists, except TZQ 5, which displayed no activity 
 pEC50
a Range n 
NECA 9.75±0.1 -34.35±2.2** 5 
TZQ 1 NR NR 5 
TZQ 2 NR NR 5 
TZQ 3 NR NR 5 
TZQ 4 9.45±0.2**** -16.59±1.1** 5 
TZQ 5 NR NR 5 
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up to 1 µM (Figure 3.13, Table 3.8). As TZQ 5 showed a very limited 
response in yeast (Figure 3.11F, Table 3.6), and none in CHO-K1 cells, it 
presumably suggests that the small response observed (only at 1 µM) in 
yeast is more of an effect of stochastic noise, rather than true agonistic 
activity. For TZQ 1-4, it was apparent that all responses are more potent 
in CHO-K1 cells than in yeast, by ~3-150 fold (Figure 3.13 and 3.11, 
Table 3.6 and 3.8). Of the selective TZQ compounds, it was identified that 
TZQ 1 and 2 are the most potent (pEC50: 7.60±0.2 and 7.21±0.4, 
respectively), with TZQ 3 displaying a reduced potency (pEC50: 6.35±0.5) 
(Figure 3.13, Table 3.8). All of these compounds are less potent than the 
known A2AR agonist, CGS21680 (pEC50: 9.16±0.2), with TZQ 4 displaying 
the smallest reduction (pEC50: 8.73±0.8) (Figure 3.13, Table 3.8). In terms 
of maximal signalling, all TZQ compounds are partial agonists relative to 
CGS21680, with TZQ 1 generating the largest response (Emax: 
73.23%±6.7) (Figure 3.13, Table 3.8). Analysis of the efficacy (Log τ) and 
pKa values obtained through fitting the operational model of 
pharmacological agonism (Black and Leff, 1983) to cAMP data appears 
to display correlations between Emax and Log τ, as well as pEC50 and pKa. 
However, whilst pKa and Log τ appear to be reduced relative to 
CGS21680, this only seems to be statistically significant for the pKa of 
TZQ 3. By testing the triazoloquinazolines in mammalian CHO-K1 cells, it 
was possible confirm the findings in yeast, and confirm that the 
compounds are indeed agonists of the A2AR.  
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CGS21680 Figure 3.13: Triazoloquinazolines display 
agonistic activity at the A2AR. 
 
CHO-K1 cells transfected with pcDNA3.1-A2AR 
were stimulated with either CGS21680 or TZQ 
1-5, and cAMP accumulation measured. Data 
represented as the percentage response 
relative to 1 µM CGS21680 stimulation, ± 
SEM, of 5 replicates. 
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3.4.3 ERK1/2 activation at the A2AR 
 
In order to investigate if the A2AR agonists are able to mediate activation 
of ERK1/2 in an A2AR-dependent manner, CHO-K1 cells transfected with 
pcDNA3.1-A2AR were again utilised. These were serum-starved overnight 
to reduce basal ERK1/2 phosphorylation, followed by stimulation with 
either CGS21680 or TZQ 1-5. This identified that each agonist is able to 
promote ERK1/2 phosphorylation, except TZQ 5 (Figure 3.14, Table 3.9). 
It was observed that CGS21680 is the most potent activator of ERK1/2 
signalling (pEC50: 9.06±0.2), with TZQ 1, 2 and 4 displaying pEC50s in the 
nM range (8.14±0.3, 8.55±0.2, and 8.53±0.2, respectively) (Figure 3.14, 
Table 3.9). In comparison to CGS21680, it was also observed that TZQ 1, 
2 and 4 are partial agonists, with TZQ 2 generating the largest response 
(Emax: 76.65%±3.8) (Figure 3.14, Table 3.9). Whilst TZQ 3 displayed an 
ability to promote ERK1/2 activation, in an A2AR-dependent manner, this 
was only observed with agonist concentrations in the µM range (Figure 
3.14, Table 3.9). Thus, it was not possible to fit a full dose-response 
curve to the data for TZQ 3. This work has thus identified that all of the 
TZQ compounds are able to mediate ERK1/2 activation to differing 
extents. 
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Figure 3.14: Triazoloquinazolines activate 
ERK1/2 signalling in an A2AR-dependent 
manner. 
 
CHO-K1 cells transfected with pcDNA3.1-A2AR 
were stimulated with either CGS21680 or TZQ 
1-5, and phosphorylation of ERK1/2 measured. 
Data represented as the percentage response 
relative to 1 µM CGS21680 stimulation, ± 
SEM, of 3 replicates. 
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3.4.4 Quantifying biased agonism of the A2AR 
 
The work upon the A2AR has identified that the five triazoloquinazolines 
tested all exhibit agonistic activity, except TZQ 5, at two distinct A2AR-
mediated signalling pathways, cAMP production and ERK1/2 activation. 
As has been observed, the responses for each ligand at each given 
pathway differ (Figures 3.13 and 3.14, Tables 3.8 and 3.9). There is, thus, 
an inherent level of biased agonism exhibited by the agonists. In order to 
quantify this, the same approach as for the A1R agonists was utilised 
(Figures 3.9 and 3.10). This identified that all of the compounds tested, 
including CGS21680, display biased agonism towards activating ERK1/2-
mediated signalling pathways, with TZQ 2 displaying the greatest extent 
of bias (Figure 3.15A). Calculation of this relative to the reference ligand, 
CGS21680, also displayed the same trend (Figure 3.15B). As TZQ 3 only 
mediated ERK1/2 activation at 1 µM, and did not generate a full dose-
response curve, it was not possible to fit the operational model of 
pharmacological agonism (Black and Leff, 1983). This also meant that it 
was not possible to calculate any parameters for pKa or Log τ, and as 
such pathway bias could not be quantitated; however, it is clear that TZQ 
3 is biased towards cAMP production, as it exhibits greater activity in 
cAMP accumulation assays (Figure 3.13, Table 3.8) than in ERK1/2 
assays (Figure 3.14, Table 3.9). This work has thus identified a series of 
chemical compounds that display agonistic activity against the A2AR, 
some of which are selective, and display biased agonism towards 
activating ERK1/2 over Gαs-mediated cAMP production. 
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3.5 Summary 
 
The work in this chapter has highlighted how diverse signalling from ARs 
actually is: it was possible to observe the ability of the A1R to activate its 
canonical Gαi/o pathway (Figure 3.4, Table 3.2), as well as the opposing 
Gαs pathway (Figure 3.5, Table 3.3). In addition, mobilisation of iCa2+ 
(Figures 3.6 and 3.7, Table 3.4), and activation of ERK1/2 (Figure 3.8, 
Table 3.5) was also observed. Activation of all such pathways was 
apparent for the cognate ligands, NECA and adenosine, as well as the 
commercially available, AR agonist, CCPA. This phenomenon had also 
been observed for the selective and non-selective A1R agonists, which 
had been developed, based upon NECA and adenosine scaffolds (Figure 
3.2). Through modulating the functional groups of NECA and adenosine 
to those in the A1R compounds (Figure 3.2), it is apparent how activity 
against the A1R is maintained, and in the case of Cmpds 5, 6, 16 and 18, 
how A1R selectivity is gained (Knight et al, 2016, Appendix 1). In addition, 
modulating the functional groups in these compounds has given each a 
distinct pattern of bias (Figure 3.9 and 3.10): with some being more 
biased towards mobilisation of iCa2+ over all other pathways (Cmpds 5 
and 21), some being most biased towards cAMP production (Cmpds 16 
and 18), and one being more biased to the activation of ERK1/2 over all 
other pathways (Cmpd 20). Having developed and characterised these 
compounds, with respect to their ability to activate different signalling 
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Figure 3.15: Bias plots for triazoloquinazolines between cAMP modulation and ERK1/2 activation. 
 
Quantification of biased agonism, Δ Log (τ/Ka) (A), and relative pathway bias, ΔΔ log (τ/Ka) (B), 
between: cAMP modulation and ERK1/2 activation, for CGS21680 and Triazoloquinazolines (TZQ) 1-5. 
Significance was calculated using a one-way ANOVA with Bonferroni’s correction (*** p < 0.001). Data 
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pathways at the A1R, it will now be possible to, potentially, utilise these 
compounds to probe differing active conformations of the A1R. They may 
also be of use for the promotion of cell survival, as A1R activation has 
been observed to be cytoprotective in vitro (Baltos et al, 2016). 
 
In addition to the pharmacology of the A1R, the A2AR has also been 
investigated. Along with collaborators in Dr. Bender’s group, we have 
identified a series of existing compounds, triazoloquinazolines, which 
have previously been identified as PDE10A inhibitors (Kehler et al, 2011) 
that are also A2AR agonists (Figure 3.11 and 3.13, Tables 3.6 and 3.8). 
For some of these, TZQ 1-3, it was possible to successfully identify 
selectivity for the A2AR, over other AR subtypes (Figures 3.11-13, Tables 
3.6-8). Having identified selective and non-selective A2AR agonists, for 
cAMP accumulation, their ability to activate ERK1/2 signalling was also 
investigated. This identified that CGS21680 is able to bring about 
activation of ERK1/2 as are TZQ 1, 2 and 4, with TZQ 3 generating a 
weak response at 1 µM (Figure 3.14, Table 3.9). Analysis of the bias 
profile for these compounds indicated that all A2AR agonists tested 
display bias towards signalling via ERK1/2 pathways, over cAMP 
production (Figure 3.15). This may potentially prove beneficial in the 
treatment of various neurodegenerative diseases, as ERK1/2 activation 
by ARs has been seen to promote cell survival and proliferation 
(Jacques-Silva et al, 2004, Migita et al, 2008, Baltos et al, 2016). 
93 
Chapter 4 
The effects of RAMPs upon CLR 
pharmacology 
 
4.1 Introduction 
 
The calcitonin-like receptor (CLR) is a family B GPCR, closely related to 
the calcitonin receptor; on its own it is non-functional, being unable to 
traffic to the cell surface. In order to allow cell surface expression, the 
CLR requires the association of one of three molecular chaperone 
proteins, receptor activity modifying proteins (RAMPs) 1, 2 or 3 
(McLatchie et al, 1998). Association of both CLR and RAMP is essential 
for surface expression of both proteins (McLatchie et al, 1998). Each 
RAMP-CLR heterodimer forms a distinct receptor phenotype: RAMP1-
CLR forms the calcitonin gene-related peptide (CGRP) receptor, RAMP2-
CLR the adrenomedullin 1 (AM1) receptor, and RAMP3-CLR the 
adrenomedullin 2 (AM2) receptor. Each of these three heterodimers bind, 
and respond, to three peptide hormones: CGRP, AM and AM2 (or 
intermedin). Each of these peptides act as agonists against each RAMP-
CLR heterodimer, with differing potencies (Poyner et al, 2002, Hong et al, 
2012). Activation of all of the CLR-based receptors has been shown to 
result in raising intracellular cAMP levels, in a Gαs-dependent manner 
(McLatchie et al, 1998, Poyner et al, 2002, Chang et al, 2004, Roh et al, 
2004, Takei et al, 2004, Hay et al, 2005, Wunder et al, 2008). Each 
receptor has also been observed to activate other signalling pathways, 
including Gαi/o (Kim, 1991, Wiley et al, 1992, Main et al, 1998, Disa et al, 
2000, Kuwasako et al, 2010). However, to date little work has been 
performed to elucidate the full signalling repertoire associated with the 
CLR, and how RAMPs modulate this. Previous work in our laboratory, 
performed by Dr. C. Weston (University of Warwick, UK), investigated the 
individual G protein couplings of the CLR using the yeast screening 
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system. Through this she identified the ability of each RAMP-CLR 
heterodimer to signal via GPA1/Gαs, GPA1/Gαi1/2 and GPA1/Gαq, in 
response to all three agonists: CGRP, AM and AM2 (Weston et al, 2016, 
Appendix 2). This work also informed upon potential biased agonism at 
the CLR, as the observed responses at each pathway were both agonist- 
and RAMP-dependent. In this chapter the ability of CGRP, AM and AM2 
to activate each RAMP-CLR heterodimer in a mammalian system, HEK 
293 cells, is characterised. This is investigated with regards to their ability 
to activate Gαs-mediated signalling, Gαi/o signalling, and intracellular 
calcium (iCa2+) mobilisation. Having characterised their signalling 
properties at these three pathways, the extent of biased agonism for each 
agonist is quantified, at each RAMP-CLR heterodimer.  These findings 
were reported in the Journal of Biological Chemistry in 2016 (Weston et 
al, 2016, Appendix 2). 
 
4.2 HEK 293 cells - a model for studying RAMP-
CLR pharmacology 
 
In order to be able to study family B GPCRs, such as the CLR, in 
mammalian cells lines, it is necessary to establish that the cells do not 
endogenously express the receptor of interest, nor RAMPs. Dr. C. 
Weston had previously identified a HEK 293 cell line that did not express 
functional RAMPs (Weston et al, 2015), thus it was sought to further 
identify if they expressed functional CLR. To determine this HEK 293 
cells were transfected with pcDNA-FLAG-RAMP1, 2, or 3, and cAMP 
accumulation measured, in response to stimulation with CGRP, AM or 
AM2, due to the well-known ability of the CLR to couple to Gαs proteins 
(McLatchie et al, 1998, Poyner et al. 2002, Chang et al, 2004, Roh et al, 
2004, Takei et al, 2004, Hay et al, 2005, Wunder et al, 2008). Agonist 
stimulation did not result in any observable increase above basal cAMP 
levels, whilst stimulation with 100 µM forskolin indicates the cells’ ability 
to produce cAMP (Figure 4.1). Thus, our HEK 293 cell line does not only 
lack expression of functional RAMPs, but also functional CLR. This 
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simple characterisation allowed the identification of the HEK 293 cell line 
to be suitable for the purposes of RAMP-CLR studies. 
 
 
 
4.3 Investigating Gαs-mediated signalling of the 
CLR 
 
In order to investigate the commonly characterised Gαs-mediated 
signalling pathway of the CLR, HEK 293 cells were co-transfected with a 
1:1 ratio of pcDNA3.1-FLAG-RAMP and pcDNA3.1-cMyc-CLR-GFP. 
Successful transfection, and expression of both RAMP and CLR, from 
these plasmids, would result in the formation of RAMP-CLR 
heterodimers. Thus, upon stimulation with CGRP, AM or AM2, for each 
RAMP-CLR complex, it should be possible to observe an increase in 
intracellular cAMP levels. In order to measure this the LANCE® cAMP 
accumulation kit was utilised. The ability of these three agonists to 
activate the CLR in terms of cAMP production is well characterised 
(McLatchie et al, 1998, Poyner et al, 2002, Chang et al, 2004, Roh et al, 
2004, Takei et al, 2004, Hay et al, 2005, Wunder et al, 2008). By further 
investigating CLR-mediated cAMP production it is possible to establish 
that functional RAMP-CLR dimers can be formed in the system of study. 
It is also necessary to characterise their functional ability due to the 
variance in cellular background of these HEK 293 cells relative to those 
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Figure 4.1: HEK 293 cells do 
not express RAMPs. 
 
Transfection of cells with 
pcDNA3.1-FLAG-RAMP 1, 2, 
or 3 followed by stimulation 
with CGRP, AM or AM2 
resulted in no increase in 
cAMP levels, above basal. 
Stimulation with 100 µM 
forskolin indicates the ability of 
these cells to produce cAMP. 
Data represented as total 
cAMP per cell, ± SEM. 
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previously used, as this has been shown to have distinct effects upon the 
response observed (Weston et al, 2016, Appendix 2). Upon co-
transfection with pcDNA3.1-FLAG-RAMP1 and pcDNA3.1-cMyc-CLR-
GFP, followed by stimulation with CGRP, AM and AM2, it was observed 
that all three agonists elicit a response (Figure 4.2A, Table 4.1), with a 
rank order of potency of: CGRP > AM = AM2 (pEC50: 9.81±0.20, 
7.92±0.19, 7.93±0.24, respectively). In addition, all three agonists were 
observed to be full agonists, generating maximal responses of 
approximately 45% (relative to 100 µM forskolin). In contrast, RAMP2-
CLR heterodimers exhibit a different response, where the rank order of 
potency is AM > CGRP > AM2 (pEC50: 10.35±0.13, 8.97±0.24, 7.48±0.23, 
respectively), with CGRP and AM2 being partial agonists (Emax: 
37.2%±2.4, 34.1%±4.0, respectively), relative to AM (Emax: 55.0%±1.7) 
(Figure 4.2B, Table 4.1). For RAMP3-CLR it was observed that AM2 
displays an increased potency compared to that observed with RAMP1 or 
2, whilst CGRP displays a reduction in potency, giving a rank order of 
potency of: AM = AM2 > CGRP (pEC50: 8.86±0.14, 9.14±0.22, 7.75±0.30, 
respectively) (Figure 4.2C, Table 4.1). As with RAMP2-CLR, both CGRP 
and AM2 are partial agonists (Emax: 22.3%±2.1, 21.9%±0.22, 
respectively) relative to AM (Emax: 32.1%±1.6) (Figure 4.2C, Table 4.1).  
 
Analysis of this data, through utilising the operational model of 
pharmacological agonism (Black and Leff, 1983), clearly shows how 
RAMPs significantly alter the action of each agonist upon the CLR. 
Investigating the effect of RAMPs upon the intrinsic affinity (pKa) of each 
agonist identified that for RAMP1-CLR, CGRP has the highest pKa, with 
AM and AM2 having equal values (Table 4.1). This correlates with the 
orders of potency for these agonists. Whilst each agonist is equally 
efficacious (Log τ) (Figure 4.2D, Table 4.1), this suggests that it is the 
affinity of each agonist for the RAMP1-CLR complex that is the main 
determinant of potency. At RAMP2-CLR complexes it was observed that 
AM displays the highest affinity, followed by CGRP, with AM2 having the 
lowest pKa (Table 4.1). This again closely correlates with what is 
observed in terms of potency order (Figure 4.2B, Table 4.1). Interestingly, 
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efficacy follows the same trend observed for the Emax of each agonist, 
where CGRP and AM2 are both partial agonists; they also display a much 
lower efficacy than AM (Table 4.1). This again correlates with the 
RAMP1-CLR data, whereby pKa appears to influence potency, but also 
suggests that efficacy determines Emax. This pattern is also apparent for 
RAMP3-CLR, where pKa follows rank order of potency (Table 4.1), and 
CGRP and AM2 both have equal lower efficacies than AM, which is a full 
agonist (Table 4.1). 
 
Characterising the ability of CGRP, AM and AM2 to mediate an increase 
in intracellular cAMP has identified that the CLR can be stimulated by all 
three agonists in the presence of each RAMP. This work has further 
identified that RAMPs modulate the ability of each agonist to stimulate the 
CLR, bringing about an increase in intracellular cAMP, in a Gαs-
dependent manner. 
 
The effects of RAMPs upon CLR pharmacology  !
! 98 
 
 
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP1-CLR
CGRP
AM
AM2 
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP3-CLR
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP2-CLRA B 
0 -12 - 1 - 0 -9 -8 -7 -6 -5
0
20
40
60
Log [A onist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP1-CLR
CGRP
AM
AM2 
0 -12 - 1 - 0 -9 -8 -7 -6 -5
0
20
40
60
Log [A onist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP3-CLR
0 -12 - 1 - 0 -9 -8 -7 -6 -5
0
20
40
60
Log [A onist] M
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP2-CLR
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP1-CLR
CGRP
AM
AM2 
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M 
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP3-CLR
0 -12 -11 -10 -9 -8 -7 -6 -5
0
20
40
60
Log [Agonist] M
%
 R
es
po
ns
e
(r
el
at
iv
e 
to
 fo
rs
ko
lin
)
RAMP2-CLR
-0.8
-0.6
-0.4
-0.2
0.0
0.2
Ef
fic
ac
y 
(lo
g 
τ)
Efficacy
CGRP
AM
AM2 ****
**
**
C D 
RAMP1-
CLR 
RAMP2-
CLR 
RAMP3-
CLR 
Figure 4.2: RAMPs modulate the ability of CGRP, AM and AM2 to elevate intracellular cAMP 
levels in a CLR-dependent manner. 
 
cAMP accumulation was measured in HEK 293 cells transfected with pcDNA3.1-FLAG-RAMP 1 (n 
= 11) (A), -RAMP 2 (n = 8) (B) or -RAMP 3 (n = 9) (C) in conjunction with pcDNA3.1-cMyc-CLR-
GFP, upon stimulation with CGRP, AM or AM2 for 30 minutes. Data are expressed relative to 
stimulation with 100 µM forskolin, ± SEM. D – Bar chart displaying the efficacy (Log τ) values for 
each ligand stimulating each RAMP-CLR heterodimer. Significance was calculated using a one-way 
ANOVA with Bonferroni’s correction (** p < 0.01). Data represented ± SEM.  
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4.4 Investigating Gαi/o-mediated signalling of the 
CLR 
 
It is well known that the activity of adenylate cyclase can be modulated 
via both Gαs and Gαi/o (Milde et al, 2013), having positive and negative 
effects upon the levels of intracellular cAMP, respectively. Thus, a GPCR 
that potentially couples to both will elicit a perceived Gαs response that is 
actually a summation of both pathways. Where increases in cAMP are 
measured, they will be ‘dampened’ by the opposing action of Gαi/o, 
potentially in terms of both maximal signalling (Emax) and potency (pEC50). 
Therefore, in order to uncover any potential couplings to Gαi/o, it is first 
necessary to inhibit its action, and look for a subsequent increase in 
either Emax or pEC50. This can be achieved via pre-treatment of cells with 
PTX, which ADP-ribosylates the C-termini of Gαi/o, serving to uncouple 
them from GPCRs (West et al, 1985). 
 
Whilst many groups have looked at the ability of the CLR to elevate 
intracellular cAMP, no extensive characterisation of their coupling to 
inhibitory G proteins has been undertaken. To address this, HEK 293 
cells were co-transfected with pcDNA3.1-FLAG-RAMP and pcDNA3.1-
cMyc-CLR-GFP and treated with 200 ng/ml PTX, for 16-18 hours, to 
inhibit the action of Gαi/o proteins. In order to confirm that any differences 
observed are due to true biological effects, mock-transfected cells 
(expressing pcDNA3.1-GFP) were treated with PTX, and the effect of 
forskolin upon cAMP levels was measured and compared to untreated 
cells. It was observed that pre-treatment with PTX had no effect (Figure 
4.3). Thus, there can be confidence that any effects observed are not due 
to PTX affecting other signalling components. 
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Having confirmed that PTX had no toxic effects on HEK 293 cells’ ability 
to signal, cells co-expressing RAMP-CLR heterodimers were treated, and 
their ability to produce cAMP compared to untreated cells, upon 
stimulation with CGRP, AM and AM2. In PTX-treated cells, transfected 
with pcDNA3.1-FLAG-RAMP1 and pcDNA3.1-cMyc-CLR-GFP, stimulated 
with CGRP, no difference in cAMP accumulation was observed, relative 
to untreated cells (Figure 4.4A). This was also apparent for the pKa and 
efficacy values (Table 4.2). However, upon challenge with AM an 
increase in maximal signalling was observed, whilst with AM2 an increase 
in both Emax and potency were observed (Figure 4.4A). These increases 
in maximal level of signalling are also concurrent with increases in 
efficacy of the agonists (Table 4.2). An increase in pKa was observed for 
AM2 upon PTX pre-treatment, however this was not significant. The 
effects upon AM and AM2 responses are indicative of removal of an 
inhibitory Gαi/o signalling component. In contrast, the lack of an effect of 
PTX upon CGRP signalling indicates that this agonist is unable to 
mediate signalling in a Gαi/o-dependent manner from RAMP1-CLR 
heterodimers.  
 
In cells transfected with pcDNA3.1-FLAG-RAMP2 and pcDNA3.1-cMyc-
CLR-GFP, it was possible to observe increases in Emax upon PTX pre-
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Figure 4.3: Pre-treatment 
with pertussis toxin does not 
affect cAMP production in 
HEK 293 cells. 
 
Pre-treatment of HEK 293 
cells, for 16-18 hours, with 200 
ng/ml pertussis toxin (PTX) did 
not affect their abil ity to 
produce cAMP in response to 
forskolin stimulation, relative to 
untreated cells. Data ± SEM, of 
3 replicates.  
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treatment for stimulation with both CGRP and AM2, with an associated 
increase in potency (Figure 4.4B). In contrast, AM displayed no difference 
to untreated cells (Figure 4.4B). These increases in Emax are again 
concurrent with an increased efficacy (Table 4.2). Interestingly, whilst 
AM2 displays an expected increased pKa, CGRP also showed a small 
increase, without an increase in pEC50 (Table 4.2). These results indicate 
a lack of ability of AM to signal in a Gαi/o-dependent manner in the 
presence of RAMP2, whilst both CGRP and AM2 are able to signal via 
this pathway. A similar pattern is observed in PTX pre-treated cells co-
transfected with pcDNA3.1-FLAG-RAMP3 and pcDNA3.1-cMyc-CLR-
GFP, with AM stimulation displaying no discernable difference relative to 
untreated cells (Figure 4.4C, Table 4.2). CGRP displayed coupling to 
Gαi/o, with an increased Emax and potency, concurrent with an associated 
increase in pKa. An increased efficacy was also observed, however this 
was not significant (Figure 4.4C, Table 4.2). AM2 also displayed PTX-
sensitivity with an increase in both Emax and efficacy (Figure 4.4C, Table 
4.2). 
 
This data thus indicates that the CLR has the ability to couple to Gαi/o in 
the presence of all three RAMPs. Interestingly, this appears to be both 
agonist- and RAMP-dependent, with the cognate agonist for each RAMP-
CLR complex (CGRP for RAMP1-CLR; AM for RAMP2, 3-CLR) being 
insensitive to PTX. This indicates that not only do RAMPs modulate the 
ability of each agonist to bring about elevations in cAMP, but that they 
also serve to modulate G protein-coupling.  
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Figure 4.4: RAMP-CLR heterodimers display PTX-sensitivity in response to stimulation with 
CGRP, AM and AM2. 
 
cAMP accumulation was measured in HEK 293 cells pre-treated, for 16-18 hours, with 200 ng/ml 
PTX, transfected with pcDNA3.1-FLAG-RAMP 1 (n = 6) (A), -RAMP 2 (n = 6) (B) or -RAMP 3 (n = 6) 
(C) in conjunction with pcDNA3.1-cMyc-CLR-GFP, upon stimulation with CGRP, AM or AM2 for 30 
minutes. Data are expressed relative to stimulation with 100 µM forskolin, ± SEM.  
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4.5 Investigating CLR-mediated iCa2+ mobilisation 
 
It has long been known that activation of many GPCRs can result in the 
mobilisation of iCa2+ (Carroll and Peralta, 1998, Yatani et al, 1999, Xu 
and Xie, 2009, Koole et al, 2010, Gao and Jacobson, 2016, Hager et al, 
2017); there is thus interest in establishing whether this also occurs at the 
CLR. From the work of Dr. C. Weston, we had observed functional 
coupling of RAMP-CLR heterodimers to GPA1/Gαq, in yeast (Weston et 
al, 2016, Appendix 2). To validate this, the aim was to determine if the 
CLR can mobilise iCa2+ in response to CGRP, AM or AM2 stimulation, 
and also if this process is modulated by RAMPs. In order to do this the 
same HEK 293 cells as for cAMP assays were utilised, co-transfected 
with pcDNA3.1-HA-CLR and each FLAG-RAMP construct (pcDNA3.1-
FLAG-RAMP1, 2, or 3). These were then loaded with the calcium dye 
FLUO-4/AM, which fluoresces (excitation: 494 nm, emission: 506 nm) 
upon binding Ca2+ (Gee et al, 2000). In each experiment, stimulation with 
10 µM ionomycin was utilised to establish sufficient dye loading, as well 
as the ability of the cells to mobilise iCa2+. The observed response was 
normalised to that obtained from 10 µM ionomycin stimulation, in order to 
account for variations in dye loading and iCa2+ content on each day. Each 
experiment was performed in Ca2+-free HBSS, thus only mobilisation of 
iCa2+ is measured, and not entry via cell surface channels. 
 
4.5.1 RAMP1-CLR-mediated iCa2+ mobilisation 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-
FLAG-RAMP1 were assayed for responses to CGRP, AM and AM2 
(Figure 4.5A-D, Table 4.3). Upon stimulation with each agonist, an 
increase in fluorescence was observed, reaching peak intensity before 
decaying, with the maximal observed intensity being dose-dependent 
(Figure 4.5A-C). The post-stimulation peak and decay indicates that only 
iCa2+ is being measured; if extracellular entry were observed, a sustained 
phase following peak intensity would be predicted. Converting this data to 
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dose-response curves (Figure 4.5D) allows calculation of the potency of 
each agonist (Table 4.3), whereby a rank order of potency of CGRP >> 
AM > AM2 (pEC50: 9.52±0.2, 7.87±0.3, 6.76±0.2, respectively) was 
observed. This data also identified that AM and AM2 are partial agonists 
(Emax: 33.94%±4.7, 25.05%±2.4, respectively), whilst CGRP is a full 
agonist (Emax: 73.84%±2.7). Analysis of the efficacy (Log τ) values for 
these three agonists at RAMP1-CLR heterodimers (Figure 4.5E, Table 
4.3) reveals a rank order of efficacy of CGRP >> AM > AM2, matching 
the same trends observed for agonist potency. Interestingly, as with 
cAMP accumulation, it was observed that the cognate agonist to RAMP1-
CLR, CGRP, is the most potent and efficacious agonist at mobilising 
iCa2+. 
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In order to elucidate the mechanism whereby CGRP, AM and AM2 
mediate iCa2+ mobilisation via RAMP1-CLR, HEK 293 cells co-
transfected with pcDNA3.1-FLAG-RAMP1 and pcDNA3.1-HA-CLR, were 
pre-treated with 200 ng/ml PTX, for 16-18 hours, to determine if the Gαi/o 
signalling component previously uncovered (Figure 4.4) plays any role. 
Cells treated in this manner were then assayed for the mobilisation of 
iCa2+ as previously. Through doing this it was still possible to observe 
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Figure 4.5: Stimulation of RAMP1-CLR 
heterodimers with CGRP, AM and AM2 results 
in mobilisation of iCa2+. 
 
iCa2+ mobilisation was measured in HEK 293 
cells, loaded with FLUO-4/AM, co-transfected 
with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-
RAMP1, stimulated with: CGRP (A), AM (B) and 
AM2 (C). Calcium traces are representative of 5 
individual traces, where the dashed line indicates 
agonist injection. Conversion of calcium traces to 
dose-response curves allows calculation of the 
potency of each agonist (D), whilst application of 
the operational model of partial agonism (Black 
and Leff, 1983) allows calculation of the coupling 
efficacy (Log τ) for each agonist (E). Significance 
was calculated, relative to CGRP, using a one-
way ANOVA with Bonferroni’s correction (** p < 
0.01). Data represented ± SEM, of 5 individual 
replicates. 
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iCa2+ mobilisation, upon stimulation with each agonist, which decreased 
in a dose-dependent manner (Figure 4.6A-C). Conversion of the raw 
traces observed for changes in fluorescence intensity, to dose-response 
curves for CGRP, AM and AM2 indicated no differences relative to 
untreated cells (Figures 4.6D-F, Table 4.3). Thus, it was concluded that 
the mobilisation of iCa2+ mediated via RAMP1-CLR heterodimers occurs 
in a PTX-insensitive manner, and not via the action of Gαi/o proteins. 
 
Having established the ability of the CLR to mediate iCa2+ mobilisation, 
when in association with RAMP1, and that this is not mediated in a PTX-
sensitive manner, it was further investigated if the classic mediator of 
Ca2+ release, Gαq, was the facilitator. In order to investigate this, a 
selective Gαq/11/14 inhibitor, YM-254890 (Takasaki et aI, 2004) was 
utilised. Pre-treatment of cells with this inhibitor, at 100 nM for 30 
minutes, was sufficient to ablate iCa2+ mobilisation upon stimulation with 
CGRP, AM or AM2 (Figures 4.7A-F). Whilst it was possible to observe 
some increases in fluorescence intensity upon agonist stimulation (Figure 
4.7 A-B), most of these responses were maintained, and did not decay 
following reaching peak intensity. As there is no extracellular Ca2+ in the 
assays, it is not believed that these responses represent mobilisation of 
iCa2+, or that they may be partial release where G protein activation has 
not been fully inhibited. Alternatively, it is plausible that iCa2+ mobilisation 
driven by exchange factor directly activated by cAMP (EPAC) could be 
occurring. Thus, it is apparent that RAMP1-CLR-mediated mobilisation of 
iCa2+ can be stimulated via CGRP, AM and AM2, and this occurs in a 
Gαq/11/14-dependent manner. 
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Figure 4.6: RAMP1-CLR-mediated iCa2+ mobilisation is insensitive to PTX pre-treatment. 
 
HEK 293 cells transfected with both pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP1, were pre-
treated with 200 ng/ml PTX for 16-18 hours, and stimulated with: CGRP (A), AM (B) and AM2 (C), 
and iCa2+ mobilisation measured. Calcium traces are representative of 5 individual traces, where the 
dashed line indicates agonist injection. Conversion of calcium traces to dose-response curves 
allows the effects of PTX, relative to untreated cells, to be observed (D-F). Data represented ± SEM, 
of 5 individual replicates. 
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Figure 4.7: RAMP1-CLR-mediated iCa2+ mobilisation is sensitive to YM-254890 pre-treatment. 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP1, were pre-treated 
with 100 nM YM-254890, for 30 minutes, to inhibit Gαq/11/14, and stimulated with: CGRP (A), AM (B) or 
AM2 (C), and iCa2+ mobilisation measured. Calcium traces are representative of 5 individual traces, 
where the dashed line indicates agonist injection. Conversion of calcium traces to dose-response curves 
shows how YM-254890 treatment has significantly reduced iCa2+ mobilisation relative to untreated cells 
(D-F). Data represented ± SEM, of 5 individual replicates. 
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4.5.2 RAMP2-CLR-mediated iCa2+ mobilisation 
 
In order to determine the effect of RAMP2 upon CLR-mediated iCa2+ 
mobilisation, the same method as for RAMP1-CLR was utilised. As 
previously, it was possible to obtain increases in FLUO-4 fluorescence, 
for all three agonists, which reached a peak post-injection maximal 
intensity, before decaying back towards resting iCa2+ levels (Figure 4.8A-
C). Conversion of the raw fluorescence values to dose-response curves 
(Figure 4.8D) identified a rank order of potency of CGRP = AM > AM2 
(pEC50: 7.71±0.1, 7.86±01, 7.41±0.4, respectively), with the same trend 
being observed for the efficacy (Log τ) values (Figure 4.8E, Table 4.3). 
Interestingly, it is now observed  that CGRP and AM are full agonists 
(Emax: 62.42±4.0, 63.00±2.8, respectively), with AM2 being a partial (Emax: 
44.41%±7.1). Whilst CGRP is observed to be a potent agonist at RAMP2-
CLR heterodimers, it displays a lower potency relative to the response 
observed at RAMP1-CLR, with the cognate agonist AM now being more 
potent and displaying a much higher efficacy (Figure 4.8E, Table 4.3).  
 
Having elucidated the mechanism of iCa2+ mobilisation from RAMP1-
CLR, there was interest to see if this occurs in the same manner for 
RAMP2-CLR. Thus, the same approach was utilised, using PTX pre-
treatment to inhibit any potential Gαi/o signalling component, and observe 
the effects of this upon iCa2+ mobilisation. As with untreated cells, it was 
still possible to observe iCa2+ mobilisation upon stimulation with CGRP, 
AM and AM2, in a dose-dependent manner (Figure 4.9A-C). As before, 
analysis of dose-response curves created from the initial calcium traces 
(Figure 4.9D-F) indicated that mobilisation of iCa2+ via RAMP2-CLR 
heterodimers occurs in a PTX-insensitive manner (Table 4.3), and is thus 
not brought about via Gαi/o proteins. 
 
Having established that, like RAMP1-CLR, RAMP2-CLR is still able to 
mediate iCa2+ mobilisation in a manner independent of Gαi/o, the action of 
Gαq/11/14 was investigated. Treatment of cells with 100 nM YM-254890, for 
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30 minutes, was sufficient to ablate all calcium release, except for when 
stimulated in the micromolar range for CGRP and AM (Figure 4.10A-C). 
This may be due to the higher efficacy observed for these agonists in the 
presence of RAMP2, indicating that the dose of YM-254890 used was, 
potentially, not sufficient to inhibit all Gαq/11/14 signalling, or alternatively 
this could again be EPAC-mediated iCa2+ mobilisation. However, the 
observed inhibition is sufficient to indicate that for all three agonists, there 
is effectively no signalling in comparison to untreated cells (Figure 4.10E-
F). Thus, as with RAMP1-CLR, RAMP2-CLR-mediated iCa2+ mobilisation 
occurs in a Gαq/11/14-dependent manner.  
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Figure 4.8: Stimulation of RAMP2-CLR 
heterodimers with CGRP, AM and AM2 results 
in mobilisation of iCa2+. 
 
iCa2+ mobilisation was measured in HEK 293 
cells, loaded with FLUO-4/AM, co-transfected 
with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-
RAMP2 stimulated with CGRP (A), AM (B) and 
AM2 (C). Calcium traces are representative of 5 
individual traces, where the dotted line indicates 
agonist injection. Conversion of calcium traces to 
dose-response curves allows calculation of the 
potency of each agonist (D), whilst application of 
the operational model of partial agonism (Black 
and Leff, 1983) allows calculation of the coupling 
efficacy (τ) for each agonist (E). Significance was 
calculated, relative to AM, using a one-way 
ANOVA with Bonferroni’s correction (** p < 0.01) 
Data represented ± SEM, of 5 individual 
replicates. 
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Figure 4.9: RAMP2-CLR-mediated iCa2+ mobilisation is insensitive to PTX pre-treatment. 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP2, were pre-treated 
with 200 ng/ml PTX for 16-18 hours, and stimulated with: CGRP (A), AM (B) and AM2 (C) and iCa2+ 
mobilisation measured. Calcium traces are representative of 5 individual traces, where the dotted line 
indicates lagonist injection. Conversion of calcium traces to dose-response curves allows the effects of 
PTX, relative to untreated cells, to be observed (D-F). Data represented ± SEM, of 5 individual 
replicates. 
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Figure 4.10: RAMP2-CLR-mediated iCa2+ mobilisation is sensitive to YM-254890 pre-treatment. 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP2, were pre-treated 
with 100 nM YM-254890, for 30 minutes, to inhibit Gαq/11/14, and stimulated with: CGRP (A), AM (B) or 
AM2 (C), and iCa2+ mobilisation measured. Calcium traces are representative of 5 individual traces, 
where the dotted line indicates agonist injection. Conversion of calcium traces to dose-response curves 
shows how YM-254890 treatment has significantly reduced iCa2+ mobilisation relative to untreated cells 
(D-F). Data represented ± SEM, of 5 individual replicates. 
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4.5.3 RAMP3-CLR-mediated iCa2+ mobilisation 
 
HEK 293 cells, co-transfected with pcDNA3.1-FLAG-RAMP3 and 
pcDNA3.1-HA-CLR, were stimulated with CGRP, AM and AM2, in order 
to determine the effect of RAMP3 upon CLR-mediated iCa2+ mobilisation. 
The same observations as in previous CLR calcium experiments were 
made, with an increase in fluorescence intensity upon agonist injection, 
which reached a peak maximal level before decaying towards basal 
levels (Figure 4.11A-C). Analysis of this data revealed a rank order of 
potency of: AM2 = AM > CGRP (pEC50: 8.21±0.3, 8.12±0.3, 7.15±0.2, 
respectively) (Figure 4.11D, Table 4.3). It was also observed that CGRP 
remained a full agonist (Emax: 90.26±9.8), with AM and AM2 being partial 
agonists (Emax: 56.59%±7.0, 19.17%±2.8, respectively) (Figure 4.11D, 
Table 4.3). Through calculation of the efficacy values of each agonist a 
rank order of: CGRP > AM > AM2 (Figure 4.11E, Table 4.3) was 
observed. The low efficacy for AM2 correlates with it being a partial 
agonist, whilst the higher value for CGRP is presumably due to its higher 
Emax (Figure 4.11D, Table 4.3). 
 
As with RAMPs 1 and 2, pre-treatment with PTX still allowed iCa2+ 
mobilisation, in response to all three agonists, in a dose-dependent 
manner (Figure 4.12A-C), with no observable difference to untreated cells 
(Figure 4.12D-F, Table 4.3). In contrast, treatment of cells with 100 nM 
YM-254890, for 30 minutes, was again able to ablate all iCa2+ 
mobilisation, in response to all agonists (except CGRP at the micromolar 
level) (Figure 4.13 A-F). It is thus possible to conclude that RAMP3-CLR 
heterodimers mediate iCa2+ mobilisation via the action of Gαq/11/14 
proteins, and that all three RAMP-CLR complexes utilise this transduction 
pathway to elevate iCa2+ levels.  
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Figure 4.11: Stimulation of RAMP3-CLR 
heterodimers with CGRP, AM and AM2 results 
in iCa2+ mobilisation . 
 
iCa2+ mobilisation was measured in HEK 293 
cells, loaded with FLUO-4/AM, co-transfected 
with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-
RAMP3 stimulated with: CGRP (A), AM (B) and 
AM2 (C). Calcium traces are representative of 5 
individual traces, where the dotted line indicates 
agonist injection. Conversion of calcium traces to 
dose-response curves allows calculation of the 
potency of each agonist (D), whilst application of 
the operational model of partial agonism (Black 
and Leff, 1983) allows calculation of the coupling 
efficacy (τ) for each agonist (E). Significance was 
calculated, relative to AM, using a one-way 
ANOVA with Bonferroni’s correction (* p < 0.05).  
Data represented ± SEM, of 5 individual 
replicates. 
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Figure 4.12: RAMP3-CLR-mediated iCa2+ mobilisation is insensitive to PTX pre-treatment. 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP3, were pre-treated 
with 200 ng/ml PTX for 16-18 hours, and stimulated with: CGRP (A), AM (B) and AM2 (C) and iCa2+ 
mobilisation measured. Calcium traces are representative of 5 individual traces, where the dotted line 
indicates agonist injection. Conversion of calcium traces to dose-response curves allows the effects of 
PTX, relative to untreated cells, to be observed (D-F). Data represented ± SEM, of 5 individual 
replicates. 
0 25 50 75 100 125
0
1000
2000
3000
4000
Time (s)
Fl
uo
re
sc
en
ce
 (A
U
)
Agonist 
Agonist 
Agonist 
The effects of RAMPs upon CLR pharmacology  !
! 120 
 
 
 
 
 
 
 
0 25 50 75 100 125 150
0
1000
2000
3000
4000
Time (s)
Fl
uo
re
sc
en
ce
 (A
U
)
0 25 50 75 100 125 150
0
1000
2000
3000
4000
Time (s)
Fl
uo
re
sc
en
ce
 (A
U
)
0 25 50 75 100 125 150
0
1000
2000
3000
4000
Time (s)
Fl
uo
re
sc
en
ce
 (A
U
)
0 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
Log [CGRP] M
%
 R
es
po
ns
e
 (R
el
at
iv
e 
to
 1
0µ
M
 Io
no
m
yc
in
)
Untreated
YM-254890
0 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
Log [AM2] M
%
 R
es
po
ns
e
 (R
el
at
iv
e 
to
 1
0µ
M
 Io
no
m
yc
in
)
Untreated
YM-254890
0 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
Log [AM] M
%
 R
es
po
ns
e
 (R
el
at
iv
e 
to
 1
0µ
M
 Io
no
m
yc
in
)
Untreated
YM-254890
1 µM
100 nM
10 nM
1 nM
100 pM
10 pM
A 
B 
C 
D 
E 
F 
Figure 4.13: RAMP3-CLR-mediated iCa2+ mobilisation is sensitive to YM-254890 pre-treatment. 
 
HEK 293 cells co-transfected with pcDNA3.1-HA-CLR and pcDNA3.1-FLAG-RAMP3, were pre-treated 
with 100 nM YM-254890, for 30 minutes, to inhibit Gαq/11/14, and stimulated with: CGRP (A), AM (B) or 
AM2 (C), and iCa2+ mobilisation measured. Calcium traces are representative of 5 individual traces, 
where the dotted line indicates agonist injection. Conversion of calcium traces to dose-response curves 
shows how YM-254890 treatment has significantly reduced iCa2+ mobilisation relative to untreated cells 
(D-F). Data represented ± SEM, of 5 individual replicates. 
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4.6 Quantification of biased agonsim at RAMP-CLR 
heterodimers 
 
The preceding data has identified that each RAMP-CLR complex displays 
an ability to: elevate cAMP levels, couple to Gαi/o proteins and mobilise 
iCa2+, in a Gαq/11/14-dependent manner. It has been observe that each 
RAMP has an ability to modulate the response to CGRP, AM and AM2 at 
each given pathway, and that the responses to a single agonist, at a 
given RAMP-CLR heterodimer, are different. There is, therefore, a degree 
of inherent pathway bias. In order to quantitate this, the operational model 
of agonism (Black and Leff, 1983) was utilised. From which it is possible 
obtain the coupling efficacy parameter (Log τ) and the intrinsic affinity 
parameter (pKa) (Tables 4.1, 4.2 and 4.3); using these allows calculation 
of the transduction coefficient (Log τ/Ka). The change in transduction 
coefficient between two given pathways (Δ Log (τ/Ka)) serves to give a 
measure of the extent of bias. In the case of the RAMP-CLR system, it is 
possible to calculate the extent of bias between mobilisation of iCa2+ and 
cAMP modulation.  
 
As has been show, the CLR is able to couple to both Gαs and Gαi/o 
proteins (Figures 4.2 and 4.4). Therefore, where cAMP accumulation 
assays are performed in the absence of PTX pre-treatment, the combined 
effect of both signalling pathways are being studied. Thus, it is only 
possible to determine the extent of bias between iCa2+ mobilisation and 
cAMP modulation as a whole. Therefore, it is possible to identify that all 
three agonists exert bias towards cAMP modulation over iCa2+ 
mobilisation at RAMP1-CLR heterodimers, with CGRP and AM2 being 
the most heavily biased (Figure 4.14A). In contrast, with RAMP2-CLR, 
AM displays a highly elevated bias towards cAMP modulation, whilst AM2 
is now weakly biased towards the mobilisation of iCa2+, with CGRP 
displaying a similar extent of bias as at RAMP1-CLR (Figure 4.14A). In 
the case of RAMP3-CLR heterodimers, it is observed that CGRP is a 
calcium-biased agonist, with both AM and AM2 being biased towards 
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signalling via cAMP, with AM being less biased than AM2 (Figure 4.14A). 
Comparing this to data obtained from PTX pre-treated cells (essentially a 
‘pure’ Gαs versus Gαq system), a different extent of bias is obtained. With 
RAMP1-CLR, it is observed that, essentially, all three agonists are still 
biased towards cAMP modulation, but AM and AM2 are more heavily 
biased than in untreated cells (Figure 4.14B). This is unsurprising as PTX 
pre-treatment served to potentiate the effect of both AM and AM2 in 
cAMP accumulation assays, through removing the inhibitory effect of 
Gαi/o (Figure 4.4A). With RAMP2-CLR, a switch in bias towards cAMP 
modulation for AM2 occurs, which now displays a similar level to that 
observed for AM (Figure 4.13B). Whilst with RAMP3-CLR, all three 
agonists display a similar extent of bias towards cAMP modulation 
(Figure 4.13B). It is therefore evident that CGRP, AM and AM2 have 
differing bias profiles at the CLR, which are heavily modulated by each of 
the three RAMPs. 
 
 
 
Pathway bias can also be calculated relative to a given agonist (ΔΔ Log 
(τ/Ka)), commonly the cognate agonist. This allows quantification of bias 
in a system-independent manner. As a given response will be perceived 
to change depending upon the system in which it is studied, the change 
will be relative to that observed for the reference agonist. This method 
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Quantification of pathway bias (Δ Log(τ/Ka)) between cAMP modulation and iCa2+ mobilisation, for both 
untreated (A) and PTX-treated (B) HEK 293 cells. Coupling efficacy (Log τ) and intrinsic affinity (pKa) 
parameters calculated through implementation of the operational model of agonism (Black and Leff, 1983). 
Significance was calculated using a one-way ANOVA with Bonferroni’s correction (* p < 0.05, ** p < 0.01 *** 
p < 0.001). Data represented ± SEM.   
i
2
 i  
-3
-2
-1
0
1
2
B
ia
s 
fa
ct
or
 (Δ
Δ
 lo
g(
τ/K
a)
Untreated 
** ****
****
**
**
cAMP
iCa2+
CGRP
AM
AM2
The effects of RAMPs upon CLR pharmacology  !
! 123 
 
therefore allows a quantification of bias that transcends all systems, and 
is thus comparable between data obtained via other methods (Kenakin et 
al, 2012). Applying this approach to the data in this chapter, using the 
cognate agonist of each RAMP-CLR heterodimer (RAMP1-CLR, CGRP; 
RAMP 2 and 3- CLR, AM), it is possible to determine the bias of each 
agonist, relative to the reference agonist. In the absence of PTX, AM is 
biased towards iCa2+ mobilisation in the presence of RAMP1-CLR 
heterodimers, whilst AM2 is biased towards cAMP modulation (Figure 
4.15A). For RAMP2-CLR, it was observe that both CGRP and AM2 are 
heavily calcium biased (Figure 4.15A). In the case of RAMP3-CLR, 
CGRP is biased towards iCa2+ mobilisation, whereas AM2 predominantly 
signals via cAMP modulation (Figure 4.15A). A similar trend is observed 
in cells treated with PTX, but the extent of bias is modulated by the loss 
of Gαi/o coupling. With RAMP1-CLR, AM has a reduced bias towards 
iCa2+ mobilisation, and AM2 has an increased extent of cAMP bias 
(Figure 4.15B). With RAMP2-CLR, a dramatic reduction in the extent of 
AM2’s bias towards iCa2+ mobilisation is apparent, whilst with RAMP3-
CLR, CGRP switches towards being cAMP biased over iCa2+ (Figure 
4.15B).  
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Figure 4.15: Relative bias plots for RAMP-CLR heterodimers. 
 
Quantification of relative pathway bias (ΔΔ log (τ/Ka)) between cAMP modulation and iCa2+ mobilisation, for 
both untreated (A) and PTX-treated (B) HEK 293 cells. Plots are relative to the cognate agonists at each 
RAMP-CLR heterodimer: RAMP1-CLR, CGRP; RAMP2 and 3-CLR, AM. Coupling efficacy (log τ) and 
intrinsic affinity (pKa) parameters calculated through implementation of the operational model of agonism 
(Black and Leff, 1983). Significance was calculated using a one-way ANOVA with Bonferroni’s correction (* 
p < 0.05, ** p < 0.01 *** p < 0.001). Data represented ± SEM.   
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Comparing these bias observations in HEK 293 cells to that obtained for 
identical experiments performed in HEK 293S cells (Figure 4.16) (Weston 
et al, 2016, Appendix 2), a similar pattern of bias is obtained to that 
observed in PTX-treated HEK 293 cells (Figure 4.14B, 4.15B). This data 
suggests there is no Gαi/o signalling component in HEK 293S cells. 
Indeed, cAMP accumulation was found to be PTX-insensitive for all 
ligand-RAMP-CLR combinations (Weston et al, 2016, Appendix 2). Thus, 
there are cell type specific effects upon CLR-mediated signalling. 
Characterising the relative expression levels of different Gα proteins 
identified that HEK 293S cells exhibit a much lower expression level of 
Gαi1 and Gαi2 (Weston et al, 2016, Appendix 2), suggesting that the PTX-
sensitivity observed in HEK 293 cells is due to effects upon inhibition of 
either of these two Gαi proteins.  
 
 
 
4.7 Summary 
 
The work in this chapter has provided an in-depth pharmacological 
analysis of the CLR, and the effects and roles played by RAMPs. It has 
highlighted the ability of the CLR to couple to, and signal via, Gαs, a 
process which is stimulated via all three agonists: CGRP, AM and AM2. 
In contrast, Gαi/o activation has also been identified (via PTX pre-
treatment leading to a potentiation of cAMP accumulation), which occurs 
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Figure 4.16: Bias plots for RAMP-CLR heterodimers expressed in HEK 293S cells. 
 
Quantification of pathway bias (Δ log (τ/Ka) (A), and relative pathway bias (ΔΔ log (τ/Ka) (B) between cAMP 
modulation and iCa2+ mobilisation, in HEK 293S cells. ΔΔ log (τ/Ka) plots (B) are relative to the cognate 
agonist at each RAMP-CLR heterodimer: RAMP1-CLR, CGRP; RAMP2 and 3-CLR, AM. Coupling efficacy 
(τ) and intrinsic affinity (Ka) parameters calculated through implementation of the operational model of 
agonism (Black and Leff, 1983). Significance was calculated using a one-way ANOVA with Bonferroni’s 
correction (* p < 0.05, ** p < 0.01 *** p < 0.001). Data represented ± SEM.  
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for all agonists, but never the cognate agonist at each RAMP-CLR 
heterodimer (RAMP1-CLR, CGRP; RAMP 2- and 3-CLR, AM). Thus, not 
only do RAMPs differentially modulate the coupling to diametrically 
opposing G proteins at the CLR, but they also modulate, both positively 
and negatively, the responses observed for stimulation with a given 
agonist. This chapter has also further highlighted how each RAMP-CLR 
complex is able to bring about the mobilisation of iCa2+, in a Gαq/11/14-
dependent manner. It is therefore possible to begin to understand how 
treatment of cells expressing a single RAMP-CLR heterodimer, with a 
given agonist, may bring about diametrically opposing effects, as well as 
activation of other signalling pathways. If cells expressing more than one 
RAMP isoform are treated with an agonist, it is therefore feasible that any 
response observed would be an amalgamation of that observed for each 
RAMP-CLR in isolation. It is also plausible that each RAMP may have 
differing affinities for the CLR, or traffic the CLR to greater or lesser 
extents. In this instance, unravelling the response and associating it to a 
given receptor phenotype would be a complex task. Thus, by using cells 
transfected with the CLR in conjunction with each RAMP, it was possible 
to pharmacologically characterise the extent of G protein-mediated 
signalling for three pathways, as well as quantitate the extent of RAMP-
engendered pathway bias at the CLR. This data has shown that at 
RAMP1-CLR, CGRP and AM2 predominantly activate cAMP signalling 
pathways, whilst AM displays little difference between both cAMP and 
calcium signalling (Figure 4.17A). In contrast, at RAMP2-CLR, AM 
predominantly activates cAMP-mediated signalling, whilst AM2 is mainly 
activating iCa2+ mobilisation. Interestingly, CGRP displays slightly greater 
activity towards cAMP production, but is the least ‘active’ of the three 
agonists (Figure 4.17B). With RAMP3-CLR, the cognate agonist, AM, 
predominantly signals via cAMP, as does AM2, whilst CGRP mainly 
mobilises iCa2+ (Figure 4.17C).  
 
In order to determine how RAMPs modulate the extent of biased agonism 
observed at the CLR, for each agonist, Professor C. Reynolds (University 
of Essex, UK) utilised molecular modelling simulations of the CLR in 
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complex with an associated RAMP. This identified that the RAMP C-
terminus is closely associated with helix 8, the intracellular portions of 
TM6 and 7, as well as the C-terminus of Gαs, but that there are no direct 
agonist-RAMP interactions (Weston et al, 2016, Appendix 2). These 
simulations provide one potential mechanism whereby RAMPs may 
modulate receptor activity: either by direct interaction with the associated 
Gα, or allosterically influencing the orientations of TM6/7 and helix 8. 
 
 
Overall, it can be appreciated how upon association with a single GPCR, 
the CLR, the three RAMPs are able to bring about three distinct 
pharmacological phenotypes. Each of these three ‘receptors’ are able to 
respond to the same three agonists, and activate the same pathways, but 
in a RAMP-specific manner. Thus, any consideration of the activity of 
CGRP, AM, or AM2, or any clinically used mimetics, needs to be 
considered with close attention paid to both the target tissue, and RAMP 
expression in target cells. In addition, the expression of RAMPs and CLR 
in other tissues, and the potential activation of other signalling pathways, 
needs to be considered. Thus, with a fuller understanding of the roles 
played by RAMPs, and their effects upon biased agonism at the CLR, 
there is potential to develop more effective, and safer, therapeutic 
intervention strategies, in the many pathological states where the CLR is 
known to play a role.  
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Figure 4.17: Extent of pathway activation at the CLR is dependent upon both agonist and RAMP. 
 
Schematic representation of the extent of pathway bias observed at RAMP1-CLR (A), RAMP2-CLR (B) and 
RAMP3-CLR (C). The thickness of each line indicates the extent of bias observed for that ligand towards 
the indicated pathway, Thicker lines being more biased, dashed lines indicating a lesser extent of bias 
towards the indicated pathway. 
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Chapter 5 
Intracellular loop 1 of the CLR influences 
biased agonism 
 
5.1 Introduction 
 
The largest and most understood group of GPCRs are those within family 
A, the rhodopsin-like receptors. For this group, numerous crystal 
structures exist; whilst these are also available for family B GPCRs, they 
are either not in active conformations, or incomplete. In contrast, those 
that exist for family A receptors come either bound to G proteins or 
nanobodies that mimic a G protein (Kruse et al, 2013, Huang et al, 2015, 
van Eps et al, 2015, Carpenter et al, 2016, Stauss et al, 2016). Beyond G 
proteins, a structure also exists for a β-arrestin-bound rhodopsin (Kang et 
al, 2015). From these structures, we now have an understanding of how 
agonist binding/retinal isomerisation leads to movement of 
transmembrane (TM) domains 2 and 3 away from one another. This thus 
has implications upon intracellular loops (ICL) 2 and 3 moving, in turn 
allowing the C-terminus of the G protein to interact directly with the 
GPCR. This knowledge, however, does not explain how GPCRs 
selectively couple to differing G proteins, or how they preferentially couple 
to one G protein over another, nor how differing agonists modulate this. 
Thus, we have little understanding of how biased agonism occurs at a 
molecular level. This is even less understood for family B receptors, 
where existing structures for the glucagon (Siu et al, 2013, Zhang et al, 
2017) and corticotropin-releasing factor (CRF) (Hollenstein et al, 2013) 
receptors are in inactive forms, whilst the glucagon-like peptide-1 (GLP-1) 
receptor has structures solved in complex with either a bound allosteric 
modulator (Song et al, 2017), agonist (Jazayeri et al, 2017), or G protein 
(Zhang et al, 2017). What we do know is that amino acids at the junctions 
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of ICL1 and the base of TM2 work in conjunction with TM3 to form a G 
protein-binding pocket (Vohra et al, 2013, Wootten et al, 2016). 
 
To date, this region, particularly ICL1, has been little studied in family B 
GPCRs; however, it has been observed that mutating this region has 
effects upon cell surface expression (Bentrop et al, 1997, Wess, 1998). 
Thus, we can be confident that ICL1 at least plays key structural roles 
within these receptors. In the existing G protein-bound crystal structure of 
the GLP-1R, ICL1 does not itself directly interact with Gα (Zhang et al, 
2017). It has, however, been shown to be an important region required for 
receptor activation in more than 10 family A and B GPCRs (Hirata et al, 
1994, Thomas III et al, 1995, Wu et al, 1997, Liu and Wu, 2003, Yu et al, 
2005, Kleinau et al, 2010). It has also been observed that differing 
agonists lead to distinct conformational changes within ICL1 (West et al, 
2011). Indeed, within the µ-opioid receptor these changes precede the 
movements of TM 5 and 6, suggesting that they are an early event in 
receptor activation, occurring soon after agonist binding (Sounier et al, 
2015), and that this may be a highly conserved phenomenon (Shihoya et 
al, 2016). Within family B, two GPCRs, CRF and the calcitonin receptor, 
also exist as isoforms containing an insert within ICL1. For the calcitonin 
receptor, this has been seen to result in reduced Gαq-mediated signalling, 
with little effect upon Gαs signalling (Furness et al, 2012). Thus, evidence 
exists to suggest that ICL1 may play key roles in receptor activation and 
G protein-mediated signalling, and, therefore, may have profound effects 
upon biased agonism.  
 
This chapter attempts to characterise ICL1, of the CLR, and gain an 
understanding of its function and possible roles played in influencing 
biased agonism. To achieve this, a saturation mutagenesis approach was 
utilised, investigating the effects of substituting all residues within ICL1 
(Y165-Q172) (Figure 5.1), to various other residues. For each substitution 
cAMP production was measured, in response to CGRP stimulation, 
where each mutant CLR is co-expressed with RAMP1 in HEK 293 cells. 
In terms of alanine substitutions further characterisation is provided, with 
Intracellular loop 1 of the CLR influences biased agonism  !
! 129 
respect to the ability of each mutant to mediate mobilisation of iCa2+ and 
activate ERK1/2. This data is then utilised in the quantification of biased 
agonism, subsequently uncovering a role of ICL1 in influencing G protein 
specificity of the CLR, and hence, bias. 
 
 
 
This chapter represents a large collaborative effort between: Professors 
D. Poyner and C. Reynolds, Heptares therapeutics (who generated 
expression constructs for each mutant, and quantified cell surface 
expression (Figure 5.7, Table 5.3)), and ourselves. It is currently part of a 
wider, ongoing study into the roles of ICL1 within the: CLR, CRF 
receptors, GCGR and the A2AR. 
 
 
 
 
 
 
 
 
 
 
K 
S L S 
C 
I R Q 
ICL1 
TM1 TM2 
Figure 5.1: Mutated residues in intracellular 
loop 1 of CLR. 
 
Location of the residues at the base of 
transmembrane domain (TM) 1, within 
intracellular loop (ICL 1), and the base of TM 2, 
which have been mutated in our saturation 
mutagenesis study. Coloured residues indicate 
those mutated, white shows those left as in wild 
type. Figure adapted from gpcrdb.org. 
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5.2 ICL1 of family B GPCRs potentially interacts 
with helix 8 
 
In silico molecular modelling studies, performed by Professor C. 
Reynolds (University of Essex, UK), identified a potential series of 
contacts between ICL1 and helix 8 (H8) of family B GPCRs. Structural 
alignment of the ICL1 region of family B GPCRs reveals that there is a 
high level of structural homology within this region (Figure 5.2). Positively 
charged residues are generally conserved at the 3rd position (position 
167, relative to the CLR), except for the GCGR, which has a serine 
(Figure 5.2). In addition, leucine/isoleucine is conserved at the 5th position 
(position 169 relative to the CLR), with a cysteine being absolutely 
conserved at the 7th position (position 171, relative to CLR), as well as an 
arginine at the base of TM2 (position 173, relative to the CLR) (Figure 
5.2). Interestingly, the CLR, CTR and both CRF1 and 2 receptors, appear 
to display a slightly differing primary structure to the rest of family B. 
Whilst most receptors contain a second positively charged residue at 
position 168, these four receptors contain a serine. Additionally, the CLR 
and CTR contain either a serine or glycine at position 170, whilst all other 
family B GPCRs contain positively charged residues (histidines, except 
for the CRF receptors which contain arginines) (Figure 5.2). At position 
172 (relative to the CLR), the CRF receptors and the growth-hormone-
releasing hormone receptor contain non-polar residues, whilst the CLR, 
CTR and the rest of family B contain polar residues at this position 
(Figure 5.2).  
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Receptor 
Position (As for CLR) 
165 166 167 168 169 170 171 172 173 
CLR Y F K S L S C Q R 
CT F F R S L G C Q R 
CRF1 R L R S I R C L R 
CRF2 A L R S I R C L R 
GHRH A L R R L H C P R 
GIP L F R R L H C T R 
GLP-1 G F R H L H C T R 
GLP-2 F L R K L H C T R 
GCGR G L S K L H C T R 
Secretin A F R R L H C T R 
PTH1 Y F R R L H C T R 
PTH2 Y F R R L H C T R 
PAC1 R F R K L H C T R 
VPAC1 L F R K L H C T R 
VPAC2 L F R K L H C T R 
Figure 5.2: Alignment of ICL1 for all family B GPCRs. 
 
Alignment of equivalent residues to CLR ICL1 (Y165-Q172) 
for all family B GPCRs. Residue numbering is shown as for 
CLR. Alignment performed in gpcrdb.org. 
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Alignment of H8 for family B reveals that two glutamic acid residues 
(positions 388 and 392, relative to the CLR), and a valine (position 389, 
relative to the CLR) are conserved (Figure 5.3). However, in the CLR, 
CTR and CRF receptors, the second glutamic acid is not present (Figure 
5.3). Analysing the structures of the inactive GCGR and GLP-1R 
identifies the possibility for charge-charge interactions between positively 
charged residues at the start of ICL1 and the base of TM2, with the 
negatively charged glutamic acids on H8. In the GCGR, this may occur 
between S167/K168 and E410, as well as between R173 at the base of 
TM2 and E406 (Figure 5.4A). Likewise, in the inactive GLP-1R the same 
phenomenon has the potential to occur by an area of positive charge 
formed by R170 and H171, creating a charge-charge interaction with 
E412, whilst R176 (equivalent to R173 in the GCGR) may also form an 
Receptor 
Position (As for CLR) 
388 387 388 389 390 391 392 393 394 
CLR N G E V Q A I L R 
CT N N E V Q T T V K 
CRF1 N S E V R S A I R 
CRF2 N G E V R S A V R 
GHRH N Q E V R T E I S 
GIP N K E V Q S E I R 
GLP-1 N N E V Q L E F R 
GLP-2 N G E V K A E L R 
GCGR N K E V Q S E L R 
Secretin N G E V Q L E V Q 
PTH1 N G E V Q A E I K 
PTH2 N G E V Q A E V K 
PAC1 N G E V Q A E I K 
VPAC1 N G E V Q A E L R 
VPAC2 N S E V Q C E L K 
Figure 5.5: Alignment for helix 8 of all family B GPCRs 
 
Alignment of equivalent residues to CLR helix 8 for all family B GPCRs. Residue 
numbering is shown as for CLR. Alignment performed using gpcrdb.org. 
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interaction with E408 (Figure 5.4B). Similar interactions, between ICL1 
and H8, to those observed in the GCGR and GLP-1R, may also 
potentially occur in other family B GPCRs due to the high level of 
conservation of positively charged residues at the equivalent positions of 
167/168 and 173, in the CLR (Figure 5.2), as well as the conservation of 
glutamic acids within H8 (Figure 5.3). However, as the CLR, CTR and 
CRFRs lack a second positive charge at positions 168 (Figure 5.2), as 
well as a second glutamic acid in H8 (Figure 5.3), it is possible that in 
these receptors there is only a single ICL1-H8 interaction, between an 
arginine at the base of TM2 and the first glutamic acid in H8. Therefore, 
the CLR, CTR, and CRF receptors potentially form a second group, which 
function differently to the majority of family B GPCRs. 
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Comparison of the inactive GLP-1R structure to that in the active state 
reveals that upon activation, R170 rotates to point away from the centre 
of the receptor and H8, whilst H171 rotates back away from H8 (Figure 
5.4C). The movement of these two residues is concurrent with a rotation 
of E412 inwards, towards H8 (Figure 5.4C). Likewise, R176 rotates to 
point away from the intra-ICL1-H8 space, whilst E408 moves to point 
towards TM2. These observations indicate that ICL1-H8 interactions may 
break upon receptor activation. The breaking of these interactions results 
in ICL1 and H8 moving apart, as observed in GLP-1R crystal structures, 
where the orientation of the TM1-ICL1-TM2 axis is altered relative to the 
inactive state, and also positioned further away from H8 (Figure 5.4B-C). 
Figure 5.4: Intracellular loop 1 of the 
g l u c a g o n a n d g l u c a g o n - l i k e 
peptide-1 receptors may form 
interactions with helix 8, which are 
broken upon activation. 
 
 
Within the inactive glucagon receptor 
(GCGR) crystal structure (PDB – 
5XEZ, Zhang et al, 2017) (A) ICL1 may 
form interactions with helix 8 (H8) 
between S167/K168 and E410, as well 
as R173 and E406. Similar interactions 
are observed within the glucagon-like 
peptide-1 receptor (GLP-1R) (PDB - 
5VEX, Song et al, 2017)  (B), where 
R170/H171 may form an area of 
positive charge, creating a charge-
charge interaction with E412, whilst 
R176 may also interact with E408. 
These interactions appear to be lost in 
the active GLP-1R (PDB – 5VAI, Zhang 
et al, 2017)  (C). Upon activation, R170 
and H171 appear to rotate away from 
H8, whilst E412 rotates towards the 
orientation of H8. Additionally, R176 
rotates away from E408, which in turn 
rotates to orientate itself pointing 
towards transmembrane (TM) bundle 
2. The movements of these resides 
correspond with an opening of the 
space between ICL1 and H8. 
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R176%
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In order to provide in vitro validation of an ICL1-H8 interaction, a 
saturation mutagenesis approach was utilised, mutating each residue 
within ICL1, Y165-Q172 (Figure 5.1), in turn, to either: alanine, arginine, 
cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, 
methionine, phenylalanine, or tryptophan. Each of these mutant CLRs 
were co-transfected with RAMP1, into HEK 293 cells, utilising a bis-
cistronic vector, containing both RAMP1 and SNAP-CLR, pIRES-RAMP1-
SNAP-CLR (WT or Y165-Q172X). In order to characterise the effects of 
these substitutions, the ability of each mutant to mediate the production of 
cAMP in response to CGRP stimulation was measured, as performed 
previously for RAMP-CLR experiments (Chapter 4). CGRP was utilised 
as the stimulating agonist, due to its inability to mediate Gαi/o signalling 
(Figure 4.4, Table 4.2). Thus, measuring cAMP production has the 
potential to study the CLR’s ability to solely couple to, and activate, Gαs. 
 
An initial screen of all these mutants (performed in duplicate, with 1 
replicate per experiment) (Figure 5.5, Table 5.1-2) identified a series of 
key substitutions as providing interesting biochemical and biophysical 
properties. Through mutating the residues within the ICL1 region (Y165-
Q172), it was possible to observe both increases and decreases in the 
potency of CGRP, as well as decreases in Emax (Figure 5.5, Tables 5.1-2). 
Glutamic acid substitution resulted in large reductions in functionality for 
most residues within ICL1 (Figure 5.5, Table 5.2). In contrast, glycine 
substitution, which is generally deleterious, was observed, for some 
residues, to have minimal effects upon potency or Emax, whilst others 
displayed a greatly reduced Emax (Figure 5.5, Tables 5.1-2). Indeed, 
glycine substitution of L169 resulted in an increased potency of CGRP, 
relative to WT CLR, which was also apparent for S168R (Figure 5.5, 
Table 5.1). Substitution of residues towards the end of ICL1 (S170-Q172) 
with isoleucine resulted in severely reduced Emaxs (Figure 5.5, Table 5.2). 
Due to the observations from this initial scan, these mutants were further 
investigated. As the initial analysis revealed that substitution of S168 with 
a positively charged arginine resulted in a gain-of-function, the effect of 
histidine substitution, upon ICL1, was also further investigated. Each of 
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these sets of mutants are characterised in terms of their ability to mediate 
the production of cAMP whilst, in order to investigate the effects of ICL1 
upon biased agonism, the alanine mutants were utilised to perform a 
more wide ranging investigation into their ability to mediate: the 
production of cAMP, iCa2+ mobilisation, and activation of ERK1/2 
signalling. The extent of bias between each pathway for each alanine 
mutant was then quantified. 
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Figure 5.5: Saturation mutagenesis of intracellular loop 1. 
 
Saturation mutagenesis of each residue across intracellular loop 1 (ICL1): Y165 (A), F166 (B), 
K167 (C), S168 (D), L169 (E), S170 (F), C171 (G), Q172 (H), reveals differential effects upon 
cAMP production, when each mutant is co-expressed with RAMP1, in HEK 293 cells, and 
stimulated with CGRP. Data represented as the percentage cAMP production relative to wild type 
(WT) CLR, ± SEM, of 2 replicates. 
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In order to provide an explanation of the effects observed for each 
substitution, the biochemical/physical properties of the substituted amino 
acid were compared to those in the WT receptor, as well as to the 
structure of ICL1. Unfortunately, no crystal structures exist for the CLR; 
thus, our findings are compared to the existing structures of the GCGR in 
an inactive form (Zhang et al, 2017), as well as the GLP1-R in both 
inactive (Song et al, 2017) and active forms (Zhang et al, 2017). Thus, 
these serve as models upon which to base our understanding of the CLR.  
 
Analysis of the ICL1 region in the crystal structure for inactive GCGR 
(Zhang et al, 2017) indicates that there is some structural similarity to that 
observed for the inactive GLP-1R (Song et al, 2017), with the backbone 
shape of ICL1 following broadly similar patterns (Figure 5.6A-B). Indeed, 
glycine and threonine residues found at the base of TM1 and TM2 display 
similar spatial orientations within both receptors, with them both being 
relatively packed into the bases of each TM bundle. Comparison of ICL1 
in the inactive (Figure 5.6B) and active (Figure 5.6C) GLP-1R reveals that 
this region undergoes a large conformational change upon activation. 
Residues F169, H171 and H173 undergo large movements, whilst L172 
and C174 are observed to slightly rotate (Figure 5.6B-C). In contrast, 
residues G165 and T175 remain in the same spatial orientations in both 
active and inactive conformations (Figure 5.6B-C), suggesting that these 
residues may play important structural roles around the bases of the TMs 
and ICL1. 
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Figure 5.6: Structures of intracellular 
loop 1 in the g lucagon and 
glucagon-like peptide-1 receptors.  
 
St ruc tu res a re shown fo r the 
intracellular loop 1 (ICL1) region of the 
inactive glucagon receptor (PDB – 
5XEZ, Zhang et al, 2017)  (A) and 
glucagon-like peptide-1 receptor 
(GLP-1R) (PDB - 5VEX, Song et al, 
2017)  (B), as well as active GLP-1R 
(PDB – 5VAI, Zhang et al, 2017)  (C). 
Comparison of inactive (B) and active 
(C) GLP-1R indicates the large extent 
of movement observed within the ICL1 
region, that occurs upon receptor 
activation, particularly for residues 
F169, R170, H171, H173 and C171. 
Residues G168 and T175 appear to 
show little movement between inactive 
(B) and active (C) GLP-1R, and also 
appear in similar orientations within the 
i n a c t i v e g l u c a g o n r e c e p t o r . 
Transmembrane (TM) bundles are 
displayed in a grey colour as helices, 
whilst the residues within ICL1 are 
differentially coloured according to 
residue. 
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5.3 Cell surface expression of CLR ICL1 mutants 
 
As mutation of the ICL1 region has previously been reported to influence 
cell surface expression of GPCRs (Bentrop et al, 1997, Wess et al, 1998), 
each mutant was transfected into HEK 293 cells, and ELISAs utilised to 
quantify the SNAP signal obtained for each mutant, relative to that of wild 
type (WT) CLR. This work was performed by Heptares therapeutics as 
part of our collaborative efforts with them.  
 
Initial quantification of cell surface expression (n = 1) revealed that each 
mutation had differing effects upon CLR’s expression, with some 
increasing expression (Y165A, S168E and C171I), and others greatly 
reducing it, as low as 4.35% for L169R (Figure 5.7, Table 5.3). The 
greatest reductions in expression, observed upon alanine substitution, 
were apparent for K167A, L169A, C171A and Q172A, with Y165A and 
F166A displaying increased expressions of ~150% and ~107%, 
respectively, relative to WT CLR (Figure 5.7, Table 5.3). Whilst 
substituting for glutamic acid results in reduced expression for residues: 
Y165-K167E and L169-Q172E, S168E displayed an elevated expression 
of ~126%, relative to WT (Figure 5.7, Table 5.3). A similar pattern to 
glutamic acid substitution for the final 4 amino acids is also observed for 
glycine substitutions, with L169-Q172 exhibiting the greatest reductions 
(Figure 5.7, Table 5.3). F166G and K167G are more greatly affected than 
the equivalent glutamic acid substitutions, with expressions of ~51% and 
~62%, relative to WT, respectively (Figure 5.7, Table 5.3). However, 
Y165G is better tolerated than Y165E with expression being ~83% that of 
WT, whilst S168G displays an elevated expression of ~110% of WT 
(Figure 5.7, Table 5.3). In terms of mutation to histidine, F166H is well 
tolerated with an expression of ~103% (relative to WT), and Y165H, S170 
and C171 displaying reductions in expression of only ~15-23% of WT 
(Figure 5.7, Table 5.3). However, histidine substitution causes reductions 
of ~60-68% for K167-L169H, and a dramatically reduced expression for 
Q172H to only 10.05%, relative to WT (Figure 5.7, Table 5.3). K167, 
Intracellular loop 1 of the CLR influences biased agonism  !
! 143 
S170 and Q172 display the greatest reductions in surface expression 
upon isoleucine substitution, with reductions of ~64-77%. (Figure 5.7, 
Table 5.3) S168I and L169I appear similarly affected, with cell surface 
expressions of ~58% and ~57%, respectively, and Y165I being 
expressed similarly to WT (~108%), whilst C171I has an increase to 
~139%, relative to WT CLR. (Figure 5.7, Table 5.3). Mutation to arginine 
has little effect upon the expression of Y165R (~103% relative to WT) and 
K167R (~94% relative to WT). In contrast, arginine substitution appeared 
to reduce expression for: F166R (~26% relative to WT), S168R (~66% 
relative to WT), S170R (~73% relative to WT), C171R (~45% relative to 
WT) and Q172R (~64% relative to WT) (Figure 5.7, Table 5.3). L169R 
appears to display the greatest reduction in surface expression, being 
only ~4% that of WT (Figure 5.7, Table 5.3). It is therefore clear that the 
differential substitution of each residue in the region of ICL1 (Y165-Q172) 
can have drastic consequences upon the cell surface expression of the 
CLR. This tends to result in decreases of > 50% when these mutations 
are at positions L169 and Q172, suggesting that these residues may play 
an important role in influencing the cell surface expression of the CLR. 
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Table 5.3: Cell surface expression data for SNAP-CLR ICL1 mutants 
(pIRES-RAMP1-SNAP-CLR (WT, Y165-Q172 A/E/G/H/I/R)), expressed in 
HEK 293 cells, as determined via ELISA. 
 
WT 
residue 
Mutation 
A E G H I R 
Y165 149.81 37.18 83.25 78.25 107.68 102.64 
F166 107.07 85.93 51.05 103.08 - 25.87 
K167 45.38 78.71 61.84 41.45 23.68 93.91 
S168 101.01 126.02 110.10 40.80 58.38 65.80 
L169 28.27 28.45 24.61 33.94 57.27 4.35 
S170 94.87 47.64 42.82 84.61 25.07 72.67 
C171 71.23 46.18 37.85 77.03 139.29 44.68 
Q172 45.91 38.63 20.82 10.05 36.35 63.63 
 
Data represented as percentage expression of wild type CLR, of 1 
replicate.
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Figure 5.7: Cell surface expression of CLR ICL1 mutants. 
 
Cell surface expression of CLR ICL1 mutants determined, upon co-
expression with RAMP 1, in HEK 293 cells. Quantified using SNAP-
tagged CLR ELISAs. Data expressed relative to expression of wild 
type RAMP1-CLR. Work performed by Heptares therapeutics. 
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5.4 Effects of ICL1 glutamic acid mutations upon 
cAMP production 
 
In order to investigate the effect of introducing negative charges within 
ICL1, each residue was mutated, in turn, to glutamic acid. This identified 
that loss of the hydrophobic properties at Y165 could be tolerated by 
replacement with a negative charge (Y165E), with signalling being 
comparable to WT (Figure 5.8A, Table 5.4), despite Y165E having a 
relative expression of only 37% (Figure 5.7, Table 5.3). In contrast, 
replacing each of the other residues (F166-Q172) with glutamic acid had 
deleterious effects upon the CLR’s ability to signal (Figure 5.8B-H, Table 
5.4). These effects may be, in part, explained for L169-Q172 by 
accompanying reductions in cell surface expression of ~52-72% (Figure 
5.7, Table 5.3). This indicates that a negative charge cannot be tolerated 
at any point across ICL1. Replacement of the aromatic, polar 
phenylalanine at position 166 results in a ~15 fold reduction in potency, 
and a ~68% reduction in Emax  (Figure 5.8B, Table 5.4). Replacement of 
the positive charge at K167 with a negative one is also detrimental, with 
similar effects to F166E, and a reduction in maximal signalling of ~62% 
being apparent (Figure 5.8C, Table 5.4). This indicates that K167 may 
possibly serve a similar function to S167 in the GCGR (Figure 5.4A), and 
R170/H171 in the GLP-1R (Figure 5.4B), in forming an interaction with 
negatively charged residues on H8. As there is only one glutamic acid in 
H8 of the CLR (Figure 5.3), K167 may potentially form an interaction with 
E388. In addition, substitution of all the remaining polar residues, S168-
Q172, with a negatively charged glutamic acid results in a reduction in 
potency for S168E and S170-C171E, with S170E displaying the largest 
reduction, of ~50 fold, relative to WT (Figure 5.8D-H, Table 5.4). These 
effects are also concurrent with large reductions in Emax for all residues 
(Figure 5.8D-H, Table 5.4). This data may suggest that negative charges 
across the ICL1 region may all result in charge-charge repulsion with the 
negative charge on E388. Interestingly, Q172E actually displays an 
increased potency, but also the greatest reduction in Emax of ~76% 
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(Figure 5.8H, Table 5.4), which may be due to effects upon TM2/ICL2. It 
is thus observed that the CLR is unable to tolerate substitution with 
glutamic acid for residues F166-Q172, and that negative charges in this 
region greatly reduce the CLR’s ability to mediate activation of Gαs. The 
only position where this can be tolerated is Y165. The equivalent residues 
to Y165 in the GCGR (G165) and GLP-1R (G168) are relatively packed 
into the base of TM1 (Figure 5.6A-C); this could also be true of the CLR. 
Thus, Y165 appears to play a minor role in signalling. 
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Figure 5.8: Glutamic acid scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR    (n = 10), or each mutant (n = 6)   :Y165E (A), 
F166E (B), K167E (C), S168E (D), L169E (E), S170E (F), C171E (G), Q172E (H). Data are 
expressed relative to levels of cAMP produced by wild type CLR, ± SEM, of n replicates. Arrows 
indicate changes in pEC50 or Emax. Significance was calculated using a one-way ANOVA with 
Dunnet’s post-test (*, p < 0.05, **, p < 0.01, ***, p < 0.001).  
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Table 5.4: Potency (pEC50) and Emax values for cAMP production in HEK 
293 cells transfected with pIRES-RAMP1-SNAP-CLR (WT, Y165-
Q172E), upon CGRP stimulation. 
 
 pEC50
a Emaxb n 
WT 8.90±0.2** 102.1±6.4  *** 10 
Y165E 8.48±0.2** 119.1±8.5  *** 6 
F166E 7.72±0.3** 31.7±6.1*** 6 
K167E 7.93±0.3** 37.8±6.0*** 6 
S168E 7.96±0.3** 43.5±7.2*** 6 
L169E 8.72±0.3** 37.8±4.2*** 6 
S170E 7.22±0.8**   37.9±12.3*** 6 
C171E 8.08±0.2** 62.8±5.6*** 6 
Q172E 9.80±0.6** 24.1±5.0*** 6 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001). 
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5.5 Effects of ICL1 glycine mutations upon cAMP 
production 
 
Having determined that negative charges are not tolerated, a glycine 
scan of this region was also performed. This would remove all side chain 
chemistry, whilst also introducing flexibility within the backbone structure 
of ICL1. Thus, by conferring increased flexibility at each position, it is 
possible to highlight how crucial the positioning of each residue is to 
CLR’s functionality. Unlike Y165E (Figure 5.8A, Table 5.4), substitution 
for glycine at this position is poorly tolerated, with reductions in both 
potency and Emax (Figure 5.9A, Table 5.5). This may suggest that Y165 
plays a key role in packing against TM1, and in holding ICL1 in an optimal 
conformation for G protein activation. Indeed, with the GLP-1R, the 
equivalent residue, G168, remains in a relatively similar position in both 
inactive and active conformations (Figure 5.6B-C). Therefore, through 
mutating Y165 to glycine, greater flexibility at this position has been 
conferred, perhaps affecting the orientation of ICL1. In contrast, F166G is 
well tolerated, with signalling being similar to WT (Figure 5.9B, Table 5.5). 
However, near total abolition of activity for K167G is observed, with 
signalling reduced to ~28% that of WT (Figure 5.9C, Table 5.5). This 
could, perhaps, be due to loss of the positive charge at this position in 
WT CLR, which appears to be required, in other family B GPCRs, for 
interaction with H8 (Figure 5.4A-B). In stark contrast, L169G, whilst 
having a reduced Emax, actually has an increased potency of ~26 fold 
over WT (Figure 5.9E, Table 5.5), despite a great reduction in cell surface 
expression of ~75% (Figure 5.7, Table 5.3). This suggests that loss of 
rigidity here makes it easier for the CLR to adopt an active confirmation, 
upon CGRP binding. Indeed, in the GLP-1R the equivalent residue, L172, 
appears to undergo little movement between inactive and active states 
(Figure 5.6 B-C). As with K167G, glycine substitution at S170 has a 
dramatic effect upon signalling, resulting in total abolition of activity 
(Figure 5.9F, Table 5.5). This occurs despite S170G being expressed at 
levels ~40% that of WT (Figure 5.7, Table 5.3), a level of expression 
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which has previously still resulted in CGRP-mediated cAMP production. 
Thus, it appears that the positioning of the polar side chain of S170 is 
critical for correct CLR function. In the GLP-1R, the equivalent residue of 
S170 is H173, which appears to undergo a large rotation away from TM1, 
towards TM2 (Figure 5.6B-C). Whilst this residue appears to play no role 
in interacting with H8, its conservation in all family B GPCRs, except the 
CLR, CT and CRF receptors, suggests its function is critical. These 
residues may therefore play some role in regulating downstream 
signalling, after ICL1 and H8 have moved apart during receptor 
activation. Unlike all other substitutions, C171G and Q172G are 
extremely well tolerated with regards to Emax, also displaying an 
increased potency relative to WT (Figure 5.9G-H, Table 5.5). The fact 
that these two substitutions are so well tolerated is in spite of the fact that 
C171G has an expression of 37.85%, and Q172G 20.82%, relative to WT 
(Figure 5.7, Table 5.3). Thus, it appears that C171 and Q172 may 
actually serve to hold the CLR in an inactive conformation. Through 
conferring flexibility at these two positions, it is possible that a 
constraining interaction has been removed, allowing for an easier 
transition from an inactive to active conformation, hence resulting in an 
increase in CGRP’s potency. Indeed, in the GLP-1R the equivalent 
residues to C171 and Q172 (C174 and T175) appear to be fairly 
immobile, with only C174 displaying a small amount of movement, 
between inactive and active states (Figure 5.6B-C). It may therefore be 
possible that these residues, in family B GPCRs, serve as ‘anchor points’ 
between ICL1 and TM2. T175 appears to be packed into the base of TM2 
in the GLP-1R, much like G168 (Figure 5.6B-C). Therefore, Q172 may 
also be similarly positioned in the CLR. Overall, glycine scanning has 
identified that: Y165, C171 and Q172 may play roles in the positioning of 
ICL1, whilst K167 and S170 are required to be held in specific positions 
for optimal activity. 
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Figure 5.9: Glycine scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR (n = 10)   , or each mutant (n = 3)    :Y165G (A), 
F166G (B), K167G (C), S168G (D), L169G (E), S170G (F), C171G (G), Q172G (H). Data are 
expressed relative to levels of cAMP produced by wild type CLR, ± SEM, of n replicates. Arrows 
indicate changes in pEC50 or Emax. Significance was calculated using a one-way ANOVA with 
Dunnet’s post-test (*, p < 0.05, **, p < 0.01, ***, p < 0.001).  
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Table 5.5: Potency (pEC50) and Emax values for cAMP production in HEK 
293 cells transfected with pIRES-RAMP1-SNAP-CLR (WT, Y165-
Q172G), upon CGRP stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
NR – No response. 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01,  ***, p < 0.001).
 pEC50
a Emaxb n 
WT 8.90±0.2**  102.1±6.4**** 10 
Y165G 7.16±0.9** 0 31.7±13.4*** 3 
F166G 9.21±0.2** 101.9±4.3*** 3 
K167G 8.30±0.5** 028.3±4.2*** 3 
S168G 7.91±0.4** 054.8±7.6*** 3 
L169G 10.32±0.2**8 069.2±3.7*** 3 
S170G NR NR 3 
C171G 9.96±0.2** 123.2±7.0*** 3 
Q172G 10.33±0.2*** 083.3±4.3*** 3 
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5.6 Effects of ICL1 histidine mutations upon cAMP 
production 
 
Having investigated the effects of glutamic acid and glycine scanning of 
ICL1 upon the CLR, a histidine scan was also performed to investigate 
how positive charges affected CGRP-mediated, CLR-dependent cAMP 
production. Unlike substitution with negatively charged glutamic acid, 
positively charged histidine is fairly well tolerated. As with glutamic acid 
substitution at Y165 (Figure 5.8A, Table 5.4), histidine is well tolerated, 
with only a small reduction in Emax being apparent (Figure 5.10A, Table 
5.6). This further implies that Y165 is relatively packed into the base of 
TM1, acting as a linker between TM1 and ICL1. A similar trend is 
observed for residues: F166 and K167 (reduction in Emax observed), 
whilst S168 displays a reduction in potency (Figures 5.10B-D, Table 5.6). 
The fact that replacing a positively charge lysine (K167), with a positively 
charged histidine has no effect upon potency, and only a small effect 
upon Emax, implies that histidine can potentially still form the same 
interactions that K167 does in the WT CLR. Substitution of S168 for 
histidine creates an analogous situation to WT GLP-1R, which has a 
histidine at the equivalent position as CLR (Figure 5.2). The fact that this 
has little effect implies that a serine, in the CLR, is able to perform similar 
functions to this histidine in the GLP-1R, a residue that undergoes a large 
rotation upon activation (Figure 5.6B-C). In contrast, histidine substitution 
at L169 results in an ~14 fold reduction in potency, relative to WT, with no 
concurrent effect upon Emax (Figure 5.10E, Table 5.6). For the remaining 
residues at the end of ICL1, S170-Q172, histidine substitution appears to 
have little effect, with slight reductions in Emax being observed for S170H 
and Q172H, along with a concurrent reduction in potency for Q172H 
(Figure 5.10F-G, Table 5.6). In fact, lack of any larger effects upon 
Q172H’s ability to signal is surprising, given that it is only expressed to 
10% that of WT CLR (Figure 5.7, Table 5.3). This indicates the great level 
of receptor reserve for RAMP1-CLR, and that the pharmacological effects 
observed in these studies may not be solely due to reductions in receptor 
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expression. Overall, this data indicates that positive charges are fairly 
well tolerated within ICL1, having minimal impact upon signalling activity 
except for L169H, which displays a reduced potency, apparent whenever 
a charge is introduced at position 169. In the GLP-1R, the equivalent of 
L169, L172, appears to undergo little movement between inactive and 
active conformations (Figure 5.6B-C). The fact that this residue is 
universally conserved amongst family B GPCRs (albeit with CRF having 
isoleucines in this position), and often found between two positively 
charged residues, may suggest it serves to prevent a large area of 
positive charge being formed, or preventing charge-charge repulsion 
between the flanking residues. By introducing a histidine at position 169 
in the CLR, a secondary charge-charge interaction with E388 in H8 may 
be formed, thereby making it harder for an ICL1-H8 interaction to be 
broken upon activation (hence the reduction in potency of CGRP for this 
mutant). 
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Figure 5.10: Histidine scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR (n = 10)   , or each mutant   : Y165H (n = 6) (A), 
F166H (n = 3) (B), K167H (n = 6) (C), S168H (n = 6) (D), L169H (n = 5) (E), S170H (n = 6) (F), 
C171H (n = 4) (G), Q172H (n = 6) (H). Data are expressed relative to levels of cAMP produced by 
wild type CLR, ± SEM, of n replicates. Arrows indicate changes in pEC50 or Emax. Significance was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, **, p < 0.01).  
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Table 5.6: Potency (pEC50) and Emax values for cAMP production in HEK 
293 cells transfected with pIRES-RAMP1-SNAP-CLR (WT, Y165-
Q172H), upon CGRP stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01). 
 pEC50
a Emaxb n 
WT 8.90±0.2** 102.1±6.4** 10 
Y165H 8.59±0.3** 073.7±7.5** 6 
F166H 9.42±0.3** 068.6±5.7** 3 
K167H 8.87±0.3** 073.8±7.6** 6 
S168H 8.16±0.2** 0  93.6±11.3** 6 
L169H 7.75±0.3** 0  87.7±10.7** 5 
S170H 8.30±0.2**   76.0±6.6** 6 
C171H 8.19±0.3**   119.4±10.3** 4 
Q172H 8.14±0.3**   71.4±7.6** 6 
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5.7 Effects of ICL1 isoleucine mutations upon 
cAMP production 
 
Scanning ICL1 with isoleucine (Y165I, K167-Q172I) identified that at most 
positions, a branched, hydrophobic side chain is not well tolerated. 
However, as with most previous substitutions, isoleucine substitution of 
Y165 is tolerated with signalling being comparable to WT CLR (Figure 
5.11A, Table 5.7). This further suggests that Y165 plays a role in helping 
to correctly position ICL1, rather than providing biochemical properties 
required for function. Isoleucine substitution of K167 results in a reduction 
in Emax by ~60% (Figure 5.11B, Table 5.7), perhaps due to loss of a 
seemingly essential positive charge at this position. A similar reduction in 
Emax is also observed for S168I, with no apparent effect on potency 
(Figure 5.11C, Table 5.7), whilst L169I substitution results in a ~21 fold 
reduction in potency, and in Emax of ~45% (Figure 5.11D, Table 5.7). The 
equivalent residue in GLP-1R (L172) appears to move little between 
active and inactive conformations (Figure 5.6B-C), suggesting that the 
positioning of this residue is critical. Therefore, changing the chirality of 
the WT residue alters its position, resulting in a loss of function. 
Interestingly, in the CRF receptors an isoleucine is present in this position 
(Figure 5.2), suggesting the possibility of a slightly different role for this 
residue within these two GPCRs. The reductions in Emax for K167-L169I 
may also be explained by each of these mutant receptors having 
reductions in cell surface expression of 42-76% (Figure 5.7, Table 5.3). 
Substitution of the uncharged, polar residues S170 and Q172 to non-
polar isoleucine results in total abolition of functionality for S170I, and a 
large reduction in Emax for Q172I (Figure 5.11E-G, Table 5.7). Whilst this 
may be explained by S170I and Q172I having greatly reduced cell 
surface expressions (Figure 5.7, Table 5.3), they are expressed at levels 
equal to, or greater than, K167I, which is still functional. Thus, these 
effects may be due to biochemical/biophysical determinants, rather than 
solely due to expression levels. In the case of Q172I this may be due to 
effects upon the positioning of ICL1, as the equivalent residue in the 
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GLP-1R shows little difference in orientation between inactive and active 
conformations (Figure 5.6B-C), but may also be due to effects upon TM2 
and/or ICL2. For C171I, CGRP is observed to act as an inverse agonist, 
with a reduction in signalling of ~17%, relative to unstimulated cells 
(Figure 5.11F, Table 5.7). This could potentially be due to non-specific 
coupling to differing G proteins (potentially Gαi/o), due to a greatly 
increased expression (Figure 5.7, Table 5.3), or stabilising a more 
inactive receptor conformation. Alternatively, an isoleucine at this position 
may promote coupling to Gαi/o, thereby resulting in a reduction in AC 
activity, mediated via some level of constitutive activity of the CLR. The 
data obtained from isoleucine scanning has thus identified how important 
the chirality of L169 is, and the crucial roles played by the polar residues 
towards the end of ICL1 (S170-Q172). 
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Figure 5.11: Isoleucine scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR (n = 10)    , or each mutant (n = 3 )    :  Y165I (A), 
K167I (B), S168I (C), L169I (D), S170I (E), C171I (F), Q172I (G). Data are expressed relative to 
levels of cAMP produced by wild type CLR, ± SEM, of n replicates. Arrows indicate changes in 
pEC50 or Emax. Significance was calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 
0.05, **, p < 0.01, ***, p < 0.001).  
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Table 5.7: Potency (pEC50) and Emax values for cAMP production in HEK 
293 cells transfected with pIRES-RAMP1-SNAP-CLR (WT, Y165I, K167-
Q172I), upon CGRP stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
NR – No response. 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001). 
 pEC50
a Emaxb n 
WT 8.90±0.2* -102.1±6.4*** 10 
Y165I 8.30±0.2* -089.2±6.5*** 3 
K167I 10.03±0.8* -041.8±7.6*** 3 
S168I 8.97±0.3* -044.5±4.9*** 3 
L169I 7.58±0.5* -  055.4±11.0*** 3 
S170I NR NR 3 
C171I 8.12±1.1* 0-16.7±7.5*** 3 
Q172I 8.54±0.9* -025.4±6.6*** 3 
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5.8 Effects of ICL1 arginine mutations upon cAMP 
production 
 
As substituting each residue in ICL1 with a positively charged histidine 
was well tolerated by the CLR, it was sought to further investigate the 
effect of other positive charges, through arginine scanning. As with 
histidine substitutions for Y165-K167 (Figure 5.10A-C, Table 5.6), 
substitution with arginine displayed little effect in terms of both potency 
and maximal signalling, with only F166R displaying a slight reduction in 
potency (Figure 5.12A-C, Table 5.8). However, substitution of S168, to 
arginine, results in a large increase, of ~29 fold, in potency, over WT, with 
no detrimental effects upon Emax (Figure 5.12D, Table 5.8). This 
substitution represents the largest gain-of-function observed of all the 
mutations studied, suggesting that a positively charged, highly branched 
side chain is actually beneficial, and improves CLR activity, compared to 
the WT serine, at this position. Through substituting S168 for an arginine 
the CLR has been made more like the consensus for family B, with a 
positive charge at this position (Figure 5.2). Indeed, the CRF receptors 
contain an arginine at this position (Figure 5.2). The fact that a gain-of-
function is now observed implies that a beneficial interaction with 
downstream signalling proteins may have been generated. This may be 
with Gβ, as H171 in the GLP-1R, the equivalent residue to S168, has 
been observed to directly interact with D312 of Gβ via an electrostatic 
interaction (Zhang et al, 2017). Therefore, through introducing a positive 
charge at this position in the CLR (S168R), which is absent in the WT 
receptor, an ICL1-Gβ interaction may be promoted, resulting in 
potentiation of CGRP-mediated signalling at the CLR. Arginine 
substitution of L169 results in a large reduction in Emax by ~55% (Figure 
5.12E, Table 5.8). It is surprising that L169R is able to function, as it has 
a surface expression of only 4.35%, relative to WT (Figure 5.7, Table 
5.3). Along with Q172H having an expression of ~10% (Figure 5.7, Table 
5.3), this data again highlights the large extent of receptor reserve in this 
system, and indicates that effects observed are not solely due to reducing 
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receptor number. In contrast to L169R, arginine substitutions at positions 
S170-Q172 appeared to have little effect, with Q172R displaying a slight 
increase in Emax (Figure 5.12F-H, Table 5.8). Therefore, as with histidine 
substitutions (Figure 5.10, Table 5.6), ICL1 appears, again, to be tolerant 
to positive charges inferred by arginine. Indeed, these even prove 
beneficial, and confer a gain of function, when at position 168, potentially 
through promoting interactions with associating G proteins. 
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Figure 5.12: Arginine scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR (n = 10)    , or each mutant    : Y165R (n = 6) (A), 
F166R (n = 6) (B), K167R (n = 6) (C), S168R (n = 6) (D), L169R (n = 6) (E), S170R (n = 6) (F), 
C171R (n = 8) (G), Q172R (n = 8) (H). Data are expressed relative to levels of cAMP produced by 
wild type CLR, ± SEM, of n replicates. Arrows indicate changes in pEC50 or Emax. Significance was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, **, p < 0.01, ***, p < 0.001).  
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Table 5.8: Potency (pEC50) and Emax values for cAMP production in HEK 
293 cells transfected with pIRES-RAMP1-SNAP-CLR (WT, Y165-
Q172R), upon CGRP stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 pEC50
a Emaxb n 
WT 18.90±0.2*** 102.1±6.4*** 10 
Y165R 19.28±0.2*** 99.01±4.8*** 6 
F166R 18.08±0.2***  122.9±11.1** 6 
K167R 18.97±0.3*** 118.6±9.9*** 6 
S168R 10.36±0.3*** 107.8±5.7*** 6 
L169R 18.70±0.3*** 145.3±6.9*** 6 
S170R 19.16±0.2*** 113.6±7.2*** 6 
C171R 18.84±0.2*** 101.9±7.4*** 8 
Q172R 19.31±0.2*** 123.3±7.2*** 8 
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5.9 Effects of ICL1 alanine mutations upon cAMP, 
iCa2+ and ERK1/2 signalling 
 
Through performing an alanine scan it was identified that substituting 
residues Y165, K167 and S168, to alanine, has minimal effects upon 
CGRP-mediated cAMP production from the CLR, in terms of potency and 
maximal signalling, relative to WT (Figure 5.13A, C and D, Table 5.9). 
This lack of effect for K167A is despite a reduction in cell surface 
expression of ~55%, relative to WT (Figure 5.7, Table 5.3). Substituting 
the remaining residues has differing effects, depending upon the residue 
mutated. F166A displays a reduction in potency of ~6 fold, relative to WT, 
and a reduced Emax (Figure 5.13B, Table 5.9). This suggests that loss of a 
bulky aromatic side chain at this position is detrimental in terms of the 
level of response mediated upon agonist stimulation. Substitution of L169 
for alanine has a similar effect to F166A, with a ~3 fold reduction in 
potency (not statistically significant), as well as an associated reduction in 
Emax (Figure 5.13E, Table 5.9). These reductions may be due to a 
reduced cell surface expression (Figure 5.7, Table 5.3). This data 
suggests that at position 169, a relatively large, non-polar R group is 
required for optimal, maximal, signalling, and that substitution for a small, 
non-polar R group is detrimental. Substitution of a polar R group at 
position 170 for a non-polar one (S170A) has no effect upon potency, but 
slightly increases Emax (Figure 5.13F, Table 5.9). In contrast, loss of a 
polar R group at position 171 (C171A) results in a reduced potency, with 
little effect on Emax (Figure 5.13G, Table 5.9). As with S170A, loss of a 
large, polar R group at position 172 (Q172A) results in a decrease in 
potency (not statistically significant), with an associated reduction in Emax 
(Figure 5.13H, Table 5.9). As with L169A, this may, in part, be due to a 
reduction in cell surface expression, of ~54% that of WT CLR.  
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Figure 5.13: Alanine scan of ICL1 (Y165-Q172) of CLR.  
 
cAMP accumulation was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either WT CLR    (n = 10), or each  mutant (n = 6)     : Y165A (A), 
F166A (B), K167A (C), S168A (D), L169A (E), S170A (F), C171A (G), Q172A (H). Data are 
expressed relative to levels of cAMP produced by wild type CLR, ± SEM, of n replicates. Arrows 
indicate changes in pEC50 or Emax. Significance was calculated using a one-way ANOVA with 
Dunnet’s post-test (*, p < 0.05, **, p < 0.01).  
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Table 5.9: Potency (pEC50), affinity (pKa) and coupling efficacy (Log τ) 
values for cAMP production in HEK 293 cells, transfected with pIRES-
RAMP1-SNAP-CLR (WT, Y165-Q172A), upon CGRP stimulation. 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
c Negative logarithm of the equilibrium dissociation constant, as 
determined using the operational model of agonism (Black and Leff, 
1983). 
d Coupling efficacy parameter as determined using the operational model 
of agonism (Black and Leff, 1983). 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001). 
 
 
Having previously identified the ability of RAMP1-CLR heterodimers to be 
able to mobilise iCa2+, in response to CGRP stimulation, in a Gαq/11-
dependent manner (Figure 4.5, Table 4.3), the effects of alanine 
substitutions upon this signalling pathway were further investigated. In 
order to achieve this, each alanine mutant was transfected into HEK 293 
cells loaded with FLUO-4/AM and iCa2+ mobilisation measured, in 
response to CGRP stimulation. Through characterising RAMP1-WT CLR 
(pIRES-RAMP1-SNAP-CLR (WT)), it was identified that 10-100 nM 
CGRP is able to generate equally large responses, with 1 nM and 100 pM 
producing intermediate responses, with no iCa2+ being mobilised at < 10 
 pEC50
a Emaxb pKac Logτd n 
WT 8.90±0.2** 102.1±6.4** 8.69±0.2** 0000-0.19±0.02*** 10 
Y165A 8.48±0.2** 119.1±8.5** 8.81±0.2** -0.000087±0.03*** 6 
F166A 8.12±0.3*** 062.9±8.2** 8.54±0.3** 0000-0.42±0.02*** 6 
K167A 8.85±0.2** 122.6±6.6** 8.72±0.2** 0000-0.14±0.02*** 6 
S168A 8.78±0.2** 115.9±7.9** 8.17±0.2** 0000-0.11±0.04*** 6 
L169A 8.44±0.2** 069.9±6.2*** 8.13±0.3** 0000-0.50±0.03*** 6 
S170A 8.85±0.2** 129.8±8.3** 8.00±0.2** 000-0.082±0.03*** 6 
C171A 7.68±0.4** 086.2±10.5 7.57±0.3** 0000-0.35±0.03*** 8 
Q172A 8.35±0.2** 068.5±5.7*** 8.09±0.3** 0000-0.42±0.02*** 8 
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pM (Figure 5.14A). In contrast, for Y165A it was observed that 1-100 nM 
CGRP is able to mediate large, robust responses, but at < 1 nM, no 
response is observed (Figure 5.14B). Mutating F166 and K167 to alanine 
had little effect upon CGRP-mediated mobilisation of iCa2+, with similar 
responses to WT CLR being observed (Figure 5.14C-D). In contrast, 
mutating residues S168-Q172 to alanine had profound effects upon iCa2+ 
mobilisation. It was possible to observe reductions in the maximal 
fluorescence intensity observed for each stimulating CGRP 
concentration, as well as those that are able to mediate mobilisation of 
iCa2+ (Figure 5.14E-J). For S168, it was observed that 1-100 nM CGRP 
stimulation results in iCa2+ mobilisation (Figure 5.14E). In contrast, 1 nM 
CGRP had no effect upon L169-Q172, whilst 10 nM generated much 
smaller responses compared to Y165-K167 (Figure 5.13). It was thus 
identified that residues at the base of (Y165), and close to (F166-K167), 
TM1 are more tolerant to alanine substitution than those across ICL1 
(S168-C171) and at the base of TM2 (Q172A), with respect to mobilising 
iCa2+. 
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In order to directly compare the effects of each mutation, the raw Ca2+ 
traces (Figure 5.14) were converted to dose-response curves (Figure 
5.15). Normalising these relative to the maximal iCa2+ response observed 
for stimulation with 100 µM ionomycin reduces variability due to 
differential dye loading and cell passage number. This data is then 
presented relative to the response observed for WT CLR, in order to 
ascertain the effects of alanine substitution. Through analysing these 
dose-response curves, two distinct populations of mutants can clearly be 
identifed: those with responses similar to WT (Y165-K167A) (Figure 
5.15A-C, Table 5.10), and those displaying a reduction in potency (S168-
C171A) (Figure 5.15D-H, Table 5.10). Concurrent with reductions in 
Figure 5.14: Effects of alanine scan upon mobilisation of iCa2+.  
 
HEK 293 cells, loaded with FLUO-4/AM, transfected with pIRES-RAMP1-SNAP-CLR for either WT CLR 
(A), Y165A (B), F166A (C), K167A (D), S168A (E), L169A (F), S170A (G), C171A (H) or Q172A (I), were 
stimulated with CGRP and increases in fluorescence measured. Data are expressed as fluorescence 
values relative to baseline, and are representative of the average response obtained from 3 replicates. 
Dotted line indicates point of CGRP injection. 
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potency, L169-C171A all display greatly reduced pKa values relative to 
WT (Table 5.10). Overall, it has been possible to identify that mutating 
ICL1 has profound effects upon CGRP-stimulated iCa2+ mobilisation for 
S168-C171, whilst having minimal effects for Y165-K167 and Q172. This 
suggests that ICL1 plays roles in mediating Gαq/11 signalling. It also 
indicates that residues at the start of ICL1 are more tolerant to alanine 
substitution (in terms of iCa2+ mobilisation) and thus, those spanning ICL1 
are more important in terms of mediating Gαq/11 coupling. 
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Figure 5.15: iCa2+ mobilisation dose-response curves for the alanine scan of ICL1 (Y165-Q172) of 
CLR.  
 
Mobilisation of iCa2+ was measured, upon CGRP stimulation, in HEK 293 cells transfected with pIRES-
RAMP1-SNAP-CLR for either WT CLR     , or each mutant    : Y165A (A), K167A (B), S168A (C), L169A 
(D), S170A (E), C171A (F), Q172A (G). Data are expressed relative response produced by wild type CLR, 
± SEM, of 3 replicates. Arrows indicate changes in pEC50 or Emax. Significance was calculated using a 
one-way ANOVA with Dunnet’s post-test (*, p < 0.05, **, p < 0.01).  
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Table 5.10: Potency (pEC50), affinity (pKa) and coupling efficacy (Log τ) 
values for iCa2+ mobilisation in HEK 293 cells, transfected with pIRES-
RAMP1-SNAP-CLR (WT, Y165-Q172A), upon CGRP stimulation. 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
c Negative logarithm of the equilibrium dissociation constant, as 
determined using the operational model of agonism (Black and Leff, 
1983). 
d Coupling efficacy parameter as determined using the operational model 
of agonism (Black and Leff, 1983). 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001). 
 pEC50
a Emaxb pKac Logτd n 
WT 9.07±0.2* 97.2±7.3** 8.85±0.2*** -0.33±0.04*** 3 
Y165A 9.49±0.3* 98.2±8.5** 9.38±0.1*** -0.28±0.03*** 3 
F166A 9.03±0.3* 97.3±9.7** 8.76±0.2*** -0.32±0.05*** 3 
K167A 9.81±0.3* 79.9±2.7** 9.61±0.1*** -0.43±0.03*** 3 
S168A 8.18±0.2* 61.7±9.1** 8.03±0.2*** -0.60±0.5***** 3 
L169A 6.45±0.7*   40.2±15.0** 6.03±0.1*** -0.21±0.03*** 3 
S170A 7.22±0.6* 94.9±18.4 6.95±0.3*** -0.31±0.0.7** 3 
C171A 6.11±0.9*   59.4±17.5** 6.18±0.2*** -0.18±0.04*** 3 
Q172A 8.07±0.5*   36.7±10.3** 8.10±0.2*** -0.85±0.04*** 3 
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In order to discern if mutation of Y165-Q172 to alanine has any effects 
upon the activation of ERK1/2, HEK 293 cells were transiently transfected 
with pIRES-RAMP1-SNAP-CLR (WT, Y165-Q172A). These cells were 
subsequently stimulated with CGRP, and levels of phospho-ERK1/2 
measured. For WT CLR, it was observed that CGRP generates a fairly 
weak response (pEC50: 7.35±0.3) (Figure 5.16, Table 5.11). Comparing 
this to the alanine mutants identified that whilst some display slight 
differences, none of these are significantly different from WT (Figure 5.16, 
Table 5.11). The only difference observed between each mutant and WT 
CLR is that Y165-K167A display lower efficacies (Log τ) (Table 5.11). It is 
thus concluded that mutation of residues Y165-Q172 had little effect upon 
the ability of RAMP1-CLR to activate ERK1/2, in a CGRP-dependent 
manner. Therefore, ICL1, potentially, plays no role in ERK1/2-mediated 
signalling. 
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Figure 5.16: Activation of ERK1/2 for the alanine scan of ICL1 (Y165-Q172) of CLR.  
 
Activation of ERK1/2 was measured, upon CGRP stimulation, in HEK 293 cells transfected with 
pIRES-RAMP1-SNAP-CLR for either: WT CLR, Y165A (A), F166A (B), K167A (C), S168A (D), 
L169A (E), S170A (F), C171A (G) or Q172A (H). Data represented as the percentage response 
obtained relative to WT CLR, ± SEM, of 3 replicates. 
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Table 5.11: Potency (pEC50), affinity (pKa) and coupling efficacy (Log τ) 
values for ERK1/2 activation in HEK 293 cells, transfected with pIRES-
RAMP1-SNAP-CLR (WT, Y165-Q172A), upon CGRP stimulation. 
 
 
Data ± SEM of n individual replicates. 
a Negative logarithm of agonist concentration producing half-maximal 
response. 
b Maximal response observed upon CGRP stimulation, as a percentage 
of that observed for wild type CLR. 
c Negative logarithm of the equilibrium dissociation constant, as 
determined using the operational model of agonism (Black and Leff, 
1983). 
d Coupling efficacy parameter as determined using the operational model 
of agonism (Black and Leff, 1983). 
Statistical difference between each mutant and wild type CLR was 
calculated using a one-way ANOVA with Dunnet’s post-test (*, p < 0.05). 
 pEC50
a Emaxb pKac Logτd n 
WT 7.35±0.3 100.1±19.20 6.49±0.4 -0.0037±0.10*-0   2 
Y165A 7.67±0.4 51.1±11.5 7.68±0.5 -0.70±0.1** 2 
F166A 7.82±0.3 73.5±11.6 7.68±0.3 -0.56±0.08* 2 
K167A 8.10±0.3 66.5±10.4 8.00±0.3 -0.59±0.08* 2 
S168A 6.82±0.4 114.5±6.900 6.78±0.4 -0.35±0.2*0 2 
L169A 6.71±0.3  110±24.2 6.51±0.3 -0.32±0.1*0 2 
S170A 6.64±0.6  130±52.2 6.44±0.6 -0.24±0.3*0 2 
C171A 7.00±0.5 85.1±22.5 6.78±0.6 -0.35±0.2*0 2 
Q172A 6.84±0.3  126±21.3 6.69±0.3 -0.27±0.1*0 2 
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5.10 Quantifying the effects of CLR ICL1 alanine 
mutations upon pathway bias 
 
From the data obtained from the alanine scan of ICL1, effects upon cAMP 
production and iCa2+ mobilisation were observed (Figures 5.13-15, Tables 
5.9-10), whilst observing minimal effects upon ERK1/2 activation (Figure 
5.16, Table 5.11). Through quantifying these differences in terms of 
pathway bias, as performed in Chapters 3 and 4, it was possible to 
elucidate the differing effects that each residue has upon influencing 
differential G protein signalling. It was also observed that RAMP1-CLR 
heterodimers stimulated with CGRP display ~100-fold bias towards 
preferentially signalling via Gαs and Gαq, over activating ERK1/2 (Figure 
5.17). As each residue in ICL1 was mutated to alanine, it was possible to 
observe decreases in the extent of this bias, to the point that L169A and 
C171A are equally biased towards iCa2+ mobilisation and ERK1/2 
activation (Figure 5.17). Comparing the extent of bias between cAMP 
production and iCa2+ mobilisation for each mutant uncovered an 
interesting trend: Y165-K167A are all more biased towards iCa2+ 
mobilisation, over cAMP production (relative to ERK1/2 activation) (Figure 
5.17). This then switches to being more biased towards cAMP production 
for S168-Q172A (Figure 5.17). An identical trend is observed when 
analysing relative bias, using ERK1/2 and WT CLR as references (Figure 
5.18). This identified that relative to WT CLR, each of the mutants are 
more biased towards ERK1/2 activation over the other studied pathways 
(Figure 5.18). However, Y165-K167A are still more biased to iCa2+ 
mobilisation over cAMP, with this switching for S168-Q172A (Figure 
5.18). What is thus observed is that residues at the base of (Y165), and 
close to, TM1 (F166-K167) potentially play roles in the determination of 
coupling to Gαs. This manifests itself as a bias towards mobilising iCa2+ 
when mutated to alanine, as these mutations have reduced the CLR’s 
ability to influence cAMP production. In contrast, the residues across the 
face of ICL1 (S168-C171) and at the base of TM2 (Q172) appear to play 
roles in influencing Gαq/11 coupling, manifesting itself as a bias towards 
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cAMP production, due to the disruptive effects of mutation upon the 
CLR’s ability to mobilise iCa2+. This work has therefore identified a 
potential role of ICL1 in the determination of G protein specificity for the 
CLR, which may begin to explain how biased agonism occurs at this 
receptor. 
 
 
 
 
 
 
Figure 5.17: Quantification of pathway bias (Δ (τ/Ka)) for WT and Y165-
Q172A CLR. 
 
Pathway bias (Δ (τ/Ka)) between cAMP production, iCa
2+
 mobilisation and ERK1/2 
activation is shown for WT CLR, Y165A, F166A, K167A, S168A, L169A, S170A, 
C171A, Q172A, when co-expressed with RAMP 1 in HEK 293 cells, and 
stimulated with CGRP. 
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Figure 5.18: Relative pathway bias (ΔΔ (τ/Ka)) for WT and Y165-Q172A 
CLR. 
 
Relative pathway bias (ΔΔ (τ/Ka)) between cAMP production, iCa
2+
 
mobilisation and ERK1/2 activation is shown for WT CLR, Y165A, F166A, 
K167A, S168A, L169A, S170A, C171A, Q172A, when co-expressed with 
RAMP 1 in HEK 293 cells, and stimulated with CGRP. 
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5.11 Summary 
 
This chapter has attempted to investigate the role of ICL1 in RAMP1-CLR 
activation and signalling. In order to achieve this, a saturation 
mutagenesis approach was utilised, mutating each residue (Y165-Q172), 
in turn, to: alanine, glutamic acid, glycine, histidine, isoleucine and 
arginine. The effect of these substitutions upon CGRP-mediated 
signalling, were characterised, when each mutant was co-expressed with 
RAMP1. To achieve this, classical pharmacological analyses: cAMP 
accumulation (for all substitutions), iCa2+ mobilisation and pERK1/2 
assays (for alanine substitutions), were utilised, subsequently analysing 
their effects in terms of pathway bias. 
 
As with previous studies (Bentrop et al, 1997, Wess et al, 1998), it was 
observed that mutating ICL1 has implications for cell surface expression 
of our receptor (Figure 5.7, Table 5.3). Interestingly, at some positions 
(Y165A, S168E, S168G, C171I) this actually results in an increase in 
expression, of between 10-50% over WT (Figure 5.7, Table 5.3). Some 
substitutions are well tolerated (F166A, S168A, S170A, F166E, F166H, 
S170H, Y165I, Y165R, K167R), with minimal impact upon expression (no 
greater than a 15% reduction) (Figure 5.7, Table 5.3). The most dramatic 
effects are observed for Q172H and L169R, with expressions of 10.05% 
and 4.35% that of WT, respectively (Figure 5.7, Table 5.3). Most other 
residues, except those specifically mentioned, tend to display levels of 
expression >30% that of WT (Figure 5.7, Table 5.3). Intriguingly, mutating 
L169 seems to be particularly susceptible to reducing expression, with all 
substitutions at this position resulting in reductions in expression of at 
least 66% (57.27% for isoleucine substitutions), relative to WT (Figure 
5.7, Table 5.3). This residue is highly conserved amongst family B 
GPCRs (Figure 5.2); combined with the large reduction in cell surface 
expression we observe upon mutating this residue in the CLR, this 
suggests that a leucine at this position appears to play key roles in 
regulating expression. Whilst it is clear that reducing cell surface 
expression of each mutant will have effects upon signalling, it was still 
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possible to observe fairly robust responses for Q172H and L169R, these 
being the lowest expressed receptors (10.05% and 4.35%, respectively) 
(Figure 5.7, Table 5.3). The fact that signalling for these mutants can still 
be observed indicates the large extent of receptor reserve inherent in the 
system under study. Thus, whilst reducing expression will influence the 
observed results, this may potentially have minimal impact.  
 
Whilst cell surface expression of the CLR was quantified in this study, no 
investigation into cell surface expression of RAMP1 was undertaken. It is 
possible that some effects upon expression of the CLR are due to 
modulating its ability to interact with RAMP1, although it would be 
expected that both CLR and RAMP1 expression would reduce in 
proportion to each other. However, it is likely that through mutating the 
CLR, potential effects upon its ability to interact with RAMP1 may occur, 
having consequences upon the CLR’s ability to signal. It has previously 
been identified that the N-termini of RAMPs play roles in influencing 
ligand binding, whilst the C-termini influence downstream signalling 
(Udawela et al, 2006a); it is therefore plausible that by affecting the ability 
of the CLR to interact with RAMP1, there may be unknown effects upon 
these regions, and hence the CLR’s ability to signal. 
 
In terms of cAMP signalling, effects as diverse of those upon cell surface 
expression were observed, with substitutions at each position in ICL1 
(Y165-Q172) having a wide range of effects: some being very tolerant to 
mutation, some having reduced activity or complete abolition of 
functionality, and others displaying a gain-of-function. It was identified 
that arginine substitution is particularly well tolerated at all positions: 
indeed, S168R results in an increase in potency of ~29 fold (Figure 5.12, 
Table 5.8). Interestingly, analysis of ICL1 of all family B GPCRs reveals 
that for all receptors, except the CLR, CT and CRF receptors, arginine (or 
positively charged lysine) is fairly well conserved at this position (Figure 
5.2). This suggests a particularly key role for a positive charge at this 
position. Indeed, by introducing an arginine at this position an interaction 
with downstream signalling proteins, potentially Gβ, may have been 
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promoted. In the GLP-1R, H171, the equivalent residue to S168, has 
been observed to directly interact with D312 of Gβ via an electrostatic 
interaction (Zhang et al, 2017).  
 
Substitution with glutamic acid within ICL1 is fairly detrimental upon 
CLR’s signalling ability, suggesting that negatively charged residues 
aren’t tolerated in this region; indeed, all WT residues here tend to be 
polar and uncharged (except K167). This may potentially be due to 
charge-charge repulsion from negatively charged phospholipids within the 
inner leaflet of the plasma membrane, or glutamic acids within H8 
(Figures 5.3 and 5.4). Upon performing glycine substitutions, a mutation 
that is generally deleterious, slight gains of function for C171 and Q172 
were observed (Figure 5.9, Table 5.5). This suggests that gaining 
flexibility in this region allows for easier activation of the CLR, by CGRP. 
Therefore, C171 and Q172 may possibly serve to hold the WT CLR in an 
inactive conformation, an ability that has been lost through gaining 
greater flexibility with glycine substitution. Indeed, this may be particularly 
true of C171, as this residue is universally conserved amongst family B 
GPCRs (Figure 5.2). Effects observed upon mutation of Q172 may also 
be explained by its influence upon the shape/positioning of TM2 and 
ICL2, and not solely due to effects upon ICL1. Mutation of Y165 is well 
tolerated for all residues, except glycine (Figure 5.8-5.13A). This may 
suggest that Y165 plays a role in ‘anchoring’ ICL1 in an optimal 
conformation for signalling. Through increasing flexibility of the peptide 
backbone at this position, it is plausible that ICL1 is allowed to ‘swivel’ 
and ‘flex’ more than in WT CLR, having detrimental effects upon its 
functionality. 
 
Through the use of an alanine scanning approach, it was possible to 
differentially affect CGRP’s ability to mediate cAMP production (Figure 
5.13, Table 5.9), compared to its ability to mediate the mobilisation of 
iCa2+ (Figure 5.14-15, Table 5.10). This data suggests that ICL1 plays 
differing roles in the determination of Gαs-mediated signalling (shown 
through cAMP accumulation assays) and coupling to Gαq/11 (shown via 
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iCa2+ mobilisation assays). In contrast, mutating this region had minimal 
effect upon CGRP-mediated ERK1/2 activation (Figure 5.16, Table 5.11). 
As it has previously been shown that ERK1/2 activation can occur in a β-
arrestin-dependent, G protein-independent, manner (Shenoy et al, 2006), 
it is plausible that CGRP-mediated ERK1/2 activation at RAMP1-CLR 
heterodimers occurs via β-arrestins. Thus, as mutating ICL1 has little 
effect upon ERK1/2 activation, it is possible that ICL1 plays no role in β-
arrestin-mediated signalling. Indeed, β-arrestins have previously been 
shown to bind the phosphorylated C-terminus of GPCRs (Lohse et al, 
1990, Gurevich et al, 1995). Thus, ICL1 appears to play roles in 
influencing G protein coupling and signalling, particularly for Gαs and 
Gαq/11, but not ERK1/2 activation. This is particularly highlighted through 
analysis of the effects of each alanine substitution upon pathway bias 
(Figures 5.17-18). This indicated how residues at the base of TM1 and 
the start of ICL1 (Y165-K167) play roles in heavily influencing coupling to 
Gαs, and hence cAMP production. In contrast, residues across the face of 
ICL1 (S168-C171) play roles in influencing iCa2+ mobilisation, via Gαq/11. 
Thus, it appears that these predominantly polar residues are important in 
Gαq/11 coupling, whilst hydrophobic/positively charged residues (Y165-
K167) at the start of ICL1 are required for Gαs coupling. Recent work by 
Flock and colleagues has identified the existence of a ‘selectivity barcode’ 
upon each individual G protein subtype, which is ‘read’ by GPCRs (Flock 
et al, 2017). This allows a given GPCR to specifically interact with only a 
given subset of G proteins, preventing aberrant G protein-GPCR 
coupling. These ‘barcodes’ have been identified to specifically interact 
with a GPCR via ICL 2 and 3 as well as TM 5 and 6 (Flock et al, 2017). 
Whilst their work does not specifically identify ICL1 as influencing 
specificity, it does provide a potential mechanism for its determination. It 
is plausible that ICL1 may play a similar, as yet, undefined role, or that by 
modulating ICL1, in the work presented in this chapter, unknown 
structural effects have occurred, resulting in rearrangements of ICL2/3 or 
TM5/6 which have affected the CLR’s ability to read the ‘selectivity 
barcodes’ on Gαs or Gαq/11. 
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By comparing the pharmacological data for cAMP production to the 
existing crystal structures for inactive GCGR and GLP-1R (Figure 5.4A-
B), and in turn comparing these to the active GLP-1R (Figure 5.4C), it 
was possible to identify how ICL1 of family B GPCRs may potentially 
interact with H8. This may occur via charge-charge interactions between 
positively charged residues on ICL1 and glutamic acid residues within H8. 
Upon activation, ICL1 undergoes large conformational rearrangements 
(Figure 5.6B-C), and the ICL1-H8 interaction breaks, with these two 
regions moving apart (Figure 5.4B-C), allowing downstream signalling to 
occur. Therefore, this data suggests that ICL1 may, potentially, interact 
with H8 to hold family B GPCRs in an inactive state, as well as being a 
region that plays a role in determining G protein specificity, and also 
influencing bias (Figure 5.19). 
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Figure 5.19: ICL1 of CLR plays roles in determining G protein specificity. 
 
Analysis of pathway bias data (Figure 5.11-12) reveals differential roles for ICL1 in determining 
G protein specificity. Residues at the base of TM1 and start of ICL1 (Y165-K167) play roles in 
influencing Gαs coupling, whilst those across ICL1 (S168-Q172) more heavily influence Gαq/11 
coupling. 
/11#
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Chapter 6  
Discussion 
 
6.1 Overview 
 
The phenomenon of biased agonism is becoming a much-studied 
subject. Many researchers, who work on GPCR-mediated signalling, are 
also investigating the extent of biased agonism. This allows for an 
informed approach to the development of new test compounds for the 
pharmaceutical industry. Through elucidating the extent of inherent bias 
exhibited by a GPCR’s endogenous agonist(s), it is possible to 
understand, and appreciate, the full signalling repertoire of a target 
receptor. Alongside this, an in-depth knowledge of the effects following 
activation of each pathway provides the potential to develop 
pharmaceutical drugs that activate selected, beneficial pathways. Further, 
knowledge of biased agonism, exhibited by endogenous ligands, can be 
used to elucidate which activated pathways are responsible for unwanted, 
off-target side effects. A fine example of this being the µ-opioid receptor, 
with Gα12 activation providing analgesia (Pradhan et al, 2010, 2012), 
whilst activation of β-arrestin-mediated signalling is responsible for most 
of the side effects associated with opioid treatment (Raehal et al, 2005). 
Such knowledge of bias has informed the development of drugs that 
preferentially activate Gα12-mediated signalling pathways (Chen et al, 
2013, DeWire et al, 2013), thereby providing pain relief, with more limited 
side effects. Thus, it is evident that knowledge of biased agonism allows 
for the informed development of novel compounds, with potentially 
enhanced therapeutic potential. Hence, knowledge of biased agonism 
may allow for increased: efficacy, safety and tolerance of novel drugs. 
 
The work presented within this thesis has applied the study of biased 
agonism to three GPCRs: two from family A, namely the A1R and A2AR, 
and the prototypical RAMP-interacting GPCR of family B, the CLR. 
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Through completion of these investigations, a framework is provided, 
upon which further work can build, providing the potential for the 
development of adenosine receptor-targeting therapeutics. In addition, 
the mechanisms of action for different signalling pathways, mediated by 
the RAMP-CLR heterodimers have been identified, as well as quantifying 
biased agonism, and providing a potential structural mechanism for such 
a phenomenon. 
 
6.2 Biased agonism of the A1R: differential Gαi/o 
coupling? 
 
In Chapter 3, work was presented pertaining to the investigation of A1R 
agonists that had previously been designed (Figure 3.2) and published 
(Knight et al, 2016, Appendix 1). The work presented within this thesis 
relates to an in-depth, pharmacological characterisation of the active 
compounds developed from this study. Of these, Cmpds 5, 6, 16 and 18 
had been found to display selectivity for the A1R, over other AR subtypes 
(Knight et al, 2016, Appendix 1), whilst Cmpds 20 and 21 were non-
selective AR agonists. For all of the investigated A1R agonists it was 
possible to observe activation of the canonical, Gαi/o-mediated signalling 
pathway, as evidenced by their ability to inhibit forskolin-stimulated cAMP 
production (Figure 3.4, Table 3.2). Upon analysis of the dose-response 
curves obtained from these experiments, it was observed that many were 
non-monotonic: at higher agonist concentrations, it was evident that the 
extent of inhibition actually started to decrease (Figure 3.4). Through the 
use of PTX pre-treatment it was identified that both prototypical and 
atypical agonists were able to mediate cAMP production (Figure 3.5, 
Table 3.3). This suggests that the upward inflections observed in cAMP 
inhibition dose-response curves are due to a switching of the A1R from 
activating predominantly Gαi/o-mediated to Gαs-mediated signalling. 
Interestingly, the points of upward inflection in our cAMP inhibition dose-
response curves closely correlate with the lowest agonist concentration 
able to mediate cAMP production. Coupling of the A1R to Gαs has also 
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previously been reported in CHO-K1 cells stimulated with NECA or CCPA 
(Cordeaux et al, 2004, Baker and Hill, 2007, Gao and Jacobson, 2016), 
as well as HEK 293T cells stimulated with adenosine (Rittiner et al, 
2012). Indeed, the potencies of the stimulating agonists in these 
published studies closely matches those observed in this thesis. 
However, most of the agonists, be they proto- or atypical, appear to be 
equipotent, with respect to activating Gαs signalling, with all being less 
potent compared to their ability to stimulate Gαi/o activation (Figure 3.4 
and 3.5, Table 3.2 and 3.3). However, in contrast to most of the 
compounds, and previously published reports, this work identified one 
agonist, Cmpd 18, which is ~10-fold more potent than previously reported 
agonists (Cordeaux et al, 2004, Baker and Hill, 2007, Rittiner et al, 2012, 
Gao and Jacobson, 2016,). Thus, what has been observed is that a 
GPCR classically associated as being Gαi/o-coupled is also able to couple 
to, and activate, Gαs. There is, therefore, potential for experiments 
measuring A1R-mediated cAMP inhibition to actually obtain results that 
are the function of the activation of two diametrically opposing signalling 
pathways. 
 
In addition to an ability of the A1R to modulate intracellular cAMP levels, 
an ability of our agonist to mediate: the mobilisation of iCa2+ was identified 
(Figure 3.6-7, Table 3.4). This investigation solely focused upon A1R-
mediated iCa2+mobilisation, which has previously been observed in 
DDT1MF-2 (hamster vas deferens smooth muscle) cells, which 
endogenously express the A1R (Fredholm et al, 2013). Additionally, the 
A1R can also mediate the influx of extracellular Ca2+ (Dickenson and Hill, 
1993). It has also been observed that PTX pre-treatment results in total 
abolition of both A1R-mediated intracellular and extracellular Ca2+ 
mobilisation (Dickenson and Hill, 1993, Gao and Jacobson, 2016). This 
indicates that the A1R mediates both the mobilisation of iCa2+, and entry 
of extracellular Ca2+, in Gαi/o-dependent manner. It has also been 
reported that PLC activation can be mediated via Gβ/γ (Camps et al, 
1992), resulting in iCa2+ mobilisation. This may also occur with the A1R, 
as treatment with UBO-QIC results in diminished NECA-induced 
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mobilisation of iCa2+, with no associated effects upon NECA-stimulated 
cAMP inhibition (Gao and Jacobson, 2016). 
 
In addition to mediating Ca2+ signalling, the A1R has also been reported to 
activate ERK1/2 (Husain et al, 2007, Migita et al, 2008, Jajoo et al, 2010, 
Baltos et al, 2016, Gao and Jacobson, 2016). Indeed, this may be an 
important pathway activated by the A1R, as it, alongside Akt activation, 
has been reported to be cytoprotective (Baltos et al, 2016). A1R-mediated 
ERK1/2 activation may also be responsible for the anti-inflammatory,        
-necrotic and -apoptotic actions of adenosine (Lee et al, 2004). Upon 
investigating the ability of the proto- and atypical agonists to activate this 
pathway, it was observed that all agonists displayed an ability to activate 
ERK1/2 (Figure 3.8, Table 3.5). However, most of these were also partial 
agonists, suggesting that they have a general propensity to activate other 
signalling pathways over ERK1/2 activation, a pathway seen to be 
sensitive to PTX treatment (Husain et al, 2007, Stewart et al, 2009, Gao 
and Jacobson, 2016). 
 
It was observed that all of the agonists tested displayed an ability to 
differentially activate four signalling pathways: cAMP inhibition, cAMP 
production, iCa2+ mobilisation and ERK1/2 activation (Figure 6.1). As 
each agonist displays differing abilities to activate these pathways, there 
is clear biased agonism occurring. What has been observed is that of the 
endogenous cognate agonists, adenosine is the only agonist found to be 
more biased toward activating the canonical Gαi/o, cAMP inhibition 
pathway, over Gαs, relative to NECA (Figure 3.9). Thus, it seems that 
only the natural agonist, adenosine, predominantly activates the classical 
A1R signalling pathway, whilst all synthetic derivatives display a greater 
preference to mediating cAMP production, relative to NECA (Figure 3.9). 
However, through our development of atypical agonists, two have been 
developed, Cmpds 6 and 20, which display the greatest relative bias 
towards ERK1/2 activation (Figure 3.10). Indeed, most of the atypical 
agonists, with the exception of Cmpd 18, display bias towards ERK1/2 
activation over cAMP inhibition, relative to NECA. AR-mediated ERK1/2 
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signalling has been reported to promote proliferation (Jacques-Silva et al, 
2004, Migita et al, 2008). Specifically, A1R-mediated ERK1/2 activation is 
cytoprotective (Baltos et al, 2016), as well as being able to promote 
neurite outgrowth in primary striatal neuronal precursor cells (Canals et 
al, 2005). There is, therefore, potential, that the agonists, along with 
CCPA, may be able to promote cell proliferation and survival, to greater 
extents than NECA.  
 
 
The fact that it was possible to observe differences between each 
agonist’s ability to activate three pathways mediated via Gαi/o proteins is, 
in itself, interesting. It would be expected that a given agonist would 
Figure 6.1: A1R agonists display differential abilities to activate differing 
signalling pathways, relative to cAMP inhibition. 
 
The A1R agonists tested in Chapter 3 display differing abilities to mediate the: 
production of cAMP, mobilisation of iCa2+, or activation of ERK1/2, relative to 
their ability to mediate the inhibition of cAMP production. !/" indicates an 
increase/decrease in potency, relative to that observed for cAMP inhibition, 
whilst ‘ – ’  indicates no difference. The number of arrows indicates the extent 
of change. 
Agonist cAMP production iCa
2+
 ERK1/2 
NECA !!! !! ! 
Adenosine !!! !! !! 
CCPA !!! !! " 
Cmpd 5 - "" "" 
Cmpd 6 !! ! " 
Cmpd 16 - - " 
Cmpd 18 ! - ! 
Cmpd 20 !!! !!! - 
Cmpd 21 !! " " 
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activate each pathway mediated by a single G protein, to similar extents. 
Thus, no bias would be observed between cAMP inhibition, iCa2+ 
mobilisation, or ERK1/2 activation for the A1R agonists. However, 
investigations into A1R-mediated ERK1/2 activation have highlighted 
different abilities of A1R agonists to specifically activate this pathway, via 
Gαoa, Gαob, and Gαi2 (Stewart et al, 2009). This study also highlighted 
how differing agonists have different efficacies, dependent upon the G 
protein being activated (Stewart et al, 2009). As it has also previously 
been shown, in yeast, that the A1R can couple to GPA/Gαi1/2 and 
GPA/Gαi3 proteins (Stewart et al, 2009), it is potentially plausible that the 
A1R is able to mediate its signalling via multiple Gαi/o isoforms. Thus, the 
apparent bias observed within Chapter 3 may arise due to each agonist 
mediating the activation of either: Gαi1, Gαi2, Gαi3, Gαoa and/or Gαob. It is 
possible that these G proteins, or their associated Gβ/γ (in the case of 
Ca2+ signalling), are responsible for activating the differing downstream 
signalling pathways of the A1R (Figure 6.2). It is also plausible that the 
agonists utilised in this study may have differing abilities to promote or 
reduce oligomerisation of the A1R. This has been observed for the 
melatonin 1 and 2 receptors (Ayoub et al, 2002), and the dopamine D2 
receptor (Tabor et al, 2016). It is plausible that through modulating 
oligomerisation, there could be potential effects upon the A1R’s ability to 
mediate activation of the signalling pathways studied in Chapter 4.  
 
In order to investigate differential Gαi/o coupling, the use of PTX-
insensitive Gαi/o proteins, transfected into CHO-K1-A1R cells, would be 
required. Following treatment with PTX, cAMP inhibition, iCa2+ 
mobilisation as well as ERK1/2 activation, could be measured. Where 
responses are still observed, this would identify: the individual G proteins 
activated by each agonist, as well as which G proteins are responsible for 
mediating the various signalling pathways studied. Further, an 
investigation into the ability of the agonists to mediate Akt activation, and 
promote both proliferation and cell survival, would add further scope and 
depth to the characterisation of these compounds. This would also 
highlight if they may have any potential therapeutic benefits. Eventually, 
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study of these agonists could be moved into various mouse models of 
CVD, to determine their effects upon the cardiovascular system.  
 
 
Overall, this work has identified how it is possible to utilise the structure of 
existing non-selective AR agonists as scaffolds upon which to build new 
AR agonists, some with improved selectivity. The recently solved 
structure of the A1R has identified the existence of a secondary ligand 
binding pocket, as well as differences in ECL2, compared to the A2AR 
(Glukhova et al, 2017). These regions provide a possible route through 
which selectivity for the A1R, over the A2AR, may be developed. What is 
not known is how the selective agonists bind to the A1R, and if they utilise 
this secondary pocket. However, by modulating specific R groups, it was 
possible to significantly alter each agonist’s ability to activate differing 
signalling pathways all mediated by the A1R, thereby having profound 
effects upon the extent of biased agonism exhibited at the A1R. These 
agonists were not developed from a therapeutic perspective; initially, they 
were developed to provide scaffolds upon which fluorescent A1R-
A1R$
Gαs$
AC$
cAMP$
Gαi1$
PLC$
Ca2+$
Figure 6.2: A1R displays an ability to activate multiple downstream signalling proteins. 
 
The A1R can mediate the production of cAMP, via the activation of Gαs, as well as mediating the inhibition 
of adenylate cyclase (AC) activity, via PTX-sensitive Gαi/o proteins. Further, Gαi/o protein activation can 
lead to the activation of ERK1/2 signalling, as well as the mobilisation of iCa2+. Increases in [iCa2+] can 
also be brought about via the action of Gβγ, which can mediate the entry of extracellular Ca2+, via 
regulating cell surface Ca2+ channels, in addition to directly activating PLC. 
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selective agonists could be developed. They do, however, hold potential 
therapeutic benefit in promoting cell survival and/or proliferation, as well 
as providing pharmacological tools to dissect the signalling pathways that 
are evident upon A1R activation, as utilised here. 
 
6.3 Triazoloquinazolines: A2AR agonists 
 
The work relating to the A2AR, presented within Chapter 3, required 
validation of the findings of an in silico screen performed by collaborators 
in the research group of Dr. A. Bender (University of Cambridge, UK). 
These compounds were identified from a screen looking for dual PDE10A 
inhibitors, and A2AR agonists. They are all known PDE10A inhibitors 
(Kheler et al, 2011), but their activity against the A2AR was unknown, 
asides in silico data suggesting they dock to the A2AR.  
 
The design rationale behind dual target agonists such as these is that 
they may provide some potential benefit in the treatment of various 
neurodegenerative diseases. Adenosine has long been known to play 
key roles in neuromodulation in the brain, particularly the A2AR, which is 
highly enriched in medium spiny neurons of the striatum (Shearman and 
Weaver, 1997, Rosin et al, 1998). In Huntington’s disease, the expression 
levels of the A2AR are aberrantly affected by mutant huntingtin protein 
(HTT), with expression further reducing with disease progression 
(Martinez-Mir et al, 1991, Chiang et al, 2005). However, the levels of 
A2AR-mediated signalling appear not to be affected by this reduction 
(Varani et al, 2001, Chou et al, 2005). In spite of this, activation of the 
A2AR, by CGS21680, in mouse models of Huntington’s, has been 
observed to delay loss of motor coordination, and accumulation of HTT 
aggregates (Chou et al, 2005, Lin et al, 2013). Further, CGS21680 has 
been reported to significantly reduce caspase 3 activation (Chiu et al, 
2015), thus providing a potential means of reducing neuronal death.  
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PDE10A is a dual cAMP-cGMP phosphodiesterase, being highly 
expressed in striatal medium spiny neurons (Fujishige et al, 1999, 
Coskran et al, 2006). In animal models of Huntington’s disease, HTT has 
been observed to aberrantly affect the expression of PDE10A (Hu et al, 
2004, Leuti et al, 2013), and it is thought that these effects may be 
detrimental for neuronal survival and correct basal ganglia function, via 
effects upon dopamine D1 and D2 signalling (Hebb et al, 2004, Giampà 
et al, 2009, 2010). Thus, there is a potential that targeting PDE10A may 
provide, some, potential therapeutic benefit in cases of Huntington’s. 
There may also be potential for multi-target drugs, targeting both the 
A2AR and PDE10A. Thus, in Chapter 3, a classical pharmacological 
approach was utilised to validate our collaborators’ in silico findings, with 
respect to TZQ test compounds’ actions upon the A2AR.  
 
To identify the ability of the TZQ compounds to act as AR agonists, the 
yeast-screening platform (Brown et al, 2000) was utilised, which 
confirmed two important points: the test compounds did indeed display 
efficacy against the A2AR; and some were selective for the A2AR, over the 
A1R and A2BR. Validating these findings in CHO-K1-A2AR cells further 
identified that the test compounds were indeed active, as agonists, 
against the A2AR. The main difference observed between yeast and 
mammalian findings was that TZQ 3 and 5 displayed much reduced 
potencies in CHO-K1 cells, compared to yeast, relative to the other TZQ 
compounds. Whilst the yeast system often displays reduced potencies, 
relative to those obtained from experiments in mammalian cells, it tends 
to faithfully recapitulate observed trends (Weston et al, 2015, 2016, 
Appendix 2, Knight et al, 2016, Appendix 1). One possible explanation for 
this lies in that, in these strains, chimeric yeast/human G proteins are 
utilised, which have had the final 5 C-terminal amino acids of the yeast 
Gα homologue, GPA1, replaced with the equivalent residues of each 
human Gα (Brown et al, 2000), which are known to be less specific 
(Dowell and Brown, 2002).  
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The experiments performed in yeast expressing the A2AR investigated 
coupling, and activation, of GPA1/Gαs, as did those looking at the A2BR. 
As this appears to be the G protein through which these two receptors 
modulate intracellular cAMP levels, these results can be taken as being 
fairly representative. However, where the A1R has been investigated, 
GPA1/Gαi1/2 was utilised. As Gαi1 and Gαi2 have identical C-termini, in 
respect to the final 5 residues, it is not possible to distinguish between 
these two G proteins in yeast. Likewise, as only the ability of the TZQ 
compounds to activate this chimeric G protein has been measured, a 
potential ability of them to signal via other G proteins, activated by the 
A1R (Stewart et al, 2009), could be missed. Despite these limitations in 
both the system of choice, and approach, it was still possible to 
successfully identify the TZQ compounds as being agonists of the A2AR. 
It was also possible to confirm their selectivity over other ARs, with the 
exception of the A3R: unfortunately, to date, there have been no 
published accounts of functional expression of the A3R in yeast, despite 
the work of others, including members of our own laboratory. Thus, to test 
for efficacy against the A3R, cAMP inhibition assays were performed in 
CHO-K1-A3R cells. This identified that only TZQ 4 was also an agonist of 
the A3R. Thus, through a combinatorial approach, of utilising both yeast 
and mammalian systems, it was possible to identify a series of 
compounds, from the triazoloquinazoline chemical series, that acted as 
agonists against the ARs, with some being selective for the A2AR. This is 
unsurprising as 9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]quinazolin-5-
amine (CGS15943), a triazoloquinazoline, has long been known to bind, 
non-selectively to the A1, A2A, and A2BR (Williams et al, 1987, Ongini et al, 
1999). It has also been seen that by using CGS15943 as a scaffold, and 
modulating specific functional R groups, AR subtype selectivity can be 
achieved (Kim et al, 1996, 1998); a process, similar to that, which was 
performed for A1R agonists (Knight et al, 2016, Appendix 1). 
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6.3.1 Triazoloquinazolines display bias toward ERK1/2-
activation: potential therapeutic benefit? 
 
The A2AR is able to mediate cAMP production; however, it also able to 
mediate ERK1/2 activation (Canals et al, 2005). As AR-mediated ERK1/2 
activation is known to be beneficial for both cell survival and proliferation 
(Jacques-Silva et al, 2004, Migita et al, 2008, Baltos et al, 2016), as well 
as promoting neurite outgrowth, in primary striatal neuronal precursor 
cells (Canals et al, 2005), there was interest to determine the efficacy of 
the TZQ agonists at activating this pathway. It was observed that all, 
except TZQ 5, were able to mediate the activation of ERK1/2, albeit only 
upon stimulation with TZQ 3 at micromolar levels (Figure 3.14, Table 3.9). 
Comparisons of the responses observed, to those for cAMP production, 
identified that TZQ 1 and 2 displayed increased potencies for ERK1/2 
activation (Figure 3.13, 3.14, Table 3.8, 3.9). It is interesting to note how, 
for the A1R, ERK1/2 activation has been reported to occur in a PTX-
sensitive, Gαi/o-dependent manner (Husain et al, 2007, Stewart et al, 
2009, Gao and Jacobson, 2016); however, the closely related A2AR is 
also able to activate ERK1/2, but no reports have been published of Gαi/o 
coupling to this GPCR. Thus, it appears that ERK1/2 activation is 
mediated, from the A2AR, in a different manner, to that from the A1R. It 
would be interesting to determine how activation of this pathway occurs 
for both receptors in greater depth, allowing us to understand how two 
receptors, with seemingly opposing actions, can activate the same 
signalling pathway. 
 
Analysing the extent of pathway bias for both of these compounds, 
determined the extent of bias towards either cAMP production or ERK1/2 
activation. This identified that all of the compounds, for which full dose-
response curves could be fitter, are biased towards ERK1/2 activation 
(Figure 3.15). Indeed, so is the reference agonist CGS21680. There is 
therefore potential that these compounds may prove beneficial in 
promoting the survival of neuronal cells, through ERK-conferred 
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cytoprotective effects (Baltos et al, 2016), or ERK-induced proliferation 
(Jacques-Silva et al, 2004, Migita et al, 2008). Indeed, their ability to 
promote cAMP production may also prove beneficial, as PKA activity has 
been reported to be required for growth of striatal neuronal precursor 
cells (Canals et al, 2005). Thus, there is some potential for these 
compounds to be of benefit in some neurodegenerative diseases, with 
respect to their agonistic activity at the A2AR, a receptor, along with the 
A1R, that is known to be one of the main mediators of adenosine 
neuromodulation within the brain. Therefore, there is merit in 
characterising these compounds in primary striatal neuronal cells, and in 
investigating their direct effects upon cell survival and growth. In this 
system it would be important to understand the expression profiles of 
other GPCRs, primarily those that have been shown to dimerise with the 
A2AR, such as the dopamine D2 (Kamiya et al, 2003, Fuxe et al, 2005) 
and D3 receptors (Torvinen et al, 2005), cannabinoid CB1 receptor (Ferré 
et al, 2009) and glutamate mGluR5 (Zezula and Freissmuth, 2008). The 
formation of heterodimers with any of these receptors may alter the 
signalling profile of the TZQ compounds identified in Chapter 3. Indeed, it 
is also possible that the triazoloquinazolines themselves may have an 
ability to promote/reduce dimerisation with other such GPCRs. The TZQ 
compounds do, however, provide good pharmacological tools, with which 
the signalling repertoire exhibited by the A2AR can be characterised, 
particularly TZQ 2 in investigating A2AR-mediatd ERK1/2 activation. 
 
To date, only the ability of the TZQ agonists to mediate cAMP 
accumulation and ERK1/2 activation, in an A2AR-dependent manner, has 
been determined. There is also a need to test the ability of these 
compounds to mediate both: iCa2+ mobilisation, and Akt activation. 
Further, it would be interesting to determine the ability of these 
compounds to promote cell survival and proliferation, as well as to inhibit 
apoptosis. Additionally, an investigation into the effects of these 
compounds upon primary striatal neuronal cells, endogenously 
expressing the A2AR and PDE10A, would also add further depth to this 
investigation. There is also a need to determine if there are any 
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synergistic effects of the dual action of triazoloquinazolines upon the 
A2AR and PDE10A. Currently, it is not known whether PDE10A is 
expressed in the cell lines used in this thesis. To address this, qPCR 
would need to be utilised in order to quantify the expression levels of 
mRNA for each PDE isoform. Where cell lines express both PDE10A and 
A2AR, the of use siRNA for PDE10A, and A2AR antagonists, both 
singularly, and in combination, would be required. This will allow 
elucidation of the effects of these compounds upon each target alone, 
and identify any synergy between targeting both PDE10A and the A2AR. 
Having quantified the effects of the TZQ compounds upon PDE10A and 
the A2AR, as well as associated signalling pathways, there may be 
potential to, eventually, move the compounds into an in vivo setting. 
 
6.4 Biased agonism of the CLR: a role for RAMPs? 
 
As observed for the A1R and A2AR, there is an inherent ability of GPCRs 
to activate multiple downstream signalling pathways, to differing extents. 
For family B GPCRs this is further modified, for some receptors, through 
the association of receptor activity-modifying proteins, which provide one 
mechanism whereby signalling from a single GPCR may be modulated. 
This is no more evident than with the prototypical RAMP-interacting 
receptor, the CLR. In Chapter 4, work was presented pertaining to the 
effects of RAMP interaction, upon the CLR’s ability to mediate: cAMP 
production and inhibition; mobilisation of iCa2+; as well as elucidating the 
mechanisms of action for these pathways (Figure 6.3). Ultimately, RAMP-
mediated modulation of biased agonism was quantified for each agonist: 
CGRP, AM and AM2. In Chapter 5 this work was expanded, focusing 
upon RAMP1-CLR, identifying how the ICL1 region plays a role in 
influencing the G protein specificity of the CLR. 
 
The CLR’s ability to couple to, and signal through, Gαs has been well 
documented (Poyner et al, 2002, Hong et al, 2012), but signalling via 
other pathways has, until know, received much more limited investigation. 
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Indeed, of the work that has been published pertaining to Gαs-mediated 
cAMP production, from the CLR, there is much variability in the 
established potencies of the three endogenous agonists: CGRP, AM and 
AM2 (Table 1.5) (Roh et al, 2004, Takei et al, 2004, Wunder et al, 2008, 
Holmes et al, 2013, Watkins et al, 2014). Such variability in measured 
responses is potentially due to the wide array of immortalised cell lines in 
which these experiments have been performed. In Chapter 4, a HEK 293 
cell line, which, as we had previously established, lack expression of any 
functional RAMPs (Weston et al, 2015) was utilised. In this thesis, it was 
further established that this cell line also lacks expression of functional 
CLR (Figure 4.1).  
 
 
Having established a suitable cell line, it was identified that at RAMP1-
CLR heterodimers, the three agonists: CGRP, AM and AM2, display a 
rank order of potency of CGRP > AM = AM2 (Figure 4.2A, Table 4.1). 
This was different to that observed with RAMP2- and RAMP3-CLR, 
where rank orders of: AM > CGRP > AM2 and AM = AM2 > CGRP, 
respectively were observed (Figures 4.2B-C, Table 4.1). These 
CLR$
Gαs$
AC$
cAMP$
Gαi/o$
PLC$
Gαq/11$
RA
M
P$
Ca2+$
F i g u r e  6 . 3 :  R A M P - C L R 
heterodimers couple to Gαs, Gαi/o 
and Gαq/11. 
 
Each RAMP-CLR heterodimer 
displays an ability to couple to, and 
s i g n a l v i a : Gα s , t o e l e v a t e 
intracellular cAMP levels; Gαi/o, to 
reduce cAMP levels, as well as    
Gαq/11 to mediate the mobilisation of 
iCa2+. All of these pathways can be 
activated by CGRP, AM or AM2, 
except the cognate ligand at each 
receptor (CGRP for RAMP1-CLR, 
and AM for RAMP2/3-CLR), which is 
unable to activate Gαi/o-mediated 
signalling. 
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observations are thus in broad agreement with those obtained from other 
studies (Roh et al, 2004, Takei et al, 2004, Wunder et al, 2008, Holmes et 
al, 2013, Watkins et al, 2014) (Table 1.5 for summary). Further to differing 
potencies at each RAMP-CLR heterodimer, it was observed that all three 
agonists affect the largest response with RAMP1-CLR, but, with the 
exception of AM at RAMP2-CLR, all other responses are greatly reduced 
(Figure 4.2, Table 4.1). This is in contrast to other published work, which 
suggests that CGRP, AM and AM2 all elicit responses of the same level 
(Hong et al, 2012); however, this work does have problems with regards 
to incomplete dose-response curves. Nevertheless, work in CHO cells 
has suggested that AM2 is a partial agonist at RAMP2-CLR heterodimers 
(Wunder et al, 2008). Therefore, what is observed in this thesis is, that for 
the same three peptide agonists: CGRP, AM and AM2, the RAMPs are 
able to modulate both the levels of response, and potency, at the same 
central GPCR, CLR, in terms of Gαs-mediated cAMP accumulation.  
 
In addition to Gαs-mediated signalling, it has also been observed that 
there is potential for the CLR to couple to Gαi/o proteins (Kim, 1991, Wiley 
et al, 1992, Main et al, 1998, Disa et al, 2000, Kuwasako et al, 2010), but 
little follow up work has been performed. Therefore, as with previous 
studies, PTX was utilised to ablate any potential Gαi/o-coupling to the 
CLR, and cAMP accumulation subsequently measured, in response to 
stimulation with either: CGRP, AM or AM2, at each RAMP-CLR 
heterodimer. This identified that all three agonists are able to couple to 
Gαi/o, but in a RAMP-dependent manner. Crucially, it was observed that 
the cognate ligand at each RAMP-CLR heterodimer: CGRP for RAMP1-
CLR, and AM for RAMP2/3-CLR, is unable to couple to Gαi/o (Figure 4.4 
Table 4.2). Therefore, what was observed through investigating Gαi/o 
coupling is that the RAMPs, in addition to modulating the CLR’s response 
to three agonists, are also able to modulate G protein coupling. This 
could have implications upon observed results from other systems. 
Where previous work has drawn conclusions about the CLR’s ability to 
mediate-Gαs signalling, without consideration of potential Gαi/o effects, 
greatly misleading results could have be obtained. This is highlighted 
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through work performed in collaboration with Dr. Harriet Watkins: who 
performed identical experiments to those in Chapter 4, but in HEK 293S 
cells. From this, she obtained data suggesting that all agonists are, or 
near to, full agonists at each RAMP-CLR heterodimer (Weston et al, 
2016, Appendix 2). These responses were subsequently found to be 
insensitive to PTX pre-treatment (Weston et al, 2016, Appendix 2). 
Through investigating the G protein content of HEK 293 versus HEK 
293S cells, it was identified that HEK 293S cells have a greatly reduced 
expression of both Gαi1 and Gαi2 (Weston et al, 2016, Appendix 2). 
Therefore, it is plausible that the CLR is able to specifically couple to Gαi1 
and/or Gαi2, as well as Gαs. This ability of the CLR to couple to Gαi/o 
proteins may primarily be relevant in neuronal and electrically excitable 
cells, as it is these cell types for which PTX pre-treatment has been found 
to predominantly display effects upon the CLR (Kim et al, 1991, Disa et 
al, 2000, Walker et al, 2010). Indeed, some of these effects may influence 
the activity of various ion channels within the nervous system. What the 
work in this thesis has not identified is the specific Gαi/o proteins 
activated. In order to achieve this, it would be necessary to expand upon 
the PTX experiments, having transfected in PTX-insensitive G proteins. If 
effects upon Emax and/or potency, for a specific PTX-insensitive G protein, 
were observed, it would identify the specific Gαi/o proteins the CLR is able 
to couple to, as well as whether or not RAMPs possess the ability to 
modulate this. 
 
As well as modulating intracellular cAMP levels, it was also observed that 
the CLR is able to mediate the mobilisation of iCa2+. The investigations 
performed within Chapter 4 determined that Gαq/11 is the direct mediator 
of iCa2+ release brought about through activation of the CLR, by CGRP, 
AM and AM2. In addition, as with cAMP production, RAMPs modulate the 
specific response brought about by each agonist. However, AM2 always 
appears to bring about a small response, with an associated reduced 
efficacy. This suggests that AM2 may play a minor role in regulating Ca2+ 
signalling from the CLR. Previous studies have observed CLR-mediated 
mobilisation of iCa2+ in alveolar epithelial cells and dorsal root ganglia, as 
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well as the trigeminal ganglia (Walker et al, 2010). This suggests that 
CLR-mediated iCa2+ release may play essential roles in regulating airway 
function, as well as nociception. Additionally, AM stimulation has been 
seen to mediate Ca2+ release in bovine aortic endothelial cells, leading to 
elevation of cGMP levels, via the action of endothelial nitric oxide 
synthase (eNOS) (Shimekake et al, 1995). There is therefore the 
potential that AM may mediate vascular dilation. Thus, RAMP-CLR 
heterodimers may provide a novel target in the treatment of hypertension. 
 
This study, into the signalling repertoire of RAMP-CLR heterodimers, 
lacks any investigation of the effect of RAMP association upon ERK1/2 
activation, nor how this occurs for the CLR. To address this, experiments 
similar to those performed in Chapter 5 would be required, investigating 
ERK1/2 activation, in response to CGRP, AM and AM2 stimulation, at 
each RAMP-CLR heterodimer. Ultimately this would give a wider 
understanding of the fuller signalling repertoire of the CLR. Having 
determined this, it would then be interesting to determine if the 
pharmacology observed in HEK 293 cells is translatable to primary cell 
lines endogenously expressing both RAMP and CLR, such as human 
umbilical vein endothelial cells (HUVECs) (Aslam et al, 2012). 
Investigations in cell lines such as these would determine if the effects 
previously observed are cell type specific, or due to overexpression of 
both RAMP and CLR. Further, it would identify the role of RAMP-CLR 
signalling within the cardiovascular system. 
 
Overall, Chapter 4 highlights the ability of the CLR to couple to: Gαs, 
eliciting cAMP production; Gαi/o, opposing the action of Gαs; and Gαq/11, 
facilitating the release of iCa2+. It has also been observed how RAMPs 
differentially modulate the extent of response to each agonist, at these 
three pathways (Figure 4.14 and 4.15), potentially though direct RAMP-G 
protein interactions (Weston et al, 2016, Appendix 2). It has been seen 
that all ligands are predominantly biased towards modulating cellular 
levels of cAMP, with the exception of AM2 at RAMP2-CLR, and CGRP at 
RAMP3-CLR heterodimers. However, by removing the action of inhibitory 
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Gαi/o proteins, an increase in the extent of response for these two 
agonists, resulting in them becoming biased toward cAMP modulation 
(Figure 4.14B) is observed. The fact that the CLR is predominantly biased 
towards modulating cAMP levels suggests that cAMP is the main 
mechanism by which the CLR mediates its effects. This is further 
validated by studies using PKA inhibitors, such as H89, which suggest 
that the effects of CGRP are predominantly brought about via cAMP-
dependent PKA signalling (Permpoonputtana et al, 2016). However, in 
OHS-4 osteosarcoma cells, CGRP is only able to mobilise iCa2+, without 
increasing cAMP levels (Drissi et al, 1999). Therefore, the pathways 
activated by the CLR may, potentially, be dependent upon cell type 
(Wootten et al, 2013). What is clearly evident from quantifying bias of the 
three agonists (Figures 4.14 and 4.15) is that they exhibit distinct 
patterns, dependent upon the RAMP associated with CLR. Further to the 
action of RAMPs upon biased agonism of the CLR, there is a potential for 
both RAMPs and agonists to mediate oligomerisation of the CLR, either 
with itself, or, in the case of agonists, modulate RAMP-CLR 
oligomerisation. The ability of the GLP-1R to form homodimers has been 
identified, whilst disruption of this interaction results in a reduced ability to 
mediate cAMP production, iCa2+ mobilisation, and ERK1/2 activation 
(Harikumar et al, 2012). Whilst this has not been investigated for the 
CLR, there is potential for a similar phenomenon to occur, which may 
influence biased agonism. 
 
6.5 Biased agonism of the CLR: a role for ICL1? 
 
In Chapter 5 it was observed that the ICL1 region of the CLR has 
implications upon downstream signalling, particularly that mediated via 
Gαs and Gαq/11 (Figure 5.8-15, Table 5.4-10), but plays a limited role in 
influencing ERK1/2 activation (Figure 5.16, Table 5.11). As ICL1 
mutations had clear effects upon known G protein-mediated signalling 
pathways, cAMP production and Gαq/11-mediated iCa2+ release (Weston 
et al, 2016), but not ERK1/2 activation, this lead to the proposal that CLR-
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mediated ERK activation occurs in a G protein-independent manner. This 
could potentially be via β-arrestin-dependent mechanisms, as observed 
for other GPCRs (Shenoy and Lefkowitz, 2005 and 2011). 
 
One interesting finding of the saturation mutagenesis study is that when 
S168 in the CLR was substituted for arginine, a significant gain-of-
function was observed in terms of a greatly increased potency for CGRP 
(Figure 5.12D, Table 5.8). The equivalent residue within the GLP-1R, 
H171, has been observed to form an electrostatic interaction with D312 of 
the associated Gβ subunit (Zhang et al, 2017). Thus, in the S168R 
mutant of the CLR, a positive charge has been introduced, which may 
now serve an analogous function to H171 in the GLP-1R. Analysis of the 
amino acid sequence for all family B GPCRs identifies that positively 
charged residues (arginines and lysines) are highly conserved at this 
position (Figure 5.2), suggesting that this residue may play a universal 
role in interacting with Gβ. However, the CLR, CTR and CRF receptors 
all contain a serine in this position, suggesting that these receptors may 
potentially interact with Gβ through the formation of salt bridges. As 
S168R in the CLR results in a gain-of-function (Figure 5.12D, Table 5.8), 
it appears that electrostatic interactions with Gβ are more favourable. 
Similar interactions with Gβ have also been observed with residues within 
H8 (Zhang et al, 2017). Thus, there is the possibility that, upon receptor 
activation, the separation of ICL1-H8 not only allows a conformational 
change, to the active state, but also opens up an area where Gβ may 
interact with the GPCR. This may explain why, when S168 was mutated 
to glutamic acid, a reduction in signalling was observed (Figure 5.8D, 
Table 5.4): potentially due to charge-charge repulsion between ICL1 and 
the Gβ subunit. Such interactions between ICL1 and an associated G 
protein suggest that ICL1 of family B GPCRs may also play roles in 
helping to stabilise receptor-G protein interactions, and/or in influencing G 
protein specificity, though Gβ. 
 
Analysis of the alanine scan data in terms of each mutation’s effect upon 
the extent of bias exhibited between cAMP production, iCa2+ mobilisation, 
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and ERK1/2 activation, revealed two distinct regions of ICL1 with differing 
effects upon signalling: the residues at the base of TM1 and start of ICL1 
(Y165-K167) appear to predominantly influence Gαs-mediated signalling, 
whilst those across ICL1 and the base of TM2 (S168-C171) 
predominantly influence Gαq/11-mediated signalling (Figure 5.17-18). This 
suggests that ICL1 plays roles in influencing G protein specificity. Indeed, 
this is something that has previously been suggested (Wess, 1997, Swift 
et al, 2006). However, what has not been accounted for in this 
mutagenesis study is any effect upon CLR-RAMP interaction. Chapter 4 
identified the key role of RAMPs in modulating biased agonism of the 
CLR. It is plausible that through mutating ICL1 of the CLR, the ability to 
interact with RAMP1 may have been affected, which may have unknown 
effects upon downstream signalling, and biased agonism. This is 
something that will need addressing in future follow up work. This study 
into Gαs and Gαq/11 also lacks any indication of if, or how, this region of 
the CLR influences the Gαi/o pathway that was identified in Chapter 4. 
Therefore, it would be interesting to investigate how the mutations affect 
AM-mediated signalling, in both untreated and PTX-treated cells. 
 
Whilst ICL3 is predominantly seen to be responsible for GPCR-G protein 
interactions (Taylor and Neubig, 1994, Liu et al, 1995 Cai et al, 2001, Itoh 
et al, 2001, Janz and Farrens, 2004), recent work by Flock et al has 
identified a ‘selectivity barcode’ upon G proteins, which determines if a G 
protein will interact with a given GPCR (Flock et al, 2017). It was 
identified that this ‘barcode’ is specifically read by a GPCR via 
interactions with ICL 2/3 as well as TM 5/6 (Flock et al, 2017). In addition, 
the work presented in Chapter 5 suggests that ICL1 may plays roles in 
influencing these interactions: either directly, through interacting with Gβ, 
influencing association of Gα, or through modulating the G protein-
binding pocket, by modulating the positioning of TM2, and hence, ICL2 
and the G protein binding pocket; something, which may be supported by 
the fact that pepducins, utilising different regions of different ICLs, can 
play roles in activating or inhibiting differential signalling pathways (Carr 
et al, 2014). 
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6.6 ICL1: a role in GPCR activation 
 
In addition to a role in influencing bias at the CLR, the possibility of direct 
interactions between ICL1 and H8, which are broken upon receptor 
activation, was identified. Similar observations have been made within the 
protease-activated receptor 1 (PAR1), where a series of ionic and H-
bonding interactions between TM7 and H8 have previously been 
observed (Swift et al, 2006). This TM7-H8-ICL1 network has been 
suggested to function in a coordinated manner to transfer ligand-induced 
signals to the associated G protein, particularly Gαq (Swift et al, 2006).  
 
Direct interactions between E377 in H8 and K135 in ICL1 of the PAR1 
have been observed, with similar interactions also occurring in many 
other family A GPCRs (Swift et al, 2006). The equivalent of E377, in 
family B GPCRs, is universally conserved (E388 in the CLR (Figure 5.3)), 
but the equivalent of K135 is a cysteine (C171 in the CLR), which is also 
conserved amongst all family B receptors (Figure 5.2). Analysis of the 
crystal structures for GCGR and the GLP-1R, identified that these 
residues (C171 and C174, respectively) are similarly positioned spatially 
(Figure 5.6A-B), and that, in the GLP-1R, this residue (C174) undergoes 
only a small amount of movement upon activation (Figure 5.6B-C). The 
work upon ICL1 of the CLR has suggested that this residue may play a 
role in stabilising the ICL1-TM2 junction, playing a structural role. As this 
residue is conserved amongst family B GPCRs, this residue may play 
similar roles across the whole family. Interestingly, conserved between all 
family B GPCRs is an arginine two positions up from C171, R173 in the 
CLR (Figure 5.2). Analysis of the existing structures for the GCGR and 
GLP-1R identified the possibility of an interaction between R173/176 
(equivalent residues in the GCGR and GLP-1R, to the R173 in the CLR) 
and E406/408 (Figure 5.4A-B). These residues may serve an analogous 
function to the K135-E377 interaction in PAR1 (Swift et al, 2006). 
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Unlike PAR1, in all family B GPCRs, with the exception of the CLR, CTR 
and CRF receptors, a second glutamic acid is present within H8 (position 
392, relative to the CLR (Figure 5.3)). Chapter 5 has highlighted a 
possible interaction between this glutamic acid in H8 and positively 
charged residues at the start of ICL1. Within the existing crystal 
structures for the GCGR and GLP-1R, in their inactive states, there is the 
possibility for an interaction between S167/K168, in the GCGR, as well as 
H171/R170, in the GLP-1R, with E410/412 (Figure 5.4A-B). Thus, there is 
the possibility that these residues, in family B GPCRs, form a second 
ICL1-H8 interaction, analogous to that played by K135-E377 in PAR1 
(Swift et al, 2006). The fact that a glutamic acid at position 392 is absent 
in the CLR, CTR and CRF receptors (Figure 5.3) suggests that these 
receptors do not form this interaction. Therefore, in the majority of family 
B GPCRs, it is probable that two ICL1-H8 interactions occur, primarily, 
between positively charged residues on ICL1, and negatively charged 
glutamic acids within H8. However, for the CTR, CLR and CRF receptors, 
there may only be a single interaction between the equivalents of R173 
and E388.  
 
Upon activation of the rhodopsin receptor, ICL1 and H8 have been 
observed to move apart (Altenbach et al, 2001, Klein-Seetharaman et al, 
2001). Likewise in the GLP-1R active structure (Figure 5.4C), a greater 
separation between ICL1 and H8, compared to the inactive structure is 
observed (Figure 5.4B). Concurrent with this are movements of R170 and 
H171 away from the axis of H8, along with a rotation of R176 away from 
E408 in H8 (Figure 5.4B-C). This suggests that breaking an ICL1-H8 
interaction may be a step that is required to occur upon GPCR activation, 
for both families A and B. Within the µ-opioid receptor, movement of 
ICL1-H8 is observed to occur prior to movement of TMs 5 and 6 (Sounier 
et al, 2015), suggesting this may be an early, key, event in receptor 
activation. 
 
Interestingly, the ICL regions of GPCRs have been utilised as a series of 
drugs that can act either as allosteric agonists or antagonists, depending 
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upon which ICL is used (Covic et al, 2001, Kuliopulos and Covic, 2003, 
Carr et al, 2014). These drugs, termed pepducins, consist of regions of 
either ICL1, 2, or 3, from a given GPCR, tethered to hydrophobic 
moieties, allowing cell penetration (Covic et al, 2001). The fact that these 
drugs can activate, or inhibit, orthosteric agonist-induced activation 
highlights how important the ICL regions of GPCRs are in both activation 
and signalling. Further, the work in Chapter 5 may also inform further 
upon how this drug class functions. 
 
This work identifying ICL1 as a key region of the CLR in receptor 
activation and mediator of signalling has so far only focused upon Y165-
Q172. As discussed, there is a potential for an ICL1-H8 interaction. To 
fully investigate this, mutants of H8 would have to be generated, 
particularly focusing upon the conserved glutamic acids, as well as 
introducing a second glutamic acid into H8 of the CLR, as per the majority 
of family B. Further, as R173 has been highlighted as a particularly key 
residue in forming an ICL1-H8 interaction, substitutions of this residue 
would be required, and experiments identical to those in Chapter 5 
performed. To support the in vitro findings, molecular dynamics 
simulations would provide a greater understanding/explanation of the 
biological effects we observe for each mutation. 
 
6.7 ICL1 influences cell surface expression 
 
As has previously been observed, mutation of ICL1 has dramatic effects 
upon GPCR cell surface expression (Bentrop et al, 1997, Wess et al, 
1998). A similar effect has been observed for the: α1B-, α2B-, and β2-
adrenergic receptors, as well as for the angiotensin II type 1 receptor 
(Duvernay et al, 2009). In these family A GPCRs, a conserved leucine 
residue within ICL1 (L48) was found to be required for export from the 
ER, and subsequent trafficking to the cell surface. Interestingly, analysis 
of the sequences of ICL1 for all family B GPCRs identifies an equally 
conserved leucine (Figure 5.2). Initial investigations into the cell surface 
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expression of our CLR mutants (performed by Heptares therapeutics), 
revealed that, when this residue (L169) is mutated, a reduction in surface 
expression of between ~66-95% that of WT was observed (Figure 5.7, 
Table 5.3). The only exception to this was where this residue is mutated 
to isoleucine, which instead exhibited a reduction of ~43% (Figure 5.7, 
Table 5.3). Thus, a similarly structured residue at this position can 
apparently rescue some reduced expression. It therefore seems that 
conserved leucines, in both family A and B GPCRs, may be key in 
regulating receptor expression. However, how this applies to the CLR, 
which absolutely requires RAMP association for trafficking (McLatchie et 
al, 1998), is unknown. In order to further determine a role of this residue 
upon cell surface expression further follow up experiments to the initial 
expression experiments, would be required. 
6.8 Models of GPCR signalling – understanding 
bias 
 
Many attempts have been made to model signalling from GPCRs, initially 
starting with the two-state model (Figure 1.7) which suggested that a 
GPCR exists in either inactive (R) or active (R*) states. It was believed 
that agonists served to shift the equilibrium of a system towards the R* 
state, thereby resulting in more active receptors and an increased 
signalling output. Whilst the two-state model may serve to explain 
relatively simple receptors activating only a single pathway, such as the 
neurotensin receptor (Mustain et al, 2011), it fails to recapitulate many of 
the behaviours observed at other GPCRs. For example, the two-state 
model fails to explain how one agonist can activate multiple differing 
pathways, with differing potencies and/or efficacies, such as what we 
observe within this thesis for the A1R and A2AR, as well as the CLR. Nor 
does it explain how differing receptor conformations have been observed 
for a given receptor, dependent upon the bound ligand (Swaminath et al, 
2004, 2005). Further, this model fails to capture the effect of the 
associating G protein; indeed, differences in antagonist affinity have been 
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observed depending upon which Gα subunit is associated with the A1R 
(Baker and Hill, 2007). 
 
Attempts to redress these imperfections in the two-state model were 
made by De Lean and colleagues, who developed the ternary complex 
model (De Lean et al, 1980). This was then further refined to produce the 
extended ternary complex (ETC) model (Samama et al, 1993). Like the 
two state model, the ETC model allows for a receptor in both active and 
inactive conformations. However, it now allows for conversion between 
these states in the absence of an agonist, thus encapsulating constitutive 
activity. The ETC model also allows for a ligand binding a receptor, but 
not resulting in activation, thereby accounting for allosteric modulators, 
inverse agonists, and antagonists. The effect of G protein association 
with a GPCR is also encompassed, by allowing a G protein to interact 
with an active receptor, or a ligand-bound active receptor. One situation 
that the ETC model does not account for is the association of a G protein 
with an inactive receptor. Adding this to the ETC model yields the cubic 
ternary complex (CTC) model (Weiss et al, 1996). This model now allows 
for a receptor to be ‘pre-coupled’ to a GPCR in both inactive and active 
states, and for the activation of a receptor, through G protein association. 
The CTC model thus explains the differences in antagonist affinity for the 
A1R in differing G protein bound states (Baker and Hill, 2007), and further 
encapsulates constitutive signalling. 
 
In an attempt to further explain GPCR-mediated signalling and biased 
agonism, we further refined the cubic ternary complex model. We 
developed a model consisting of multiple CTC models, accounting for 
differing active conformations of a GPCR, as well as association of 
differing G proteins (Appendix 3). The ETC and CTC models, whilst 
accounting for G protein association, treat them all as one single entity, 
essentially a ‘black box’ that transduces signals. We separate this box 
into several parameters accounting for multiple G proteins. Likewise, we 
apply the same principle for multiple active receptor conformations. Our 
model thus allows for a single receptor to couple to, and activate, multiple 
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downstream signalling pathways, both in the presence and absence of an 
agonist, thus encapsulating constitutive activity. We utilised our multi-
CTC model to account for two active receptor states and two associating 
G proteins. From this, we identify that a ligand acting as an agonist of one 
pathway also acts as an antagonist of the 2nd pathway, by reducing the 
number of receptors available to be activated for pathway 2. Our model is 
also able to account for differing receptor number, as well as temporal 
aspects of signalling output and how these influence perceived biased 
agonism (Herenbrink et al, 2016). Further, our model is novel in that it 
allows for receptor ‘cross-states’, whereby one given active receptor state 
can associate with any given G protein. We also apply parameters 
accounting for differing affinities of an agonist for active or inactive 
receptor states, as well as for G protein-free or -bound receptors. 
Through this we are able to produce a new method of quantifying biased 
agonism, accounting for factors not apparent in the operational model of 
pharmacological agonism (Black and Leff, 1983). By applying our multi-
CTC model to data obtained in Chapter 3, relating to the abilities of 
NECA, Cmpds 6 and 20 to produce non-monotonic dose-response 
curves (Figure 3.4) due to their ability to activate both Gαi/o and Gαs 
(Figures 3.4 and 3.5, Table 3.2 and 3.3), we are fully able to recapitulate 
the observed in vitro responses. Thus, our model is able to successfully 
reproduce experimental data, and therefore provides one possible 
alternative method of both analysing, and quantifying, biased agonism of 
GPCRs. 
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6.9 Conclusion 
 
The work presented within this thesis has further highlighted the extent of 
biased agonism and pathway bias at GPCRs in both families A and B. It 
has identified, and quantitated, the abilities of the A1R and CLR to 
activate various signalling pathways, and how both can activate opposing 
pathways with respect to cAMP production. In addition, this work has 
identified the mechanism of RAMP-CLR mediated iCa2+ mobilisation to be 
Gαq/11-mediated, and further shown the ability of RAMPs to modulate 
CLR-mediated signalling, with respect to both the efficacy of the 
stimulating agonist, and G protein specificity. Further, a role of ICL1 in 
influencing G protein specificity at the CLR has been identified, as well as 
identifying a potential ICL1-H8 interaction, which is broken upon receptor 
activation. In addition to uncovering mechanisms of signalling from the 
A1R and CLR, this thesis has also identified and characterised both 
selective, and non-selective agonists of both the A1 and A2AR, which may 
pose, as yet undetermined, therapeutic benefit for various pathological 
states. 
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ABSTRACT: A series of N6-bicyclic and N6-(2-hydroxy)-
cyclopentyl derivatives of adenosine were synthesized as novel
A1R agonists and their A1R/A2R selectivity assessed using a
simple yeast screening platform. We observed that the most
selective, high potency ligands were achieved through N6-
adamantyl substitution in combination with 5′-N-ethylcarbox-
amido or 5′-hydroxymethyl groups. In addition, we
determined that 5′-(2-ﬂuoro)thiophenyl derivatives all failed to generate a signaling response despite showing an interaction
with the A1R. Some selected compounds were also tested on A1R and A3R in mammalian cells revealing that four of them are
entirely A1R-selective agonists. By using in silico homology modeling and ligand docking, we provide insight into their
mechanisms of recognition and activation of the A1R. We believe that given the broad tissue distribution, but contrasting
signaling proﬁles, of adenosine receptor subtypes, these compounds might have therapeutic potential.
■ INTRODUCTION
Adenosine receptors (ARs) belong to the family of G protein-
coupled receptors (GPCRs) and exist as four diﬀerent subtypes,
A1, A2A, A2B, and A3. All subtypes respond to the purinergic
nucleoside adenosine, but they have a wide and varying tissue
distribution. Many ARs have been linked to cardiovascular,
respiratory, and inﬂammatory disorders.1 Furthermore, in the
central nervous system they have been implicated in acute
pathological conditions such as epilepsy, hypoxia, and
ischemia,2,3 and chronic neurodegenerative disorders, such as
Parkinson’s, Alzheimer’s, and Huntington’s diseases.4 In human
cells, the A1R and A3R predominantly couple to the Gαi family
of G proteins, inhibiting the production of cAMP, while the
A2R subtypes couple to the Gαs subunit, stimulating adenylate
cyclase to elevate cAMP levels. Given their common ligands,
diametrically opposed eﬀects, and overlapping tissue distribu-
tion, the ARs have been the focus of extensive research to
discover subtype selective ligands. However, limitations of
mammalian systems can hinder the testing and development of
these compounds. For instance, the A1R can signal through the
Gαi1, Gαi3, and Gαo,
5 but it is currently diﬃcult to diﬀerentiate
between these eﬀectors in an in vivo mammalian cell-based
assay.
Most of the known AR agonists are based on the adenosine
scaﬀold, and receptor subtype selectivity can be achieved by
substituting the purine ring of the nucleoside at positions C-2
and/or N6 with appropriate functional groups. For instance,
substitution of the N6-position with bulky cycloalkyl- and
bicycloalkyl groups has resulted in A1R-selective agonists.
6−10
Introduction of a wide range of N6-substituents is conveniently
achieved by nucleophilic aromatic substitution of the
corresponding 6-chloro purine precursor with primary or
secondary amines. The ribose moiety, in particular at the C-2′,
C-3′, and C-5′ positions, has also been the subject of many
modiﬁcations which can inﬂuence A1R aﬃnity, selectivity, and
eﬃcacy.8,11,12 5′-Carboxamido adenosine derivatives, such as
the prototypical AR agonist 5′-N-ethylcarboxamidoadenosine
(NECA), among many other examples, are known to be potent
activators. More bulky groups, such as substituted 5′-thioaryl
and 5′-oxoaryl moieties, have also been explored, and these
studies have provided novel A1R-selective and potent
agonists.13,14 In light of this, we designed a series of adenosine
analogues that feature diﬀerent cyclic and bicyclic substituents
at the N6 of the purine ring and various functional groups at the
C-5′ of the ribose in order to assess the eﬀect of these
modiﬁcations on AR activity and subtype selectivity.
We15−20 and others5,21−23 have previously described the use
of modiﬁed Saccharomyces cerevisiae strains containing chimeric
(yeast-human) G protein alpha subunits to functionally couple
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heterologously expressed GPCRs. Speciﬁcally, the chimeric G
proteins enable mammalian GPCRs to functionally couple to
the yeast-mating pathway. This pathway includes a reporter
(FUS1-lacZ) gene providing a quantitative assay for GPCR
activation.16 The yeast platform provides a simple, aﬀordable,
and robust assay with which to identify novel GPCR ligands
and their interactions with a single eﬀector.17,24,25 This system
has also been established to study A1R, A2AR, and A2BR in a
number of G protein backgrounds,5,18,21−23 although evidence
of functional couplings of the A3R has not been reported.
In this study, we exploit the yeast system to characterize
novel synthetic adenosine derivatives for their agonist activity
against the A1R, A2AR, and A2BR. We explored subtype
selectivity further at the A1R and A3R in mammalian CHO-
K1 cells for the compounds that were active against the A1R in
the yeast screen. Moreover, we use homology modeling and
docking to gain insight into the binding of our agonists at the
A1R. Our yeast-based screen and mammalian cell assays have
identiﬁed novel adenosine nucleosides exhibiting interesting
A1R selective proﬁles. Hence, they constitute valuable tool
Scheme 1. Synthesis of Adenosine Derivativesa
aReagents and conditions: (a) procedures according to ref 29; (b) R-NH2, Et3N or DIPEA, EtOH, reﬂux, 18 h to 5 days (for speciﬁc conditions and
yields see Experimental Section); (c) K2CO3, MeOH, rt, 3 h, 99%; (d) 4, Pd(OH)2, cyclohexene, ethanol, reﬂux, 18 h, 99%; (e) (1R,3r,5S)-9-methyl-
9-azabicyclo[3.3.1]nonan-3-amine, DIPEA, EtOH, reﬂux, 18 h, 54%; (f) K2CO3, MeOH, rt, 3 h, 99%.
Scheme 2. Synthesis of Novel NECA Derivativesa
aReagents and conditions: (a) procedures according to ref 32; (b) R-NH2, Et3N or DIPEA, EtOH, reﬂux, 18 h to 5 days (for speciﬁc conditions and
yields see Experimental Section); (c) acetic acid, water, 80 °C, 18 h, 99%; (d) tert-butyl-9-azabicyclo[3.3.1]nonan-3-yl carbamate (22), DIPEA,
EtOH, reﬂux, 18 h, 85%; (e) acetic acid, water, 80 °C, 18 h, 99%; (f) formic acid, formaldehyde (37% aq.), reﬂux, 18 h, 63%; (g) 20, Pd(OH)2,
cyclohexene, ethanol, reﬂux, 18 h, 99%.
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compounds for cellular studies and might have therapeutic
potential.
■ RESULTS AND DISCUSSION
Chemistry. Known compounds 5,26 6,27 and 728 have
previously been shown to be selective for the A1R with respect
to their binding aﬃnity. These analogues were prepared for
assessment using our yeast-based assay. Bulky bicyclic groups
have been highlighted as beneﬁcial for A1R selectivity,
7−10 so
we also prepared novel compound 9. Intermediate 2 was
required for eﬃcient generation of the analogues (Scheme 1).
This was synthesized according to the procedure adopted by
Kotra et al.,29 with minor experimental modiﬁcations.
Aromatic substitution of the N6-chloro group with 1-
adamantylamine or (1R,2R)-1-amino-2-benzyloxycyclopentane
was carried out in the presence of triethylamine or Hünig’s
base. This resulted in partial deacetylation to give the
monoacetylated products (3 and 4), which could be attributed
to the use of excess base. The presence of the acetyl on the
primary alcohol was conﬁrmed using 1H NMR and was then
removed using potassium carbonate in methanol to give 5 and
6 in quantitative yield. The choice of base did not appear to
have an eﬀect on the reaction. Attempts to directly remove the
benzyl group from 6 using hydrogenolysis returned unreacted
starting material. However, treatment of monoprotected 4 with
Pearlman’s catalyst and cyclohexene aﬀorded 7. Interestingly,
aromatic substitution with (1R,3r,5S)-9-methyl-9-azabicyclo-
[3.3.1]nonan-3-amine (granatanamine) using less base did not
result in deacetylation and aﬀorded the expected product 8.
Deprotection was again carried out with potassium carbonate
and methanol. Granatanamine was prepared according to a
procedure previously developed in our group.30
Despite the widespread use of 5′-N-ethylcarboxamidoadeno-
sine (NECA) as an A1R agonist, we found that the analogous
cyclopentyl (21) and adamantyl (16) congeners were novel
compounds and to the best of our knowledge untested at the
A1R. This is possibly a consequence of the nonselective nature
of NECA at the AR subtypes.31 In this case, intermediate 10
was required to allow the generation of novel analogues
(Scheme 2).
The amide building block 10 was prepared from 1 as
previously reported by Middleton et al.32 Displacement of the
chloride in 10 with the appropriate amine in the presence of
either Hünig’s base or triethylamine gave intermediates 11−15.
This reaction proceeded with ease in reﬂuxing ethanol
overnight in the case of 13−15; however, all 1-adamantyl
analogues required 1 week at reﬂux to generate suﬃcient
quantities of desired compounds. Interestingly, the 2-
adamantylamine reaction was complete within 1 day. Acetonide
deprotection was achieved by heating overnight in acetic acid
and water to generate 16−20 with the quantitative yields
observed. Removal of the benzyl protecting group from 20 with
palladium hydroxide and cyclohexene to generate 21 proceeded
in quantitative yield. We decided to prepare analogues 24 and
25 with the alternative bicyclic architecture to allow us to probe
the necessity for a secondary amine at the adenine N6 position.
Chloride 10 was reacted with granatyl secondary amine 22,
which was prepared according to a literature protocol.33 Like
the adamantyl analogues, this reaction was very slow and
required reﬂux for 1 week to generate suﬃcient quantities of
the product to give 23. Concomitant deprotection of the
acetonide and Boc group occurred on treatment with acetic
acid and water to give 24. Dimethylamine 25 was then prepared
using formic acid and formaldehyde.
Given the prior studies on CVT-3619 (37) showing that it is
a speciﬁc partial agonist at the A1R,
14 we prepared this
compound for assessment using our yeast-based assay and
planned to prepare new analogues with the 2-ﬂuorothiophenol
group at the C-5′ position of the ribose ring. In alignment with
our strategy for adenosine and NECA analogues, we required
Scheme 3. Synthesis of CVT-3619 and New Derivativesa
aReagents and conditions: (a) CCl4, PPh3, DMF, rt, 18 h, 53%; (b) 2-ﬂuorothiophenol, NaH, DMF, 0 °C to rt, 3 h, then chloride 27, DMF, rt, 18 h,
48%; (c) SOCl2, DMF, DCM, 50 °C, 5 h, 88%; (d) R-NH2, Et3N or DIPEA, EtOH, reﬂux, 18 h to 3 days (for speciﬁc conditions and yields see
Experimental Section); (e) acetic acid, water, 80 °C, 18 h, 99%.
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chloride 27, which would allow eﬃcient generation of
analogues with various cyclic groups at the N6 position of the
adenine (Scheme 3). Primary chloride 27 was prepared from
protected 26 using Appel conditions according to the
previously reported procedure.34 Treatment with 2-ﬂuorothio-
phenol and sodium hydride gave 28 in 48% yield, and
subsequent chlorination with our previously adopted con-
ditions of thionyl chloride and DMF gave 29 in 88% yield.
Introduction of the cyclic component was accomplished by
reacting with the appropriate primary amine in the presence of
DIPEA or triethylamine to give 30−33. Again, the preparation
of the adamantyl analogue required 1 week at reﬂux to obtain
the product in suﬃcient yield. Initial attempts to directly
remove the benzyl protecting group from 32 with palladium
hydroxide and cyclohexene to generate 37 were unsuccessful.
However, 6-chloropurine 29 reacted readily with (1R,2R)-2-
aminocyclopentanol to generate the desired product directly.
Acetonide deprotection with acetic acid and water at reﬂux
generated ﬁnal compounds 34−37 in excellent yields.
Biological Activity. We expressed all four AR subtypes,
under the control of the constitutive GAPDH promoter, in a
panel of transplant yeast strains engineered to contain chimeric
Gα-subunits in which the 5 C-terminal amino acids of Gpa1p
have been replaced with those of mammalian Gαq, Gα12, Gαo,
Gαi1/2, Gαi3, Gαz, and Gαs. Eﬃcient traﬃcking of the A1R,
A2AR, and A2BR to the cell surface in yeast cells was conﬁrmed
using modiﬁed receptors engineered to contain a GFP
ﬂuorophore at the C-terminus (Figure 1A). NECA is a
nonsubtype selective AR agonist and was used to determine
through which Gα-subunits each receptor signaled. Yeast cells
were exposed to 100 μM NECA for 16 h, and reporter gene
activity (as measured through β-galactosidase production) was
determined (Figure 1B−D).
Consistent with previous reports,5,22 the A1R generated
signiﬁcant (p < 0.05) responses in strains expressing G protein
chimeras corresponding to Gαo, Gαi1, and Gαi3 (Figure 1B). In
addition, we also report for the ﬁrst time, functional coupling of
the A1R signaling through the GPA1/Gαz transplant. Signaling
was not observed via GPA1/Gαq, GPA1/Gα12, or GPA1/Gαs
or the unmodiﬁed Gpa1p (n ≥ 16 isolates screened for
functionality). Further, we observed that the A2AR and A2BR
(Figure 1C and D) signaled through both GPA1/Gαs and
GPA1/Gαi1, but we failed to identify any functional coupling
for the A3R in our panel of strains (Figure S1). Moreover, we
report that the A2AR displayed signiﬁcantly elevated levels of
ligand-independent signaling which is consistent with previous
observations in yeast.18 While we have observed that these
GPCRs can couple to a number of diﬀerent Gpa1p chimeras,
we have chosen to focus on the ones that are widely reported to
be the most physiologically relevant in mammalian cells.
Consequently, the A1R-GPA1/Gαi1, A2AR-GPA1/Gαs, and
A2BR-GPA1/Gαs strains were chosen for further compound
characterization.
Subtype Selectivity of Adenosine Derivatives in
Yeast. Having identiﬁed yeast strains that functionally express
the A1R, A2AR, and A2BR, we sought to validate their
pharmacology in response to a range of agonists. Dose−
response curves were determined for NECA, adenosine, 2-
chloro-N6-cyclopentyladenosine (CCPA), and CGS-21680
(Figure 2) using the yeast reporter assay. Sigmoidal dose−
Figure 1. NECA-activated yeast-mating pathway via speciﬁc AR/Gα protein chimeras. (A) A C-terminal GFP tag was engineered onto the A1R,
A2AR, and A2BR, and expression at the plasma membrane was conﬁrmed using ﬂuorescence microscopy. Scale bar = 5 μm. (B−D) Yeast strains
expressing the human (B) A1R, (C) A2AR, and (D) A2BR were stimulated with 0 or 100 μM NECA for 16 h and assayed for the activation of the
FUS1-lacZ reporter gene as previously described.15−17,19 β-Galactosidase units (mU) are expressed as the ratio of o-nitrophenol product to cell
density (determined colorimetrically; see Experimental Section). Data are the mean of 5 independent experiments ± SEM. Data were determined as
signiﬁcantly diﬀerent from the nonligand response using Student’s t-test where *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01402
J. Med. Chem. 2016, 59, 947−964
950
! 216 
!!
!!!!
response curves were observed allowing the maximum response
(Emax) and potency (pEC50) to be determined (Table 1).
NECA, adenosine, and CCPA are full agonists at the A1R (Emax
compared with NECA by one-way ANOVA, p > 0.05) but have
diﬀering potencies (Table 1). This generates a rank order of
potency for the ligands of CCPA > NECA > adenosine. CGS-
21680 had a much lower potency than the other ligands (pEC50
= 3.2 ± 0.1) and failed to reach a maximal response. While the
overall potency values are lower than observed in mammalian
cells, the rank order of the ligands is conserved between yeast
and mammalian systems.35 Application of the operational
model of pharmacological agonism36 enabled calculation of the
ligand binding aﬃnity (pKA) and eﬃcacy (τ) (Table 2). In
comparison to NECA, both adenosine and CCPA have a
greater pKA and a reduced τ.
We next sought to investigate the pharmacological properties
of the A2AR expressed in our GPA1/Gαs expressing strains.
Both CGS-21680 and NECA displayed strong agonism at the
A2AR, while adenosine and CCPA showed weak partial agonism
(Figure 2B). Further, all ligands assayed display weak potency
at the A2BR (rank ligand potencies, NECA > adenosine =
CCPA ≫ CGS-21680), with CGS-21680 failing to generate a
maximal response at the ligand concentrations assayed. Thus, in
our strains, CGS-21680 would appear to be largely A2AR
selective, and this is consistent with mammalian cell aﬃnity
data.31,35
We next sought to compare the selectivity/preference that
ligands may possess for each of the ARs. Expression of the ARs
in yeast generates a clean, robust assay, with no competing
signaling machinery, so enabling the proportioning of receptor
responses to individual signaling pathways. We have previously
used the methods developed by Figuero et al.37 to quantify
ligand bias for receptors expressed in yeast.19,20 Here, we report
the adaptation of the equimolar method of comparison37 to
quantify ligand selectivity for a given receptor (see
Experimental Section for more details). Since NECA is a full
agonist for all three ARs expressed in yeast, it can be used as a
reference ligand. By calculating the change in log (τ/KA), for an
agonist relative to NECA, for each AR subtype we have
generated a quantitative means of comparing receptor
selectivity for all our agonists (Figure 2D−F). Adenosine and
CCPA are A1R-selective but also preferentially activate A2BR
over A2AR. In contrast, CGS-21680 is A2R subtype-selective
with an overall preference for the A2AR.
Bulkier N6-adamantyl agonists have previously been shown
to be A1R selective with respect to binding aﬃnity at rat
receptors.26 Therefore, we extended our studies to include
novel AR agonists containing an adamantyl group. Compounds
5 and 16−18 were derived from adenosine and NECA,
respectively (Schemes 1,2). These compounds appeared to be
A1R selective full agonists compared with NECA, with no
signiﬁcant response detected at the A2AR and A2BR (p > 0.05)
(Figure 3A−C). However, 5 and 16−18 displayed reduced
potency to the A1R compared to that of their precursors and
cyclopentyl variants (Table 1). Furthermore, pKA values
suggested that this might be a consequence of reduced ligand
binding aﬃnities (Table 2).
A1R agonists derived from adenosine with substituted
cyclopentyl groups at the adenine N6 position have been
reported previously (e.g., GR79236, N-[(1S,2S)-(2-hydroxy)-
cyclopentyl]adenosine).38 We found that N6-cyclopentyl
derivatives 6, 7, 20, and 21 mainly signal through the A1R,
but for the latter two compounds, minimal responses were also
detected at A2AR and A2BR (Table 1 and Figure 4).
Adenosine derivative 6 was highly A1R-selective but failed to
produce a maximal signal. In a patent in 2011,27 6 was
described as an A1R-selective agonist for reducing elevated
intraocular pressure in the treatment of glaucoma or ocular
hypertension, and this compound was assessed for selectivity
with respect to binding aﬃnity (Ki) at human subtypes A1, A2A,
and A3.
27 In accordance with our results, it was shown, using a
radioligand displacement assay, that 6 binds with greater than
250-fold aﬃnity at the A1 over the A2A subtype. In the yeast-
based assays, the novel NECA analogues 20 and 21 have equal
Figure 2. AR agonists display receptor subtype selectivity. Dose−response curves for various AR agonists were generated from yeast strains
expressing (A) A1R, (B) A2AR, and (C) A2BR following stimulation for 16 h with (●) NECA, (○) adenosine, (■) CCPA, or (□) CGS-21680.
Activation of the reporter gene was calculated and is expressed as the percentage of the maximum response achieved when cells were stimulated with
the reference agonist NECA. (D−F) Receptor selectivity was calculated as the change in log (τ/KA), relative to NECA, for the data in A−C. Data
were determined as statistically diﬀerent (**, p < 0.01; ***, p < 0.001) from NECA, using a one-way ANOVA with Bonferroni’s post-test. All data
are the mean of 5−8 independent experiments ± SEM.
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Table 1. Potency (pEC50) and Maximal Response (Emax) of Reference Compounds and Synthetic Adenosine Derivatives at A1R,
A2AR, and A2BR As Measured in Yeast
a
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or higher potency, respectively, than the parent compound
NECA at the A1R. However, in contrast to the N
6-cyclopentyl
adenosine derivatives 6 and 7, N6-cyclopentyl NECA
derivatives 20 and 21 are nonselective and signal through the
A1R, A2AR, and A2BR (Table 1). Calculation of selectivity
factors conﬁrm that 21 preferentially signals A1R > A2BR >
A2AR.
As described above, the N6-adamantyl derivatives only
induced a detectable response in A1R-expressing yeast strains,
suggesting that bulky N6-substituents promote total A1R/A2R
selectivity. To explore this further, we created a series of ligands
containing an N6-azabicyclo (granatane) moiety. Compounds
9, 19, 24, and 25 were screened for activity; however, no
signiﬁcant response was detected for these compounds via the
Table 1. continued
aA1R and A2R receptors in GPA1/Gαi1 and GPA1/Gαs yeast transplants, respectively. Values are the mean ± SEM from 5 to 8 independent repeats.
Statistical signiﬁcance compared to that of NECA (*, p < 0.05; **, p < 0.01; ***, p < 0.001) was determined by one-way ANOVA with Dunnett’s
post-test. bNegative logarithm of the agonist concentration required to induce a half-maximal response. cThe maximal response to a ligand expressed
as a percentage of that obtained for NECA. dN.R., no response. eN.D., not determined. Full dose−response curve was not feasible.
Table 2. Ligand Aﬃnity (pKA) and Eﬃcacy (log τ) of Reference Compounds and Synthetic Adenosine Derivatives at A1R, A2AR,
and A2BR expressed in Yeast
a
A1R A2AR A2BR
compd pKA
b log τc pKA
b log τc pKA
b log τc
NECA 4.4 ± 0.1 1.5 ± 0.1 5.9 ± 0.2 0.5 ± 0.1 4.2 ± 0.1 0.6 ± 0.1
adenosine 4.6 ± 0.2 0.9 ± 0.1 5.6 ± 0.2 0.0 ± 0.3 3.8 ± 0.1 0.3 ± 0.1
CCPA 6.1 ± 0.1 0.6 ± 0.1 4.7 ± 0.3 −0.1 ± 0.1 4.4 ± 0.1 3.5 ± 0.1***
CGS-21680 2.1 ± 0.9* 1.1 ± 0.9 4.9 ± 0.1 −0.3 ± 0.0 3.4 ± 0.1 −0.2 ± 0.0
5 3.0 ± 1.1 1.8 ± 1.1 N.R.d N.R.
6 4.9 ± 0.1 0.5 ± 0.1 N.R. N.R.
7 5.5 ± 0.1 0.7 ± 0.1 N.R. N.R.
9 N.R. N.R. N.R.
16 4.2 ± 0.3 1.2 ± 0.3 N.R. N.R.
17 3.5 ± 0.1 1.0 ± 0.1 N.R. N.R.
18 2.4 ± 0.1* 2.4 ± 0.0 N.R. N.R.
19 N.R. N.R. N.R.
20 4.3 ± 0.5 1.6 ± 0.5 3.9 ± 0.7** 0.5 ± 0.5 3.5 ± 0.6 0.1 ± 0.5
21 4.8 ± 0.5 1.6 ± 0.5 4.6 ± 0.4 0.3 ± 0.1 4.2 ± 0.1 −0.2 ± 0.1
24 N.R. N.R. N.R.
25 N.R. N.R. N.R.
34 N.R. N.D.e N.R.
35 N.R. N.R. N.R.
36 N.R. N.R. N.R.
37 N.R. N.R. N.R.
aA1R and A2R in GPA1/Gαi1 and GPA1/Gαs yeast transplants, respectively. Values are the mean ± SEM from 5 to 8 independent repeats. Statistical
signiﬁcance compared to that of NECA (*, p < 0.05; **, p < 0.01; ***, p < 0.001) was determined by one-way ANOVA with Dunnett’s post-test.
bNegative logarithm of the relative equilibrium disassociation constant for each compound generated through use of the operational model of
agonism.36 cThe coupling eﬃciency parameter (τ), generated by comparison to NECA. dN.R., no response. eN.D., not determined. The full dose−
response curve was not feasible.
Figure 3. N6-Adamantyl derivative selectivity at the human A1R. Yeast strains expressing (A) A1R, (B) A2AR, and (C) A2BR were stimulated with N
6-
adamantyl derivatives (▼) 5, (∇) 16, (◇) 17, (●) 18, and (◆) 34 for 16 h and reporter gene activity determined. Data are expressed as the
percentage of the maximum response achieved when cells were stimulated with the reference agonist NECA (gray dotted line). All data are the mean
of 5−8 independent experiments ± SEM.
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A1R, A2AR, or A2BR (p > 0.05, one-way ANOVA). Some
minimal response was observed for 9 and 19 at very high
concentration (100 μM), but it was not feasible to generate full
dose−response curves (Table 1).
Replacement of the 5′-ethyl carboxamide or 5′-hydroxy
group with a 2-ﬂuorothiophenyl moiety, as in adenosine
analogues 34−37, resulted in compounds that failed to produce
any detectable response in the A1R, A2AR, and A2BR strains
(Table 1). In fact, 34 was only able to activate the A2AR but at
concentrations of greater than 100 μM. These results were
somewhat surprising since the N6-hydroxycyclopentyl congener
37 (CVT-3619, later named GS 9667) has previously been
described as a selective, partial agonist of the A1R, with
reported Ki values of 113 nM and 1.1 μM when challenged with
the antagonist [3H]CPX, binding in hA1R-expressing
DDT1MF-2, and CHO cells, respectively.
14 To determine if
the lack of functional activity for 34, 36, and 37 in our yeast
assays resulted from the compounds failing to cross the
membrane, we performed a competition assay between 34, 36,
and 37 and either NECA, adenosine, or CCPA at the A1R
(Figure S2).
In line with the previously reported data,14 we conﬁrmed 37
does appear to compete with all three ligands at the A1R (pA2 =
5.3 ± 0.4). Interestingly, despite the fact that 37 interacts with
the A1R, in our experimental system, it appears unable to
induce a measurable response. It is worth noting that, A1R
agonist activity of 37 (CVT-3619) was previously demon-
strated in rat adipocytes where it reduced cAMP content and
consequently lipolysis,14 although it is entirely possible that the
observed response in these cell lines resulted from “oﬀ-target
activation” of other receptors. Despite entering clinical trials
where it was evaluated for its eﬃcacy to lower lipids and thus
improve glycemia, CVT-3619 (37) showed inadequate
pharmacokinetics, and it was discontinued.39 Furthermore,
some recent studies suggest that the A1R may not play a
signiﬁcant role in hepatic regulation of lipid metabolism.40
Similar to 37, close analogue 36 also acted as a competitive
antagonist at A1R (pA2 = 6.4 ± 0.2, Figure S2), but 34 did not
appear to bind to the A1R at all.
Determining A1R versus A3R Selectivity in Mamma-
lian Cells. Traditionally, many compounds that display
selectivity for the A1R compared to the A2Rs frequently also
display activity to the A3R. However, as described previously,
we were unable to obtain functional coupling of the A3R to the
yeast pheromone−response pathway (Figure S1). Thus, to
provide a complete characterization of the A1R-selective
compounds isolated in the yeast screen, we utilized mammalian
CHO-K1 cells transiently transfected with either the A1R or the
A3R. CHO-K1 are an established cell line frequently used to
assay the activity of adenosine receptors.41,42 Both the A1R and
the A3R couple to the inhibitory G protein family (Gαi),
thereby reducing the cellular concentration of cAMP.
Figure 4. N6-(2-Hydroxy)cyclopentyl derivatives of both adenosine and NECA display bias toward the A1 receptor. Yeast strains expressing the A1R
(A and D), the A2AR (B and E), and the A2BR (C and F) were stimulated for 16 h with N
6-(2-hydroxy)cyclopentyl derivatives (▲) 7 and (Δ) 21 or
N6-(2-benzyloxy)cyclopentyl derivatives (□) 6, (■) 20, and (○) 36 and assayed for activation of the FUS1> lacZ reporter gene. Data are expressed
as the percentage of the maximum response achieved when cells were stimulated with the reference agonist NECA (gray dotted line). Data are the
mean of at least ﬁve independent experiments ± SEM.
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Using CHO-A1R cells (CHO-K1 cells expressing the A1R),
we ﬁrst conﬁrmed that NECA, adenosine, and CCPA were able
to inhibit forskolin-stimulated cAMP production (Figure 5A)
generating pIC50 values (Table 3) equivalent to those
previously reported.41,42 Further, all compounds (5, 6, 7, 16,
17, 18, 20, and 21) identiﬁed in yeast as eliciting a functional
A1R response displayed full agonist activity against the A1R in
the mammalian cells but with varying potencies (Figure 5B and
Table 3). Signiﬁcantly, when these compounds were assayed
against the CHO-A3R cells (Figure 5C and D, and Table 3),
only 7, 17, 20, and 21 were able to inhibit forskolin-stimulated
cAMP production. Thus, taken together these data suggest that,
at concentrations ≤1 μM, 5, 6, 16, and 18 display A1R-
selectivity. Intriguingly, 2-adamantyl derivative 18 is almost as
potent an agonist of A1R as NECA but completely A1R-
selective.
Molecular Simulation of Agonist Docking into the
A1R. On the basis of the pharmacological experimental ﬁndings
that most of our N6-substituted 5′-N-ethylcarboxamido and 5′-
hydroxymethyl derivatives activated the A1R but that all of the
5′-(2-ﬂuoro)thiophenyl derivatives failed to do so, we used a
molecular modeling approach to dock all our synthetic
adenosine derivatives into a homology model of the human
A1R. The recently solved crystal structure of the human A2AR
complexed with the agonist UK-432097 (PDB ID: 3QAK)43
served as the template for this homology model. We reasoned
that the bound agonist UK-432097 has a large N6-substituent
(Figure 6A) as is the case for our synthetic adenosine
analogues.
In order to validate the utility of this A2AR crystal structure as
a template for generating the A1R homology model, we docked
compounds 20, 21, and 34, which also showed activity at the
A2AR in our assays, into the A2AR crystal structure. Indeed, the
Figure 5. Determining the A1R-selectivity of compounds isolated in the yeast screen against the A1R and A3R expressed in mammalian cells. CHO-
K1 cells transiently transfected with A1R (A, C, and E) or A3R (B, D, and F) were stimulated with (●) NECA, (○) adenosine, (■) CCPA (A and
B), or the compounds determined to be active at the A1R from the yeast screen (▲) 7, (◇) 17, (■) 20, (Δ) 21 (C and D) (▼) 5, (□) 6, (∇) 16,
and (●) 18 (E and F). In panels (C−F), the NECA dose-inhibition curve is shown as a gray dashed line with gray symbols. All cells were assayed for
the inhibition of 10 μM forskolin-stimulated cAMP. Data are expressed as the percentage of the maximum response achieved when cells were
stimulated with 10 μM forskolin. Data are the mean of 4−8 independent repeats ± SEM.
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proposed positions and side chain interactions for these
compounds (Figure 6C and Figures S3A and S3B) are very
similar to those of known agonists bound to the A2AR (Figure
6A and B).
Furthermore, after closely inspecting the crystal structures of
the adenosine-, NECA- (Figure 6B), and UK-432097-bound
(Figure 6A) human A2AR (PDB IDs: 2YDO, 2YDV, and
3QAK, respectively),43,44 we would argue that hydrogen bond
formation between the ligand and the homologous Thr-913.36,
Asn-2546.55, Thr-2777.42, and His-2787.43 (superscript: Balles-
teros−Weinstein numbering45) in the A1R is important to
stabilize the active conformation of the receptor.43,44 These
residues are highly conserved across the AR family. Taking this
into consideration (for details, see Experimental Section), the
Table 3. Potency (pIC50) and Response Range of Reference Ligands and Putative A1R Selective Compounds at the A1R and A3R
As Measured in Transfected CHO-K1 Cellsa
A1R A3R
compd pIC50
b response rangec n pIC50
b response rangec n
NECA 9.68 ± 0.16 −73.4 ± 5.8 6 9.31 ± 0.17 −44.1 ± 3.0 8
adenosine 8.63 ± 0.11* −66.4 ± 3.7 6 8.94 ± 0.14 −38.7 ± 2.4 5
CCPA 9.30 ± 0.15 −71.4 ± 4.3 6 7.95 ± 0.13** −46.6 ± 4.8 8
5 7.72 ± 0.20** −61.0 ± 6.1 5 N.R. N.R. 8
6 9.17 ± 0.15 −55.28 ± 3.6 4 N.R. N.R. 6
7 8.36 ± 0.17* −60.0 ± 4.4* 6 7.56 ± 0.11** −35.1 ± 2.2 5
16 8.54 ± 0.3* −52.15 ± 6.0* 6 N.R. N.R. 6
17 7.43 ± 0.19 −39.3 ± 3.9** 4 7.1 ± 0.12** −32.7 ± 2.2* 6
18 9.40 ± 0.34 −51.07 ± 7.9 6 N.R. N.R. 6
20 10.53 ± 0.28* −48.35 ± 5.6* 4 6.57 ± 0.15*** −38.0 ± 4.0 5
21 8.21 ± 0.2* −47.67 ± 4.3* 4 8.64 ± 0.08 −37.9 ± 1.2 5
aData are the mean ± SEM of n individual sets. Statistical signiﬁcance compared to that of NECA (*, p < 0.05; **, p < 0.01; ***, p < 0.001) was
determined by one-way ANOVA with Dunnett’s post-test. bThe negative logarithm of the agonist concentration required to produce a half-maximal
response. cThe response range of the agonists expressed as a percentage of total forskolin range (0−100%).
Figure 6. Docking of N6-substituted adenosine derivatives into an A1R homology model. (A) Crystal structures of human A2AR bound with agonist
UK-432097 (gold, PDB ID: 3QAK) and (B) with agonist NECA (yellow, PDB ID: 2YDV) for comparison, indication key binding residues and
interactions. Representative examples of proposed binding poses of N6-substituted adenosine derivatives in the A2AR crystal structure and in the A1R
homology model. (C) 21 (orange) docked into A2AR crystal structure. (D) 16 (light green), (E) 9 (light blue) and (F) 24 (pink) docked into A1R
homology model. Black dotted lines represent potential hydrogen bonds. Numbering of residues in (A-C) according to P29274 (hA2AR) and of
homologous residues in (D-F) according to P30542 (hA1R). Ballesteros-Weinstein (BW) numbering: T88 (A2A), T91 (A1): BW 3.36; F168 (A2A),
F171 (A1): BW ECL2; E169 (A2A), E172 (A1): BW ECL2; N181 (A2A), N184 (A1): BW 5.42; W246 (A2A), W247 (A1): BW 6.48; H250 (A2A),
H251 (A1): BW 6.52; N253 (A2A), N254 (A1): BW 6.55; T270 (A1): BW 7.35; Y271 (A2A), Y271 (A1): BW 7.36; S277 (A2A), T277 (A1): BW 7.42;
H278 (A2A), H278 (A1): BW 7.43. For activities of docked compounds see Table 1. Proposed binding poses for the remaining compounds are
shown in (Figure S3).
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docking yielded ligand orientations for 5-7, 16-18, 20, and 21
(Figure 6D and Figure S3C−I) that closely resemble the
orientations of UK-432097- and NECA-bound to the human
A2AR (Figure 6A and B). In this distinct position, the ribose
moiety binds deeply into the binding pocket potentially
forming hydrogen bonds with Thr-913.36, Asn-1845.42, Thr-
2777.42, and His-2787.43. The purine ring pi-stacks against Phe-
171ECL2 and can form hydrogen bonds with Asn-2546.55,
whereas the bulky N6-substitutes are located near the exit of
the binding pocket. We found experimentally that all of these
compounds were agonists at the A1R in our yeast-based
functional assay. Intriguingly, 6 and 20 were docked before they
were tested and based on our model predicted to be active
agonists, which indeed was the case.
The predicted binding positions for granatane derivatives 9
and 19 are somewhat similar; however, the purine ring is
further away from Asn-2546.55 so that no hydrogen bonds are
suggested (Figure 6E and Figure S3J). At very high
concentration, 9 and 19 were able to partially activate the
A1R, but it was experimentally not possible to obtain full dose−
response curves.
Docking of both inactive compounds 24 and 34 yielded
binding positions where the purine ring adopts a syn-
conformation with respect to the ribose (Figure 6F and Figure
S3K). It is also noticeable that 24 is not in close contact with
Trp-2476.48, a residue which is highly conserved across the AR
family and in a recent molecular dynamics simulation was
shown to act as a conformational toggle switch in the receptor
activation mechanism.46 The docking simulations with
adenosine derivatives 25 and 35−37, all of which failed to
activate the A1R, did not return any binding positions for our
model.
■ CONCLUSIONS
Herein, we report the synthesis of a series of adenosine
derivatives that were modiﬁed at the N6-position of the purine
ring and the C-5′ positions of the ribose moiety. These
compounds were evaluated using a yeast-based and mammalian
cell-based assay for quantifying their AR subtype selectivity.
Our biological data show that compounds bearing a granatane
azabicyclic moiety at N6 and/or a 5′-(2-ﬂuorothiophenyl)
substituent at the ribose fail to produce responses in A1R, A2AR
or A2BR cells. Conversely, N
6-adamantyl adenosine and NECA
congeners were completely A1R selective. Moreover, it emerged
that N6-(2-hydroxy)cyclopentyl and N6-(2-benzyloxy)-
cyclopentyl derivatives are potent agonists, preferentially
activating A1R over the other subtypes. It is worth noting
that novel NECA derivative 20 exhibited higher potency and
A1R selectivity than its parent compound. Further, we present
an A1R homology model that corroborates our experimental
ﬁndings. Notably, adenosine derivatives 5 and 6 and novel
NECA analogues 16 and 18 are completely A1R-selective,
potent agonists. Therefore, they should represent useful tool
compounds in purinergic signaling research and warrant further
assessment of their therapeutic potential.
■ EXPERIMENTAL SECTION
General Chemistry. All reactions were performed under an inert
argon atmosphere. Anhydrous tetrahydrofuran (THF), toluene, and
dichloromethane (DCM) were obtained by ﬁltration through a system
of alumina columns under a positive pressure of argon. Anhydrous
dimethylformamide (DMF) was purchased as dry over molecular
sieves from Sigma-Aldrich. Solvents were evaporated under reduced
pressure at approximately 45 °C using a Buchi Rotavapor or under
high vacuum on a Schlenk line. Reagents were purchased from Sigma-
Aldrich, Acros, Alfa Aesar, Fischer Scientiﬁc, or Han̈seler and used
without further puriﬁcation. Reactions were monitored by thin layer
chromatography (TLC) using aluminum sheets precoated with silica
(Macherey-Nagel ALUGRAM Xtra SII, G/UV254). Detection was
under UV light source (λmax 254 nm) or through staining with
potassium permanganate solution (5%), vanillin spray, or ninhydrin,
with subsequent heating. Flash column chromatography was carried
out using silica gel from Sigma-Aldrich (pore size 60 Å, 230−400 mesh
particle size) as the stationary phase.
Proton nuclear magnetic resonance spectra (1H NMR) were
recorded using a Bruker Avance 300 or an Avance II 400 spectrometer.
Chemical shifts (δH) are reported in parts per million (ppm) and are
referenced to the residual solvent peak. The order of citation in
parentheses is (1) number of equivalent nuclei (by integration), (2)
multiplicity, s (singlet), d (doublet), t (triplet), q (quartet), quint
(quintet), m (multiplet) etc., (3) coupling constants (J) in Hertz (Hz),
and (4) assignment. Carbon nuclear magnetic resonance spectra (13C
NMR) were recorded using a Bruker Avance 300 or an Avance II 400
spectrometer. Chemical shifts are quoted in parts per million (ppm)
and are referenced to the residual solvent peak. The assignment is
quoted in parentheses. COSY, HSQC, and DEPT were routinely used
to assign peaks in 1H and 13C NMR spectra. Addition of D2O was used
to conﬁrm the assignment of OH and NH peaks. Mass spectra and
high resolution mass spectra (HRMS) were recorded on a
ThermoScientiﬁc LTQ Orbitrap XL spectrometer consisting of a
linear ion trap (LTQ) featuring a HCD collision cell, coupled to the
Orbitrap mass analyzer, equipped with a nanoelectrospray ion source
(NSI). MS and HRMS spectra were determined by the Mass
Spectrometry Group at the Department of Chemistry and
Biochemistry, University of Bern (PD Dr. S. Schürch).
The purity of the compounds was determined with UPLC-MS on a
Dionex Ultimate 3000 using a reversed-phase column Dionex Acclain
RSLC, 120C18, 3 × 50 mm, 2.2 μm, 120 Å pore size, ﬂow 1.2 mL/
min. The gradient used was 100%A to 100%D over 7 min, with A
(water with 0.1% TFA) and D (10% H2O/90% ACN+0.1% TFA).
Purity was determined by total absorbance at 254 nm. All tested
compounds were ≥95% pure, except 17 which was 94% pure.
Established Adenosine Agonists. 5′-N-Ethylcarboxamidoade-
nosine (NECA), 2-chloro-N6-cyclopentyladenosine (CCPA), CGS-
21680, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), and SLV-320
were purchased from R & D Systems (Bristol, UK). Where possible,
compounds were prepared as 10 mM stocks in DMSO.
Chemical Synthesis. Intermediates 2,29 10,32 26,32 and 2734 were
synthesized as described in the literature with only slight experimental
modiﬁcations. (3-endo)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine
was synthesized as described previously by our group.30 tert-Butyl-9-
azabicyclo[3.3.1]nonan-3-ylcarbamate (22) was synthesized as de-
scribed previously.33 Intermediate 2947 is known but was obtained
with diﬀerent methodology. Intermediate 28 is a novel compound.
Further details on the synthesis and characterization of these
intermediates are available in the Supporting Information. 3-Amino-
1-adamantanol and (1R,2R)-2-aminocyclopentanol hydrochloride
were prepared as described in the Supporting Information.
General Procedure A for the Synthesis of Intermediates 3, 4, 8,
11−15, 23, and 30−33. The appropriate chloride was dissolved in
ethanol (20 mL/mmol). The amine and triethylamine or DIPEA were
then added, and the reaction mixture was reﬂuxed until TLC analysis
indicated completion. The solvent was removed in vacuo, and the
resultant material was puriﬁed with column chromatography. The
choice of base did not appear to have an eﬀect on the yield or reaction
time. In the case of compounds 4, 8, 13−15, and 31−33, the reaction
was complete after 18 h, whereas sterically hindered 3, 11, 12, 23, and
30 required 5 days of reﬂuxing at 120 °C to obtain suﬃcient amounts
of product. In cases where the amine is a hydrochloride salt, this was
ﬁrst stirred for 20 min with the base, before the addition of the
appropriate chloride in ethanol. For speciﬁc puriﬁcation conditions,
see individual compounds.
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General Procedure B for the Synthesis of Compounds 16−20, 24,
and 34−37. Acetonide protected compounds 11−15, 23, or 30−33
were dissolved in water and acetic acid and stirred at 80 °C overnight.
The water was removed in vacuo, and the resultant crude material was
puriﬁed with column chromatography.
General Procedure C for the Synthesis of Compounds 7 and 21.
Benzyl protected compounds 4 and 20 were dissolved in ethanol (8
mL/mmol). Cyclohexene and Pd(OH)2/C were added and reﬂuxed at
100 °C until TLC indicated completion. The reaction mixture was
allowed to cool to room temperature and ﬁltered through Celite. The
crude material was puriﬁed with column chromatography.
General Procedure D for the Synthesis of Compounds 5, 6 and 9.
Acetyl protected compounds 3, 4, and 8 were dissolved in methanol
(20 mL/mmol). Potassium carbonate was added and stirred vigorously
for 3 h. The solvent was removed in vacuo, and the crude material was
puriﬁed with column chromatography.
6-N-(1-Adamantyl)-5′-O-acetyladenosine (3). Compound3 was
synthesized according to general procedure A, using chloride 2 (0.2 g,
0.48 mmol), amantadine hydrochloride (0.14 g, 0.72 mmol), and
DIPEA (0.84 mL, 4.80 mmol). After puriﬁcation with column
chromatography (methanol/DCM, 2−6%), monoacetylated 3 was
obtained as a white solid as the major product (0.13 g, 62% yield). 1H
NMR (300 MHz, DMSO-d6) δ 8.31 (1H, s, adenine H), 8.22 (1H, s,
adenine H), 6.61 (1H, s, NH), 5.89 (1H, d, J 5.1, 1′-H), 5.56 (1H, d, J
5.7, 2′−OH), 5.37 (1H, d, J 5.4, 3′−OH), 4.67 (1H, dd, J 10.5, 5.2, 2′-
H), 4.32 (1H, dd, J 11.8, 3.7, 5′-HH), 4.26 (1H, dd, J 10.5, 5.4, 3′-H),
4.16 (1H, dd, J 11.8, 6.1, 5′-HH), 4.07 (1H, m, 4′-H), 2.21 (6H, m, 6
× adamantyl H), 2.08 (3H, m, 3 × adamantyl H), 2.00 (3H, s, CH3),
1.68 (6H, m, 6 × adamantyl H); 13C NMR (100 MHz, DMSO-d6) δ
170.1, 154.4, 151.9, 148.4, 139.5, 119.9, 87.9, 81.5, 72.8, 70.3, 63.9,
52.1, 41.0, 36.0, 29.0, 20.6; HRMS (ESI+) m/z calcd for C22H30N5O5
[MH]+ 444.2241, found 444.2229; purity UPLC-MS 99%, retention
time = 2.92 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)-5′-O-acetyladenosine (4).
Compound 4 was synthesized according to general procedure A, using
chloride 2 (0.20 g, 0.48 mmol), (1R,2R)-1-amino-2-benzyloxycyclo-
pentane (0.13 mL, 0.72 mmol), and triethylamine (0.19 mL, 1.34
mmol). After puriﬁcation with column chromatography (methanol/
DCM, 1−4%), monoacetylated product 4 was obtained as a pale
yellow solid as the major product (0.12 g, 52% yield). 1H NMR (300
MHz, DMSO-d6) δ 8.34 (1H, s, adenine H), 8.25 (1H, br s, adenine
H), 7.90 (1H, m, NH), 7.33−7.18 (5H, m, 5 × phenyl H), 5.93 (1H,
d, J 5.1, 1′-H), 5.57 (1H, d, J 5.7, 2′−OH), 5.37 (1H, d, J 5.3, 3′−OH),
4.68 (1H, dd, J 10.4, 5.1, 2′-H), 4.63−4.51 (3H, m, CH2Ph and 1-H),
4.33 (1H, dd, J 11.8, 3.6, 5′-HH), 4.27 (1H, dd, J 10.4, 5.3, 3′-H), 4.18
(1H, dd, J 11.8, 6.2, 5′-HH), 4.09 (1H, m, 4′-H), 4.01 (1H, m, 2-H),
2.13−1.90 (5H, m, 2 × cyclopentyl H and CH3), 1.80−1.55 (4H, m, 4
× cyclopentyl H); 13C NMR (100 MHz, DMSO-d6) δ 170.1, 154.2,
152.5, 139.4, 138.9, 128.1, 127.3, 127.1, 114.5, 87.8, 84.1, 81.5, 72.9,
70.3, 70.1, 63.9, 56.4, 30.2, 21.4, 20.6; HRMS (ESI) calcd for
C24H30O5N6 [MH]
+ 484.2191, found 484.2172; purity UPLC-MS
99%, retention time = 2.55 min.
6-N-(1-Adamantyl)adenosine (5).48 Compound 5 was synthesized
according to general procedure D, using 3 (0.03 g, 0.06 mmol) and
potassium carbonate (0.005 g, 0.04 mmol). After puriﬁcation with
column chromatography (methanol/DCM, 4%), product 5 was
obtained as a white solid (0.03 g, 99% yield). 1H NMR (300 MHz,
DMSO-d6) δ 8.35 (1H, s, adenine H), 8.21 (1H, s, adenine H), 6.65
(1H, s, NH), 5.87 (1H, d, J 6.1, 1′-H), 5.44 (1H, d, J 6.1, 2′−OH),
5.37 (1H, dd, J 7.1, 4.6, 5′−OH), 5.19 (1H, d, J 4.6, 3′−OH), 4.62
(1H, dd, J 11.1, 6.1, 2′-H), 4.15 (1H, m, 3′-H), 3.97 (1H, m, 4′-H),
3.69 (1H, m, 5′-HH), 3.55 (1H, m, 5′HH), 2.23 (6H, m, 6 ×
adamantyl H), 2.10 (3H, m, 3 × adamantyl H), 1.69 (6H, m, 6 ×
adamantyl H); 13C NMR (100 MHz, DMSO-d6) δ 154.5, 151.6, 148.2,
139.6, 120.1, 88.0, 85.8, 73.4, 70.6, 61.6, 52.2, 41.0, 36.0, 29.0; HRMS
(ESI+) m/z calcd for C20H28N5O4 [MH]
+ 402.2136, found 402.2137;
purity UPLC 99%, retention time = 2.66 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)adenosine (6).49 Com-
pound 6 was synthesized according to general procedure D, using 4
(0.01 g, 0.02 mmol) and potassium carbonate (0.01 g, 0.07 mmol).
After puriﬁcation with column chromatography (methanol/DCM, 2−
3%), product 6 was obtained as a white solid (0.01 g, 99% yield). 1H
NMR (300 MHz, DMSO-d6) δ 8.37 (1H, s, adenine H), 8.24 (1H, br
s, adenine H), 7.94 (1H, m, NH), 7.33−7.19 (5H, m, 5 × phenyl H),
5.89 (1H, d, J 6.1, 1′-H), 5.46−5.37 (2H, m, 2′−OH and 5′−OH),
5.19 (1H, d, J 4.6, 3′−OH), 4.68−4.50 (4H, m, 1-H, 2′-H and
CH2Ph), 4.15 (1H, dd, J 7.8, 4.6, 3′-H), 4.05−3.94 (2H, m, 2-H and
4′-H), 3.68 (1H, dt, J 12.0, 4.1, 5′-HH), 3.56 (1H, m, 5′-HH), 2.14−
1.89 (2H, m, 2 × cyclopentyl H), 1.77−1.56 (4H, m, 4 × cyclopentyl
H); 13C NMR (100 MHz, DMSO-d6) δ 154.2, 152.2, 139.6, 138.9,
128.1, 127.3, 127.1, 87.9, 85.8, 84.1, 73.5, 70.6, 70.1, 61.6, 30.1, 21.4;
HRMS (ESI) calcd for C22H28O5N5 [MH]
+ 442.2085, found
442.2097; purity UPLC-MS 98%, retention time = 2.30 min.
6-N-((1R,2R)-2-(Hydroxy)cyclopentyl)adenosine (7).28 Compound
7 was synthesized according to general procedure C, using 4 (0.03 g,
0.06 mmol), cyclohexene (0.25 mL, 2.43 mmol), and Pd(OH)2/C (20
wt %, 0.01 g). After puriﬁcation with column chromatography
(methanol/DCM, 2−8%), product 7 was obtained as a white solid
(0.02 g, 95% yield). Minor quantities of the monoacetylated product
were also isolated. 1H NMR (300 MHz, DMSO-d6) δ 8.37 (1H, s,
adenine H), 8.20 (1H, br s, adenine H), 7.74 (1H, d, J 6.8, NH), 5.89
(1H, d, J 6.1, 1′-H), 5.48−5.36 (2H, m, 2′−OH and 5′−OH), 5.19
(1H, d, J 4.6, 3′−OH), 4.87 (1H, m, 2-OH), 4.62 (1H, app. dd, J 11.3,
6.1, 2′-H), 4.29 (1H, br s, 1-H), 4.15 (1H, m, 3′-H), 4.06 (1H, m, 2-
H), 3.97 (1H, m, 4′-H), 3.68 (1H, dt, J 11.9, 3.9, 5′-HH), 3.55 (1H, m,
5′-HH), 2.07 (1H, m, 1 × cyclopentyl H), 1.88 (1H, m, 1 ×
cyclopentyl H), 1.74−1.59 (2H, m, 2 × cyclopentyl H), 1.59−1.45
(2H, m, 2 × cyclopentyl H); 13C NMR (100 MHz, DMSO-d6) δ
154.7, 152.2, 139.6, 87.9, 85.9, 76.0, 73.5, 70.6, 61.6, 58.8, 32.3; HRMS
(ESI) calcd for C15H22O5N5 [MH]
+ 352.1615, found 352.1616; purity
UPLC-MS 99%, retention time = 1.46 min.
Tri-O-acetyl-6-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-
yl]adenosine (8). Compound 8 was synthesized according to general
procedure A, using chloride 2 (0.3 g, 0.73 mmol), (3-endo)-9-methyl-
9-azabicyclo[3.3.1]nonan-3-amine (0.45 g, 2.91 mmol), and DIPEA
(0.15 mL, 0.88 mmol). After puriﬁcation with column chromatography
(methanol/DCM, 5−10%), product 8 was obtained as a white solid
(0.21 g, 54% yield). 1H NMR (400 MHz, MeOD-d4) δ 8.30 (1H, br s,
adenine H), 8.25 (1H, s, adenine H), 6.24 (1H, d, J 5.3, 1′-H), 6.03
(1H, t, J 5.3, 2′-H), 5.73 (1H, dd, J 5.3, 4.8, 3′-H), 4.83 (1H, br s, 3-
H), 4.49−4.37 (3H, m, 4′-H and 5′-H2), 3.44−3.42 (2H, m, 1- and 5-
H), 2.77 (3H, s, NCH3), 2.70−2.61 (2H, m, 2 × granatyl H), 2.20−
2.03 (12H, m, 3 × CH3 and 3 × granatyl H), 1.77−1.61 (3H, m, 3 ×
granatyl H), 1.43−1.40 (2H, m, 2 × granatyl H); 13C NMR (100
MHz, MeOD-d4) δ 172.2, 171.4, 171.2, 155.6, 154.3, 140.9, 87.9, 81.6,
74.3, 72.0, 64.2, 54.0, 41.7, 40.0, 32.6, 25.7, 20.6, 20.4, 20.2, 14.0;
HRMS (ESI+) m/z calcd for C25H35N6O7 531.2562 [MH]
+, found
531.2553; purity UPLC-MS 96%, retention time = 2.14 min.
6-N-[(3-endo)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]adenosine
(9). Compound 9 was synthesized according to general procedure D,
using 8 (0.05 g, 0.10 mmol) and potassium carbonate (0.005 g, 0.03
mmol). The crude product was dissolved in acetone and passed
through ﬁltered paper to give 9 as a white solid (0.04 g, 99% yield). 1H
NMR (300 MHz, MeOH-d4) δ 8.24 (1H, s, adenine H), 8.21 (1H, br
s, adenine H), 5.95 (1H, d, J 6.5, 1′-H), 4.77 (1H, br s overlapping, 3-
H), 4.74 (1H, dd, J 6.4, 5.2, 2′-H), 4.32 (1H, dd, J 5.1, 2.5, 3′-H), 4.17
(1H, app q, J 2.4, 4′-H), 3.89 (1H, dd, J 12.6, 2.4, 5′-HH), 3.74 (1H,
dd, J 12.6, 2.6, 5′-HH), 3.13−3.10 (2H, m, 1- and 5-H), 2.60−2.50
(5H, m, NCH3 and 2 × granatyl H), 2.16−1.98 (3H, m, 3 × granatyl
H), 1.58−1.45 (3H, m, 3 × granatyl H), 1.16−1.12 (2H, m, 2 ×
granatyl H); 13C NMR (100 MHz, MeOH-d4) δ 153.7, 141.4, 128.5,
91.4, 88.3, 75.5, 72.7, 63.6, 52.7, 42.7, 40.8, 33.4, 25.8, 15.0; HRMS
(ESI) calcd for C19H29O4N6 [MH]
+ 405.2245, found 405.2243; purity
UPLC-MS 99%, retention time = 1.41 min.
6-N-(1-Adamantyl)-5′-ethylamino-2′,3′-O-isopropylidene-5′-
oxo-5′-deoxyadenosine (11). Compound 11 was synthesized
according to general procedure A, using chloride 10 (0.3 g, 0.82
mmol), amantadine hydrochloride (0.46 g, 2.45 mmol), and DIPEA
(2.61 mL, 15.01 mmol). After puriﬁcation with column chromatog-
raphy (methanol/DCM, 2%), product 11 was obtained as a white solid
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(0.28 g, 72% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.27 (1H, s,
adenine H), 8.17 (1H, s, adenine H), 7.51 (1H, t, J 5.6, amide NH),
6.62 (1H, s, amine NH), 6.34 (1H, d, J 1.5, 1′-H), 5.41 (1H, dd, J 6.1,
1.5, 2′-H), 5.38 (1H, dd, J 6.1, 1.8, 3′-H), 4.53 (1H, d, J 1.8, 4′-H),
2.80 (2H, m, CH2CH3), 2.21 (6H, m, 6 × adamantyl H), 2.09 (3H, m,
3 × adamantyl H), 1.68 (6H, m, 6 × adamantyl H), 1.54 (3H, s, CH3),
1.35 (3H, s, CH3), 0.62 (3H, t, J 7.2, CH2CH3);
13C NMR (100 MHz,
DMSO-d6) δ 168.1, 154.4, 151.8, 148.0, 139.9, 119.6, 112.9, 89.5, 85.8,
83.2, 83.0, 52.1, 41.0, 36.0, 33.0, 29.0, 26.7, 25.0, 13.8; HRMS (ESI+)
m/z calcd for C25H35N6O4 [MH]
+ 483.2714, found 483.2718.
6-N-(3-Hydroxy-1-adamantyl)-5′-ethylamino-2′,3′-O-isopropyli-
dene-5′-oxo-5′-deoxyadenosine (12). Compound 12 was synthesized
according to general procedure A, using chloride 10 (0.07 g, 0.19
mmol), 3-amino-1-adamantanol (0.05 g, 0.29 mmol), and triethyl-
amine (0.5 mL, 3.6 mmol). After puriﬁcation with column
chromatography (methanol/DCM, 2−5%), product 12 was obtained
as a white solid (0.07 g, 78% yield). 1H NMR (300 MHz, DMSO-d6) δ
8.26 (1H, s, adenine H), 8.16 (1H, s, adenine H), 7.49 (1H, t, J 5.6,
amide NH), 6.74 (1H, s, amine NH), 6.33 (1H, d, J 1.1, 1′-H), 5.43−
5.35 (2H, m, 2′-H and 3′-H), 4.53 (2H, s, 4′-H and OH), 2.81 (2H,
m, CH2CH3), 2.18−2.01 (8H, m, 8 × adamantyl H), 1.65−1.43 (9H,
m, 6 × adamantyl H and CH3), 1.34 (3H, s, CH3), 0.62 (3H, t, J 7.2,
CH2CH3);
13C NMR (100 MHz, DMSO-d6) δ 168.1, 154.3, 151.7,
148.1, 140.0, 119.6, 112.9, 89.5, 85.6, 83.2, 83.0, 67.5, 54.6, 48.9, 44.2,
34.9, 33.0, 30.1, 26.7, 25.0, 13.8; HRMS (ESI+) m/z calcd for
C25H35N6O5 499.2663 [MH]
+, found 499.2650; purity UPLC-MS
99%, retention time = 2.62 min.
6-N-(2-Adamantyl)-5′-ethylamino-2′,3′-O-isopropylidene-5′-
oxo-5′-deoxyadenosine (13). Compound 13 was synthesized
according to general procedure A, using chloride 10 (0.02 g, 0.06
mmol), 2-adamantylamine hydrochloride (0.03 g, 0.18 mmol), and
DIPEA (0.05 mL, 0.27 mmol). After puriﬁcation with column
chromatography (methanol/DCM, 2%), product 13 was obtained as
a white solid (0.02 g, 69% yield). 1H NMR (300 MHz, DMSO-d6) δ
8.29 (1H, s, adenine H), 8.17 (1H, br s, adenine H), 7.48 (1H, t, J 5.7,
amide NH), 7.05 (1H, br s, NH), 6.34 (1H, s, 1′-H), 5.45−5.36 (2H,
m, 2′- and 3′-H), 4.53 (1H, s, 4′-H), 4.36 (1H, br s, adamantyl H),
2.80 (2H, m, CH2CH3), 2.11−2.05 (4H, m, 4 × adamantyl H), 1.84
(6H, m, 6 × adamantyl H), 1.72 (2H, m, 2 × adamantyl H), 1.53−1.50
(5H, m, 2 × adamantyl H and CH3), 1.34 (3H, s, CH3), 0.59 (3H, t, J
7.2, CH2CH3);
13C NMR (100 MHz, DMSO-d6) δ 168.1, 154.1, 152.3,
140.3, 112.9, 89.5, 85.9, 83.2, 83.1, 37.1, 36.9, 36.8, 33.0, 30.9, 26.7,
26.6, 25.0, 13.8; HRMS (ESI) calculated for C25H35N6O4 [MH]
+
483.2714, found 483.2707; purity UPLC-MS 94%, retention time =
3.12 min.
6-N-[(3-endo)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5′-ethyla-
mino-2′,3′-O-isopropylidene-5′-oxo-5′-deoxyadenosine (14). Com-
pound 14 was synthesized according to general procedure A, using
chloride 10 (0.1 g, 0.27 mmol), (3-endo)-9-methyl-9-azabicyclo[3.3.1]-
nonan-3-amine (0.17 g, 1.09 mmol), and DIPEA (0.06 mL, 0.33
mmol). After puriﬁcation with column chromatography (methanol/
DCM, 5−10%), product 14 was obtained as a white solid (0.11 g, 85%
yield). 1H NMR (300 MHz, MeOD-d4) δ 8.21 (2H, m, 2 × adenine
H), 6.35 (1H, d, J 1.0, 1′-H), 5.63 (1H, dd, J 6.1, 1.8, 3′-H), 5.51 (1H,
m, 2′-H), 4.77 (1H, br s, 3-H), 4.64 (1H, d, J 1.7, 4′-H), 3.27−3.23
(1H, m, 1- and 5-H), 2.85 (2H, m, CH2CH3), 2.67−2.50 (5H, m,
NCH3 and 2 × granatyl H), 2.20−2.00 (3H, m, 3 × granatyl H), 1.65−
1.51 (6H, m, CH3 and 3 × granatyl H), 1.42 (3H, s, CH3) 1.34−1.19
(2H, m, 2 × granatyl H), 0.63 (3H, t, J 7.3, CH2CH3); 13C NMR (75
MHz, CDCl3) 171.6, 155.6, 154.1, 142.0, 114.9, 92.4, 88.7, 85.3, 85.2,
53.3, 42.2, 40.4, 34.7, 33.1, 27.1, 25.8, 25.3, 14.6, 14.0; HRMS
calculated for C24H36O4N7 [MH]
+ 486.2823, found 486.2810; purity
UPLC-MS 99%, retention time = 1.97 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)-5′-ethylamino-2′,3′-O-
isopropylidene-5′-oxo-5′-deoxyadenosine (15). Compound 15 was
synthesized according to general procedure A, using chloride 10 (0.2 g,
0.54 mmol), (1R,2R)-1-amino-2-benzyloxycyclopentane (0.15 mL,
0.82 mmol), and triethylamine (0.21 mL, 1.51 mmol). Following the
removal of the solvent from the reaction mixture, the residue was
dissolved in ethyl acetate (100 mL) and washed with water (2 × 50
mL). The organic phase was then dried over anhydrous Na2SO4, and
the solvent was removed in vacuo. After puriﬁcation with column
chromatography (methanol/DCM, 1−3%), product 15 was obtained
as a pale yellow solid (0.22 g, 79% yield). 1H NMR (300 MHz,
DMSO-d6) δ 8.27 (1H, s, adenine H), 8.20 (1H, br s, adenine H), 7.91
(1H, m, amine NH), 7.51 (1H, t, J 5.7, amide NH), 7.33−7.20 (5H, m,
5 × phenyl H), 6.34 (1H, s, 1′-H), 5.43−5.36 (2H, m, 2′- and 3′-H),
4.66−4.49 (4H, m, 4′-H, CH2Ph and 1-H), 4.01 (1H, m, 2-H), 2.81
(2H, m, CH2CH3), 2.12−1.89 (2H, m, 2 × cyclopentyl H), 1.80−1.56
(4H, m, 4 × cyclopentyl H), 1.54 (3H, s, CH3), 1.34 (3H, s, CH3),
0.61 (3H, t, J 7.2, CH2CH3);
13C NMR (100 MHz, DMSO-d6) δ
168.1, 154.1, 152.4, 148.2, 139.9, 138.9, 128.1, 127.3, 127.1, 112.9,
89.5, 85.8, 84.0, 83.2, 83.1, 70.1, 56.4, 33.0, 30.2, 26.7, 25.0, 21.3, 13.8;
HRMS (ESI) calculated for C27H35O5N6 [MH]
+ 523.2663, found
523.2649; purity UPLC-MS 99%, retention time = 3.08 min.
6-N-(1-Adamantyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine
(16). Compound 16 was synthesized according to general procedure
B, using 11 (0.10 g, 0.21 mmol), acetic acid (10 mL), and water (3
mL). After puriﬁcation with column chromatography (methanol/
DCM, 2−6%), product 16 was obtained as a white solid (0.09 g, 96%
yield). 1H NMR (300 MHz, DMSO-d6) δ 8.89 (1H, t, J 5.5, amide
NH), 8.39 (1H, s, adenine H), 8.27 (1H, s, adenine H), 6.77 (1H, s,
amine NH), 5.95 (1H, d, J 7.7, 1′-H), 5.75 (1H, d, J 3.8, 3′−OH), 5.56
(1H, d, J 6.2, 2′−OH), 4.61 (1H, m, 2′-H), 4.30 (1H, d, J 1.2, 4′-H),
4.14 (1H, m, 3′-H), 3.22 (2H, m, CH2CH3), 2.23 (6H, m, 6 ×
adamantyl H), 2.09 (3H, m, 3 × adamantyl H), 1.68 (6H, m, 6 ×
adamantyl H), 1.08 (3H, t, J 7.2, CH2CH3);
13C NMR (100 MHz,
DMSO-d6) δ 169.1, 154.6, 151.6, 148.0, 140.4, 120.4, 87.9, 84.7, 73.1,
71.9, 52.2, 41.0, 36.0, 33.2, 29.0, 14.7; IR [cm−1] 3218, 2905, 2847,
1644; HRMS (ESI+) m/z calcd for C22H31N6O4 [MH]
+ 443.2401,
found 443.2393; purity UPLC 99%, retention time = 3.06 min.
6-N-(3-Hydroxy-1-adamantyl)-5′-ethylamino-5′-oxo-5′-deoxya-
denosine (17). Compound 17 was synthesized according to general
procedure B, using 12 (0.01 g, 0.02 mmol), acetic acid (3.6 mL), and
water (1.2 mL). After puriﬁcation with column chromatography
(methanol/DCM, 1−5%), product 17 was obtained as a white solid
(0.007 g, 78% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.88 (1H, t, J
5.5, amide NH), 8.40 (1H, s, adenine H), 8.27 (1H, s, adenine H),
6.89 (1H, s, amine NH), 5.95 (1H, d, J 7.6, 1′-H), 5.74 (1H, d, J 4.2,
3′−OH), 5.57 (1H, d, J 6.4, 2′−OH), 4.61 (1H, m, 2′-H), 4.55 (1H, s,
adamantyl OH), 4.30 (1H, d, J 1.2, 4′-H), 4.14 (1H, m, 3′-H), 3.21
(2H, m, CH2CH3), 2.20−2.05 (8H, m, 8 × adamantyl H), 1.66−1.43
(6H, m, 6 × adamantyl H), 1.08 (3H, t, J 7.2, CH2CH3); 13C NMR
(100 MHz, DMSO-d6) δ 169.1, 154.5, 151.6, 148.0, 140.4, 120.3, 87.8,
84.7, 73.1, 72.0, 67.5, 54.7, 48.8, 44.2, 34.9, 33.3, 30.1, 14.7; HRMS
(ESI+) m/z calcd for C22H31N6O5 [MH]
+ 459.2350, found 459.2346;
purity UPLC 94%, retention time = 2.18 min.
6-N-(2-Adamantyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine
(18). Compound 18 was synthesized according to general procedure
B, using 13 (0.02 g, 0.04 mmol), acetic acid (1.6 mL), and water (0.4
mL). After puriﬁcation with column chromatography (methanol/
DCM, 3−10%), product 18 was obtained as a white solid (0.02 g, 99%
yield). 1H NMR (300 MHz, DMSO-d6) δ 8.86 (1H, m, amide NH),
8.43 (1H, s, adenine H), 8.27 (1H, s, adenine H), 7.15 (1H, br s,
amine NH), 5.97 (1H, d, J 7.5, 1′-H), 5.74 (1H, d, J 4.3, 3′−OH), 5.54
(1H, d, J 6.4, 2′−OH), 4.62 (1H, m, 2′-H), 4.37 (1H, br s, adamantyl
H), 4.30 (1H, d, J 1.4, 4′-H), 4.14 (1H, m, 3′-H), 3.21 (2H, m,
CH2CH3), 2.13−2.08 (4H, m, 4 × adamantyl H), 1.85 (6H, m, 6 ×
adamantyl H), 1.73 (2H, m, 2 × adamantyl H), 1.56−1.52 (2H, m, 2 ×
adamantyl H), 1.08 (3H, t, J 7.2, CH2CH3);
13C NMR (100 MHz,
DMSO-d6) δ 169.1, 154.3, 152.3, 140.6, 114.5, 87.8, 84.6, 73.1, 71.9,
37.2, 36.9, 33.3, 30.9, 26.8, 14.7; HRMS (ESI) calcd for C22H31N6O4
[MH]+ 443.2401, found 443.2392; purity UPLC-MS 99%, retention
time = 2.69 min.
6-N-[(3-endo)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5′-ethyla-
mino-5′-oxo-5′-deoxyadenosine (19). Compound 19 was synthe-
sized according to general procedure B, using 14 (0.03 g, 0.06 mmol),
acetic acid (4.8 mL), and water (1.2 mL). After puriﬁcation with
column chromatography (methanol/DCM, 5−10%, with an additional
1% aqueous ammonia), product 19 was obtained as a white solid (0.03
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g, 99% yield). 1H NMR (300 MHz, MeOD-d4) δ 8.30 (1H, br s,
adenine H), 8.27 (1H, s, adenine H), 6.01 (1H, d, J 7.7, 1′-H), 4.81
(1H partially behind solvent signal, m, 3-H), 4.75 (1H, dd, J 7.6, 4.8,
2′-H), 4.47 (1H, d, J 1.5, 4′-H), 4.31 (1H, dd, J 4.8, 1.4, 3′-H), 3.37
(2H, m, CH2CH3), 3.28 (2H partially behind solvent signal, m, 1-, and
5-H), 2.69−2.56 (5H, m, NCH3 and 2 × granatyl H), 2.21−2.04 (3H,
m, 3 × granatyl H), 1.68−1.56 (3H, m, 3 × granatyl H), 1.30 (2H, m,
2 × granatyl H), 1.21 (3H, t, J 7.3, CH2CH3); 13C NMR (100 MHz,
MeOD-d4) δ 172.1, 155.8, 153.9, 142.1, 90.5, 86.5, 75.0, 73.4, 53.5,
42.1, 40.2, 35.1, 33.0, 25.7, 15.0, 14.4; HRMS (ESI) calcd for
C21H32N7O4 [MH]
+ 446.2510, found 446.2523; purity UPLC-MS
99%, retention time = 1.62 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)-5′-ethylamino-5′-oxo-5′-
deoxyadenosine (20). Compound 20 was synthesized according to
general procedure B, using 15 (0.01 g, 0.02 mmol), acetic acid (1.6
mL), and water (0.4 mL). After puriﬁcation with column
chromatography (methanol/DCM, 2−4%), product 20 was obtained
as a white solid (0.01 g, 99% yield). 1H NMR (400 MHz, DMSO-d6) δ
8.90 (1H, t, J 5.6, amide NH), 8.41 (1H, s, adenine H), 8.30 (1H, br s,
adenine H), 8.03 (1H, m, amine NH), 7.33−7.20 (5H, m, 5 × phenyl
H), 5.98 (1H, d, J 7.6, 1′-H), 5.73 (1H, d, J 4.3, 3′−OH), 5.53 (1H, d,
J 6.5, 2′−OH), 4.67−4.53 (4H, m, 2′-H, CH2Ph and 1-H), 4.32 (1H,
d, J 1.5, 4′-H), 4.15 (1H, m, 3′-H), 4.03 (1H, m, 2-H), 3.23 (2H, m,
CH2CH3), 2.08 (1H, m, 1 × cyclopentyl H), 1.96 (1H, m, 1 ×
cyclopentyl H), 1.79−1.60 (4H, m, 4 × cyclopentyl H), 1.09 (3H, t, J
7.2, CH2CH3);
13C NMR (100 MHz, DMSO-d6) δ 169.1, 154.3, 152.3,
140.4, 138.9, 128.1, 127.3, 127.1, 120.1, 87.8, 84.7, 84.1, 73.1, 72.0,
70.1, 56.4, 33.2, 30.2, 21.4, 14.7; HRMS (ESI) calcd for C24H31O5N6
[MH]+ 483.2350, found 483.2339; purity UPLC-MS 98%, retention
time = 2.59 min.
6-N-((1R,2R)-2-(Hydroxy)cyclopentyl)-5′-ethylamino-5′-oxo-5′-
deoxyadenosine (21). Compound 21 was synthesized according to
general procedure C, using 20 (0.08 g, 0.17 mmol), cyclohexene (0.66
mL, 6.55 mmol), and Pd(OH)2/C (20 wt %, 0.02 g). After puriﬁcation
with column chromatography (methanol/DCM, 2−8%), product 21
was obtained as a white solid (0.07 g, 99% yield). 1H NMR (300 MHz,
DMSO-d6) δ 8.91 (1H, t, J 5.4 Hz, amide NH), 8.41 (1H, s, adenine
H), 8.26 (1H, br s, adenine H), 7.84 (1H, m, amine NH), 5.97 (1H, d,
J 7.6, 1′-H), 5.75 (1H, d, J 4.3, 3′−OH), 5.55 (1H, d, J 6.5, 2′−OH),
4.86 (1H, m, 2-OH), 4.62 (1H, m, 2′-H), 4.31 (2H, m, 1-H and 4′-H),
4.14 (1H, m, 3′-H), 4.06 (1H, m, 2-H), 3.23 (2H, m, CH2CH3), 2.10
(1H, m, 1 × cyclopentyl H), 1.90 (1H, m, 1 × cyclopentyl H), 1.74−
1.42 (4H, m, 4 × cyclopentyl H), 1.09 (3H, t, J 7.2, CH2CH3); 13C
NMR (100 MHz, DMSO-d6) δ 169.1, 154.8, 152.2, 140.3, 87.8, 84.6,
76.0, 73.1, 72.0, 58.8, 33.3, 32.3, 20.4, 14.7; HRMS (ESI) calcd for
C17H25O5N6 [MH]
+ 393.1881, found 393.1873; purity UPLC-MS
99%, retention time = 2.21 min.
6-N-[(3-endo)-3-tert-Butyloxycarbonylamino-9-azabicyclo[3.3.1]-
non-3-yl]-5′-ethylamino-2′,3′-O-isopropylidene-5′-oxo-5′-deoxya-
denosine (23). Compound 23 was synthesized according to general
procedure A, using chloride 10 (0.03 g, 0.08 mmol), tert-butyl-9-
azabicyclo[3.3.1]nonan-3-ylcarbamate (22) (0.04 g, 0.16 mmol), and
triethylamine (0.41 mL, 2.94 mmol). Following the removal of the
solvent from the reaction mixture, the residue was dissolved in ethyl
acetate (100 mL) and washed with water (2 × 50 mL). The organic
phase was then dried over anhydrous Na2SO4, and the solvent was
removed in vacuo. After puriﬁcation with column chromatography
(methanol/DCM, 1−2%), product 23 was obtained as a pale yellow
solid (0.03 g, 67% yield). 1H NMR (300 MHz, MeOD-d4) δ 8.18 (1H,
s, adenine H), 8.13 (1H, m, adenine H), 6.33 (1H, s, 1′-H), 6.16 (1H,
m, 1- or 5-H), 5.61 (1H, m, 2′-H), 5.49 (1H, m, 3′-H), 5.42 (1H, m, 1-
or 5-H), 4.62 (1H, d, J 1.7, 4′-H), 3.29 (1H, m, granatyl H), 2.85 (2H,
m, CH2CH3), 2.42−2.16 (3H, m, 3 × granatyl H), 1.79−1.34 (22H, m,
2 × CH3, −C(CH3)3 and 7 × granatyl H), 0.66 (3H, dt, J 14.7, 7.2,
CH2CH3);
13C NMR (75 MHz, CDCl3) 171.8, 155.4, 153.7, 140.6,
117.1, 115.0, 93.0, 88.9, 85.5, 85.3, 45.1, 44.1, 35.0, 33.6, 33.2, 32.5,
31.8, 30.9, 28.9, 27.2, 25.5, 15.0, 14.3; HRMS calculated for
C28H42O6N7 [MH]
+ 572.3191, found 572.3187.
6-N-[(3-endo)-3-Amino-9-azabicyclo[3.3.1]non-3-yl]-5′-ethylami-
no-5′-oxo-5′-deoxyadenosine (24). Compound 24 was synthesized
according to general procedure B, using 23 (0.02 g, 0.03 mmol), acetic
acid (1.5 mL), and water (0.5 mL). The crude product was puriﬁed by
prep-LC, with an eluent gradient of 100% A to 60% D in 40 min. The
fractions were collected and dried by lyophilization, and product 24
was obtained as a white solid as the TFA salt (0.03 g, 99% yield). 1H
NMR (400 MHz, MeOD-d4) δ 8.34 (1H, s, adenine H), 8.28 (1H, s,
adenine H), 6.35 (1H, br s, 1- or 5-H), 6.03 (1H, d, J 7.6, 1′-H), 5.59
(1H, br s, 1- or 5-H), 4.74 (1H, dd, J 7.5, 4.8, 2′-H), 4.48 (1H, d, J 1.6,
4′-H), 4.30 (1H, dd, J 4.8, 1.5, 3′-H), 3.36 (2H, q, J 7.3, CH2CH3),
3.00 (1H, ddd, J 18.3, 12.2, 5.8, 3-H), 2.57 (2H, m, 2 × granatyl H),
2.18 (1H, m, 1 × granatyl H), 1.87−1.64 (7H, m, 7 × granatyl H),
1.20 (3H, t, J 7.3, CH2CH3);
13C NMR (100 MHz, MeOD-d4) δ
172.2, 155.2, 152.6, 150.7, 141.1, 121.8, 90.6, 86.4, 75.0, 73.5, 45.1,
35.1, 31.0, 15.0, 14.7; 19F NMR (376 MHz, DMSO-d6) δ −77.3;
HRMS (ESI) calcd for C20H30O4N7 [MH]
+ 432.2354, found
432.2343; purity UPLC-MS 99%, retention time = 1.80 min.
6-N-[(3-endo)-3-Aminodimethyl-9-azabicyclo[3.3.1]non-3-yl]-5′-
ethylamino-5′-oxo-5′-deoxyadenosine (25). Formic acid (0.02 mL)
and formaldehyde (37% aq. solution, 0.04 mL) were added to 24 (0.01
g, 0.02 mmol) and stirred at 90 °C overnight. Additional formic acid
(0.02 mL) and formaldehyde (37% aq. solution, 0.04 mL) were added
and stirred at 105 °C for 3 h. The reaction mixture was allowed to cool
to room temperature and made alkaline with 1 M NaOH solution.
This was then thoroughly extracted with ethyl acetate (3 × 100 mL),
and the combined organic extracts were washed with sat. aq. NaHCO3
(50 mL), water (50 mL), and brine (50 mL), dried over anhydrous
Na2SO4, and the solvent removed in vacuo to give 25 as white solid
(0.006 g, 67% yield). 1H NMR (300 MHz, MeOH-d4) δ 8.27 (1H, s,
adenine H), 8.21 (1H, s, adenine H), 6.26 (1H, br s, 1- or 5-H), 6.01
(1H, d, J 7.6, 1′-H), 5.49 (1H, br s, 1- or 5-H), 4.78 (1H, dd, J 7.7, 4.8,
2′-H), 4.46 (1H, d, J 1.4, 4′-H), 4.30 (1H, dd, J 4.8, 1.4, 3′-H), 3.38
(2H, m, CH2CH3), 2.45 (9H, m, 2 × CH3 and 3 × granatyl H), 2.18
(1H, m, 1 × granatyl H), 1.77−1.58 (7H, m, 7 × granatyl H), 1.20
(3H, t, J 7.3, CH2CH3);
13C NMR (100 MHz, DMSO-d6) δ 172.1,
155.1, 153.3, 151.5, 140.8, 121.6, 90.4, 86.4, 75.0, 73.2, 58.6, 41.8, 35.1,
30.8, 15.1, 14.9; HRMS (ESI) calcd for C22H34O4N7 [MH]
+ 460.2667,
found 460.2661; purity UPLC-MS 99%, retention time = 1.87 min.
6-N-(1-Adamantyl)-5′-(2-ﬂuorophenylthio)-2′,3′-O-isopropyli-
dene-5′-deoxyadenosine (30). Compound 30 was synthesized
according to general procedure A, using chloride 29 (0.1 g, 0.23
mmol), amantadine hydrochloride (0.13 g, 0.69 mmol), and DIPEA
(0.18 mL, 1.03 mmol). After puriﬁcation with column chromatography
(methanol/DCM, 0.5%), product 30 was obtained as a white solid
(0.09 g, 69% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.29 (1H, s,
adenine H), 8.23 (1H, s, adenine H), 7.38 (1H, td, J 7.8, 1.6, Ar H),
7.31−7.07 (3H, m, 3 × Ar H), 6.67 (1H, s, amine NH), 6.17 (1H, d, J
2.2, 1′-H), 5.51 (1H, dd, J 6.2, 2.2, 2′-H), 5.05 (1H, dd, J 6.2, 2.7, 3′-
H), 4.20 (1H, td, J 6.9, 2.5, 4′-H), 3.25 (2H overlapping with solvent
signal, m, 5′-H2), 2.22 (6H, m, 6 × adamantyl H), 2.09 (3H, m, 3 ×
adamantyl H), 1.75−1.63 (6H, m, 6 × adamantyl H), 1.49 (3H, s,
CH3), 1.31 (3H, s, CH3);
13C NMR (100 MHz, DMSO-d6) δ 161.3,
158.9, 154.4, 151.9, 147.7, 139.8, 131.1, 128.5 (d, J 7.9), 124.9 (d, J
3.6), 121.8 (d, J 17.1), 119.9, 115.6 (d, J 21.9), 113.2, 89.5, 85.1, 83.4,
83.2, 52.2, 41.0, 36.0, 34.4, 29.0, 26.8, 25.1; 19F NMR (376 MHz,
DMSO-d6) δ −110.4; HRMS (ESI+) m/z calcd for C29H35N5O3FS
[MH]+ 552.2439, found 552.2425.
6-N-[(3-endo)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5′-(2-ﬂuoro-
phenylthio)-2′,3′-O-isopropylidene-5′-deoxyadenosine (31). Com-
pound 31 was synthesized according to general procedure A, using
chloride 29 (0.1 g, 0.23 mmol), (3-endo)-9-methyl-9-azabicyclo[3.3.1]-
nonan-3-amine (0.14 g, 0.92 mmol), and DIPEA (0.04 mL, 0.28
mmol). After puriﬁcation with column chromatography (methanol/
DCM, 5−10%), product 31 was obtained as a pale yellow solid (0.08
g, 61% yield). 1H NMR (400 MHz, CDCl3) δ 8.33 (1H, s, adenine H),
7.76 (1H, s, adenine H), 7.36 (1H, m, Ar H), 7.20 (1H, m, Ar H),
7.04−6.97 (2H, m, 2 × Ar H), 6.01 (1H, d, J 2.0, 1′-H), 5.54 (1H, dd,
J 6.3, 1.9, 2′-H), 5.52 (1H overlapping with 2′-H signal, br s, NH),
5.10 (1H, dd, J 6.3, 2.8, 3′-H), 4.75 (1H, br s, 3-H), 4.37 (1H, td, J 7.2,
2.8, 4′-H), 3.25 (H, dd, J 13.7, 7.6, 5-HH), 3.17 (1H, dd, J 13.7, 6.5, 5-
HH), 3.11 (2H, m, 1- and 5-H), 2.65−2.52 (2H, m, 2 × granatyl H),
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01402
J. Med. Chem. 2016, 59, 947−964
960
! 226 
!!
!!!!
2.50 (3H, s, NCH3), 2.04−1.91 (3H, m, 3 × granatyl H), 1.56 (3H, s,
CH3), 1.53 (1H, m, granatyl H), 1.37 (3H, s, CH3), 1.35−1.29 (2H,
m, 2 × granatyl H), 1.02 (2H, m, 2 × granatyl H); 13C NMR (75
MHz, CDCl3) 163.5, 160.2, 154.6, 153.5, 139.3, 133.3, 129.2 (d, J 8.0),
124.5 (d, J 3.8), 122.0 (d, J 17.5), 115.9 (d, J 22.5), 114.3, 91.3, 86.6,
84.2, 84.1, 51.4, 40.3, 36.2, 33.6, 27.1, 25.4, 24.2, 14.4; 19F NMR (376
MHz, DMSO-d6) δ −108.4; HRMS calculated for C28H36O3N6FS
[MH]+ 555.2548, found 555.2548; purity UPLC-MS 93%, retention
time = 2.88 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)-5′-(2-ﬂuorophenylthio)-
2′,3′-O-isopropylidene-5′-deoxyadenosine (32). Compound 32 was
synthesized according to general procedure A, using chloride 29 (0.05
g, 0.11 mmol), (1R,2R)-1-amino-2-benzyloxycyclopentane (0.03 mL,
0.17 mmol), and triethylamine (0.04 mL, 0.31 mmol). After
puriﬁcation with column chromatography (methanol/DCM, 2%),
product 32 was obtained as a sticky yellow oil (0.06 g, 99% yield). 1H
NMR (300 MHz, DMSO-d6) δ 8.32 (1H, s, adenine H), 8.26 (1H, br
s, adenine H), 7.96 (1H, m, amine NH), 7.39 (1H, td, J 7.8, 1.6, Ar H),
7.32−7.06 (8H, m, 8 × Ar H), 6.19 (1H, d, J 2.1, 1′-H), 5.51 (1H, dd,
J 6.2, 2.1, 2′-H), 5.07 (1H, dd, J 6.2, 2.6, 3′-H), 4.67−4.47 (3H, m, 1-H
and CH2Ph), 4.21 (1H, td, J 7.1, 2.6, 4′-H), 4.01 (1H, m, 2-H), 3.25
(2H overlapping with solvent signal, m, 5′-H2), 2.13−1.89 (2H, m, 2 ×
cyclopentyl H), 1.79−1.57 (4H, m, 4 × cyclopentyl H), 1.49 (3H, s,
CH3), 1.31 (3H, s, CH3);
13C NMR (100 MHz, DMSO-d6) δ 161.3,
158.9, 154.2, 152.5, 147.9, 139.8, 138.9, 131.1, 128.5 (d, J 7.9), 128.1,
127.3, 127.1, 124.9 (d, J 3.5), 121.8 (d, J 17.1), 115.6 (d, J 22.0), 113.2,
89.4, 85.2, 84.0, 83.4, 83.2, 70.1, 56.5, 34.4, 30.1, 26.8, 25.1, 21.4; 19F
NMR (376 MHz, DMSO-d6) δ −110.4; HRMS (ESI) calculated for
C31H35O4N5FS [MH]
+ 592.2388, found 592.2378; purity UPLC-MS
94%, retention time = 3.98 min.
6-N-((1R,2R)-2-(Hydroxy)cyclopentyl)-5′-(2-ﬂuorophenylthio)-
2′,3′-O-isopropylidene-5′-deoxyadenosine (33). Compound 33 was
synthesized according to general procedure A using chloride 29 (0.05
g, 0.11 mmol), (1R,2R)-2-aminocyclopentanol hydrochloride (0.02 g,
0.14 mmol), and triethylamine (0.04 mL, 0.31 mmol). After
puriﬁcation with column chromatography (methanol/DCM, 2%),
product 33 was obtained as a white solid (0.04 g, 73% yield). 1H NMR
(300 MHz, DMSO-d6) δ 8.31 (1H, s, adenine H), 8.22 (1H, br s,
adenine H), 7.76 (1H, m, NH), 7.39 (1H, td, J 7.8, 1.6, Ar H), 7.31−
7.07 (3H, m, 3 × Ar H), 6.18 (1H, d, J 2.1, 1′-H), 5.51 (1H, dd, J 6.2,
2.1, 2′-H), 5.06 (1H, dd, J 6.2, 2.7, 3′-H), 4.86 (1H, m, 2-OH), 4.27
(1H, br s, 1-H), 4.21 (1H, td, J 7.1, 2.6, 4′-H), 4.06 (1H, m, 2-H), 3.26
(2H overlapping with solvent signal, m, 5′-H2), 2.06 (1H, m, 1 ×
cyclopentyl H), 1.89 (1H, m, 1 × cyclopentyl H), 1.72−1.60 (2H, m, 2
× cyclopentyl H), 1.60−1.43 (5H, m, 2 × cyclopentyl H and CH3),
1.32 (3H, s, CH3);
13C NMR (100 MHz, DMSO-d6) δ 161.3, 158.9,
154.7, 152.5, 139.8, 131.1, 128.6 (d, J 7.9), 124.9 (d, J 3.5), 121.8 (d, J
17.1), 115.6 (d, J 22.0), 113.2, 89.5, 85.1, 83.4, 83.2, 76.0, 58.9, 34.4,
32.3, 26.8, 25.1, 20.4; 19F NMR (376 MHz, DMSO-d6) δ −110.4;
HRMS (ESI) calculated for C24H29O4N5FS [MH]
+ 502.1919, found
502.1912; purity UPLC-MS 99%, retention time = 3.14 min.
6-N-(1-Adamantyl)-5′-(2-ﬂuorophenylthio)-5′-deoxyadenosine
(34). Compound 34 was synthesized according to general procedure
B, using 30 (0.01 g, 0.02 mmol), acetic acid (3.2 mL), and water (0.8
mL). After puriﬁcation with column chromatography (methanol/
DCM, 1−3%), product 34 was obtained as a white solid (0.004 g, 40%
yield). 1H NMR (400 MHz, DMSO-d6) δ 8.32 (1H, s, adenine H),
8.21 (1H, s, adenine H), 7.46 (1H, td, J 7.8, 1.6, Ar H), 7.29−7.12
(3H, m, 3 × Ar H), 6.60 (1H, s, NH), 5.87 (1H, d, J 5.7, 1′-H), 5.51
(1H, d, J 6.1, 2′−OH), 5.37 (1H, d, J 5.0, 3′−OH), 4.82 (1H, dd, J
11.1, 5.7, 2′-H), 4.22 (1H, dd, J 8.7, 4.9, 3′-H), 4.00 (1H, m, 4′-H),
3.42 (1H, dd, J 13.8, 5.5, 5′-HH), 3.31 (1H overlapping with solvent
signal, m, 5′-HH), 2.23 (6H, m, 6 × adamantyl H), 2.10 (3H, m, 3 ×
adamantyl H), 1.68 (6H, m, 6 × adamantyl H); 13C NMR (100 MHz,
DMSO-d6) δ 161.1, 158.7, 154.4, 151.9, 148.5, 139.7, 130.5, 128.1 (d, J
7.9), 125.0 (d, J 3.4), 122.6 (d, J 17.1), 119.9, 115.5 (d, J 21.8), 87.7,
82.8, 72.7, 72.5, 52.1, 41.0, 36.0, 34.6, 29.0; 19F NMR (376 MHz,
DMSO-d6) δ −110.78; HRMS (ESI+) m/z calcd for C26H31N5O3FS
[MH]+ 512.2126, found 512.2130.
6-N-[(3-endo)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5′-(2-ﬂuoro-
phenylthio)-5′-deoxyadenosine (35). Compound 35 was synthesized
according to general procedure B, using 31 (0.01 g, 0.02 mmol), acetic
acid (3.2 mL), and water (0.8 mL). After puriﬁcation with column
chromatography (methanol/DCM, 1−10%, with an additional 1%
aqueous ammonia), product 35 was obtained as a white solid (0.005 g,
50% yield). 1H NMR (400 MHz, MeOD-d4) δ 8.24 (1H, s, adenine
H), 8.17 (1H, s, adenine H), 7.45 (1H, m, Ar H), 7.21 (1H, m, Ar H),
7.07−7.01 (2H, m, 2 × Ar H), 5.95 (1H, d, J 5.2, 1′-H), 4.84 (1H, 2′-
H under solvent signal as determined by COSY analysis), 4.83 (1H, br
s, 3-H, partially hidden by solvent signal), 4.37 (1H, m, 3′-H), 4.20
(1H, m, 4′-H), 3.40 (2H, m, CH2CH3), 3.31 (2H, 1- and 5-H under
solvent signal as determined by COSY analysis), 2.70−2.57 (5H, m,
NCH3 and 2 × granatyl H), 2.16−2.04 (3H, m, 3 × granatyl H), 1.69−
1.59 (3H, m, 3 × granatyl H), 1.32−1.29 (2H, m, 2 × granatyl H); 13C
NMR (100 MHz, MeOD-d4) δ 163.8, 155.6, 154.0, 140.9, 133.2, 129.7
(d, J 7.9), 125.7 (d, J 3.7), 116.5 (d, J 22.5), 90.1, 85.0, 74.7, 74.1, 53.7,
40.2, 36.5, 32.9, 25.7, 14.3, 7.6; 19F NMR (376 MHz, DMSO-d6) δ
−111.5; HRMS (ESI+) m/z calcd for C25H32N6O3FS [MH]+
515.2235, found 515.2240; purity UPLC-MS 99%, retention time =
2.24 min.
6-N-((1R,2R)-2-(Benzyloxy)cyclopentyl)-5′-(2-ﬂuorophenylthio)-
5′-deoxyadenosine (36).47 Compound 36 was synthesized according
to general procedure B, using 32 (0.02 g, 0.03 mmol), acetic acid (3.2
mL), and water (0.8 mL). After puriﬁcation with column
chromatography (methanol/DCM, 1−3%), product 36 was obtained
as a pale yellow solid (0.02 g, 99% yield). 1H NMR (300 MHz,
DMSO-d6) δ 8.35 (1H, s, adenine H), 8.24 (1H, br s, adenine H), 7.89
(1H, m, amine NH), 7.46 (1H, m, Ar H), 7.33−7.10 (8H, m, 8 × Ar
H), 5.90 (1H, d, J 5.6, 1′-H), 5.52 (1H, d, J 6.0, 2′−OH), 5.38 (1H, d,
J 5.1, 3′−OH), 4.81 (1H, dd, J 11.1, 5.6, 2′-H), 4.68−4.50 (3H, m, 1-
H and CH2Ph), 4.21 (1H, dd, J 8.7, 4.8, 3′-H), 4.00−3.97 (2H, m, 4′-
H and 2-H), 3.42 (1H, dd, J 13.8, 5.5, 5′-HH), 3.32 (1H overlapping
with solvent signal, m, 5′-HH) 2.14−1.91 (2H, m, 2 × cyclopentyl H),
1.77−1.58 (4H, m, 4 × cyclopentyl H); 13C NMR (100 MHz, DMSO-
d6) δ 161.1, 158.7, 154.2, 152.5, 139.6, 139.0, 130.5, 128.1, 128.0,
127.3, 127.1, 125.0 (d, J 3.4), 122.6 (d, J 17.2), 155.5 (d, J 21.9), 87.6,
84.1, 82.8, 72.7, 72.6, 70.1, 56.4, 34.6, 30.2, 21.4; 19F NMR (376 MHz,
DMSO-d6) δ −110.8; HRMS (ESI) calcd for C28H31O4N5FS [MH]+
552.2075, found 552.2071; purity UPLC-MS 99%, retention time =
3.14 min.
6-N-((1R,2R)-2-(Hydroxy)cyclopentyl)-5′-(2-ﬂuorophenylthio)-5′-
deoxyadenosine (37).14 Compound 37 was synthesized according to
general procedure B, using 33 (0.01 g, 0.02 mmol), acetic acid (3.2
mL), and water (0.8 mL). After puriﬁcation with column
chromatography (methanol/DCM, 1−5%), product 37 was obtained
as a white solid (0.005 g, 56% yield). The O-acetylated product was
also isolated in small quantities. 1H NMR (300 MHz, DMSO-d6) δ
8.34 (1H, s, adenine H), 8.21 (1H, br s, adenine H), 7.69 (1H, d, J 7.1,
amine NH), 7.47 (1H, td, J 7.8, 1.6, Ar H), 7.31−7.10 (3H, m, 3 × Ar
H), 5.89 (1H, d, J 5.7, 1′-H), 5.54 (1H, d, J 6.0, 2′−OH), 5.40 (1H, d,
J 5.0, 3′−OH), 4.87 (1H, d, J 4.0, 2-OH), 4.80 (1H, dd, J 10.9, 5.6, 2′-
H), 4.30 (1H, br s, 1-H), 4.21 (1H, dd, J 8.6, 4.7, 3′-H), 4.09−3.95
(2H, m, 4′-H and 2-H), 3.42 (1H, dd, J 13.7, 5.5, 5′-HH), 3.32 (1H,
m, 5′-HH), 2.07 (1H, m, 1 × cyclopentyl H), 1.90 (1H, m, 1 ×
cyclopentyl H), 1.72−1.42 (4H, m, 4 × cyclopentyl H); 13C NMR
(100 MHz, DMSO-d6) δ 161.1, 158.7, 154.6, 152.4, 139.6, 130.5 (d, J
1.7), 128.1 (d, J 7.9), 125.0 (d, J 3.4), 122.6 (d, J 17.1), 115.5 (d, J
21.8), 87.6, 82.8, 76.1, 72.7, 72.6, 58.8, 34.6, 32.3, 20.4; 19F NMR (376
MHz, DMSO-d6) δ −110.8; HRMS (ESI) calcd for C21H25O4N5FS
[MH]+ 462.1606, found 462.1590; purity UPLC-MS 95%, retention
time = 2.35 min.
Biology Materials. Yeast extract and yeast nitrogen base were
purchased from Difco (Franklin Lakes, NJ). All other reagents were
purchased from Sigma-Aldrich (St. Louis, MO).
Constructs and DNA Manipulation. p426-GPD-A1R was kindly
provided by Professor Arthur Christopoulos and Dr. Lauren May
(Monash University, Australia). Mammalian expression vectors
containing the A1R, A2AR, A2BR, and A3R were purchased from
Missouri S&T cDNA Resource Center (http://cdna.org) (Rolla,
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MO). DNA manipulations were performed using standard techniques.
Oligonucleotides were supplied by Invitrogen and PCR ampliﬁcation
performed using FastStart Taq polymerase (Roche Diagnostics,
Burgess Hill, UK). All constructs generated by PCR were sequenced
by GATC (GATC Biotech, London, UK) prior to use.
General Yeast Methods. General yeast procedures were
performed as described previously.16 Cells were routinely cultured in
YPDA (yeast, peptone, dextrose, and adenine). Yeast transformations
were achieved using the lithium acetate/single-stranded DNA/
polyethylene glycol method as previously described.50 Cells were
selected for uracil biosynthesis and routinely cultured in synthetic
dropout media lacking uracil (SD-URA).
Yeast Strain Construction. The production of the dual reporter
strains expressing chimeras of ﬁve C-terminal amino acids of human
Gα protein with the yeast Gpa1p, 1−467 (GPA1/Gα) has been
described previously.16 Mammalian GPCRs were introduced into the
yeast strains (MMY12, MMY14, MMY19, MMY22, MMY23, MMY25,
and MMY28) using the p426-GPD expression plasmid. Positive
isolates were selected upon their ability to generate β-galactosidase
activity above the basal level when stimulated with 100 μMNECA. For
chimeric strains that did not initially appear to functionally couple (n
≥ 16 isolates) to the ARs, and expression and membrane localization
were conﬁrmed using ﬂuorescence microscopy.
Yeast Reporter Gene Assay. Yeast cells were treated with
compounds as described in Dowell and Brown.16 Initially, cells were
cultured overnight in SD-URA at 30 °C. Cells were diluted 1:10 in SD-
URA and allowed to grow for 8 h at 30 °C. Finally, cell density was
adjusted to an OD600 of 0.02 and treated with 1% (v/v) of the
appropriate compound dissolved in DMSO in a 96-well plate for 16 h
at 30 °C. For compounds dissolved in other solvents, the media were
supplemented with 1% (v/v) DMSO prior to treatment. To
compensate for an elevated basal signal, the A2AR was routinely
cultured in SD-URA lacking histidine (SD-URA-HIS) and treatment
media supplemented with 5 mM 3-amino-triazole. All strains used in
this study contain the lacZ gene under the control of the pheromone-
responsive FUS1 promoter. To assess β-galactosidase activity, cells
were lysed as previously described.19,51−53 2-Nitrophenyl β-D-
galactopyranoside (ONPG) was used as a chromogenic substrate for
β-galactosidase and detected by OD430. Absorbance was measured
using a Mithras LB940 microplate reader (Berthold Technologies,
Harpenden, UK). The strains are Δfar1 and are therefore incapable of
cell cycle arrest induced by the pheromone-response. Consequently,
these cells grow throughout treatment. To compensate for variability
in cell number and bleed through from the chromogenic reporter, cell
density was measured by OD620 and a response calculated as (OD430-
OD620)/OD620.
Confocal Microscopy of Yeast. To visualize receptor expression
C-terminal in-frame fusion constructs between the A1R, A2AR, and
A2BR and GFP were generated using the two-step cloning method
described by Ladds et al.54 These receptors were expressed in yeast
using the p426-GPD vector consistent with their untagged counter-
parts. Isolates were cultured for 24 h in SD-URA. One hundred
microliters of cells was harvested by centrifugation, washed in PBS,
and brieﬂy sonicated. Cells were imaged using a True Confocal
Scanner Leica TCS SP5 microscope (Leica Microsystems Ltd., Milton
Keynes, UK) and were processed using ImageJ as described
previously.55
Mammalian Cell Culture and Transfection. CHO-K1 cells,
provided by Dr. Ewan St. John Smith (University of Cambridge), were
routinely cultured in Hams-F12, supplemented with 10% fetal bovine
serum (FBS), and maintained at 37 °C, in humidiﬁed air with 5% CO2.
Cells were transfected with 2 μg of DNA using FuGene 6 at a 3:1 (w/
v) DNA/FuGene 6 ratio. Cells were harvested 48 h post-transfection
for assaying.
cAMP Accumulation Assay. Transfected cells were washed with
PBS and resuspended in stimulation buﬀer (PBS containing 0.1% BSA
and 25 μM rolipram). Cells were seeded at 2500 cells per well in 384-
well white Optiplates. Cells were then simultaneously incubated with
10 μM forskolin (to stimulate cAMP production) and adenosine
receptors ligands (ranging between 1 μM to 10 pM) for 30 min at
room temperature. Cells were then lysed, and the extent of cAMP
accumulation measured using a LANCE cAMP Detection Kit
(PerkinElmer). Plates were read using a Mithras LB 940 multimode
plate reader (Berthold Technologies).
Data Analysis. Data were analyzed using Prism 6.0e (Graphpad
Software, San Diego, CA). Concentration−response curves were ﬁtted
using the three-parameter logistic equation to obtain EC50 and Emax.
Schild analysis was performed in Prism as described by Motulsky and
Christopoulos.56 Nonlinear regression of the operational model of
pharmacological agonism36 was used to obtain values for eﬃcacy (log
τ) and the equilibrium dissociation constant (log KA). These values
were then used to quantify signaling bias as the change in log (τ/KA)
relative to NECA.37 We have used this method previously to enable
the quantiﬁcation of G protein bias,19,20 but here, we have extended
the analysis to include receptor selectivity. Since the receptors are
expressed in the same cell background and NECA is a full potent
agonist against all receptor subtypes, we reasoned that changes in log
(τ/KA) for a given ligand, relative to NECA for each AR, would
provide a quantitative means of comparing receptor selectivity.
Statistically signiﬁcant diﬀerences were detected using one-way
ANOVA with Bonferroni’s or Dunnett’s multiple comparison tests
or Student’s t tests as appropriate, and a probability (p) < 0.05 was
considered signiﬁcant.
Homology Modeling and Docking. The protein sequence of the
human A1R (accession number P30542) was aligned with an agonist
(UK-432097)-bound human A2AR template (PDB ID: 3QAK) using
PSI-Coﬀee57 (Figure S4). MODELER v9.1458 was used to build 500
models and the best model selected according to the inbuilt molecular
probability function. The ligands were constructed ab initio in
Chem3D Pro v14.0 (PerkinElmer, Waltham, MA) and energy-
minimized using the included MM2 force ﬁeld. For each ligand, a
library of 200 conformers was generated using OMEGA v2.5
(OpenEye Scientiﬁc Software, Santa Fe, NM). FRED RECEPTOR
v2.2.5 (OpenEye Scientiﬁc Software) was utilized to generate a
docking template, whereas the binding site was deﬁned as a box of V =
9486 Å3 around the bound UK-432097 agonist. For predicting the
binding poses, the ligands were docked into this binding site template
using FRED v2.1 (OpenEye Scientiﬁc Software), which utilizes an
exhaustive process to position and score all conformers of a ligand at
all possible positions within the deﬁned binding site. Binding poses
that did not form a hydrogen bond with Thr-913.36, Asn-2546.55, or
Thr-2777.42 were discarded (hA1R numbering according to P30542;
superscript, Ballesteros−Weinstein numbering45). Ten docking poses
were generated for each ligand, ranked using the inbuilt Chemgauss3
scoring function, and visualized with PyMOL v1.7 (Schrödinger LLC,
Portland, OR).
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The calcitonin gene-related peptide (CGRP) family of G pro-
tein-coupled receptors (GPCRs) is formed through the associa-
tion of the calcitonin receptor-like receptor (CLR) and one of
three receptor activity-modifying proteins (RAMPs). Binding
of one of the three peptide ligands, CGRP, adrenomedullin
(AM), and intermedin/adrenomedullin 2 (AM2), is well
known to result in a G!s-mediated increase in cAMP.Here we
used modified yeast strains that couple receptor activation to
cell growth, via chimeric yeast/G! subunits, and HEK-293
cells to characterize the effect of different RAMP and ligand
combinations on this pathway. We not only demonstrate
functional couplings to both G!s and G!q but also identify a
G!i component to CLR signaling in both yeast and HEK-293
cells, which is absent in HEK-293S cells. We show that the
CGRP family of receptors displays both ligand- and RAMP-
dependent signaling bias among the G!s, G!i, and G!q/11
pathways. The results are discussed in the context of RAMP
interactions probed through molecular modeling and molec-
ular dynamics simulations of the RAMP-GPCR-G protein
complexes. This study further highlights the importance of
RAMPs to CLR pharmacology and to bias in general, as well as
identifying the importance of choosing an appropriate model
system for the study of GPCR pharmacology.
Calcitonin gene-related peptide (CGRP),3 adrenomedullin
(AM), and adrenomedullin 2 (AM2, also known as intermedin)
are members of the calcitonin peptide family (1). This family
also includes calcitonin and amylin. CGRP, an extremely abun-
dant neuropeptide, is widely distributed throughout the sen-
sory nervous system. It is a very potent vasodilator released
during neurogenic inflammation and is particularly implicated
in the onset of migraine. It is also cardioprotective and is asso-
ciated with both pro- and anti-inflammatory actions (2, 3). AM
is produced by the vascular endothelium and has extensive
effects on the cardiovascular system including stimulation of
angiogenesis and the modulation of vascular tone (4–6).
AM2 affects the vascular system in a similar manner to AM
(7–9). Like CGRP, AM and AM2 are also cardioprotective,
and their administration results in decreased blood pressure
and increased speed of recovery from myocardial infarction
(10, 11).
CGRP, AM, and AM2 activate three receptors that share a
common class B G protein-coupled receptor (GPCR) subunit,
the calcitonin receptor-like receptor (CLR) (12). In each recep-
tor, CLR forms a heterodimer with receptor activity-modifying
protein (RAMP) 1, 2, or 3. The formation of this heterodimer is
obligatory for receptor function and efficient translocation of
both subunits to the cell surface (13). Heterodimerization with
RAMP1, RAMP2, or RAMP3 forms the CGRP, AM1, or AM2
receptor, respectively (13). The peptide ligands activate each
receptor with differing potencies (1, 12).
Activation of all threeCLR-based receptors byCGRP,AM, or
AM2 generates increased cAMP production through coupling
to the stimulatory G protein, G!s (1, 12, 14). However, CGRP,
AM, and AM2 can signal through other pathways (1, 15, 16).
Several studies have indicated that the CGRP family of recep-
tors can also couple to G!i/o subunits, because their cAMP
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responses can be significantly increased through treatment
with pertussis toxin (PTX), particularly in electrically excitable
cells (17–20). The AM/AM2 receptor cAMP signaling in HEK-
293 cells has also been shown to be PTX-sensitive (21). The
existing information on the stimulation of signaling by CGRP,
AM, or AM2 other than through the G!s-cAMP pathway has
been gained predominantly from physiological studies, and the
relative signaling bias of CGRP, AM, and AM2 at the three
CLR-based receptors, even for the cAMP pathway, remains to
be determined.
The study of signaling bias in vivo is complicated by cross-
talk from the wide range of signaling pathways present in cer-
tain cell lines or primary cell cultures. The Saccharomyces
cerevisiae growth system (22) provides a robust assay that
enables the examination of the coupling of a GPCR of choice to
single G protein subunits. This is achieved through replacing
the last five amino acids of the native yeast G protein with the
corresponding sequence from the human G protein of choice
(22, 23). This assay has recently been successfully employed to
characterize the signaling pathways underlying glucagon-like
peptide 1 (GLP-1) receptor response to GLP-1 and the many
receptor agonist mimetics available (24, 25). Miret et al. (26) in
2002 very elegantly described the functional expression of the
CLR with RAMP1 and RAMP2 in yeast. However, somewhat
surprisingly, given the more recent interest in signaling bias, a
further characterization of RAMP-CLR combinations in yeast
has not been performed.
In this study we have utilized S. cerevisiae to express either
RAMP1, -2, or -3 along with CLR to assess the coupling of the
three CGRP family receptors to different human G! subunits
upon stimulation with CGRP, AM, or AM2. We demonstrate
that all members of the CGRP receptor family successfully cou-
ple to GPA1/G!s, GPA1/G!i, and GPA1/G!q yeast chimeras
and that the coupling preference of each receptor is dependent
upon the stimulating ligand. The results obtained from the
yeast systemwere verified in HEK-293mammalian cell lines by
the assessment of cAMP accumulation (which showed sensitiv-
ity to PTX) andmobilizations of intracellular calcium ((Ca2!)i).
The data confirm that RAMPs alter the ability of each peptide
to couple to G proteins; they also indicate that the G proteins
influence the rank order of agonist potency at the different
receptors. For CGRP, AM, and AM2 this means that potent
activation of what would not generally be considered their
“normal” receptors can be observed when alternative down-
streampathways, such as stimulation of G!i ormobilizations of
(Ca2!)i, are considered.
Considerable understanding of class B GPCR structure,
function, and dynamics has been gained (27), primarily through
molecular dynamics simulations (28–33). Consequently, to
gain insight into the possible mechanisms behind our experi-
mental results, we used molecular modeling and molecular
dynamics simulations of RAMP complexes with CLR and the
glucagon receptor (GCGR) to suggest a mechanism whereby
the C-terminal tail of the RAMPs may influence G protein bias
at the CLR. Finally we demonstrate that care is required when
selecting an appropriate mammalian cell line to use when
investigating G protein bias, as analysis of a HEK-293S cell line
failed to show G!i coupling for any of the RAMP-CLR com-
plexes, thus highlighting the fact that agonist bias can be
directly influenced by the cellular background.
Results
G!s Coupling of CLR-based Receptors—We co-expressed
CLR under the control of the strong PGK promoter with
RAMP1, RAMP2, or RAMP3 independently in a yeast strain
containing a chimeric G! subunit in which the C-terminal five
amino acids of GPA1 had been replaced with those of mamma-
lian G!s, in order to study the coupling of the resultant recep-
tors to a system expressing just a single G protein. Concen-
tration-response curves were constructed for growth of
S. cerevisiae for each RAMP-CLR combination (i.e. the CGRP,
AM1, and AM2 receptors) using the agonists CGRP, AM, and
AM2. When CLR was co-expressed with RAMP1, all three
ligands appeared to generate an equivalent level of response but
with differing potencies (Fig. 1A and Table 1). This generated a
rank order of potency for the three ligands of CGRP " AM "
AM2. Application of the operational model of pharmacological
agonism (34) indicates that all three ligands exhibit similar effi-
cacies (log ") in yeast when CLR and RAMP1 are co-expressed
(Fig. 1D and Table 1). RAMP2 co-expression with CLR gener-
ated a functional receptor (Fig. 1B) with rank ligand potencies
of AM " AM2 # CGRP. AM2 appeared to behave as a partial
agonist with a reduced log " at the RAMP2-CLR heterodimer
when compared with the other peptide agonists (Table 1). AM
had a significantly higher efficacy (p$ 0.05) than that displayed
by CGRP. Expression of RAMP3 with CLR in S. cerevisiae gen-
erated a functional receptor where all three ligands activated
GPA1/G!s-coupled signaling with similar potencies and effica-
cies (Fig. 1C).
We sought to confirm the pharmacology observed in the
S. cerevisiae growth assay of the RAMP-CLR complexes in
mammalian cell lines. For this we used HEK-293 cells that do
not functionally express any RAMPs (25). Co-transfection of
CLR and RAMP1 generated a rank order of ligand potency of
CGRP"" AM# AM2. The rank order of ligand potency with
co-transfection of CLR and RAMP2was AM"CGRP""AM2
and for CLR and RAMP3 was AM2# AM" CGRP (Fig. 2 and
Table 2). It is worth noting that, in our HEK-293 cells, only AM
acted as a full agonist against the CLR when in complex with
either RAMP2 or RAMP3. Overall the mammalian and yeast
data showed similar results, with themost potent ligand at each
receptor remaining the same in each case.
G!i Coupling of CLR-based Receptors—To address the possi-
bility that the CGRP family of receptors may couple not only to
G!s but also to other subunits, we returned to the S. cerevisiae
growth assay. In this case the yeast strain used contained a chi-
meric GPA1/G! subunit including the last five residues of
mammalian G!i. We once again constructed concentration-
response curves for yeast growth to the three agonists, CGRP,
AM, andAM2. The co-expression of CLR and RAMP1 resulted
in similar potencies for CGRP, AM, and AM2 (Table 1); how-
ever, AM and AM2 displayed significantly increased efficacy
relative to CGRP for the activation of GPA1/G!i (Table 1
and Fig. 3,A andD). In contrast, when RAMP2 and CLRwere
co-transformed into the GPA1/G!i yeast strain, the rank
order of ligand potency for GPA1/G!i yeast-based growth
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was CGRP!AM"AM2 (Table 1 and Fig. 3B). AM2 showed
a significantly decreased efficacy compared with the other
peptides (Table 1 and Fig. 3D). As with the RAMP1-CLR
heterodimer, the combination of CLR and RAMP3 expressed
in the GPA1/G!i strain resulted in similar potencies for
CGRP, AM, and AM2 (Table 1 and Fig. 3C). However, AM2
displayed a significantly reduced efficacy when compared
with AM (Table 1 and Fig. 3D).
FIGURE1.Functional expressionofCLRco-transformedwithall threeRAMPs inyeast cells.Dose-response curves toCGRP,AM, andAM2were constructed
in yeast strains containing the GPA1/G!s chimera and expressing CLRwith RAMP1 (n" 6) (A), RAMP2 (n" 7) (B), and RAMP3 (n" 8) (C). Reporter gene activity
was determined following 20 h of stimulationwith each ligand. Data are expressed as a percentage of themaximum response observed in yeast strainMMY11
(lacking GPA1) and aremeans# S.E. of n individual data sets.D, bar chart showing the efficacy of each ligand for each RAMP-CLR combination as determined
via application of the operational model of receptor agonism (see Ref. 34 and Table 1). Data were determined as statistically different from the cognate ligand
for each receptor (*, p$ 0.05; **, p$ 0.01; ***, p$ 0.001) using a one-way ANOVA with Bonferroni’s post-test.
TABLE 1
Summary of pharmacological parameters for various ligands upon expression of the CLRwith each RAMP in yeast strains containingGPA1/G!s,
GPA1/G!i, or the GPA1/G!q chimera
Data are themean# S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p$ 0.05; **, p$ 0.01; ***, p$ 0.001; ****, p$ 0.0001) for each
receptor heterodimer (CGRP for RAMP1% CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
RAMP1-CLR RAMP2-CLR RAMP3-CLR
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2
GPA1/G!s
pEC50a 9.35# 0.2* 8.80# 0.4*** 7.22# 0.3*** 7.60# 0.3* 8.82# 0.3* 8.05# 0.3* 8.24# 0.2 8.15# 0.4 8.85# 0.3
Emaxb 27.10# 1.6* 20.39# 2.8*** 20.65# 1.1*** 30.34# 4.1 37.46# 3.5 19.90# 2.5*** 30.17# 2.7 25.51# 3.6 22.80# 2.3
pKac 9.22# 0.2* 8.81# 0.3*** 7.31# 0.3*** 7.70# 0.3* 8.77# 0.3 8.10# 0.3 8.30# 0.3 8.10# 0.3 8.61# 0.4
log "d &0.43# 0.04 &0.59# 0.07* &0.61# 0.08 &0.38# 0.08* &0.23# 0.06 &0.61# 0.06** &0.42# 0.08 &0.51# 0.08 &0.57# 0.08
n 6 6 6 7 7 7 8 8 8
GPA1/G!i
pEC50a 8.26# 0.5 8.38# 0.3 * 8.57# 0.2** 8.89# 0.2** 7.91# 0.2** 8.42# 0.5** 8.52# 0.2 7.89# 0.8 8.49# 0.2
Emaxb 19.80# 3.0* 34.20# 3.7*** 41.5# 3.3**** 24.43# 1.7* 24.49# 2.0* 15.71# 2.5* 22.60# 1.8* 26.71# 1.8* 15.71# 2.1*
pKac 8.40# 0.5 8.20# 0.3** 8.24# 0.2 8.64# 0.2 7.75# 0.2 8.30# 0.5 8.37# 0.2 8.00# 0.2 8.30# 0.3
log "d &0.70# 0.1** &0.33# 0.07** &0.18# 0.1*** &0.50# 0.04** &0.51# 0.05* &0.89# 0.1** &0.56# 0.06* &0.50# 0.05* &0.78# 0.07*
n 6 6 6 6 6 6 7 7 7
GPA1/G!q
pEC50a 7.53# 0.1 7.26# 0.2 7.99# 0.2 7.14# 0.2 7.93# 0.2 9.22# 0.4* 6.19# 0.5* 7.83# 0.2 6.76# 0.25
Emaxb 26.50# 1.2 14.08# 1.2**** 16.73# 1.1**** 27.74# 2.3 29.03# 2.6 11.33# 1.3**** 20.7# 4.2 25.56# 2.0 32.11# 3.7
pKac 27.40# 0.1 7.19# 0.2 7.91# 0.03 7.01# 0.2 7.78# 0.2 9.16# 0.4* 6.10# 0.6* 7.71# 0.2 6.60# 0.3
log "d &0.46# 0.03 &0.79# 0.04*** &0.70# 0.04*** &0.42# 0.05 &0.39# 0.05 &0.88# 0.08*** &0.63# 0.2 &0.48# 0.05 &0.34# 0.1
n 7 7 7 6 6 6 6 6 6
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained from a yeast strain (MMY11) lacking GPA1.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log " is the coupling efficacy parameter of each ligand.
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In mammalian cells the G!s and G!i subunits act in opposi-
tion to regulate cAMP production. Therefore if a receptor can
couple to both subunits in mammalian cells, the cAMP
response measured is the result of a combination of the contri-
bution from both pathways. Treatment of cells with PTX has
been shown to uncouple receptors from the G!i subunit and
therefore remove any inhibition of cAMP production. We
sought to confirm the apparent G!s-G!i coupling bias exhib-
ited by the different RAMP-CLR combinations in the yeast
reporter strains by measuring cAMP production from tran-
siently transfected mammalian cells following PTX treatment.
Pretreatment of HEK-293 cells co-expressing RAMP1 with
the CLR resulted in little overall increase in CGRP-mediated
cAMP production (Fig. 4A). However, a significant elevation in
Emax was observed in the same PTX-treated, RAMP1-CLR-ex-
pressing cells when challenged with either AM or AM2 (Fig. 4
andTable 3), suggesting that aG!i component for both of these
ligands had been removed (Table 3). HEK-293 cells expressing
CLRwith either RAMP2 (Fig. 4B) or RAMP3 (Fig. 4C) displayed
PTX-induced increases inEmax for cAMPaccumulation follow-
ing stimulation with both CGRP and AM2 (Table 3). However,
for both combinations, the AM response appeared to be unaf-
fected by PTX treatment, suggesting that little G!i coupling
was present. Indeed, it is worth noting, that the cognate ligand
for each receptor (CGRP for RAMP1-CLR and AM for
RAMP2-CLR or RAMP3-CLR) did not appear to display an
FIGURE 2. Expression of CLR in combination with each RAMP generates functional G!s-coupled receptors in HEK-293 cells. cAMP accumulation was
determined inHEK-293 cells transiently transfectedwith theCLRandRAMP1 (n!11) (A), RAMP2 (n!8) (B), andRAMP3 (n!9) (C) following30-min stimulation
with CGRP, AM, and AM2. Data are expressed as percentage of cAMP production, determined using 100 "M forskolin stimulation, and are means" S.E. of n
individual data sets. D, bar chart showing the efficacy of each ligand for each RAMP-CLR combination as determined via application of the operational model
of receptor agonism (34). Data were determined as statistically different from the cognate ligand for each receptor (*, p# 0.05; **, p# 0.01) using one-way
ANOVA with Bonferroni’s post-test.
TABLE 2
Potency (pEC50), affinity (pKa) and coupling efficacy (log ") values for cAMPproduction at the CLR co-expressedwith each RAMPand stimulated
with various agonists measured in HEK-293 cells
Data are the mean " S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p # 0.05; **, p # 0.01; ***, p # 0.001) for each receptor
heterodimer (CGRP for RAMP1-CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
RAMP1-CLR RAMP2-CLR RAMP3-CLR
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2
pEC50a 9.81" 0.20 7.92" 0.19** 7.93" 0.24** 8.97" 0.24*** 10.35" 0.13 7.48" 0.23*** 7.75" 0.3** 8.86" 0.14 9.14" 0.22**
Emaxb 45.0" 2.2 45.2" 3.7 43.6" 4.2** 37.2" 2.4*** 55.0" 1.7 34.1" 4.0** 22.3" 2.1** 32.1" 1.6 21.9" 1.7**
pKac 9.60" 0.18 7.64" 0.28** 7.76" 0.20** 8.71" 0.2** 9.95" 0.23 7.16" 0.24** 7.64" 0.26** 8.50" 0.19 9.00" 0.18**
log #d $0.08" 0.04 $0.08" 0.09** $0.11" 0.06** $0.23" 0.05*** 0.09" 0.05 $0.29" 0.07** $0.54" 0.06** $0.33" 0.04 $0.56" 0.04**
n 11 11 11 8 8 8 9 9 9
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 "M forskolin stimulation.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log # is the coupling efficacy parameter of each ligand.
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increased Emax upon PTX treatment, suggesting limited G!i
components in these cases. Importantly, PTX treatment of
untransfected HEK-293 cells did not result in a change in the
overall levels of cAMPaccumulation as determinedby forskolin
stimulation (untreated, 16.57 ! 2.5 pmol cell"1; treated,
16.45 ! 2.4 pmol cell"1), thereby confirming that the effects
observed were specific to the RAMP-CLR combinations. Thus,
there is abundant evidence that receptor and ligands can acti-
vate G!i in a mammalian cell, albeit in a complex pattern.
Cell Line Variability in G Protein Expression—The HEK-293
human cell lineage has undergone a number of modifications
(35). One such lineage, HEK-293S, was adapted for growth in
suspension (36). Interestingly, HEK-293S lines have also been
reported to lack expression of RAMPs and therefore provide an
alternative background for investigating the modulation of
GPCR signal transduction (37, 38). Given that previous reports
suggest that some of the effects observed with RAMPs are cell
type-dependent (37, 39), we utilizedHEK-293S cells as an alter-
native cell line. Surprisingly, and in contrast to what was
observed for HEK-293 cells, HEK-293S cells pretreated with
PTX and co-expressing RAMP1, RAMP2, or RAMP3with CLR
failed to demonstrate any significant change in either potency
or Emax when challenged with CGRP, AM, or AM2 (Fig. 5 and
Table 4; compare with Fig. 4). These results suggest that in
HEK-293S cells, the RAMP-CLR combinations display little
G!i-mediated responses. This led us to speculate about the
respective G protein content for the two cell lines. Using semi-
quantitative RT-PCR we assessed the expression of 12 G! sub-
units (Fig. 6, A and B) in both mammalian cell lines. In the
HEK-293 cells we were able to detect the expression of ten G!
subunits, with a profile similar to that documented previously
for these cells (40). Transcriptswere not detectable for theG!14
or G!15 subunits. Interestingly, in comparison with the HEK-
293 cells, the HEK-293S cells displayed significantly lower
expression of two G!i subunits (relative to GAPDH) but
broadly similar levels of all others G! subunits. Furthermore,
there was a much better correlation between the pEC50 values
for the ligands on HEK-293 and HEK-293S cells when the for-
mer had been pretreated with PTX, to remove the G!i compo-
nent, suggesting that the differences in G!i expression between
the two cell lines have functional significance (Fig. 6C, r# 0.80
(95% confidence interval, 0.27–0.96)with PTX versus 0.52 (95%
confidence interval, "0.22 to 0.89) without PTX; p $ 0.05).
Importantly, these data demonstrate the need for cautionwhen
choosing cells for assessing G protein-mediated signaling
responses.
G!q/11 Coupling of CLR-based Receptors—To provide a com-
plete investigation of the G protein coupling of the RAMP-CLR
complexes, we extended our study to include the remaining
nine GPA1/G! yeast chimera-expressing strains. Coupling
with the RAMP-CLR heterodimers was observed only in one
additional strain that representing G!q (strain MMY89). Con-
centration-response curves were generated (Fig. 7, A–C, and
Table 1), demonstrating that at RAMP1-CLR all three ligands
displayed similar potencies, with CGRP being the most effica-
cious (log ", Table 1) as expected for the cognate ligand at this
FIGURE3.Co-transformationofCLRwithall threeRAMPs inyeast cells generates receptors that couple functionally to theG!i chimera.Dose-response
curves to CGRP, AM, and AM2 were constructed in yeast strains containing the GPA1/G!i chimera and expressing CLR with RAMP1 (n# 6) (A), RAMP2 (n# 6)
(B), andRAMP3 (n#7) (C). Reporter gene activitywasdetermined following20hof stimulation. All data are expressed aspercentageof themaximumresponse
observed in yeast strain MMY11 (lacking GPA1) and are means ! S.E. of n individual data sets. D, bar chart showing the efficacy of each ligand for each
RAMP-CLR combination asdeterminedvia applicationof theoperationalmodel of receptor agonism (Ref. 34 andTable 1). Dataweredeterminedas statistically
different from the cognate ligand for each receptor (*,p$0.05; **,p$0.01; ***,p$0.001; ****,p$0.0001) usingaone-wayANOVAwithBonferroni’s post-test.
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receptor. AM2 is the most potent ligand when activating the
RAMP2-CLR complex, having a reduced Emax and log ! relative
to CGRP andAM (Table 1).With RAMP3-CLR, a rank order of
ligand potency of AM ! AM2 ! CGRP was observed (Fig. 7C
and Table 1), with all three ligands displaying broadly similar
efficacies (Table 1).
Ligand-engendered G Protein Bias—To provide a means by
which to determine the relative bias each agonist displays at
each RAMP-CLR complex for the three different chimeric G
proteins (in yeast), we calculated the bias factor (expressed
as""(!/Ka)) (41). For theRAMP1-CLRheterodimer, the values
were calculated relative to CGRP, whereas when CLR was
expressed with RAMP2 or RAMP3 the reference ligand was
AM. In all cases the reference pathway used was GPA1/G"s
(Fig. 7E). The bias plots demonstrated that at the RAMP1-CLR
complex, AM2 showed a much greater bias toward signaling
via GPA1/G"i and GPA1/G"q relative to CGRP, whereas AM
showed a bias profile approximately equal to CGRP. With
RAMP2-CLR, however, CGRP showed a much greater bias
toward GPA1/G"i signaling over GPA1/G"s and GPA1/G"q,
whereas AM2wasmore biased toward GPA1/G"q. In the pres-
ence of RAMP3 all three ligands were equally biased toward
GPA1/G"s and GPA1/G"i, but CGRP and AMwere less biased
toward GPA1/G"q signaling relative to AM2.
Activation of RAMP-CLRComplexes Leads toMobilization of
Intracellular Ca2# inMammalian Cells—To confirm our find-
ings from S. cerevisiae, we again utilized HEK-293 cells tran-
siently expressing theCLR in conjunctionwith each RAMPand
measured the release of (Ca2#)i upon stimulation with CGRP,
AM, and AM2. Although all three ligands resulted in calcium
FIGURE 4. CLR in combination with each RAMP generates receptors that display PTX-sensitive effects in response to ligand stimulation. cAMP accu-
mulationwas determined in the presence (treated) and absence (untreated) of PTX fromHEK-293 cells transiently transfectedwith CLR and RAMP1 (n$ 6) (A),
RAMP2 (n$ 5) (B), and RAMP3 (n$ 5) (C). Cells were stimulated for 30 min with CGRP, AM, and AM2. Data are expressed as percentage of the maximal cAMP
production as determined using 100 #M forskolin stimulation in the presence of PTX and are means% S.E. of n individual data sets.
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mobilization at each RAMP-CLR complex (Fig. 8 and Table 5),
these results differed slightly from that observed in S. cerevisiae.
At both RAMP1 and RAMP2-CLR a rank order of ligand
potency of CGRP! AM" AM2 was seen, whereas CGRP was
the most efficacious ligand (Table 5). With RAMP3-CLR, both
AM and AM2 were equipotent, with CGRP being the least
potent agonist. Treatment with PTX was seen to have no effect
upon the levels of calcium released in response to the three
ligands, at any RAMP-CLR complex.
To confirm our yeast findings that the CLR can couple to
G!q and thereby promote (Ca2#)i mobilization in mammalian
cells, we utilized the known selective G!q/11 inhibitor
YM-254890 (42). Pretreatment with YM-254890 for 30 min
prior to stimulationwithAMandAM2was sufficient to abolish
all (Ca2#)imobilization at all RAMP-CLR complexes. Further-
more, the response toCGRP at all three RAMP-CLR complexes
was also considerably attenuated with (Ca2#)i release, being
detected only when cells were stimulated with CGRP in the
micromolar range. Similar data were obtained using HEK-293S
cells (Table 5), suggesting that despite differences in G!i con-
tent, the release of (Ca2#)i was consistent between the two cell
types. These finding suggest that all three ligands are able to
initiate calcium mobilization at all three RAMP-CLR com-
plexes in a G!q-dependent manner in both mammalian cell
lines.
Pathway Bias at the RAMP-CLR Complexes—Through cal-
culating the change in the ratio of log("/Ka) between cAMP
accumulation and the release of (Ca2#)i, it is possible to deter-
mine the extent of signaling bias for a ligand (Fig. 9A). In HEK-
293 cells all ligands showed cAMP bias over (Ca2#)i, except for
AM2 and CGRP at RAMP2-CLR and RAMP3-CLR, respec-
tively. In contrast, in HEK-293S cells all ligands showed clear
bias toward cAMP at each RAMP-CLR complex. Interestingly,
treatment of HEK-293 cells with PTX generated bias profiles
similar to that observed for HEK-293S cells (Fig. 9).
Further analysis of these bias factors relative to the cognate
ligand at eachRAMP-CLR complex (Fig. 9B) indicates that only
AM2 displays bias toward cAMP at the RAMP1- and RAMP3-
CLR complexes, whereas all other ligands display a preference
tomobilize (Ca2#)i. Again, this is slightly different than the bias
profile forHEK-293S cells. At theRAMP1-CLR complex, AM is
biased toward (Ca2#)i, and AM2 is cAMP-biased. For RAMP2-
CLR, CGRP is biased toward (Ca2#)i mobilization, whereas
AM2 is neutral. At RAMP3-CLR all ligands are neutral and
display no bias. As noted above, the inhibition of any signaling
input fromG!i in HEK-293 cells via PTX treatment generates a
relative bias profile comparable with that seen in HEK-293S
cells. Thus, we show that not only do RAMPs play a significant
role inmodulating signaling bias but also that cellularG protein
content can drastically modulate any perceived bias.
Molecular Modeling of CLR and GCGR in Complex with
RAMPs—Our experimental data suggest that RAMPsmay per-
form a critical role in modulating G protein coupling and bias.
However, we do not as yet have any insight into themechanism
by which this may be achieved. To at least partially address this
issue, we turned to the use of molecular modeling. We gener-
ated models of GCGR in complex with RAMP2 and CLR in
complex with RAMP1. We used the GCGR system because it
provides a reference system. The interaction between the pep-
tide and the ligand is particularly well defined in the homo-
logous GLP-1R system through reciprocal mutagenesis and
photoaffinity labeling (28, 29); also we have shown that the
interaction between GCGR and RAMP2 affects G protein bias
(25). Models taken from the last step in the 500-ns trajectory
show that in both cases, the C-terminal region of the RAMP
resides in the vicinity of helix 8 (H8), the intracellular ends of
TM6 andTM7, and theC-terminal region ofG!s (Fig. 10,A and
B). There are differences in the orientation of the extracellular
domain and the precise location of the RAMP transmembrane
(TM) helix due to the dynamic nature of the systems, the longer
“stalk” (the region between the extracellular domain and TM1)
in GCGR, and the sequence differences between the receptors
and between RAMP1 and RAMP2. There are no direct interac-
tions between the RAMPs and the peptide ligands.
Analyses of the MD trajectories show that for GCGR and
CLR, theC-terminal region of the RAMPapproaches theC-ter-
TABLE 3
Potency (pEC50), affinity (pKa), and coupling efficacy (log !) values for cAMP production at the CLR co-expressed with each RAMP, stimulated
with various agonists measured in HEK-293 cells in the presence and absence of pertussis toxin
Data are the mean$ S.E. of n individual data sets. Statistical difference between PTX-treated and untreated cells was determined using Student’s t test (*, p% 0.05; **, p%
0.01; ***, p% 0.001; ****, p% 0.0001).
Untreated Treated
pEC50a Emaxb pKac log !d n pEC50a Emaxb pKac log !d n
RAMP1
CGRP 9.66$ 0.2 47.07$ 2.2 9.43$ 0.2 &0.11$ 0.04 9 9.65$ 0.2 44.95$ 2.2 9.33$ 0.3 &0.11$ 0.07 6
AM 7.93$ 0.2 48.06$ 2.5 7.67$ 0.2 &0.09$ 0.05 9 8.14$ 0.07 72.17$ 1.7*** 7.66$ 0.2 & 0.36$ 0.1** 6
AM2 7.93$ 0.2 46.10$ 4.1 7.70$ 0.2 &0.11$ 0.07 9 9.15$ 0.1*0 72.15$ 2.4*** 8.56$ 0.3 & 0.40$ 0.1** 6
RAMP2
CGRP 19.00$ 0.2 36.97$ 2.4 18.82$ 0.2 &0.27$ 0.05 9 18.25$ 0.4 56.27$ 1.4*** 7.92$ 0.2* 0 0.1$ 0.06** 6
AM 10.35$ 0.1 56.33$ 1.6 10.00$ 0.1 &0.07$ 0.02 9 10.16$ 0.07 56.07$ 1.1 9.83$ 0.2 0.07$ 0.02 6
AM2 17.46$ 0.2 36.61$ 3.5 17.24$ 0.2 &0.29$ 0.07 9 19.13$ 0.1** 56.05$ 2.2*** 8.84$ 0.2** 00.1$ 0.06* 6
RAMP3
CGRP 7.75$ 0.3 22.38$ 2.6 7.64$ 0.3 &0.54$ 0.07 8 8.90$ 0.1* 32.61$ 1.5* 8.74$ 0.2* &0.29$ 0.06 7
AM 8.98$ 0.2 32.00$ 1.5 8.83$ 0.1 &0.33$ 0.03 8 9.10$ 0.2 35.95$ 2.2 8.94$ 0.2 &0.34$ 0.05 7
AM2 9.10$ 0.2 21.92$ 1.7 9.08$ 0.2 &0.51$ 0.06 8 8.74$ 0.2 44.35$ 2.7**** 8.43$ 0.1* &0.07$ 0.07*** 7
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 #M forskolin stimulation in the presence of per-
tussis toxin treatment.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log " is the coupling efficacy parameter of each ligand.
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minal peptide of the G protein within the first 100 ns (Fig. 10C).
For GCGR the primary interaction is with the G protein, but
there are also interactions with H8. For CLR the first part of the
tail interacts with the G protein, whereas the tip of the tail
interacts with H8; in both CLR and GCGR there are also inter-
actions with the intracellular end of TM6. The interactions are
driven by a combination of steric, hydrophobic, and electro-
static factors. Movies of both simulations are provided as sup-
porting information (supplemental Movies 1 (RAMP2-GCGR-
G!s) and 2 (RAMP1-CLR-G!s)).
The extracellular end of TM7 of GCGRmoves inward under
the influence of RAMP2. Analysis of the distances between the
extracellular end of TM2 (C! of residue Lys-205), TM7 (C! of
residue Gly-375), the RAMP2 linker (C! of residue Val-145),
and the peptide (C! of residue Tyr-13) shows that the RAMP
TM, TM7, and the peptide move as a collective unit toward
TM2 (Fig. 11), indicating a mechanism whereby the peptide
ligand can influence the RAMP and vice versa even in the
absence of a direct interaction.
Discussion
The pharmacology of the CGRP family of receptors is rela-
tively well characterized with respect to G!s coupling and the
resultant accumulation of cAMP (1, 12). G!q and G!i coupling
to these receptors, however, is less well characterized. Here we
report the extension of the use of the S. cerevisiae system to
investigate signaling bias in the CGRP family of receptors.
These receptors are obligate heterodimers of the GPCR,
namely CLR with one of three RAMPs. This dimerization adds
an increased level of complexity to the system.We find that the
FIGURE 5. RAMP-CLR responses appear PTX-insensitive when assayed using HEK-293S cells. cAMP accumulation was determined in the presence
(treated) and absence (untreated) of PTX fromHEK-293S cells transiently transfectedwith CLR and RAMP1 (n! 5) (A), RAMP2 (n! 5) (B), and RAMP3 (n! 5) (C).
Cells were stimulated for 30 min with CGRP, , and AM2. Data are expressed as percentage of the maximal cAMP production as determined using 100 "M
forskolin stimulation in the presence of PTX and are means" S.E. of n individual data sets.
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RAMPs influence the G protein coupling in a ligand- and
receptor-dependent manner, in some cases radically changing
ligand selectivity.
WhenGPA1/G!i coupling in the yeast systemwas compared
with coupling toGPA1/G!s, markedly different responses were
observed for each ligand. Most significantly, at all three recep-
tors, the rank order of potency of the ligands was altered, either
being reversed or with differences abolished. Efficacy calcula-
tions for each ligand in the presence of GPA1/G!i also revealed
G protein-directed changes in the activity of each ligand. AM2
displayed a much greater efficacy at the RAMP1-CLR het-
erodimer than AM, and surprisingly CGRP efficacy was greatly
reduced. These data indicate that the ligands display a degree of
G protein bias at each receptor; this was further supported
through the construction of bias plots through calculation of
!!("/Ka). The data contrast with the established potency pro-
files for G!s-coupled receptors observed in mammalian cells
and also yeast. Although G!s is recognized as the main signal-
ing pathway activated by CLR-based receptors (15), the data
illustrate that if G!i or G!q activation occurs, the conventional
agonist potency ratiosmay lead to erroneous conclusions about
the nature of the receptor. Caution should at least be taken
when referring to these receptors, because it is clear that CGRP
will preferentially activate the G!s-coupled CGRP receptor
(RAMP1-CLR), but this is not the situationwhen the receptor is
coupled to other G proteins. Indeed, this trend is observed for
all receptors in this family, with AM being the preferential
ligand for both the AM1 (RAMP2-CLR) and AM2 (RAMP3-
CLR) receptors coupled to G!s but not when G!i coupled. To
avoid confusion we have, for the most part, described these
receptors as RAMP1/2/3-CLR in this study.A further point that
arises from these observations is that the reversals in potency
ratios that we observed suggest that differences in the ability of
the peptides to penetrate the yeast cell wall are not a contribut-
ing factor to our observations.
Our data also shed new light on the comparative efficacies of
CGRP, AM, and AM2 at the three receptors for G!s coupling.
Typically, they have been reported to show similar maximal
responses, although there are issues with incomplete concen-
tration-response curves (1). However, there is evidence for par-
TABLE 4
Potency (pEC50) andmaximal response (Emax) for cAMP production at
the CLR co-expressed with each RAMP stimulated with various ago-
nistsmeasured inHEK-293S cells in thepresence or absence of pertus-
sis toxin
Data are themean" S.E. ofn individual data sets.No statistical differencewas found
between untreated and PTX-treated HEK-293S cells using Student’s t test.
Untreated Treated
pEC50a Emaxb n pEC50a Emaxb n
RAMP1
CGRP 9.88" 0.1 59.98" 1.1 5 9.87" 0.1 72.92" 2.3 5
AM 8.13" 0.1 60.00" 3.1 5 8.03" 0.1 61.26" 2.6 5
AM2 8.74" 0.1 68.94" 1.2 5 8.78" 0.1 68.30" 1.6 5
RAMP2
CGRP 8.00" 0.1 32.56" 1.0 5 7.88" 0.1 39.32" 1.7 5
AM 9.39" 0.1 30.34" 0.8 5 9.38" 0.1 33.28" 1.2 5
AM2 8.57" 0.1 40.30" 1.5 5 18.58" 0.16 30.52" 2.0 5
RAMP3
CGRP 8.42" 0.1 40.84" 0.6 5 8.38" 0.1 39.84" 1.0 5
AM 9.63" 0.1 39.09" 1.2 5 9.49" 0.2 42.26" 1.6 5
AM2 8.01" 0.1 33.75" 1.5 5 7.79" 0.2 28.21" 2.4 5
a The negative logarithm of the agonist concentration required to produce a half-
maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal
cAMP production as determined using 100 #M forskolin stimulation in the pres-
ence of PTX treatment.
FIGURE 6. Reduced G!i expression in HEK-293S cell lines leads to PTX
insensitivity. A, expression profiles of G! genes were assessed in HEK-293
andHEK-293S cells. RNAwas extracted fromcells and treatedwithDNase 1 to
remove genomic DNA contamination. G! gene expression was examined by
RT-PCRusinggene-specific primers. *, indicates a lack of detectable transcript
for G!i2. The band shown is a nonspecific product as confirmed by DNA
sequencing. B, semiquantitative expression (relative to GAPDH) for the G!
genes from A (n# 4). Statistical difference between HEK-293 and HEK-293S
cells was determined using Student’s t test: *, p $ 0.05; **, p $ 0.01. C, the
correlation of log agonist potencies" S.E. for CGRP, AM, and AM2 at RAMP-
CLR combinations expressed in HEK-293S (Table 4) cells and HEK-293 cells
eitherwith (red symbol) orwithout (blue symbol) pretreatmentwithPTX (Table
3) was analyzed by a scatter plot, and Pearson’s correlation coefficients (r)
were calculated. A significant correlation was observed only between HEK-
293S cells and HEK-293 cells pretreated with PTX.
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tial agonism of AM2 in CHO cells when RAMP2 is co-ex-
pressed with CLR (43). By its nature, the measurement of
efficacy is very sensitive to the cell or tissue being studied aswell
as the experimental protocol. In this study, the use of the yeast
assay enabled us to calculate the efficacy and potency values for
each ligand-receptor combination for specific G protein sub-
FIGURE 7. Functional coupling of CLR co-transformed with all three RAMPs to the G!q chimera. Dose-response curves to CGRP, AM, and AM2 were
constructed in yeast strains containing the GPA1/G!q chimera and expressing CLRwith RAMP1 (n! 7) (A), RAMP2 (n! 6) (B), and RAMP3 (n! 7) (C). Reporter
gene activity was determined following 24-h stimulation. All data are expressed as percentage of themaximum response observed in yeast strainMMY11 and
aremeans" S.E. of n individual data sets.D, Bar chart showing the efficacy of each ligand for each RAMP-CLR combination at the G!q chimera determined via
application of the operationalmodel of receptor agonism (Ref. 34 and Table 1). Datawere determined as statistically different from the cognate ligand for each
receptor (***, p# 0.001; ****, p# 0.0001) using one-way ANOVA with Bonferroni’s post-test. E, signaling bias plots were calculated as $$("/Ka) values on a
logarithmic scale for each ligand and for each chimeraGprotein for the three individual RAMP-CLR complexes. Determination of values requires normalization
to a reference ligand (CGRP for RAMP1-CLR and AM for CLR with RAMP2 or RAMP3) and a reference pathway (in all cases, GPA1/G!s).
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units without the complication of pathway cross-talk. Our data
revealed that all ligands have similar efficacies in cells express-
ing the RAMP1-CLR combination coupled to GPA1/G!s. In
contrast, AM has a significantly increased efficacy at the
RAMP2-CLR heterodimer.
The relative potencies of the three peptides at the CGRP,
AM1, and AM2 receptors that we observed in our current stud-
ies for G!s coupling largely agree with previous observations (1
for review, 7–9, 43, and 44) (Table 2 and Fig. 12). Importantly
when each receptor was expressed in S. cerevisiae strains, ena-
bling us to measure the activation of GPA1/G!s, the rank
potency order for the peptides fit the pattern observed inmam-
malian cells (Table 1 and Fig. 9), with the exception of CGRP,
which displayed an unexpectedly high potency at the RAMP3-
CLR heterodimer. These data indicate that, as with the GLP-1
and glucagon receptors, the yeast system is a valid model for
studying G protein coupling to class BGPCRs. The comparable
pharmacology of the three receptors demonstrates the value of
the yeast system for assessment of the effect of complex forma-
tion by GPCRs and could be applied not only to dimerization of
these receptors with RAMPs but also othermodifying or down-
stream signaling proteins.
An important consideration is whether the G!i/G!q cou-
pling observed in yeast has any relevance to mammalian cell
systems. The yeast strains express only chimeric G proteins
(containing the C-terminal five amino acids of the human G
protein), which are reported to be less specific when compared
with equivalent G proteins expressed in mammalian cells (22).
To establish the extent of G!i coupling in HEK-293 cells, we
investigated cAMPproduction before and after PTX treatment;
the greater the enhancement of cAMP production following
toxin addition, the greater the extent of G!i coupling that the
toxin inactivates. When compared with the coupling seen in
yeast to GPA1/G!i, although the correlation is not exact, there
FIGURE 8.CLR in combinationwith eachRAMPgenerates receptors thatmobilize (Ca2!)i releasewhenexpressed inHEK-293 cells. (Ca
2!)imobilization
was determined fromHEK-293 cells transiently transfectedwith CLR and RAMP1 (n" 5) (A), RAMP2 (n" 5) (B), and RAMP3 (n" 5) (C). Cells were stimulated for
2 min with CGRP, AM, and AM2. Data are expressed as percentage of the maximal (Ca2!)i release as determined using 10 "M ionomycin. To determine the
contribution made by different G proteins to the (Ca2!)i response, cells were preincubated with either PTX (to inhibit G!i) or YM-254890 (a selective G!q
inhibitor). All values are means# S.E. of n individual data sets.
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is at least a measure of agreement between the HEK-293 and
yeast data, suggesting that the latter may be a guide as to what
could be seen in mammalian cells given the appropriate condi-
tions. Comparing the relative bias plots for yeast and HEK-293
cells in Figs. 7 and 9 further emphasizes this correlation; the
pattern shown for the two systems is broadly similar. As the
effects of RAMPs on GPCR pharmacology are known to be
sensitive to the cell line background (37, 42) and significant
heterogeneity in PTX sensitivity of CGRP has been reported
previously (20, 45), it would perhaps be surprising if the HEK-
293 cells were a perfect match to yeast. Indeed, as we have
shown (Fig. 6), in terms of the expression levels of G!i subunits,
two similar HEK-293 cell lines are, in fact, very different; HEK-
239S cells appear to have a reduced level of G!i expression
compared with HEK-293 cells. When combined with our
observation of the PTX sensitivity of the CLR response inHEK-
293S cell lines, it becomes apparent that we need to carefully
consider the G protein content of cell lines that we utilize when
investigating G protein-mediated signaling bias.
Our results have demonstrated that the CGRP family of
receptors can couple to G!s, G!i and G!q subunits. Further,
using the yeast system we observed a ligand-dependent G pro-
tein coupling bias with each receptor, highlighting the ability of
the yeast platform to uncover potential G protein bias for other
GPCRs. Importantly, this ability is, at least partially, transferred
into mammalian cells and provides an excellent starting point
for subsequent investigations into both the extent to which this
bias occurs in native mammalian cells and the molecular basis
for the phenomenon. Any examination of the physiological sig-
nificance of G protein promiscuity needs to consider the cellu-
lar background in which the CLR/RAMP receptor is expressed;
we observed significant differences between our three cell hosts
that depend, at least partly, on the G proteins they express (Fig.
13). Indeed, it is worth highlighting that, as a direct conse-
quence of the reduced overall G!i content in HEK-293S cells,
all three ligands at the CGRP family of receptors display bias
toward cAMP accumulation over (Ca2!)i release (Fig. 9). Cou-
pling to G!i (or possibly G!o) may be particularly relevant in
neuronal and other electrically excitable cells where many (18,
19) of the effects of PTX on CGRP have been observed
(reviewed in Ref. 15). In neuronal and other cells, the direct
G!i/G!o effects on ion channelsmay also be particularly signif-
icant. For example, there is the potential for a complex interplay
between neuronally released CGRP and the AM or AM2 pep-
tides released locally through cross-talk among all three CLR-
based receptors, with the potential for the G!i coupling to nat-
urally limit excitation produced via G!s.
The role ofG!q/11 coupling inmediating responses toCGRP,
AM, and AM2 has not been well investigated; the few relevant
studies have examined activation of protein kinase C or release
of calcium from internal stores rather than directly studying
G!q/11. For CGRP, a further complication is that it can also
activate the amylin-1 receptor with high affinity (46), so it is not
always clear that the observed effects are mediated via CLR.
However, in HEK-293 cells, alveolar epithelial cells, dorsal root
ganglia, and trigeminal ganglia, there is evidence for either
release of intracellular calcium or activation of PKC alongside
PKA activation (15). A similar pattern has been seen for AM in
bovine aortic endothelial cells (47). Although evidence from
PKA inhibitors such as H89 suggests that cAMP is the primary
second messenger that mediates many effects of CGRP (48),
there is the potential for spatial and temporal modulation of
this primary signal via (Ca2!)i, a possibility that remains to be
explored.
By utilizing molecular models of two diverse class B GPCR
systems, namely the RAMP1-CLR-CGRP and RAMP2-GCGR-
glucagon systems, we have gained insight into signaling bias.
Webelieve the simulations reported here are the firstmolecular
dynamics simulations on RAMP-GPCR heterodimers. The
interaction of the RAMP TM helix with TM6/TM7 is sup-
ported both by docking experiments onCLR (27) and by studies
on the secretin-GLP-1 chimeric receptor (49); this interaction
remains stable throughout both 500-ns simulations of the
active receptors, with the RAMP retaining a straight helix
through both simulations, despite the presence of proline(s).
The interaction is primarily with TM7 and the N-terminal end
of TM6. This provides some evidence that GCGR andCLRmay
interact with RAMP in a similar way. Despite the persistence
TABLE 5
Potency (pEC50), affinity (pKa), and coupling efficacy (log !) values for (Ca
2")imobilization at the CLR co-expressed with each RAMP stimulated
with various agonists measured in HEK-293 and HEK-293S cells
Data are themean" S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p# 0.05; **, p# 0.01; ***, p# 0.001; ****, p# 0.0001) for each
receptor heterodimer (CGRP for RAMP1-CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
HEK-293 HEK-293S
pEC50a Emaxb pKac log !d n pEC50a Emaxb pKac log !d n
RAMP1
CGRP 8.19" 0.1 79.68" 0.7 7.50" 0.1 0.60" 0.05 5 8.06" 0.1 67.64" 2.0 7.57" 0.1 0.32" 0.04 5
AM 7.90" 0.2 37.00" 3.5**** 7.69" 0.4 $0.24" 0.10 5 7.63" 0.2 38.18" 3.8**** 7.42" 0.2 $0.21" 0.07**** 5
AM2 6.76" 0.2*** 25.05" 2.4**** 6.64" 0.1** $0.48" 0.06** 5 6.94" 0.1*** 33.28" 1.7**** 6.76" 0.1** $0.30" 0.03**** 5
RAMP2
CGRP 7.86" 0.1 63.20" 3.0 7.43" 0.1 0.54" 0.10 5 7.55" 0.3 55.35" 4.5 7.21" 0.3 0.07" 0.08 5
AM 7.86" 0.1 63.00" 1.8 7.45" 0.2 $0.19" 0.06 5 7.68" 0.2 52.26" 4.5 7.39" 0.2 0.03" 0.10 5
AM2 7.41" 0.4 44.41" 7.1* 7.15" 0.4 $0.10" 0.13** 5 7.42" 0.4 20.17" 2.8**** 7.33" 0.2 $0.65" 0.13*** 5
RAMP3
CGRP 7.47" 0.2* 84.39" 8.5* 6.66" 0.4* 0.74" 0.26 5 7.51" 0.2 65.3" 4.7 7.07" 0.2** 0.24" 0.10* 5
AM 8.12" 0.1 56.69" 6.6 7.76" 0.3 0.13" 0.13 5 8.02" 0.2 44.3" 3.2 8.56" 0.2 $0.11" 0.06 5
AM2 8.05" 0.3 19.99" 2.4* 7.95" 0.3* $0.63" 0.08* 5 7.44" 0.3 20.1" 4.3 7.35" 0.3** $0.62" 0.07** 5
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal (Ca2!)i release as determined using 10 "M ionomycin stimulation.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log # is the coupling efficacy parameter of each ligand.
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and stability of the TM interactions, the C terminus is quite
flexible, sampling a wide region of space in both simulations.
RAMP2 interacted primarily with the C terminus of G!s,
whereas RAMP1 interacted primarily with H8 but also made
contact with TM6 and most importantly G!s. These simula-
tions therefore indicate that the RAMP could affect the bias
shown inGprotein coupling byCLR either by direct interaction
and/or allosterically by altering the orientation of TM6 and
TM7 or H8. These simulations were carried out on a model of
the active receptor in complex with a C-terminal fragment of
G!s (Arg-374 to Leu-394). The C-terminal helix of G!s sits
above the face of the G protein. Models of RAMP2-GCGR in
complex with the G protein heterotrimer indicated that the
RAMP could also interact directly with residues around Gly-
353 of G!s (results not shown).
In addition, the allosteric effects of the RAMP linker may
alter the extracellular face of the receptor (as seen in CLR with
RAMP2 and RAMP3 (27)), and these effects could be transmit-
ted to the intracellular end of the helix. In our simulations, we
see some evidence for the top of TM7moving in toward theTM
bundle under pressure of the RAMP (Fig. 11) as part of a col-
lective unit comprising TM7, the peptide, and the RAMP TM.
This concerted movement provides a possible mechanism
whereby the influence of the ligand can be conveyed to the
RAMP and thereby affect the bias via interactions of the C ter-
minus of the RAMP. The inwardmovement of the extracellular
FIGURE 9. Quantification of biased agonism at the three RAMP-CLR complexes. A, normalized transduction coefficients, !log ("/Ka), for cAMP
accumulation and (Ca2")imobilization obtained for the three RAMP-CLR complexes upon stimulated with CGRP, AM, or AM2 in untreated HEK-293 cells,
HEK-293 cells treated with PTX, and HEK-293S cells. B, relative bias factors, !!("/Ka), for cAMP accumulation and (Ca
2")i mobilization for the three
individual RAMP-CLR complexes upon stimulatedwith CGRP, AM, or AM2 in untreated HEK-293 cells, HEK-293 cells treatedwith PTX, and HEK-293S cells.
Determination of values requires normalization to a reference ligand (CGRP for RAMP1-CLR and AM for CLR with RAMP2 or RAMP3) and a reference
pathway (in all cases cAMP accumulation). Data were determined as statistically different from the cognate ligand for each receptor (*, p# 0.05; **, p#
0.01; ***, p # 0.001; ****, p # 0.0001).
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end of TM7 has been linked explicitly to activation (50), but
movement of TM6 and/orH8 under the influence of the RAMP
may also affect bias and activation. Thus we suggest that
RAMPs have the potential to interact allosterically with not
only the GPCR but also the bound G protein. This leads to the
possibility that, upon ligand binding, the RAMPs contribute to
the G protein bias. To confirm this likelihood, we aim to extend
this project to investigate all ligand-RAMP-CLR-G protein
complexes and further elucidate the role that RAMPs play in
modulating G protein coupling and bias at the CGRP family of
receptors.
Finally, we suggest that this study has broader implications.
Our results shown here are similar to those described for the
GCGR (25) in that RAMPs alter the ability of peptides to stim-
ulate different G proteins. However, as we have shown, signifi-
cant pharmacological differences can be observed in differing
recombinant cell lines and expression systems. These differ-
ences can be explained through several factors; these systems
rely firstly upon overexpression of the receptor and chaperone
proteins under study and secondly upon the cellular content of
further downstream signaling proteins such as G proteins. It is
therefore important that findings in systems such as those
FIGURE 10. Class B GPCR-RAMP heterodimericmodels andmolecular dynamics simulations.Molecular models and dynamic simulation suggest that the
C-terminal tail of RAMP1/2 (olive/yellow, when in complex with either GCGR (A, blue) or CLR (B, teal), interacts directly with the bound C-terminal of G!s (green)
and/orhelix 8. Theglucagonpeptideagonist is shown inmagenta, andCGRP is shown inpurple.C, theRAMP2C terminus approaches theG!s (redarrow) during
amolecular dynamics simulation of an active GCGR-RAMP2-glucagon complex. RAMP2 is shown in yellow andG!s in green, and theGCGR is colored according
to time progression from red (0 ns) to blue (500 ns).
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explained here be further validated. This would be best
achieved in cell lines endogenously expressing the GPCR and
RAMPof interest. This is thus something that we aim to under-
take as a follow-up to the work presented here for CLR-RAMP
complexes. It is clear that there is a complex interplay among
the ligand, the RAMP, and the CLR that alters G protein acti-
vation for these receptors. Further, our data presented here add
to the growingwealth of literature suggesting thatmany ligands
for class B GPCRs display either a G!s or G!i signaling prefer-
ence. To date, this ligand-engendered bias has been observed
for receptors binding corticotropin-releasing factor, urocortin
1, GLP-1, and glucagon (24, 25, 51). In the current study, the
yeast growth assay system was able to provide a valuable indi-
cation of the potential of the CGRP family of receptors to cou-
ple to either G!s or G!i when stimulated by CGRP, AM, or
AM2, allowing us to uncover novel G protein signaling prefer-
ences for each ligand.We therefore conclude that this system is
a good platform from which to explore the effect of RAMP
dimerization to other members of the class B GPCRs.
Experimental Procedures
Materials—Human (h) !CGRP, hAM, and hAM2 (1–47)
were purchased from Bachem (Bubendorf, Switzerland) and
made to 1 mM stocks in water containing 1% BSA. Yeast nitro-
gen base and yeast extract were purchased fromDifco (Franklin
Lakes, NJ). Fluorescein-di-"-D-glucopyranoside was purchased
from Invitrogen. Forskolin was from Tocris Bioscience (Wilt-
shire, UK), andYM-254890was supplied byAlpha Laboratories
(Hampshire, UK). Both theALPHAScreen andLANCE! cAMP
detection assay kits and all reagentswere fromPerkinElmer Life
Sciences.
Expression Constructs—To enable expression of the human
CLR, we used either a previously described (25) Myc-tagged
cDNA construct provided by Dr. Michel Bouvier (University of
Montreal, Canada) or a human CLR with an N-terminal HA
epitope tag. All human FLAG-tagged RAMPs were used as
described previously (37).
Yeast Strain Construction and Assay—General yeast proce-
dures were performed as described previously (22, 24). The
humanCLRwas introduced into yeast cells under the control of
the PGK promoter using a plasmid containing ura3 (pDT-
PGK). The three human RAMPs were introduced into yeast
under the control of theGAPDH promoter using plasmids con-
FIGURE 11. The peptide agonist, the GPCR , and the RAMP TM helix move as a collective unit during molecular dynamics simulations. A, schematic
diagram of the distances between themembers of the collective unit and TM2. Top, arrow bars indicate the following distances in order: RAMP2-TM2 (green),
TM7-TM2 (cyan), and peptide-TM2 (orange). Bottom, arrow bars indicate the distances within the members of the collective unit in order: RAMP2-peptide
(purple), RAMP-TM7 (black), and TM7-peptide (red). B, distances from each of the collective unit components (RAMP TM, TM7, and glucagon agonist) to TM2
(ordered as in A). These distances decrease in a similar manner, reflecting their concerted movement. C, distances between each of the collective unit
components (RAMP, TM7, and glucagon agonist) (ordered as in A). These distances are relatively constant, reflecting their movement as a collective unit.
FIGURE 12. Agonist potency ratios for CGRP, AM, and AM2 at the CLR in
combinationwitheachRAMP.Logpotency ratios (asmeasuredby theaccu-
mulation of intracellular cAMP) are defined as log(EC50 AM2/EC50 agonist).
Data are taken fromHong et al. (1) and others (43, 44). HEK-293 andHEK-293S
cell data from the current study are shown in red and blue, respectively, and
yeast G!s coupling is shown in green.
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taining leu2 (p425-GPD) (25). S. cerevisiae dual reporter strains
expressing chimeras of yeast GPA1(1–467) (GPA1/G!) with
the five C-terminal amino acids of 11 human G proteins repre-
senting G!s, G!16, G!q, G!o, G!i1/2, G!i3, G!z, G!12, G!13, and
G!14 (MMY84–MMY93) were used in this study (52). The
human CLR and RAMPs were transformed into yeast cells (at a
ratio of 1:1 to enable equal expression) using the lithium ace-
tate/single-stranded DNA/polyethylene glycol method as
described previously (53). Positive transformants were selected
and maintained on synthetic dropout (SD) medium lacking
both uracil and leucine (SD-Ura-Leu). Receptor signaling was
measured using the yeast growth assay as described previously
(24). Cell growth was initially performed in SD-Ura-Leu
medium at 30 °C to select cells expressing only both plasmids.
Cells were then cultured to remove basal activity in SD-Ura-
Leu-His medium overnight at 30 °C and assayed using medium
supplemented with fluorescein-di-"-D-glucopyranoside. A flu-
orescein signal was detected as an increase in fluorescence
(excitation wavelength! 485 nm, emission wavelength! 535
nm) as a measure of growth. Different concentrations of ligand
(0.01 nM–100 #M) were assayed using 96-well plates, and fluo-
rescence was detected using a Tecan Infinite M200 microplate
reader (Tecan Ultra Evolution, Reading, UK) or a Mithras LB
940 microplate reader (Berthold Technologies, Harpenden,
UK) for 20 h. Positive isolates were selected for their ability to
grow above basal level in SD-Ura-Leu-Hismedium, when stim-
ulated with 10 #M CGRP or AM as appropriate for the RAMP-
CLR complex being studied. Chimeric strains were deemed not
to functionally couple when n " 16 isolates had been assayed
and none showed growth above basal levels. In this study func-
tional couplings were only observed for MMY84, MMY86, and
MMY88 representing G!s, G!i1/2, and G!q, respectively.
FIGURE 13. Aworkingmodel of biased agonism at the different RAMP-CLR complexes. The individual RAMP-CLR complexes can bind the agonists CGRP
(red), AM (green), and AM2 (blue) to activate different downstream chimeric GPA1/G! subunits (in yeast) or promote increases in intracellular cAMP and/or
mobilize release of (Ca2#)i (in HEK-293/HEK-293S cells). The thickness of the lines indicates the bias that each agonist displays for either the chimeric G protein
or the specific downstream signaling cascade. The yeast system enabled the comparison of different individual G proteins (G!s, G!i1/2, and G!q), whereas in
mammalian cells we investigated cAMP accumulation ($ PTX) and elevation of (Ca2#)i.
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Mammalian Cell Culture and Transfection—HEK-293 cells,
provided by Dr. Jügen Müller (University of Aston), were cul-
tured in DMEM supplemented with 10% heat-inactivated FBS
and kept at 37 °C in a humidified 95% air, 5% CO2 incubator.
HEK-293S cells (a gift from AstraZeneca) were cultured in
DMEM supplemented with 8% heat-inactivated FBS and kept
at 37 °C in a humidified 95% air, 5% CO2 incubator. HEK-293
cells were transfected with FuGENE 6 (Roche Applied Science)
in accordance with the manufacturer’s instructions using a 1:3
(w:v) DNA:FuGENE ratio and a 1:1 ratio of RAMP to CLR.
HEK-293S cells were seeded into 96-well poly-D-lysine-coated
plates at a density of 15,000 cells/well (determined using a
CountessTM cell counter, Invitrogen) 1 day prior to transfec-
tion. HEK-293S cells were transiently transfected as described
previously (38) using a 1:1 ratio of RAMP to CLR. The trans-
fected cell lines were grown for 24–48 h prior to assaying.
Where appropriate, PTX (200 ng/ml) was added to ADP-ribo-
sylate G!i for 16 h prior to assaying, thereby uncoupling recep-
tor-mediated G!i-dependent inhibition of cAMP production.
cAMPAccumulationAssays—The transfectedHEK-293 cells
were washed in PBS, resuspended in stimulation buffer (PBS
containing 0.1% BSA and 0.5 mM IBMX), and seeded at 2000
cells/well in 384-well white Optiplates. Ligands were added in
the range of 1 pM to 1 mM, and cAMP accumulation was mea-
sured after 30min of stimulation using a LANCE! cAMPdetec-
tion kit (PerkinElmer Life Sciences). We had found previously
that a 30-min stimulation was the optimum time for assaying
cAMP accumulation for family B GPCRs (24, 25). Plates were
read using a Mithras LB 940 multimode microplate reader
(Berthold Technologies). HEK-293S cells were assayed for
cAMP accumulation as described elsewhere (54). Values were
converted to concentration using a cAMP standard curve per-
formed in parallel.
Calcium Mobilization Assays—Transfected HEK-293 cells
were grown to confluence in black, clear bottomed, 96-well
plates. On the day of assay cells were washed with calcium-free
Hanks’ balanced salt solution and incubated for 1 h at room
temperature in the presence of 10 "M Fluo-4/AM (Invitrogen)
containing 2.5 mM probenecid. Cells were then washed fol-
lowed by the addition of 100 "l of Ca2!-free Hanks’ balanced
salt solution. Ligandswere added robotically using aMithras LB
940multimodemicroplate reader in the range of 10 pM to 1"M,
and fluorescence was determined immediately post-injection
with an excitation wavelength set to 485 nm and an emission
wavelength set to 535 nm. Recordings were obtained every 0.5 s
for 120 s. Peak magnitude was calculated using five-point
smoothing followed by correction against background fluores-
cence. The peak was used to generate concentration-response
curves and normalized relative to 10 "M ionomycin. To deter-
mine the role played by G!q/11 in (Ca2!)i mobilization, cells
were pretreated (for 30 min) with 100 nM YM-254890, which
inhibits G!q/11 signaling (42).
RT-PCR—RNAwas extracted fromHEK-293 and HEK-293S
cells using a RNAqueous-4PCR kit (ThermoFisher Scientific)
as per the manufacturer’s protocol. All RNA samples were
treated with DNase I to remove contaminating genomic DNA.
Reverse transcription was performed using a QuantiTect
reverse transcription kit (Qiagen, Manchester, UK). The PCR
amplification was performed as described previously (55) using
gene-specific primers to humanG! subunits: G!s, forward (5"-
CGACGACACTCCCGTCAAC-3") and reverse (5"-CCCGG-
AGAGGGTACTTTTCCT-3") (PrimerBank ID, 3297877a1
(56)); G!i1, forward (5"-TTAGGGCTATGGGGAGGTTGA-
3") and reverse (5"-GGTACTCTCGGGATCTGTTGAAA-3")
(PrimerBank ID, 156071490c1 (56)); G!i2, forward (5"-TACC-
GGGCGGTTGTCTACA-3") and reverse (5"-GGGTCGGCA-
AAGTCGATCTG-3") (PrimerBank ID, 261878574c1 (56));
G!i3, forward (5"-ATCGACCGCAACTTACGGG-3") and
reverse (5"-AGTCAATCTTTAGCCGTCCCA-3") (Primer-
Bank ID, 169646784c1 (56)); G!q, forward (5"-TGGGTCAG-
GATACTCTGATGAAG-3") and reverse (5"-TGTGCATGA-
GCCTTATTGTGC-3") (PrimerBank ID, 312176363c1 (56));
G!11, forward (5"-GGCTTCACCAAGCTCGTCTAC-3") and
reverse (5"-CACTGACGTACTGATGCTCG-3") (PrimerBank
ID, 115511048c1) (56)); G!z, forward (5"-GGTCCCGGAGAA-
TTGACCG-3") and reverse (5"-ATGAGGGGCTTGTACTC-
CTTG-3") (PrimerBank ID, 45580725c1) (56)); G!0, forward
(5"-GGAGCAAGGCGATTGAGAAAA-3") and reverse
(5"-GGCTTGTACTGTTTCACGTCT-3") (PrimerBank ID,
162461737c1 (56)); G!12, forward (5"-CCGCGAGTTCGACC-
AGAAG-3") and reverse (5"-TGATGCCAGAATCCCTCCA-
GA-3") (PrimerBank ID, 42476110c1) (56)); G!13, forward
(5"-CAGCAACGCAAGTCCAAGGA-3") and reverse(5"-
CCAGCACCCTCATACCTTTGA-3") (PrimerBank ID,
215820623c1) (56)); G!14, forward (5"-GAGCGATGGACAC-
GCTAAGG-3") and reverse (5"-TCCTGTCGTAACACTCC-
TGGA-3") (PrimerBank ID, 222418795c1 (56)); G!15, forward
(5"-CCAGGACCCCTATAAAGTGACC-3") and reverse
(5"-GCTGAATCGAGCAGGTGGAAT-3") (PrimerBank ID,
156104882c1 (56)); and GAPDH, forward (5"-AATGGGCAG-
CCGTTAGGAAA-3") and reverse (5"-GCGCCCAATACGA-
CCAAATC-3"). All products were resolved on a 2% agarose gel
and imaged using a G:Box iChemi gel documentation system
utilizing GeneTools analysis software (Syngene, Cambridge,
UK), and densitometry was performed using GeneTools.
Molecular Modeling—Models of the GCGR in complex with
RAMP2 and CLR in complex with RAMP1 were based on the
previously reported models of GLP-1R in complex with GLP-1
and CLR in complex with RAMP2/3, respectively (27–29).
These models were built using MODELLER 9.16 (57) from the
GCGR and CRFR x-ray structures of the TM domain (58, 59),
the x-ray structures of the extracellular domain (60, 61), and
NMR structures of closely related peptides (62, 63). The helical
region of the CGRP peptide was structurally aligned to the cor-
responding region in GLP-1 based on the sequence alignment
(27) because the position of the GLP1 helix within GLP-1R is
well defined by experimentation; the initialmodels are available
as supporting information. The RAMP-GPCR complexes were
placed in a hydrated POPC membrane using CHARMM GUI
(64) to generate a system containing 20,482 and 28,013 TIP3P
water molecules (65), as well as 183 and 243 lipid molecules for
the RAMP2-GCGR and RAMP1-CLR heterodimers, respec-
tively. The histidine protonation was determined using the
PDB2PQR server (66). TheAMBERSP99 force field parameters
for the protein (67), and the lipid14 force field parameters for
POPC (68, 69) were added using AmberTools (70). Molecular
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dynamics simulations were run for 500 ns at 298 K using
ACEMD (71).
Data Analysis—Data analysis for cAMP assays was per-
formed in GraphPad Prism 6.0f (San Diego, CA). Data were
fitted to obtain concentration-response curves using either the
three-parameter logistic equation (for pEC50 values) or the
operational model for partial agonism (34) to obtain values of
efficacy (log !) and the equilibrium dissociation constant (log
Ka). These values were then used to quantify signaling bias as
change in log (!/Ka) relative to the natural cognate ligand for
the respective receptor (41). We denoted these as CGRP for
CLR with RAMP1 and AM for CLR with either RAMP2 or
RAMP3. Statistical differences were analyzed using one-way
ANOVA or Student’s t test as appropriate with post hoc Bon-
ferroni’s or Dunnett’s multiple comparisons, and p! 0.05 was
considered significant. Correlations between pEC50 values for
cAMP assays of HEK-293 andHEK-293S cells were assessed by
scatter plot and Pearson’s correlation coefficient (r). For RT-
PCR, normalization to the internal standard GAPDH was per-
formed to reduce variance and enable a comparison between
different cell lines. To quantitate the ligand-dependent
response in the yeast system, a strain lacking GPA1 (MMY11),
grown in rich medium, was used as a standard (72). As GPA1 is
not present in this strain, theG"# subunits are unregulated and
free to signal, allowing us to determine themaximal response of
our system. Emax values are reported as a percentage of this
maximum response, and statistical analysis was performed on
these data. For the mammalian cell-based assays, data analysis
was carried out as for the yeast curves. To account for the day-
to-day variation experienced from transient transfections, we
used the maximal level of cAMP accumulation from cells in
response to 100 $M forskolin stimulation as our reference and
10 $M ionomycin for (Ca2")i assays. Emax values from these
curves are reported as a percentage of these controls, and all
statistical analysis has been performed on these data. Where
appropriate the operational model for partial agonism (34) was
used to obtain efficacy (log !) and equilibrium disassociation
constant (log Ka) values. In both cases, this normalization
removes the variation due to differences in transfection or
transformation but retains the variance for control values. The
means of individual experiments were combined to generate
the curves shown.
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There were some errors in Tables 3 and 4 whereby some data values were increased by the addition of 10 units to each data point. These errors
have now been corrected and do not affect the results or conclusions of this work.
TABLE 3
Potency (pEC50), affinity (pKa) andcouplingefficacy (log!) values for cAMPproductionat theCLRco-expressedwitheachRAMP, stimulatedwith
various agonists measured in HEK-293 cells in the presence and absence of pertussis toxin
Data are the mean! S.E. of n individual data sets. Statistically different between PTX-treated and untreated was determined using Student’s t test (*, p" 0.05; **, p" 0.01;
***, p" 0.001; and ****, p" 0.0001).
Untreated Treated
pEC50a Emaxb pKac log !d n pEC50a Emaxb pKac log !d n
RAMP1
CGRP 9.66! 0.2 47.07! 2.2 9.43! 0.2 #0.11! 0.04 9 9.65! 0.2 44.95! 2.2 9.33! 0.3 #0.11! 0.07 6
AM 7.93! 0.2 48.06! 2.5 7.67! 0.2 #0.09! 0.05 9 8.14! 0.07 72.17! 1.7*** 7.66! 0.2 0.36! 0.1** 6
AM2 7.93! 0.2 46.10! 4.1 7.70! 0.2 #0.11! 0.07 9 9.15! 0.1* 72.15! 2.4*** 8.56! 0.3 0.4! 0.1** 6
RAMP2
CGRP 9.00! 0.2 36.97! 2.4 8.82! 0.2 #0.27! 0.05 9 8.25! 0.4 56.27! 1.4*** 7.92! 0.2* 0 0.1! 0.06** 6
AM 10.35! 0.1 56.33! 1.6 10.00! 0.1 0.07! 0.02 9 10.16! 0.07 56.07! 1.1 9.83! 0.2 0.07! 0.02 6
AM2 7.46! 0.2 36.61! 3.5 7.24! 0.2 #0.29! 0.07 9 9.13! 0.1** 56.05! 2.2*** 8.84! 0.2** 0.1! 0.06* 6
RAMP3
CGRP 7.75! 0.3 22.38! 2.6 7.64! 0.3 #0.54! 0.07 8 8.90! 0.1* 32.61! 1.5* 8.74! 0.2* #0.29! 0.06 7
AM 8.98! 0.2 32.00! 1.5 8.83! 0.1 #0.33! 0.03 8 9.10! 0.2 35.95! 2.2 8.94! 0.2 #0.34! 0.05 7
AM2 9.10! 0.2 21.92! 1.7 9.08! 0.2 #0.51! 0.06 8 8.74! 0.2 44.35! 2.7**** 8.43! 0.1* #0.07! 0.07*** 7
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 !M forskolin stimulation in the presence of per-
tussis toxin treatment.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log " is the coupling efficiency parameter of each ligand.
TABLE 4
Potency (pEC50) andmaximal response (Emax), for cAMP production at the CLR co-expressed with each RAMP, stimulated with various agonists
measured in HEK-293S cells in the presence or absence of pertussis toxin
Data are the mean! S.E. of n individual data sets. No statistical difference was found between untreated and PTX-treated HEK-293S cells using Student’s t test.
Untreated Treated
pEC50a Emaxb n pEC50a Emaxb n
RAMP1
CGRP 9.88! 0.1 59.98! 1.1 5 9.87! 0.1 72.92! 2.3 5
AM 8.13! 0.1 60.00! 3.1 5 8.03! 0.1 61.26! 2.6 5
AM2 8.74! 0.1 68.94! 1.2 5 8.78! 0.1 68.30! 1.6 5
RAMP2
CGRP 8.00! 0.1 32.56! 1.0 5 7.88! 0.1 39.32! 1.7 5
AM 9.39! 0.1 30.34! 0.8 5 9.38! 0.1 33.28! 1.2 5
AM2 8.57! 0.1 40.30! 1.5 5 8.58! 0.2 30.52! 2.0 5
RAMP3
CGRP 8.42! 0.1 40.84! 0.6 5 8.38! 0.1 39.84! 1.0 5
AM 9.63! 0.1 39.09! 1.2 5 9.49! 0.2 42.26! 1.6 5
AM2 8.01! 0.1 33.75! 1.5 5 7.79! 0.2 28.21! 2.4 5
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b Themaximal response to the ligand expressed as a percentage of themaximal cAMP production as determined using 100!M forskolin stimulation in the presence of PTX treatment.
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Modelling and simulation of biased agonism dynamics at a
G protein-coupled receptor
L. J. Bridge∗1, J. Mead2, E. Frattini2, I. Winfield2,3 and G. Ladds∗2
Abstract
Theoretical models of G protein-coupled receptor (GPCR) concentration-response relationships
often assume an agonist producing a single functional response via a single active state of the recep-
tor. These models have largely been analysed assuming steady-state conditions. There is now much
experimental evidence to suggest that many GPCRs can exist in multiple receptor conformations
and elicit numerous functional responses, with ligands having the potential to activate different sig-
nalling pathways to varying extents - a concept referred to as biased agonism, functional selectivity
or pluri-dimensional efficacy. Moreover, recent experimental results indicate a clear possibility for
time dependent bias, whereby an agonists bias with respect to different pathways may vary dy-
namically. Efforts towards understanding the implications of temporal bias by characterising and
quantifying ligand effects on multiple pathways will clearly be aided by extending current equi-
librium binding and biased activation models to include G protein-activation dynamics. Here, we
present a new model of time-dependent biased agonism, based on ordinary differential equations
for multiple cubic ternary activation models with G protein cycle dynamics. The model is generally
applicable to systems with NG G proteins and N∗ active receptor states. Numerical simulations for
NG = N∗ = 2 reveal new insights into the effects of system parameters (including cooperativities,
and ligand and receptor concentrations) on bias dynamics, revealing new phenomena including the
dynamic inter-conversion of bias direction. Further, we have fitted this model to ‘wet’ experimen-
tal data for two competing G proteins (Gi and Gs) that become activated upon stimulation of the
adenosine A1 receptor with adenosine derivative compounds. We also show that our model can
qualitatively describe the temporal dynamics of this competing G protein activation.
Keywords: Mathematical pharmacology, G protein coupled receptors, receptor theory, biased sig-
nalling, ordinary differential equations.
1 Introduction
Mathematical modelling and scientific computing are powerful tools for the analysis of cell signalling in
pharmacology. “Analytical pharmacology”, which has its roots in classical receptor theory and largely
focuses on equilibrium cell responses to drugs, provides a vital theoretical basis which underpins drug
classification and prediction of drug mechanism of action [19]. Much of the analysis has centered on
assumptions of a single ligand binding a monomeric G protein-coupled receptor (GPCR), activating
a single active state and coupling a single G protein. Concepts like allosterism, inverse agonism,
oligomerisation and “biased signalling” are now widely accepted and have enhanced receptor theory
towards better understanding of drug-receptor interactions and informed drug discovery [22]. GPCRs
represent a target for perhaps up to half of all current drugs [48], and as such, development of the
theory for ligand-GPCR interactions and their consequences is key.
Biased agonism is now a widely accepted phenomenon whereby a ligand may activate multiple
different pathways at the same receptor, via multiple active conformations [44, 32, 16, 35]. Other
terms for this phenomenon include functional selectivity and pluri-dimensional efficacy, while receptor
promiscuity refers to the ability of a receptor to couple different G proteins with different affinities,
via different active states. The possibility of multi-pathway activation may lead to a breakdown in the
common classifications of ligands based on single active state theory [16], or errors in the interpretation
of data using simple models [43]. Therefore, development of biased agonism theory has become an
important field of pharmacological research.
1Department of Mathematics, Swansea University, Singleton Park, Swansea SA2 8PP. Email:
l.bridge@swansea.ac.uk
2Department of Pharmacology, University of Cambridge , Tennis Court Road, Cambridge CB2 1PD, U.K.
3Division of Biomedical Sciences, Warwick Medical School, University of Warwick , Coventry CV4 7AL, U.K.
∗corresponding authors
1
! 254 
!!
Bridge et al. Biased agonism dynamics gpcr_bias_working_paper_august2017f 8th August, 2017 20:31
Biased signalling has implications for drug discovery, including the prospect of clinical selectivity
and the potential of reduced side effects [41, 20, 18]. A schematic of biased agonism is shown in
Figure 1.1, indicating possibility for a ligand to activate two (or more) G protein pathways at the
same receptor, one of which may be a “target” therapeutic pathway, while the other may be an
unwanted “side-effect” pathway (panel (b)). To understand, quantify and exploit the potential for
biased agonism, theoretical models for such schematics are required.
bias?
R1
G1
α1GTP
pathway 1
R2
G2
α2GTP
pathway 2
(a) (b) (c)
“target” “side-effect”
pathwaypathway
4 active states
5 G proteins
Figure 1.1: Pluri-dimensional efficacy and biased agonism at a GPCR. (a) A classical view of signalling - two
different receptors, each bound and activated (to a single active conformation) by a specific ligand, and bound
by a specific G protein. The activated G protein subunit αGTP signals to a downstream pathway specific to
the G protein. (b) A two-active-state, two-G protein biased signalling schematic. The receptor has two active
states, and the proportion of receptors in either active state, and the inactive state, may be affected (biased) by
a single ligand. Two different G proteins, specific to the active conformations, couple to the receptors and signal
to two pathways. (c) Pluri-dimensional efficacy - multi-active receptor with multiple G proteins, not necessarily
each specific to a single receptor conformation. Here we have N∗ = 4 active states and NG = 5 G proteins.
A two-active-state model of ligand binding and receptor activation at equilibrium was presented
in [27]. This equilibrium model addressed the limitations of single-active-state theory which could not
recapitulate different pathway potency and efficacy patterns at the same receptor. It was found that
theoretically, an agonist may enrich one active receptor state at the expense of another, and pathway-
dependent efficacy was observed in simulations. For an intact system, however, pathway-dependent
potency (with active receptor as the pathway readout) was not possible. G protein coupling and
activation were not explicitly modelled, but their importance for future modelling was acknowledged.
Later equilibrium models included the binding of G proteins [38, 13], which give further scope for
pathway-dependent pharmacology. An alternative model for biased agonism is given in [36], where
downstream effects are modelled not explicitly via G protein binding, but by coupling the operational
model of agonism [5] to active receptor stimuli. This model does not include constitutive activity
of the receptors. Further equilibrium modelling for promiscuous coupling of receptors to multiple G
proteins has been presented in [24, 43].
The direction and magnitude of a ligand’s bias towards one pathway over another has largely been
quantified using equilibrium assumptions and empirical models such as the operational model [34,
14, 21, 17]. A recent study [15] has highlighted the role of “kinetic context” in approaching such
calculations, whereby the apparent bias of a ligand towards any given pathway may vary over time.
Interpretation of experimental readouts in terms of bias must therefore take into account the signalling
dynamics and associated timescales of the measured pathway. Thus, dynamic models of GPCR biased
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signalling are proposed here to give new theoretical insights into the effects of biased agonists.
In [10], an ordinary differential equation (ODE) model for the dynamics of biased signalling at
GPCRs is presented. The steady-state behaviour of the model is analysed, with particular attention
paid to the effect of G protein, where the model output is active G protein. The dynamics are
not examined in detail, but extensive analysis of GPCR signalling dynamics have been presented
in [8, 47, 48], for mathematical models which also allow G proteins binding to inactive receptors, and
constitutive receptor activity. In these models, the active G protein α subunit bound to guanisine
triphosphate (αGTP ) is taken as a model readout which is representative of downstream signalling
pathway activity.
In this paper we develop a new mathematical model for the dynamics of biased agonism at GPCRs.
In Section 2, we formulate a general ODE model for the dynamics of a receptor which can activate
multiple G protein-mediated pathways. The general model has receptor with N∗ active conformations
and NG G proteins available for coupling, but our focus computationally (driven by [27]) throughout
is the case N∗ = NG = 2. In Section 3, we present time course and concentration-response simulation
results for our model, focusing on αGTP dynamics. In particular, we highlight that our model has
the propensity for agonist-inverse agonist interconversion both with respect to time and constitutive
activity. A numerical analysis of the effects of multiple cooperativity factors is performed. In Section 4,
we propose an heuristic method for quantifying dynamic bias, by way of bias factors, and show how
these bias factors relate to our model parameters. It is shown that the bias rank order for a bank of
ligands may change dynamically. In Section 5, we show that our model simulations fit well to new
experimental data where biased agonism at the adenosine A1 receptor is suspected. We conclude in
Section 6 with a discussion of our main results, underlining our contribution to the biased signalling
literature.
2 Model formulation
Here we formulate an ODE model for the dynamics of signalling for multi-active state GPCRs capable
of binding multiple G proteins, in response to a single ligand binding. The model allows for a receptor
which may have an inactive conformation R, or one of N∗ active receptor conformations R∗j , for
j = 1, .., N∗. Also, a receptor may couple to one of NG G proteins Gθ, for θ = 1, .., NG. The model
encompasses ligand binding, receptor activation, G protein binding and the G protein cycle, whereby
the model output is activated G protein αGTP , which signals to second messengers, and is therefore
taken as an indicator of pathway response, as in [48, 47, 8].
2.1 A three-state (two active states) model
While the model is formulated for general NG and N∗, we largely focus throughout on the case
N∗ = NG = 2. A schematic for the transitions between 18 receptor states for this particular case is
shown in Figure 2.1. R denotes inactive receptor, while R∗j (j = 1, 2) denotes the jth active state.
Any species including L is a complex including ligand-bound receptor, while any species including Gθ
(θ = 1, 2) is a complex including receptor coupled to the θth G protein. Double arrows represent the
reversible binding and activation reactions between receptor states. As described in previous GPCR
signalling studies (eg. [48, 47, 8]), a R∗Gθ or LR∗Gθ complex may dissociate and exchange GDP for
GTP on the α subunit of the G protein, leading to the signalling response αθGTP and the G protein
cycle.
2.2 The (j, θ) receptor/G protein block
In order to formulate the ODE model for the schematic shown in Figure 2.1 (or, indeed, the general
N∗, NG-case), we consider the (j, θ) receptor/G protein block (where j = 1, 2 and θ = 1, 2 for Fig-
ure 2.1). Each such block is seen to be a cubic ternary complex schema for activation of receptor
from inactive state R to active state R∗j , with coupling to G protein Gθ [48]. In Figure 2.2, the
equilibrium rate constants K• and cooperativity factors µ, ν, ζ are labelled on each reversible reaction.
For the individual kinetic rate constants and factors, we use lower case k, and subscripts + and − to
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R∗2G2
RG2
R∗1G2
R∗2
R
R∗1
R∗2G1
RG1
R∗1G1
LR∗2G2
LRG2
LR∗1G2
LR∗2
LR
LR∗1
LR∗2G1
LRG1
LR∗1G1
G protein cycle
to G1αGTP
G protein cycle to G2αGTP
Figure 2.1: A multi-cubic ternary complex model schematic for biased signalling with two active receptor states
and two G proteins.
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denote the forward and backward reactions respectively. The descriptions of the rate constants and
cooperativity factors are given in Table 2.1. The G protein cycle and αGTP responses follow from
dissociation of R∗Gθ and LR∗Gθ according to the following reactions (see [48]):
R∗jGθ
k
j,θ
GTP+
−→ R∗j + αθGTP + βγ
θ, LR∗jGθ
νθ
−
k
j,θ
GTP+
−→ LR∗j + αθGTP + βγ
θ, (2.1a)
αθGTP
khyd+
−−⇀
↽−−
khyd−
αθGDP , α
θ
GDP + βγ
θ
kRA+
−−⇀
↽−−
kRA−
Gθ. (2.1b)
RGθ
R∗jGθ
R
R∗j
LRGθ
LR∗jGθ
LR
LR∗j
νθKL
νθKθG
KL
KθG
µj,θζjKjact
ζjνθKL
µj,θKjact
ζjKjact
Kjact
ζjKL
µj,θνθKθGµ
j,θKθG
Figure 2.2: The (j, θ) receptor/G protein block of the multi-cubic ternary complex schematic, for ligand binding
to, and activation of, receptor j, with coupling to G protein θ.
Table 2.1: Equilibrium rate constants and cooperativity factors for the (j, θ) block of the biased signalling
schematic.
label description of equilibrium constant
KL Association of ligand L and receptor R.
KθG Binding of G protein G
θ to receptor R.
Kjact Activation of receptor R to give active state R
∗j.
µj,θ Preference of Gθ for R∗j over R.
Equally, the factor increase in propensity for R→ R∗j activation when R is Gθ-bound.
νθ Preference of L for RGθ over R.
Equally, the preference of Gθ for LR over R.
ζj Preference of L for R∗j over R.
Equally, the factor increase in propensity for R→ R∗j activation when R is L-bound.
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2.2.1 Governing equations
Suppose in general that a receptor has N∗ distinct active states, and that each receptor may couple
one of NG distinct G proteins. Then applying Mass Action kinetics to our schematic and G protein
cycle reactions gives a system of n nonlinear ODEs for the species concentrations, where
n = 3 + 2N∗ + 6NG + 2N∗NG. (2.2)
The first term here is given by species L, R and LR. The second term is given by active non-coupled
receptor states R∗j, LR∗j and the third term corresponds to G protein not coupled to active receptor
(G, RG, LRG, αθGTP , aGDP , βγ
θ). Finally, the number of active receptor/G protein complexes,
R∗jGθ and LR∗jGθ, is 2N∗NG, since we consider j = 1, ..., N∗ and θ = 1, ..., NG. If ligand concentra-
tion is considered constant, then we will not have an ODE for [L] (so omitting equation (2.3b) below),
and instead n = 2
(
1 +N∗ + 3NG +N∗NG
)
.
d[R]
dt
= kL−[LR]− kL+[L][R] +
N∗∑
j=1
(
kjact−[R
∗j]− kjact+[R]
)
+
NG∑
θ=1
(
kθG−[RG
θ]− kθG+[R][G
θ]
)
, (2.3a)
d[L]
dt
= kL−[LR]− kL+[L][R] +
N∗∑
j=1
(
ζj
−
kL−[LR
∗j]− ζj+kL+[L][R
∗j]
)
+
NG∑
θ=1
(
νθ
−
kL−[LRG
θ]− νθ+kL+[L][RG
θ]
)
+
NG∑
θ=1
N∗∑
j=1
(
ζj
−
νθ
−
kL−[LR
∗jGθ]− ζj+ν
θ
+kL+[L][R
∗jGθ]
)
, (2.3b)
d[LR]
dt
= kL+[L][R]− kL−[LR] +
N∗∑
j=1
(
ζj
−
kjact−[LR
∗j]− ζj+k
j
act+[LR]
)
+
NG∑
θ=1
(
νθ
−
kθG−[LRG
θ]− νθ+k
θ
G+[LR][G
θ]
)
, (2.3c)
d[R∗j ]
dt
= kjact+[R]− k
j
act−[R
∗j ] + ζj
−
kL−[LR
∗j]− ζj+kL+[L][R
∗j]
+
NG∑
θ=1
(
µj,θ
−
kθG−[R
∗jGθ]− µj,θ+ k
θ
G+[R
∗j ][Gθ]
)
+
NG∑
θ=1
(
kj,θGTP+[R
∗jGθ]
)
, for j = 1, ..., N∗ (2.3d)
d[LR∗j]
dt
= ζj+k
j
act+[LR]− ζ
j
−
kjact−[LR
∗j ] + ζj+kL+[L][R
∗j]− ζj
−
kL−[LR
∗j]
+
NG∑
θ=1
(
µj,θ
−
νθ
−
kθG−[LR
∗jGθ]− µj,θ+ ν
θ
+k
θ
G+[LR
∗j][Gθ]
)
+
NG∑
θ=1
(
νθ
−
kj,θGTP+[LR
∗jGθ]
)
, for j = 1, ..., N∗
(2.3e)
d[RGθ]
dt
= kθG+[R][G
θ]− kθG−[RG
θ] + νθ
−
kL−[LRG
θ]− νθ+kL+[L][RG
θ]
+
N∗∑
j=1
(
µj,θ
−
kjact−[R
∗jGθ]− µj,θ+ k
j
act+[RG
θ]
)
, for θ = 1, ..., NG, (2.3f)
d[LRGθ]
dt
= νθ+k
θ
G+[LR][G
θ]− νθ
−
kθG−[LRG
θ] + νθ+kL+[L][RG
θ]− νθ
−
kL−[LRG
θ]
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+
N∗∑
j=1
(
µj,θ
−
ζj
−
kjact−[LR
∗jGθ]− µj,θ+ ζ
j
+k
j
act+[LRG
θ]
)
, for θ = 1, ..., NG, (2.3g)
d[R∗jGθ]
dt
= µj,θ+ k
θ
G+[R
∗j ][Gθ]− µj,θ
−
kθG−[R
∗jGθ] + ζj
−
νθ
−
kL−[LR
∗jGθ]− ζj+ν
θ
+kL+[L][R
∗jGθ]
+ µj,θ+ k
j
act+[RG
θ]− µj,θ
−
kjact−[R
∗jGθ]
− kj,θGTP+[R
∗jGθ] for j = 1, ..., N∗ and θ = 1, ..., NG, (2.3h)
d[LR∗jGθ]
dt
= µj,θ+ ν
θ
+k
θ
G+[LR
∗j ][Gθ]− µj,θ
−
νθ
−
kθG−[LR
∗jGθ] + ζj+ν
θ
+kL+[L][R
∗jGθ]− ζj
−
νθ
−
kL−[LR
∗jGθ]
+ µj,θ+ ζ
j
+k
j
act+[LRG
θ]− µj,θ
−
ζj
−
kjact−[LR
∗jGθ]
− νθ
−
kj,θGTP+[LR
∗jGθ] for j = 1, ..., N∗ and θ = 1, ..., NG, (2.3i)
d[Gθ]
dt
= kθG−[RG
θ]− kθG+[R][G
θ] + νθ
−
kθG−[LRG
θ]− νθ+k
θ
G+[LR][G
θ]
+ kθGRA+[α
θ
GDP ][βγ
θ]− kθGRA−[G
θ]
+
N∗∑
j=1
(
µj,θ
−
kθG−[R
∗jGθ]− µj,θ+ k
θ
G+[R
∗j ][Gθ]
)
+
N∗∑
j=1
(
µj,θ
−
νθ
−
kθG−[LR
∗jGθ]− µj,θ+ ν
θ
+k
θ
G+[LR
∗j][Gθ]
)
, for θ = 1, ..., NG, (2.3j)
d[αθGDP ]
dt
= kθhyd+[α
θ
GTP ]− k
θ
hyd−[α
θ
GDP ] + k
θ
GRA−[G
θ]− kθGRA+[α
θ
GDP ][βγ
θ], for θ = 1, ..., NG,
(2.3k)
d[βγθ]
dt
= kθGRA−[G
θ]− kθGRA+[α
θ
GDP ][βγ
θ]
+
N∗∑
j=1
(
kj,θGTP+[R
∗jGθ] + νθ
−
kj,θGTP+[LR
∗jGθ]
)
, for θ = 1, ..., NG, (2.3l)
d[αθGTP ]
dt
= kθhyd−[α
θ
GDP ]− k
θ
hyd+[α
θ
GTP ]
+
N∗∑
j=1
(
kj,θGTP+[R
∗jGθ] + νθ
−
kj,θGTP+[LR
∗jGθ]
)
, for θ = 1, ..., NG. (2.3m)
For the model “outputs”, or downstream responses of the system to an input ligand concentration,
we take the concentrations [αθGTP ] for θ = 1, ..., N
G, as we consider these as indicators of downstream
activity in signalling pathways as in [7, 8]. For our computational results, we will consider the case
with two G proteins and two active receptor states, such that N∗ = NG = 2, and our model has 18
receptor states and 8 non-receptor-bound G protein species (2× (G + αGTP + αGDP + βγ)). Taking
ligand concentration constant (as in previous studies), the system (2.3) in this case consists of 26
ODEs.
Initial conditions for our simulations have [R]t=0 = Rtot (the total receptor concentration), [Gθ]t=0 =
Gθtot (the total concentration for each G protein), and all other species zero at t = 0.
3 Simulation results
Here we present numerical results (for αθGTP concentrations) which illustrate the variety of dynamic
behaviour which is possible for a system of two active states and two-G proteins. These results are
7
! 260 
!!
Bridge et al. Biased agonism dynamics gpcr_bias_working_paper_august2017f 8th August, 2017 20:31
intended to demonstrate potential dynamics rather than provide exhaustive or accurate predictions
for any particular receptors or ligands. For all simulations, we first compute the system with [L] = 0
for a long time (108 seconds) to allow the system to come to a steady-state equilibrium before the
addition of ligand, and all parameters except those explicitly stated are maintained at the values in
Table A.1.
3.1 Time Courses
3.1.1 Ligand is an agonist for both pathways
By varying the values of ζ1 and ζ2 , the preference of the ligand for a receptor in the respective active
state over the inactive receptor state, we vary the efficacy with respect to the G protein pathways 1 and
2 respectively. In Figure 3.1, we show time courses of the responses to a ligand which is an equilibrium
agonist for both pathways, for a range of concentrations. Three different ligand concentrations are
used, and the αθGTP responses for θ = 1, 2 are shown. The higher efficacy with respect R
∗1 gives an
increased response, and we note the peak-plateau dynamics. With increased ligand concentration,
we see a higher αθGTP response for both pathways, both at peak and plateau (end-point). Further,
the peak timing is reduced with increased ligand concentration, in keeping with previous single active
state studies [48, 7].
0 100 200 300 400 500 600 700 8000
0.5
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1.5
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2.5
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3.5
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4.5
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t
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GT
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αGTP
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αGTP
2   [L]=1e−5
Figure 3.1: Graph showing the αθGTP response (M) against time (in seconds) of two competing pathways with
ζ1+ = 1000 and ζ
2
+ = 100 after the addition of [L] = 10
−7, 10−6, and10−5M. Here, ζ2+ = 200.
3.1.2 Ligand is agonist for one pathway and antagonist for the other
Neutral antagonists may be used as competitive ligands to endogenous agonists. Mathematical mod-
elling of agonist-antagonist competition at a single active state GPCR has been considered in [8].
Within our two-active state model, we may simulate the dynamics of a system for which a given lig-
and is an agonist for one pathway but an antagonist for the other. In Figure 3.2, we show αGTP and
receptor time courses for this scenario, for a ligand which is an (equilibrium) agonist for pathway 1
(ζ1+ = 1000, ζ
1
−
= 1) and an (equilibrium) antagonist for pathway 2 (ζ2+ = 1, ζ
2
−
= 1), over a range
of ligand concentrations. We note the peak-plateau α1GTP dynamics, and the nearly neutral effect on
α2GTP dynamics. However, closer inspection of [α
2
GTP ] reveals that the ligand in fact has an inverse
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agonist effect on pathway 2. Since the ligand is an agonist for pathway 1, its effect on overall receptor
activation is an increase in pathway 1 active states, given by
R∗1tot = [R
∗1] + [LR∗1] + [R∗1G1] + [LR∗1G1], (3.1)
and a corresponding decrease in pathway 2 active states and free inactive receptor states, given,
respectively, by
R∗2tot = [R
∗2] + [LR∗2] + [R∗2G2] + [LR∗2G2], (3.2)
and
Rinactivetot = [R] + [LR] + [RG
1] + [LRG1] + [RG2] + [LRG2]. (3.3)
Upon ligand addition, there are, therefore, fewer receptors available to activate pathway 2, giving a
decrease in [α2GTP ], and the inverse agonist effect of the “antagonist”. For [L] = 10
−7M, we also see the
undershoot αGTP response previously reported for inverse agonists [7]. We note that a true neutral
antagonist effect with constant [α2GTP ] would be seen if we considered pathway 2 as an “isolated
pathway” (see [27]) by setting k1act+ = 0.
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R*1tot    L=1e−5
1000*R*2tot    L=1e−5
Rtot    L=1e−5
Figure 3.2: The αθGTP response (M) against time (in seconds) for two pathways with ζ
1
+ = 1000 and ζ
2
+ = 1
after the addition of [L] = 10−7, 10−6, 10−5M so that the ligand is an agonist for pathway 1 and an antagonist
for pathway 2. Receptor concentrations are given in the bottom right panel. Here, ζ1+ = 1.
3.1.3 Ligand is agonist for one pathway and inverse agonist for the other
Having seen apparent inverse agonist activity in the biased system for a ligand which would neutrally
antagonise an isolated pathway, we now turn attention to a ligand which is a true inverse agonist
for one pathway in the biased system, and an agonist for the other. In Figure 3.3, we show αGTP
time courses for this scenario, for a ligand which is an (equilibrium) agonist for pathway 1 (ζ1+ = 100,
ζ1
−
= 1) and an (equilibrium) inverse agonist for pathway 2 (ζ2+ = 0.01, ζ
2
−
= 1), over a range of
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ligand concentrations. These simulations are for a system with increased R∗2 constitutive activity, to
represent conditions under which inverse agonism may be detectable. We note the peak-plateau α1GTP
dynamics, and drop-off in α2GTP level. Further, we observe “undershoot” dynamics in the inversely
agonised pathway, which may be seen in a single-active state system [7]. An interesting feature here
is that while increasing ligand concentration decreases α1GTP peak time as before, this is accompanied
by an increase in α2GTP peak time.
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2   L=0.0001
Figure 3.3: Graph showing the αθGTP response (M) against time (s) after the addition of a range of ligand
concentrations, where the ligand is an agonist for pathway 1 and an inverse agonist for pathway 2. Here,
ζ1+ = 100, ζ
2
+ = 0.01, k
2
act− = 10.
3.1.4 Time course surfaces
In order to summarise the effect that efficacy parameter ζ has on a system, in Figure 3.4 we show
summary time course surfaces for [L] = 10−5M, where we vary ζ1+ over a spectrum of efficacy ranging
from strong inverse agonist to strong agonist, while keeping all other parameters fixed. We clearly
see that the stronger L is an agonist for pathway 1, the lesser its effect on pathway 2. When L
is an agonist for both pathways, the peak-plateau dynamic response is clear for both α1GTP and
α2GTP , but increasing agonist strength for pathway 1, the pathway 2 response drops off. Similarly,
for a pathway 2 antagonist, the α2GTP dynamic response varies from apparent antagonism to inverse
agonism with increasing ζ1+. Also, for a pathway 2 inverse agonist, the magnitude of α
2
GTP inverse
agonism increases with ζ1+.
3.1.5 Observed agonist effect is system-dependent - constitutive activity and inter-
conversion
A feature of the equilibrium three-state model in [27] is that a ligand’s effect on a pathway can change
qualitatively from agonist to inverse agonist, depending on the system-specific level of constitutive
activity in that pathway. This so-called “inter-conversion” of ligand effect is demonstrated at steady-
state in [27], with respect to active receptor states. In Figure 3.5, we show the effects of increasing the
constitutive activity in pathway 2 by decreasing k2act−. With low constitutive activity (k
2
act− = 100),
the time courses for α1,2GTP are indistinguishable. As pathway 2 constitutive activity is increased, it is
clear that pathway 2 basal αGTP increases at the expense of pathway 1 basal αGTP , similarly to the
active receptor trend in [27, 37]. The agonist effect on α2GTP becomes less pronounced with decreased
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Figure 3.4: Time course surfaces for αθGTP response (M) dynamically changing for system with varying agonist
efficacy parameter ζ1+, acting under a ligand concentration of 10
−5M . Column (a): ζ2+ = 1000; column (b):
ζ2+ = 1; column (c): ζ
2
+ = 0.001.
k2act−, as the G protein response is largely effected via the basal activity, but the ligand remains a
pathway 2 agonist. In contrast, with high activation of pathway 2 (k2act− = 1), the long-time α
1
GTP
response decreases with “agonist” concentration, so that the ligand is now having an apparent inverse
agonist effect, despite its isolated pathway classification as an agonist. It is also worth noting that
for (k2act− = 10), we observe non-monotonicity in the peak and plateau α
1
GTP as functions of [L].
Thus non-monotonic concentration-response curves may result from multi-active state receptors with
varying constitutive activity levels.
3.1.6 Observed agonist effect may be time-dependent: G protein cycle and dynamic
inter-conversion
With our new model, we are able to examine the αθGTP dynamics under variation of constitutive re-
ceptor activation. In the final plot of Figure 3.5, we see the phenomenon of dynamic inter-conversion
between agonist and inverse agonist action. The ligand is an agonist for both pathways under equi-
librium classification, but after initially displaying a typical agonist response, α1GTP eventually drops
below basal levels in an apparent inverse agonist response. The dynamic peak response to agonism
occurs as in previous simulations [48]. The below basal long-time level is a result of G protein cy-
cle dynamics on active receptor equilibration. As α1GTP is inactivated and G
1 reassociates, any new
free receptors resulting from LRG complex dissociation are pulled towards a pathway 2 dominant
equilibrium, and the receptor pool for G1 activation decreases below basal level.
3.2 Concentration-response relationships
3.2.1 Peak and plateau responses with varying ligand activation efficacy and constitutive
receptor activity
The ligand concentration-dependent features which summarise the αGTP equilibrium and dynamic
behaviour may be summarised using conventional concentration-response curves. In Figure 3.6, we
show concentration response curves for both pathways, where the measured responses are the peak
and plateau αGTP levels. The non-monotonicity first noted in subsection 3.1.5 is clearly a possibility.
For a ligand which agonises both pathways, with high constitutive activity in one pathway, the plateau
response in the other pathway is non-monotonic. The peak concentration-response curve is yet more
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Figure 3.5: Time courses for αθGTP response (M) dynamically changing for systems with differing constitutive
receptor activation level in pathway 2, varying k2act−. Here, ζ
1
+ = ζ
2
+ = 100, k
1
act− = 100, k
2
act− = 100.
complex; it is also non-monotonic, with a biphasic structure. We remark that biased agonism together
with constitutive activity in our new model for αGTP response is a mechanism by which non-monotonic
concentration-response relationships can occur. Such behaviour cannot be observed for three-state
models [27, 37] where the “readout” is a particular active receptor fraction.
Further demonstration of the dynamic and concentration-dependent features of the system is given
in Figure 3.7, where we clearly see decreasing peak timing for both pathways where the ligand is an
agonist for both, but an increasing trough time at the pathway for which the ligand is an inverse
agonist.
3.2.2 Effect of total receptor number on concentration-response
The total concentration of receptor can considerably affect the appearance of bias in a system [34].
In Figure 3.8, we investigate the effect of differing receptor expression by examining concentration-
response curves for two pathways being agonised by a ligand (L1) with different efficacies (ζ1+ = 1000
and ζ2+ = 100) at a range of receptor concentrations Rtot (from 4.15 ×10
−11M to 4.15× 10−8M). As
Rtot is decreased, we observe both a rightward shift of the curves (increased EC50), together with a
drop in the maximal responses, for both the peak and plateau values of αGTP .
Whilst overall efficacy depends partly on the preference of the ligand for an active rather than
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Figure 3.6: Concentration-response curves (αθGTP concentration against ligand concentration) where the ligand
is an agonist for both pathways (ζ1+ = 1000, ζ
1
−
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Figure 3.7: Concentration-response curves (αθGTP maximum and minimum timing against ligand concentration)
where the ligand is an agonist for both pathways (ζ1+ = 1000, ζ
1
−
= 1, ζ2+ = 100, ζ
2
−
= 1, top row) and agonist
for pathway 1 but an inverse agonist for pathway 2 (ζ1+ = 1000, ζ
1
−
= 1, ζ2+ = 0.01, ζ
2
−
= 1, bottom row).
Constitutive activity for pathway 2 is low (k2act− = 1000, left column), medium (k
2
act− = 10, middle column),
and high (k2act− = 1, left column). Here, ζ
2
+ = 100.
inactive receptor (controlled through variation of the ζ parameters), it is important to note that it
can also depend on the preference of a ligand-bound receptor for each of the G proteins (mediated
by the ν parameters). In the case of a system in which the ligand-dependent parameters affecting
efficacy are chosen so as to counteract each other (ζ1+ = 2000, ζ
2
+ = 100, ν
1
+ = 1, ν
2
+ = 25), we see
that (Figure 3.9) not only the magnitude of the preference for one pathway, but even the direction
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Figure 3.8: Concentration-response curves for peak and plateau αGTP for two pathways being agonised by
L1, a ligand with different efficacies for the two pathways (ζ1+ = 1000 and ζ
2
+ = 100), under varying receptor
concentrations.
(in terms of which pathway experiences the higher response) can be affected by a changing receptor
concentration. In this case, peak αGTP exhibits a change in direction, while plateau level does not.
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Figure 3.9: Concentration-response curves for two pathways being agonised by L2, a ligand with parameters
ζ1+ = 2000, ζ
2
+ = 100, ν
1
+ = 1, ν
2
+ = 25, vary under changing receptor concentrations.
3.3 Response surfaces
Parameter sensitivity and concentration-response relations may be conveniently summarised using
response surfaces which show the effects of varying two system parameters [6, 48, 8]. We now use this
method to show the sensitivity of simulated response (α1,2GTP peak and plateau) to variations in system
parameters, in particular the microaffinity coefficients ζ, ν and µ.
14
! 267 
!!
Bridge et al. Biased agonism dynamics gpcr_bias_working_paper_august2017f 8th August, 2017 20:31
3.3.1 Effect of ζ - the possibility of biphasic relationships
In Figure 3.10, we see the effect of varying ζ1+ and ζ
2
+ for a fixed ligand concentration. The reciprocal
effects on the two G protein pathways mediated by the competing receptor states are clear. As ζ1+ is
increased, both peak and plateau α1GTP increase, accompanied by decreases in α
2
GTP . Furthermore, it
is clear that biphasic relationships are possible.
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Figure 3.10: Response surfaces for varying ligand efficacy, for fixed ligand concentration [L] = 10−5M. Param-
eters ζ1+ and ζ
2
+ are varied through the spectrum of efficacy for each receptor active state.
3.3.2 Effect of G protein non-specificity and receptor “cross-states”
Thus far in our computations, we have focussed on systems in which the two G proteins are each
specific to a particular active receptor conformation. By setting µ1,1 = 1, µ2,2 = 1, µ1,2 = 0, µ2,1 = 0,
we have simulated systems whereby G protein 1 can neither activate a pre-coupled receptor towards
R∗2, nor bind to R∗2, and vice-versa. It is a novel aspect that our model allows receptor “cross-states”,
where there is not exclusive specificity of each G protein for one particular active receptor state. We
see in Figure 3.11 the effects of non-exclusive specificity and accessibility of these cross states on
the αGTP responses. The general trend is that with all cross states signalling (with k
j,θ
GTP = 1,∀θ),
increasing µ21 gives a decreased peak α1GTP and slight increase in plateau α
1
GTP .
Our model allows for variation in specificity of not only the G proteins for each receptor confor-
mation, but also the propensity for G protein cycling with respect to these active states, controlled
by kj,θGTP+. With cross states which do not signal (with k
j,θ
GTP = 0 for j "= θ), increasing µ12 now
gives a decreased peak and plateau α2GTP as the general trend, with non-monotonicity, which may be
explained by considering the effects on basal conditions. Further explanation and discussion of these
effects is given in Appendix B.
3.3.3 Effect of ν, the preference of ligand for specific G protein-coupled receptor
The microaffinity constant νθ controls the preference of ligand for RGθ over R. The effect of varying
νθ is as expected, in that increasing νθ increases both peak and plateau αθGTP (see Figure C.1 in
Appendix C).
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Figure 3.11: Response surfaces for varying ligand accessibility of receptor cross states for fixed ligand concen-
tration [L] = 10−5M.
4 Detecting and quantifying bias
A balanced agonist is one which signals with equal efficacy to available downstream pathways, whereas
a biased agonist has different efficacies for signalling to different pathways [34]. There is a need to detect
and quantify the level of bias towards one pathway over another, considering that physiologically and
clinically, certain pathways represent therapeutic targets while others are “side effect” pathways [14].
Here, we employ current quantification methods for the level of ligand bias within our two-pathway
system.
4.1 Bias factors and the Operational Model
The operational model of agonism [5] provides a standardised and widely adopted method for estimat-
ing ligand affinity and “operational efficacy” parameters from functional response data in the form of
hyperbolic concentration-response curves. Briefly, for a single downstream readout E resulting from
ligand concentration [A] at a receptor,
E([A]) = Emax
τ [A]
KD + (τ + 1)[A]
, (4.1)
where Emax is the maximum response of the system, KD is the ligand’s equilibrium dissociation
constant, and τ is a measure of ligand efficacy, in particular measuring the propensity of the ligand
and the system to yield a response. A modified form of the model is sometimes used to account for
nonzero basal responses [39], namely
E([A]) = basal + (Emax − basal)
τ [A]
KD + (τ + 1)[A]
. (4.2)
Further generalisation of this model is possible by introducing a Hill coefficient to the signal trans-
duction sub-model [5, 39]. Recently, the operational model has been used to quantify the level of bias
in systems exhibiting multi-dimensional efficacy (ie. the activation of multiple pathways at a single
receptor). Bias is typically defined with respect to a reference ligand, and “bias factors” are computed
using fitted values of τ [34] or both τ and KD [20, 17, 14]. Here, we follow the transduction coefficients
method [20] by defining a transduction coefficient for a ligand A at a given pathway as
TA = log10
(
τ
KD
)
ligA
. (4.3)
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The difference in transduction coefficients for two ligands A and B is usually written in ∆ log notation,
with
∆ log10
(
τ
KD
)
ligA−ligB
= ∆TA−B = TA − TB
= log10
(
τ
KD
)
ligA
− log10
(
τ
KD
)
ligB
= log10
(
τ
KD
∣∣∣∣
A
KD
τ
∣∣∣∣
B
)
. (4.4)
The relative bias factor for a ligand A, relative to ligand B, for pathway 1 over pathway 2, is usually
defined by first calculating its logarithm, written in ∆∆ log notation as
log10 bias
1−2
A−B = ∆∆ log10
(
τ
KD
)path1−path2
ligA−ligB
= ∆Tpath1A−B −∆T
path2
A−B
= log10
(
τ
KD
∣∣∣∣path1
A
KD
τ
∣∣∣∣path1
B
KD
τ
∣∣∣∣path2
A
τ
KD
∣∣∣∣path2
B
)
, (4.5)
so that
bias1−2A−B =
τ
KD
∣∣∣∣path1
A
KD
τ
∣∣∣∣path1
B
KD
τ
∣∣∣∣path2
A
τ
KD
∣∣∣∣path2
B
. (4.6)
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Figure 4.1: Bias factor surface for fixed ligand 1 parameters, varying ligand 2 parameters ζ2 and ν2. Bias factor
bias1−2A represents the bias for pathway 1 over pathway 2 signalling. Here, kL+ = 10
5, k1act+ = k
2
act+ = 0.05,
and k1hyd− = k
2
hyd− = 10
−8.
4.2 Bias factor’s dependence on ζ and ν
The bias factor, bias1−2A =
τ
KD
∣∣∣path1
A
KD
τ
∣∣∣path2
A
, is a standard measure of a ligand’s bias for effecting
a response in pathway 1 over pathway 2. While this is defined in terms of the parameters τ and
KD which are fitted to the semi-mechanistic operational model, rather than explicitly in terms of the
parameters in our new αGTP model, we expect correlations between the bias factor and ligand-specific
parameters in our model. In particular, when αGTP is measured at equilibrium and taken as the
response E, we expect, on the whole, bias factor should increase with decreased ζ2 and ν2, which
control a ligand’s effect on R∗2 activation and G2 coupling to the receptor. In Figure 4.1, we show
the bias factor bias1−2A for a bank of ligands generated by varying ζ
2
+ and ν
2
+, while keeping all other
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parameters fixed. The correlation is clear. The overall trend is the expected increase in bias1−2A with
decreasing ζ2+ and ν
2
+, while the relationship is approximately a power law over much of the parameter
space shown.
4.3 Kinetic context and dynamic bias factors
0 500 1000 1500 2000 2500 3000 3500 4000
10−2
10−1
100
101
102
103
t
op
 m
od
el 
bia
s f
ac
to
r
 
 
1 2 3 4 5 6 7 8 9
10−2
10−1
100
101
102
103
ligand
alt
 b
ias
 fa
cto
r
ligand #1  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =1000   ζ−
2 =1   ν+
2=1000   ν−
2=1
ligand #2  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =1000   ζ−
2 =1   ν+
2=10   ν−
2=1
ligand #3  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =1000   ζ−
2 =1   ν+
2=1   ν−
2=1
ligand #4  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =100   ζ−
2 =1   ν+
2=1000   ν−
2=1
ligand #5  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =100   ζ−
2 =1   ν+
2=10   ν−
2=1
ligand #6  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =100   ζ−
2 =1   ν+
2=1   ν−
2=1
ligand #7  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =10   ζ−
2 =1   ν+
2=1000   ν−
2=1
ligand #8  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =10   ζ−
2 =1   ν+
2=10   ν−
2=1
ligand #9  kL+=100000  kL−=0.31   ζ+
1 =1000   ζ−
1 =1   ν+
1=1   ν−
1=1   ζ+
2 =10   ζ−
2 =1   ν+
2=1   ν−
2=1
Figure 4.2: Bias factor dynamics for a bank of nine ligands. The operational model bias factor bias1−2A represents
the bias for pathway 1 over pathway 2 signalling is shown for each time point, and the alternative bias factor is
shown in the right hand panel. Reference ligand is ligand 7, a strong agonist for pathway 1. Here, kL+ = 105,
k1act+ = k
2
act+ = 0.05, k
1
hyd− = k
2
hyd− = 10
−8 and k1RA− = k
2
RA− = 1.3× 10
−4.
It has recently been demonstrated that binding, activation and signalling dynamics may signif-
icantly affect bias measurements, and hence the classification of biased ligands, and that “kinetic
context” is an important consideration in the quantification of bias [15]. Although bias calculations
based on the operational model implicitly assume equilibrium conditions, this method is shown to
be an effective and simple heuristic approach to investigating and quantifying dynamic bias in [15].
In Figure 4.2, we show bias factor time courses for a bank of ligands, generated by constructing a
concentration-response curve for each ligand at each time point, then fitting each of these curves to
the operational model (using optimisation routines in MATLAB). Here, the bias factor is calculated
with respect to the reference ligand (ligand 7), and we see that the long-time bias factor bias1−2A−ref
indeed increases with decreased ζ2+ and/or ν
2
+. We also plot, in the right hand panel, an alternative
bias factor based on our model parameters, specifically
alt-bias1−2A−ref =
kL+,A
kL−,A
(
ν1Aζ
1
A
ν2Aζ
2
A
)
kL+,ref
kL−,ref
(
ν1refζ
1
ref
ν2refζ
2
ref
) , (4.7)
which should also indicate ligand bias. We note the excellent agreement between the dynamic bias
factors from operational model fitting and our alternative bias factor. Dynamically, there is the
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possibility of a change of order of bias factors, and this phenomenon is even more marked for the
bank of ligands shown in Figure 4.3. Clearly, the order of bias factors may change dynamically, so the
classification of ligands requires consideration of kinetic context, as described in [15].
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Figure 4.3: Bias factor dynamics for a bank of four ligands. Bias factor bias1−2A represents the bias for pathway
1 over pathway 2 signalling. Here, kL+ = 105, k1act+ = k
2
act+ = 0.01, k
1
hyd− = k
2
hyd− = 10
−8 and k1RA− =
k2RA− = 1.3× 10
−4.
5 Fitting to a model of downstream functional antagonism via bi-
ased signalling
Our model outputs thus far have been the αGTP levels of the two G proteins in the system, which
represent responses downstream of ligand binding, and may correspond to a downstream functional
experimental readout. We now consider whether our model can be used to explain, and fit to, exper-
imental end point data in a system where biased agonism is suspected.
5.1 Experimental method
The adenosine A1 receptor (A1R) is well known for mediating the protective effects of adenosine in
the heart [12, 31]. How these effects are brought about is not fully understood, as the A1R is able to
couple to multiple signalling pathways [3]. This makes interpretation of physiological effects difficult to
attribute to an individual, signalling pathway. While the A1R is a predominantly Gi-coupled receptor,
which inhibits the accumulation of the second messenger, cyclic adenosine monophosphate (cAMP),
it has been observed that at higher agonist concentrations, the levels of cAMP begin to rise again
producing a non-monotonic response profile. This accumulation of cAMP arises through the ability
of the A1R to switch its G protein coupling and now promote activation of Gs [11, 2]. The extent to
which an individual agonist either inhibits or stimulates cAMP production at the A1R may vary.
To obtain data to enable fitting of our models, experiments were performed using Chinese hamster
ovary-K1 (CHO-K1) cells stably expressing the A1 receptor, treated with a range of concentrations of
a single agonist each time, and the effect on intracellular concentration of cAMP determined (see Ap-
pendix D and [45, 23, 46] for details). In particular, the experiments were carried out for three different
agonists individually, namely 5’(N-ethyl carboxamido) adenosine (NECA), and two test compounds
which bind the A1R, denoted here as Compound 6 (Cmpd6) and Compound 20 (Cmpd20) ([23]). The
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measured response was the accumulated cAMP concentration in the presence of the phosphodiesterase
(PDE) inhibitor rolipram, which blocks cAMP degradation.
For each concentration of each agonist, two experiments were performed. Firstly, intact (wild-
type) cells were used, which allow for coupling and activation of both Gi and Gs proteins to the A1R,
thereby allowing activation of both the Gi pathway which inhibits cAMP production via an increased
αGTP,i signal, and the Gs pathway which stimulates cAMP production via an increased αGTP,s signal.
For these cells, the recorded response is the percentage inhibition of cAMP when compared with cells
treated with forskolin (which promotes maximal stimulation of cAMP production [4]). The second
experimental condition is for cells that have been treated with pertussis toxin (PTX), which both
inhibits binding of Gi to its receptor and blocks its signal transduction, thereby locking αi in its
inactive, GDP-bound state [30]. For these cells, the recorded response is the percentage stimulation
of cAMP when compared with forskolin-stimulated cells. Time courses of cAMP were not recorded,
and the signalling readout in each case is taken at the endpoint of the experiment (t = 1800s).
Further details of the experiments are given in Appendix D.
5.2 Experimental results
In Figure 5.1, we show the experimental cAMP endpoint signals in response to three ligands indi-
vidually in turn (NECA, Cmpd6 and Cmpd20) for the two different experimental conditions. For
wild-type cells the log concentration response curves for the inhibition of cAMP show non-monotonic
behaviour with a downturn at higher concentrations, whereas the log concentration response curves
for the production of cAMP in PTX-treated cells show, with the exception of one data point for the
NECA experiment, monotonic behaviour. By blocking the inhibitory pathway, we largely see “stan-
dard” monotonic behaviour, which suggests that the non-monotonic wild-type response results from
crosstalk between the inhibitory and stimulatory pathways. Since in each case a single ligand has been
introduced, we hypothesise that the target receptor may exhibit biased agonist effects, via two active
conformations, one of which is specific to the Gi protein and the other to the Gs protein.
5.3 Modelling considerations
Since the data shown in Figure 5.1 are hypothesised to result from biased agonism with competition
between two activated G protein pathways, we now seek to fit our model to the data, in order to add
support to this hypothesis and understand the possible underlying mechanisms.
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Figure 5.1: Using the model of biased agonism with functional antagonism at level of αGTP to fit cAMP readouts
(signalstim(1800) and signalinhib(1800)) for three different ligands (NECA, Cmpd6 and Cmpd20). Experimental
data points are given (red squares with dashed lines for percentage cAMP inhibition for wild-type cells, blue
circles with dashed lines for percentage cAMP production in PTX-treated cells, each compared with forskolin-
treated cells which give maximal cAMP response) for end point readouts over a range of ligand concentrations.
Solid curves are the fitted log concentration response curves for our model.
Within our modelling framework, we let G1 and G2 represent the Gs and Gi proteins respectively.
We simulate the PTX effect of blocking Gi binding and activation by setting k2G+ = k
22
GTP+ = k
2
GRA− =
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0. Since cAMP is produced in response to Gs activation [4, 25], for a simple, minimal model of cAMP
levels in PTX-treated cells, with blocked cAMP degradation, we take the cAMP production rate
proportional to αGTP,s levels, so that
d[cAMP ]
dt ∝ αGTP,s, and hence the stimulation signal is given by
signalstim(t) =
∫ t
0
Cs[αGTP,s](t) dt =
∫ t
0
Cs[α
1
GTP (t)] dt, (5.1)
where Cs is a constant.
For the wild-type cells in which both stimulatory and inhibitory cAMP pathways are intact, we
require a model for crosstalk between Gi and Gs pathways. Here we use a simple “functional an-
tagonism” model for the competing effects of these pathways. Functional antagonism refers to the
response of a cell in which signalling via one pathway is antagonised by signalling via another pathway,
and simple theoretical models have been presented which are based on differences between pathway
signals [28, 42, 26]. Here, we use such a model where αGTP,s and αGTP,i are stimuli to the cAMP
stimulatory and inhibitory pathways respectively, and the cAMP production rate is simply a scaled
difference between the two αGTP levels. The inhibition signal is then given by
signalinhib(t) =
∫ t
0
Ci[αGTP,i](t)− Cs[αGTP,s](t) dt =
∫ t
0
Ci[α
2
GTP ](t)− Cs[α
1
GTP ](t) dt, (5.2)
where Ci is a constant, and Cs is the constant as in (5.1). Since functionally opposite signalling can
result in non-monotonic concentration-response curves with downturns ([42, 33]) such as those seen
in the cAMP inhibition curves in Figure 5.1, our biased agonism model augmented by the simple
functional readout models (5.1) and (5.2) may be able to recapitulate the experimental data, at least
qualitatively. We proceed to employ parameter estimation methods to pursue a fit to the concentration-
response curves for each ligand.
5.4 Parameter estimation
We fit the experimental data to the model given by (2.3) with N∗ = NG = 2, together with (5.1)
and (5.2), where simulations are first run to a time of 108 seconds with [L] = 0, to pre-equilibrate
the system before ligand addition. For each ligand, the experimental data for the intact and PTX
cells were fitted simultaneously, using optimisation algorithms to minimise the squared error between
simulation and data points. The methods used were the trust region algorithm implemented in Pot-
tersWheel [29], followed by a genetic algorithm routine implemented in MATLAB [1]. A subset of the
kinetic parameters were varied; for each reversible reaction, we fixed one rate constant (typically for
the reverse reaction), and allowed one rate constant to float. Further, we consider systems where the
active receptor cross states are inaccessible, such that µj,θ = kj,θGTP+ = 0 are fixed for j #= θ, since
these have been shown to largely have little effect. Fitted parameters for the NECA data set were
used as initial parameter guesses for Cmpd6 and Cmpd20, to speed up the overall fitting for Cthese
compounds. For each ligand, the model can clearly fit the data very well qualitatively. In Figure 5.1,
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Figure 5.2: Log concentration response curves for
∫
α1GTP dt and
∫
α2GTP dt levels using fitted parameter values.
we see that the model fit for the stimulation curve is monotonic, with maximal and basal signals, and
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EC50 values in good agreement with the data. Further, the fitted inhibition curve in each case is
non-monotonic, with the concentration which gives the peak value in good agreement with the data.
The basal, peak and plateau levels are in good agreement with the data, and the model recapitulates
the differences in peak “spread” between the three ligands. Values for the fitted parameters are given
in Table E.1.
In Figure 5.2, simulations from the fitted parameter sets for each ligand show the
∫
αGTP con-
tributions to the overall measured signal for both cell types. In each case, the stimulatory responses
for the intact cells and the PTX cells are almost indistinguishable, and while the individual
∫
αGTP
curves are monotonic, the difference between them for the intact cells is not.
Having estimated parameters which fit the experimental data (taken at a single time point t =
1800s), we may now simulate the underlying αGTP dynamics up to this time point. In Figure 5.3,
we show time courses for αGTP,i and αGTP,s levels, using the NECA-fitted parameters. With the
ligand being an agonist for both G protein pathways, the peak-plateau αGTP dynamics are clear,
and consistent with the temporal characteristics observed in our earlier numerical simulations. Peak
values are monotonic with [L], with α1GTP peaking later than α
2
GTP . We conclude that our model
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Figure 5.3: Underlying αGTP,i and αGTP,s dynamics for NECA-fitted parameters, for a range of agonist con-
centrations. Time is on a logarithmic scale to clearly show the peak-plateau time scales.
recapitulates, and fits to, experimental data well in the cases shown, therefore adding support to the
biased agonism conjecture for the experiments discussed, and validating our model. Our functional
model for cAMP production is very simple, comprising a linear combination of αGTP,i and αGTP,s. It
is reasonable to expect that a more detailed model of cAMP signalling with more degrees of freedom
would result in an even better fit to the data.
6 Discussion
Biased agonism is now a widely accepted phenomenon for signalling via GPCRs [44, 20], and exploit-
ing this is a potential route to developing novel therapeutics [20, 18]. Theoretical (mathematical)
models are key tools towards understanding biased signalling, and have previously been presented for
equilibrium conditions [27, 38]. These models have enabled a foundation biased agonism theory to
be established, largely at the level of receptor activation. For functional readouts downstream of the
receptor, further detail has been added at the level of G protein binding [13], and simple empirical
models for pathway signalling [36]. In this paper, we have developed a new model for biased agonism
which includes the detail of G protein activation via a cubic ternary complex/G protein cycle model,
with αGTP as a readout, and serving as an indicator/proxy of pathway activity. This model is general
in terms of the number of active receptor conformations and G proteins, and also that it is not specific
to any particular pathway; it can thus be used to model biased signalling at any GPCR, and detailed
further signalling components can be added downstream of αGTP to model particular pathways as
desired. Potentially, our model could provide a foundation for simulating single-ligand multi-pathway
dynamics, such as recent experimental work revealing dynamic biased signalling behaviour at the
dopamine D2 receptor [15].
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An important advance in the present study is the analysis of signalling dynamics as predicted by
our model. The role of kinetic context in the investigation of biased agonism has recently been high-
lighted [15] and, as such, a model and method for analysing dynamics represents a timely contribution
to the literature. A number of dynamic features have been observed here, including the apparent
inverse agonist effect of an “antagonist”, dynamic inter-conversion of agonist effect, and the time-
dependence of bias factor order. Non-monotonic concentration-response relationships for endpoint
signals are possible from our model, for both a single αGTP readout within a two-pathway system,
and downstream crosstalk between two αGTP signals.
The current standard method for quantifying bias from experimental data uses parameters fitted
to the equilibrium operational model of agonism [5, 21]. Calculating bias factors using this empirical
model applied to timecourse data shows the dynamic nature of bias [15], and our model and com-
putations have reproduced this phenomenon. We propose that such analysis may provide important
new insights into, and quantitative characterisation of, experimental timecourse results. The use of
operational model appears to be the current state-of-the-art in bias quantification, but it has a num-
ber of limitations: it is empirical rather than mechanistic, it does not consider dynamics, and it does
not account for constitutive activity [41]. An alternative model which includes constitutive activity is
given in [40], but this equilibrium model has yet to be fully explored with respect to biased signalling.
While beyond the scope of our current work, a valuable future investigation will focus on further
formulation and definition of dynamic bias factors, including constitutive activity.
We have shown our model to be capable of reproducing endpoint trends in experimental data
for cAMP levels in response to ligands at the A1R receptor, through multi-pathway (αGTP,s and
αGTP,i) signalling with functionally opposite downstream signals. This endpoint analysis has resulted
in parameterisations of the model which then predict the underlying αGTP dynamics, qualitatively
consistent with our earlier agonist-induced simulations. This validation of our model allows us to
propose its use for further study of downstream signalling, and fitting to time-course data when it
becomes available. For example, for any future dynamic cAMP experimental readouts, our simple
functional models (5.1)-(5.2) can be used to fit to time-courses, with better fits expected by letting a
greater number of parameters float, or using a more detailed cAMP model (eg. [25]). The simulation
and fitting in the current work also clearly shows that single-ligand multi-pathway activation at a
single receptor provides a mechanism for non-monotonic concentration-response relations either for
αGTP itself or for downstream signals, by way functional antagonism. While functional signalling
experiments often results in monotonic concentration-response curves, relationships with downturns
at high concentrations are not uncommon [9, 49, 33], and the current work provides a plausible
mechanistic model for understanding such results in systems where multi-pathway signalling via a
single receptor is possible.
The mathematical work here represents a theoretical framework for further study of the potential
benefits of developing biased agonists as therapeutics. The multidimensionality of GPCR signalling
now constitutes a new paradigm in drug discovery, and the potential benefits of new understanding
of multi-pathway signalling lie in the development of “functionally selective” drugs which preserve
efficacy in target pathways, while minimising activation of unwanted side-effect pathways at the same
receptor [35]. Further mechanistic modelling encompassing G protein binding and activation, down-
stream signalling, dynamics and complexity of the level we have studied here is acknowledged as a
potentially very valuable advance towards such drug discovery goals [44, 41].
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A Parameter values
In Table A.1, we give a base parameter set for all computations. Any variations from this parameter
set are shown in figure titles and captions.
Table A.1: Parameter values for 2 G protein, 2 active receptor state model.
label meaning cell
or ligand
specific
value units source
kL+ Ligand binding rate Ligand 9.40E+04 M
−1s−1 Bridge
et al (2010)
kLm Ligand unbinding rate Ligand 3.10E-01 s
−1 ”
k1act+ Receptor activation rate to R
∗1 Cell 1.00E+00 s−1 ”
k1act− Receptor deactivation rate from
R∗1
Cell 1.00E+03 s−1 ”
k2act+ Receptor activation rate to R
∗2 Cell 1.00E+00 s−1 ”
k2act− Receptor deactivation rate from
R∗2
Cell 1.00E+03 s−1 ”
k1G+ G protein 1 binding rate Cell 1.00E+08 M
−1s−1 ”
k1G− G protein 1 unbinding rate Cell 1.00E-01 s
−1 ”
k2G+ G protein 2 binding rate Cell 1.00E+08 M
−1s−1 ”
k2G− G protein 2 unbinding rate Cell 1.00E-01 s
−1 ”
k1GRA+ G protein 1 reassociation rate Cell 7.00E+05 M
−1s−1 ”
k1GRA− G protein 1 dissociation rate Cell 1.30E-03 s
−1 ”
k2GRA+ G protein 2 reassociation rate Cell 7.00E+05 M
−1s−1 ”
k2GRA− G protein 2 dissociation rate Cell 1.30E-03 s
−1 ”
k1hyd+ Hydrolysis rate of Gα
1
GTP Cell 1.00E-02 s
−1 ”
k1hyd− Exchange rate of GTP for GDP
at G1α
Cell 1.00E-04 s−1 ”
k2hyd+ Hydrolysis rate of Gα
2
GTP Cell 1.00E-02 s
−1 ”
k2hyd− Exchange rate of GTP for GDP
at G2α
Cell 1.00E-04 s−1 ”
k1,1GTP+ R
∗1G1 dissociation rate Cell 1.00E+00 s−1 ”
k1,2GTP+ R
∗1G2 dissociation rate Cell 1.00E+00 s−1 ”
k2,1GTP+ R
∗2G1 dissociation rate Cell 1.00E+00 s−1 ”
k2,2GTP+ R
∗2G2 dissociation rate Cell 1.00E+00 s−1 ”
νθ+ Forward cooperativity factor for
ligand binding a Gθ bound recep-
tor
Ligand 1.00E+00 ”
νθ
−
Backward cooperativity factor for
ligand binding a Gθ bound recep-
tor
Ligand 1.00E+00 ”
ζj+ Forward cooperativity factor for
ligand-bound Rj activation
Ligand 1.00E+03 ”
ζj
−
Backward cooperativity factor for
ligand-bound Rj activation
Ligand 1.00E+00 ”
µj,θ+ Forward cooperativity factor for
Gθ-bound Rj activation
Cell 1.00E+00 (j = θ),
0 (j != θ)
”
µj,θ
−
Backward cooperativity factor for
Gθ-bound Rj activation
Cell 1.00E+00 ”
Rtot Total receptor concentration Cell 4.15E-10 M ”
G1tot Total G
1 concentration Cell 4.15E-10 M ”
G2tot Total G
2 concentration Cell 4.15E-10 M ”
Ltot Total Ligand concentration Ligand 1.00E+07 M ”
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B Receptor cross states
In Figure B.1, we show simulated time courses for αGTP , under variation of receptor cross state
activation and accessibility. In the top row, we allow activation of both G proteins by either active
state (by setting kj,θGTP = 1 ∀j, θ), and vary the propensity for G protein binding to the active states
by varying µ1,2+ . With µ
2,1
+ = 0.001 (so that there is very little R
∗2G1, top left plot), as µ1,2+ increases,
basal α2GTP increases due to increased signalling via pre-coupled R
∗1G2. Also there is a slight increase
in plateau α2GTP . In this case, the perhaps unexpected trend in the peak response, whereby peak
α2GTP does not increase with µ
1,2
+ , is due to the fact that for large µ
1,2
+ , the basal conditions are “near
equilibrium”, and the peak may increase or decrease with increased µ1,2+ . The α
1
GTP equilibrium and
dynamics are not significantly affected by changes in µ1,2+ . Performing the same simulations with
µ2,1+ = 1000 (top right plot), α
1
GTP dynamics are again largely unaffected by the variation in µ
1,2
+ , but
this time the system is closer to equilibrium and α1GTP has a lower peak than for µ
2,1
+ = 0.001 .
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Figure B.1: Time courses for varying agonist accessibility of receptor cross states. Here, [L] = 10−5M.
In the case where cross states are accessible in the G protein binding sense, but there is specificity
with respect to g protein activation (so k1,2GTP = k
1,2
GTP = 0), for increasing µ
1,2
+ , we now have more
of G2 trapped in a non-signalling complex R∗1G2, giving reduced basal and equilibrium α2GTP . The
basal and equilibrium levels are monotonic with µ1,2+ , but the peak levels are not. For µ
2,1
+ = 0.001,
as µ1,2+ increases, more R
∗1 is trapped in non-signalling complexes, so there is less R∗1G1 available
to signal, resulting in a lower α1GTP . For µ
2,1
+ = 1000, we see the same trends, but with lower α
1,2
GTP
signals, since there is more non-signalling R∗2G1.
C Effect of ν
In Figure C.1, we show that the effect of varying νθ (the microaffinity constant νθ that controls the
preference of ligand for RGθ over R) is as expected; increasing νθ increases both peak and plateau
αθGTP .
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Figure C.1: Response surfaces for varying ν1,2+ , with expected monotonic relationships. Here, [L] = 10
−5M.
D Further experimental detail for cAMP experiments
CHO-K1 cells, expressing the A1R were routinely grown in Hams F-12 media (supplemented with 10%
FBS), at 37◦C, in a humidified atmosphere, containing 5% CO2. Where Gs assays were performed,
cells were pre-treated, for 16-18 hours with 200 ng/ml PTX. Upon day of assay, cells were harvested
and brought to single cells suspension using trypsin (containing 0.05 EDTA). Cells were washed and
resuspended in stimulation buffer (PBS containing 0.1% BSA and 25 µM rolipram). Cells were seeded
onto 384-well, white, optiplates and stimulated with either agonist alone, or co-stimulated with agonist
and 10 M forskolin, for 30 minutes. cAMP levels were then detected using a LANCE R©cAMP detection
kit (PerkinElmer, Boston, MA), and plates read using a LB 940 multimode microplate reader (Berthold
technologies, Germany) (excitation: 340 nm, emission: 665 nm).
E Parameter estimates for cAMP experiments
In Table E.1, we show parameter estimates for the experimental data shown in Figure 5.1. Inspection
of the values shows that ligand-dependent parameter values vary over orders of magnitude across the
three experiments, while cell-only parameter value estimates are all within an order of magnitude of
each other, as expected. Also, our estimates for the G protein totals are consistent with the observation
that in most membranes, the amount of Gi protein exceeds the amount of Gs
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